{"PMC7252125": [["In the Aesop fable, \u201cThe Hare and the Tortoise,\u201d the tortoise unexpectedly beats the hare in a race.", [["tortoise", "ORGANISM", 53, 61], ["Tortoise", "OBSERVATION_MODIFIER", 38, 46], ["tortoise", "OBSERVATION_MODIFIER", 53, 61]]], ["This same moral also appears in the wisdom literature of the Old Testament book of Ecclesiastes 9:11, which more generally concerns the limitations of human wisdom\u2014which is nearly always disregarded by humans themselves.", [["human", "ORGANISM", 151, 156], ["humans", "ORGANISM", 202, 208], ["human", "SPECIES", 151, 156], ["humans", "SPECIES", 202, 208], ["human", "SPECIES", 151, 156], ["humans", "SPECIES", 202, 208]]]], "901136116f2c4fbe1126a3b36c5b31fbf27675c3": [["urgent/nonelective, (b) semi-urgent, and (c) nonurgent/elective.", [["nonurgent/elective", "TREATMENT", 45, 63]]], ["The purpose of this manuscript is to provide a priority plan for invasive cardiac electrophysiology procedures during the COVID-19 pandemic that is consistent with, yet simplified in comparison to, prior recommendations.", [["cardiac", "ANATOMY", 74, 81], ["cardiac", "ORGAN", 74, 81], ["invasive cardiac electrophysiology procedures", "TREATMENT", 65, 110], ["the COVID", "TEST", 118, 127], ["pandemic", "PROBLEM", 131, 139], ["consistent with", "UNCERTAINTY", 148, 163]]], ["[6] [7] [8] [9] [10] 2 | SAFETY AND RESOURCE UTILIZATION", [["[6] [7] [8] [9] [10] 2", "SIMPLE_CHEMICAL", 0, 22]]]], "2a8b8ebfe4e0e1e2ed8bcf526f3acccfc06f33cc": [["The distinguishing feature of public health research is its focus on assessing, measuring, and monitoring the health of populations; in contrast, traditional biomedical research focuses on studying disease and treatment for individual patients [1] .", [["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 235, 243], ["treatment", "TREATMENT", 210, 219]]], ["Compared with most medical specialties, emergency medicine (EM) is well positioned to bridge biomedical and public health approaches for preventing disease and injury and promoting health through population-based strategies targeted at the community [2] .", [["public health approaches", "TREATMENT", 108, 132], ["disease", "PROBLEM", 148, 155], ["injury", "PROBLEM", 160, 166]]], ["In its strategically vital position at the boundary between the hospital and the surrounding community, the emergency department (ED) is actually the linchpin for multiple systems of care.", [["position", "OBSERVATION_MODIFIER", 27, 35]]], ["When all systems are functioning, EM offers access for all patients 24 hours a day, 7 days a week, regardless of their ability to pay.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67]]], ["EM provides triage and care for both mental and physical health conditions, and links patients with the most appropriate providers and care settings for their presenting conditions.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]], ["The ED also collects data used for surveillance of infectious diseases (eg, sexually transmitted infections, tuberculosis, severe acute respiratory syndrome [SARS] ) and environmental emergencies (eg, heat waves, toxic spills) and forwards patient-level data to public health departments.", [["infectious diseases", "DISEASE", 51, 70], ["sexually transmitted infections", "DISEASE", 76, 107], ["tuberculosis", "DISEASE", 109, 121], ["acute respiratory syndrome", "DISEASE", 130, 156], ["SARS", "DISEASE", 158, 162], ["patient", "ORGANISM", 240, 247], ["patient", "SPECIES", 240, 247], ["infectious diseases", "PROBLEM", 51, 70], ["sexually transmitted infections", "PROBLEM", 76, 107], ["tuberculosis", "PROBLEM", 109, 121], ["severe acute respiratory syndrome", "PROBLEM", 123, 156], ["environmental emergencies", "PROBLEM", 170, 195], ["heat waves", "TREATMENT", 201, 211], ["toxic spills", "PROBLEM", 213, 225], ["infectious", "OBSERVATION", 51, 61], ["tuberculosis", "OBSERVATION", 109, 121], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["respiratory syndrome", "OBSERVATION", 136, 156]]], ["However, research advances and practical innovations are needed to enhance surveillance data by enabling ''real-time'' reporting of more cases and more complete data about each case.", [["practical innovations", "TREATMENT", 31, 52], ["surveillance data", "TEST", 75, 92]]], ["In addition, the ED is well positioned to recognize and call attention to major social problems that impact the health of the public (breaches in food safety, homelessness, lack of health insurance or care coordination, child abuse, interpersonal violence).", [["interpersonal violence", "DISEASE", 233, 255]]], ["EM has great potential as a public health partner capable of monitoring and providing input into policies affecting the health of populations along a number of dimensions.Background: EM and public healthThe specialty of EM was launched in the 1970s in response to patients' needs for improved access to care.", [["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 264, 272]]], ["Indeed, the topic of access, particularly for vulnerable populations, pervades much of EM public health research.", [["vulnerable populations", "PROBLEM", 46, 68]]], ["The original emergency rooms were started in response to unattached patients.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["At that time, those individuals without primary care physicians who presented to the hospital in acute distress would be evaluated by the charge nurse and, if necessary, the on-call physician.", [["acute distress", "PROBLEM", 97, 111], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["distress", "OBSERVATION", 103, 111]]], ["The growth of the specialty of EM was very much consumer driven as the volume increased to the point that overwhelmed existing staff, who were all trying to do other jobs.", [["growth", "OBSERVATION_MODIFIER", 4, 10]]], ["Finally, small groups of physicians began providing full-time coverage of EDs as attending physicians dedicated to providing emergency care; the Pontiac Plan and the Alexandria Plan were examples.", [["small", "OBSERVATION_MODIFIER", 9, 14]]], ["The new specialty grew exponentially and was amazingly successful both for hospitals and EM physician groups [4] .", [["new", "OBSERVATION_MODIFIER", 4, 7]]], ["However, major changes in the financing and delivery of health care in the 1980s resulted in increasing rates of uninsured patients [5] .", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131]]], ["Many private hospitals started to baulk at absorbing this burden and developed policies of referring or transferring uninsured ED patients to publicly funded county hospitals.", [["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138]]], ["Emergency physicians and patients responded to these ''patient dumping'' policies with research and advocacy [6] .", [["patients", "ORGANISM", 25, 33], ["patient", "ORGANISM", 55, 62], ["patients", "SPECIES", 25, 33], ["patient", "SPECIES", 55, 62]]], ["Understanding this close relationship between EM, the needs of health care consumers, and the development of current health care policies gives a framework for a discussion of the past challenges, successes, and potential for future EM public health research.Background: EM and public healthMonitoring health care access: negotiating emergency care during changes in health policy Past challenges, research findings, and their impact Like EM itself, EM research has its roots in advocacy efforts by emergency physicians to provide access to care for vulnerable patient populations.", [["patient", "ORGANISM", 561, 568], ["patient", "SPECIES", 561, 568], ["negotiating emergency care", "TREATMENT", 322, 348], ["vulnerable patient populations", "PROBLEM", 550, 580]]], ["Much of this work was composed of descriptive studies designed to document disparities in care for the poor and uninsured.", [["descriptive studies", "TEST", 34, 53]]], ["Among these studies were descriptive analyses of ''patient dumping,'' a practice in which private hospitals transferred uninsured patients to public hospital EDs, regardless of medical condition [7] .", [["patient", "ORGANISM", 51, 58], ["patients", "ORGANISM", 130, 138], ["patient", "SPECIES", 51, 58], ["patients", "SPECIES", 130, 138], ["these studies", "TEST", 6, 19]]], ["This analytic work influenced landmark federal legislation, the Emergency Medical Treatment and Active Labor Act (EMTALA), which established a statutory duty for Medicare-participating hospitals with EDs to serve any person seeking emergency care [8] .Background: EM and public healthIn the early 1990s, governmental and free market cost-containment strategies, including the penetration of health maintenance organizations, accelerated.", [["person", "SPECIES", 217, 223], ["the Emergency Medical Treatment", "TREATMENT", 60, 91], ["governmental and free market cost-containment strategies", "TREATMENT", 304, 360]]], ["Many policy analysts questioned the opportunity costs of paying for the high cost of emergency care.", [["emergency care", "TREATMENT", 85, 99]]], ["Several researchers, however, reported that the marginal costs of ED care, especially for nonurgent problems, were actually much less than widely believed.", [["nonurgent problems", "PROBLEM", 90, 108], ["marginal", "OBSERVATION_MODIFIER", 48, 56]]], ["Williams [9] provided evidence that the majority of ED costs were fixed because of the necessity of standby capacity for unexpected trauma and acute medical emergencies, and that the excess charges primarily reflected cost shifting to pay for the uninsured.", [["trauma", "DISEASE", 132, 138], ["unexpected trauma", "PROBLEM", 121, 138], ["acute medical emergencies", "PROBLEM", 143, 168], ["the excess charges", "PROBLEM", 179, 197], ["acute", "OBSERVATION_MODIFIER", 143, 148]]], ["Tyrance and colleagues [10] found that ''ED use accounts for a small fraction of medical spending'' and suggested that ''Attempts to restrict ED use would disproportionately burden minorities and the poor who receive much of their out patient care in EDs.''", [["patient", "ORGANISM", 235, 242], ["patient", "SPECIES", 235, 242]]], ["They also recommended that ''Strategies that reduce demand for ED services should be pursued to improve health, not because of anticipated cost savings.''", [["ED services", "TREATMENT", 63, 74]]], ["Nonetheless, many health policy experts and politicians considered ''inappropriate ED use'' to be an important cause of high medical costs.", [["high medical costs", "PROBLEM", 120, 138]]], ["This led to attempts by managed care organizations to constrain patient access to emergency services.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71]]], ["These criticisms may have had more validity if, at the same time, there hadn't been a lack of access to primary care for a large portion of Americans based on inadequate or lack of health insurance [12] [13] [14] [15] .Background: EM and public healthIn 1994, a group of emergency physicians formed the multisite Medicaid Access Study Group to study the problems that Medicaid recipients were experiencing when they tried to access primary care.", [["[12] [13] [14] [15]", "SIMPLE_CHEMICAL", 198, 217], ["recipients", "ORGANISM", 377, 387]]], ["In the nine cities, they trained research assistants to pose as patients seeking care for relatively minor, but physically uncomfortable health problems [16] .", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]], ["The authors concluded that Medicaid patients have few options outside of the ED.Background: EM and public healthOther studies in the mid-1990s focused on the impact of HMO-mediated ED access barriers [17] [18] [19] .Background: EM and public healthThese research studies and advocacy efforts on the part of organized emergency medicine and health care consumers eventually led to the Healthy People (HP) 2010 objective 1-10, to ''reduce the proportion of persons who delay or have difficulty in getting emergency medical care'' and the overarching goal to ''improve access to high-quality health care services'' [18] .", [["patients", "ORGANISM", 36, 44], ["HMO", "SIMPLE_CHEMICAL", 168, 171], ["persons", "ORGANISM", 455, 462], ["patients", "SPECIES", 36, 44], ["People", "SPECIES", 392, 398], ["persons", "SPECIES", 455, 462], ["public healthOther studies", "TEST", 99, 125], ["These research studies", "TEST", 248, 270], ["emergency medical care", "TREATMENT", 503, 525]]], ["Many state governments and the federal Medicare and Medicaid programs adopted the ''prudent layperson standard'' in defining a medical emergency for purposes of health insurance coverage.", [["Medicaid programs", "TREATMENT", 52, 69], ["health insurance coverage", "TREATMENT", 161, 186]]], ["The prudent layperson standard also was incorporated into a federal legislative proposal that would make it applicable to emergency care reimbursement decisions by all health care plans nationwide [18] .", [["The prudent layperson standard", "TREATMENT", 0, 30]]], ["This standard obligated managed care plans to provide coverage for ED services based on an enrollee's presenting symptoms (including severe pain) rather than the final diagnosis.", [["pain", "DISEASE", 140, 144], ["ED services", "TREATMENT", 67, 78], ["symptoms", "PROBLEM", 113, 121], ["severe pain", "PROBLEM", 133, 144]]], ["The test for triggering reimbursement under this standard was whether a prudent layperson (a person who possesses an average knowledge of health and medicine) would reasonably expect that the absence of immediate medical attention could result in harm [6] .Future research: access to careNew research insights into access problems and their solutions can be achieved through studies that focus on patient flow and care processes outside the ED.", [["patient", "ORGANISM", 397, 404], ["person", "SPECIES", 93, 99], ["patient", "SPECIES", 397, 404], ["The test", "TEST", 0, 8], ["their solutions", "TREATMENT", 335, 350]]], ["EM investigators have already taken the important step of moving from merely observing access problems to measuring and quantifying the factors that keep people from accessing needed care and linking these barriers to adverse patient outcomes [20] [21] [22] .", [["people", "ORGANISM", 154, 160], ["patient", "ORGANISM", 226, 233], ["people", "SPECIES", 154, 160], ["patient", "SPECIES", 226, 233]]], ["Next steps include designing and evaluating interventions to reliably link patients to appropriate services.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["interventions", "TREATMENT", 44, 57]]], ["For some patients, the most efficient gateway to primary and specialty health care services may be through the ED, because of its 24-hour availability.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["One example might be a system where the ED provides initial triage for all acute ambulatory care and has the capacity to make urgent primary and specialty appointments for patients in an open access framework.", [["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["all acute ambulatory care", "TREATMENT", 71, 96], ["an open access framework", "TREATMENT", 184, 208]]], ["On the other hand, it might turn out that other options such as open access systems or allowing patients to make their own appointments on the Internet are more reliable or cost-effective [23, 24] .", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["open access systems", "TREATMENT", 64, 83]]], ["Regardless, creative reengineering of the current health system will allow the ED to function as effectively as possible in delivering care directly and enabling patients to access other health care and social services that may be needed.", [["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170]]], ["Ideally, EM will not only be involved in the development of any new system changes but also their evaluation.Future research: access to careOne important unresolved conceptual challenge will be for EM to help define the ideal ''access''da term whose meaning has shifted over time along with differing policies and expectations of the American health care system.", [["any new system changes", "PROBLEM", 60, 82], ["their evaluation", "TEST", 92, 108]]], ["Consensus on the meaning of access is still lacking: many might consider access to be the provision of medical care that is adequate and timely enough to prevent adverse health outcomes.", [["medical care", "TREATMENT", 103, 115], ["adverse health outcomes", "PROBLEM", 162, 185]]], ["Keeping in mind that health services are only one of several means to the desired outcome of ''health,'' a public health approach to access would include a consideration of population-based health indicators and outcome measures.", [["outcome measures", "TREATMENT", 212, 228]]], ["Moreover, we need to consider the opportunity costs of the proportion of the gross national product (GNP) and other resources going to health care services versus housing, education, recreation, environmental protection, and other social obligations that impact the health of the public.Surveillance of diseases, injuries, and health risksWhile health departments bear the responsibility for surveillance and monitoring the health of the public, emergency departments are at the front line of any emerging health hazard and, as such, have the potential to play a more immediate and sentinel role [25, 26] .", [["injuries", "DISEASE", 313, 321], ["environmental protection", "TREATMENT", 195, 219], ["diseases", "PROBLEM", 303, 311], ["injuries", "PROBLEM", 313, 321], ["surveillance", "TEST", 392, 404], ["diseases", "OBSERVATION", 303, 311]]], ["Public health surveillance was originally developed as part of local, state, and national efforts to control infectious diseases.", [["infectious diseases", "DISEASE", 109, 128], ["infectious diseases", "PROBLEM", 109, 128]]], ["Early detection and response are longstanding priorities, and the premium placed on rapid reporting has only increased in recent years.", [["Early detection", "TEST", 0, 15], ["increased", "OBSERVATION_MODIFIER", 109, 118]]], ["New emerging infectious diseases, which are rapidly spread in our global economy (eg, SARS) [27] , and recent acts of bioterrorism [28] have focused attention on the need for real-time reporting from EDs to public health agencies.Surveillance of diseases, injuries, and health risksMore rapid public health reporting from EDs is part of a larger vision of EM's role in public health [29, 30] .", [["infectious diseases", "DISEASE", 13, 32], ["SARS", "DISEASE", 86, 90], ["injuries", "DISEASE", 256, 264], ["New emerging infectious diseases", "PROBLEM", 0, 32], ["diseases", "PROBLEM", 246, 254], ["injuries", "PROBLEM", 256, 264], ["infectious", "OBSERVATION", 13, 23], ["rapidly", "OBSERVATION_MODIFIER", 44, 51], ["spread", "OBSERVATION_MODIFIER", 52, 58], ["diseases", "OBSERVATION", 246, 254]]], ["An early exception was the northeastern Ohio trauma study in the early 1980s [31] .", [["trauma", "DISEASE", 45, 51], ["early", "OBSERVATION_MODIFIER", 3, 8]]], ["Usage of ED data to describe the scope and nature of specific problems has been limited because of selection biases, retrospective information, and inability to acquire timely data.", [["specific problems", "PROBLEM", 53, 70]]], ["ED-based surveillance began to receive serious attention and discussion in the 1990s, most notably in the areas of infectious diseases and violence.", [["infectious diseases", "DISEASE", 115, 134], ["violence", "DISEASE", 139, 147], ["infectious diseases", "PROBLEM", 115, 134], ["infectious", "OBSERVATION", 115, 125]]], ["The Weapon Reporting Injury Surveillance System (WRISS) of Massachusetts collected information on all weapon-related injuries treated in all of the EDs within Massachusetts and proved very useful for the development and evaluation of prevention strategies [32] .", [["Injury", "DISEASE", 21, 27], ["injuries", "DISEASE", 117, 125], ["evaluation", "TEST", 220, 230], ["Injury", "OBSERVATION", 21, 27], ["injuries", "OBSERVATION", 117, 125]]], ["EMER-GEncy Net ID was established in 1995 to sample ED-based infectious diseases.", [["infectious diseases", "DISEASE", 61, 80], ["based infectious diseases", "PROBLEM", 55, 80], ["infectious", "OBSERVATION", 61, 71]]], ["The network is not population-based and is significantly retrospective in its timeliness, but it provides an important demonstration of the value of ED data for surveillance purposes [33] .Surveillance of diseases, injuries, and health risksOther subjects for ED-based surveillance included intimate partner violence [34] and firearms [35] .", [["injuries", "DISEASE", 215, 223], ["intimate partner violence", "DISEASE", 291, 316], ["ED data", "TEST", 149, 156], ["surveillance purposes", "TEST", 161, 182], ["diseases", "PROBLEM", 205, 213], ["injuries", "PROBLEM", 215, 223], ["not", "UNCERTAINTY", 15, 18], ["population", "OBSERVATION_MODIFIER", 19, 29], ["significantly", "OBSERVATION_MODIFIER", 43, 56], ["diseases", "OBSERVATION", 205, 213]]], ["As an example of the latter, Atlanta-based EDs were among the first to enroll in a firearm surveillance project with Emory's Injury Control Center that provided timely information to law enforcement and public health officials on the scope and nature of firearm injuries in the metro-Atlanta area [35] .", [["Injury", "DISEASE", 125, 131], ["firearm injuries", "DISEASE", 254, 270], ["the scope", "TEST", 230, 239], ["firearm injuries", "PROBLEM", 254, 270], ["injuries", "OBSERVATION", 262, 270]]], ["These state and local efforts complement national-level surveillance of ED-treated injuries by the National Electronic Injury Surveillance System (NEISS) of the US Consumer Product Safety Commission.", [["injuries", "DISEASE", 83, 91], ["treated injuries", "PROBLEM", 75, 91]]], ["National estimates of nonfatal firearm-related injuries are derived using weighted data for patients treated in a nationally representative, stratified probability sample of US hospital emergency departments [36] .Surveillance of diseases, injuries, and health risksED encounter databases in which external cause of injury codes are assigned for each injury-related visit are another resource for injury surveillance.", [["injuries", "DISEASE", 47, 55], ["injuries", "DISEASE", 240, 248], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["related injuries", "PROBLEM", 39, 55], ["diseases", "PROBLEM", 230, 238], ["injuries", "PROBLEM", 240, 248], ["injury codes", "PROBLEM", 316, 328], ["each injury", "PROBLEM", 346, 357], ["injury surveillance", "TEST", 397, 416], ["diseases", "OBSERVATION", 230, 238], ["injury", "OBSERVATION", 316, 322]]], ["Paramedic and emergency medical systems (EMS) can provide additional data for surveillance purposes.", [["surveillance purposes", "TEST", 78, 99]]], ["However, not all public health departments currently have data in electronic format and there is a noted lack of uniformity among regional and state-based surveillance systems.Future ED-based surveillanceCurrently, most health departments conduct surveillance on a limited set of diseases and injuries.", [["injuries", "DISEASE", 293, 301], ["surveillance", "TEST", 247, 259], ["diseases", "PROBLEM", 280, 288], ["injuries", "PROBLEM", 293, 301], ["diseases", "OBSERVATION", 280, 288], ["injuries", "OBSERVATION", 293, 301]]], ["Additional investments are needed to close gaps in existing surveillance capacity and extend surveillance to other conditions.", [["existing surveillance capacity", "TEST", 51, 81]]], ["Currently, work on uniform data collection systems [38] and ED-based research networks [39, 40] is still in its infancy.", [["collection systems", "TEST", 32, 50]]], ["Real time ED-based surveillance has become an increasingly important concept but is currently limited to sampling EDs in the United States for specific problems: product-related injuries NEISS for the Consumer Product Safety Commission, and The Drug Abuse Working Network (DAWN), an ED-based system for surveillance of drug abuse.Future ED-based surveillanceEM researchers have opportunities to help develop more efficient and real-time public health surveillance systems as part of an overall public health strategy [41] .", [["injuries", "DISEASE", 178, 186], ["drug abuse", "DISEASE", 319, 329]]], ["These efforts will require careful attention to the quality of ED data and safeguards for privacy and confidentiality [37, 41] .Preventive services in the EDHistorically, in most Western societies, advances in antimicrobials and vaccines and improvements in sanitation have shifted much of the burden of disease morbidity and mortality from infections to injuries and chronic diseases [42] .", [["infections", "DISEASE", 341, 351], ["injuries", "DISEASE", 355, 363], ["chronic diseases", "DISEASE", 368, 384], ["antimicrobials", "TREATMENT", 210, 224], ["vaccines", "TREATMENT", 229, 237], ["sanitation", "TREATMENT", 258, 268], ["disease morbidity", "PROBLEM", 304, 321], ["infections to injuries", "PROBLEM", 341, 363], ["chronic diseases", "PROBLEM", 368, 384], ["infections", "OBSERVATION", 341, 351], ["chronic", "OBSERVATION_MODIFIER", 368, 375], ["diseases", "OBSERVATION", 376, 384]]], ["Clinical preventive services aimed at reducing behavioral antecedents of injuries and chronic diseases (such as excessive use of alcohol, obesity, tobacco use) provide an important way to further reduce morbidity and mortality.", [["injuries", "DISEASE", 73, 81], ["chronic diseases", "DISEASE", 86, 102], ["alcohol", "CHEMICAL", 129, 136], ["obesity", "DISEASE", 138, 145], ["alcohol", "CHEMICAL", 129, 136], ["tobacco", "ORGANISM", 147, 154], ["injuries", "PROBLEM", 73, 81], ["chronic diseases", "PROBLEM", 86, 102], ["obesity", "PROBLEM", 138, 145], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["diseases", "OBSERVATION", 94, 102]]], ["Initially, chronic diseases such as cancer and heart disease were viewed as hereditary and incurable.", [["cancer", "ANATOMY", 36, 42], ["heart", "ANATOMY", 47, 52], ["chronic diseases", "DISEASE", 11, 27], ["cancer", "DISEASE", 36, 42], ["heart disease", "DISEASE", 47, 60], ["hereditary", "DISEASE", 76, 86], ["cancer", "CANCER", 36, 42], ["heart", "ORGAN", 47, 52], ["chronic diseases", "PROBLEM", 11, 27], ["cancer", "PROBLEM", 36, 42], ["heart disease", "PROBLEM", 47, 60], ["chronic", "OBSERVATION_MODIFIER", 11, 18], ["diseases", "OBSERVATION", 19, 27], ["cancer", "OBSERVATION", 36, 42], ["heart", "ANATOMY", 47, 52], ["disease", "OBSERVATION", 53, 60], ["incurable", "OBSERVATION_MODIFIER", 91, 100]]], ["It was not until 1957 that the Surgeon General issued a warning against ''excessive cigarette smoking'' [42] .", [["cigarette", "ORGANISM_SUBDIVISION", 84, 93]]], ["It still took a tremendous effort on the part of physicians and public health professionals to change the public's perception that smoking cessation, control of blood pressure, improved diet, decreased stress, and greater exercise could increase life expectancy and lead to more quality years of healthy living.", [["blood", "ANATOMY", 161, 166], ["smoking", "CHEMICAL", 131, 138], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["blood pressure", "TEST", 161, 175], ["decreased stress", "PROBLEM", 192, 208]]], ["However, the success of these efforts on the part of the American Heart Association, American Cancer Society, and the US Preventive Services Task Force is evidenced in the declining age-adjusted mortality rates for several cardiovascular diseases.", [["cardiovascular", "ANATOMY", 223, 237], ["Cancer", "DISEASE", 94, 100], ["cardiovascular diseases", "DISEASE", 223, 246], ["cardiovascular", "ANATOMICAL_SYSTEM", 223, 237], ["several cardiovascular diseases", "PROBLEM", 215, 246], ["Heart", "ANATOMY", 66, 71], ["Cancer", "OBSERVATION", 94, 100], ["cardiovascular", "ANATOMY", 223, 237], ["diseases", "OBSERVATION", 238, 246]]], ["Likewise, both passive (seatbelts) and active (speed limits, helmets) injury-prevention strategies have been associated with a decline in death rates from motor vehicle crashes.", [["death", "DISEASE", 138, 143], ["motor vehicle crashes", "DISEASE", 155, 176], ["injury", "PROBLEM", 70, 76], ["prevention strategies", "TREATMENT", 77, 98], ["a decline in death rates", "PROBLEM", 125, 149], ["passive", "OBSERVATION_MODIFIER", 15, 22]]], ["The Healthy People initiative began in the late 1970s to increase health promotion and prevent disease [42] .", [["disease", "PROBLEM", 95, 102]]], ["Gradually, prevention became widely regarded as the answer for preventing premature death and prolonging years of healthy life.", [["death", "DISEASE", 84, 89], ["premature death", "PROBLEM", 74, 89]]], ["However, to date, it is recognized that the patients who most need preventive services are those least likely to receive them [43] .Preventive services in the EDThe US Preventive Services Task Force (USPSTF) recommended that all physicians take advantage of acute care visits to provide preventive services.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["preventive services", "TREATMENT", 67, 86], ["preventive services", "TREATMENT", 287, 306]]], ["However, nearly all the preventive services identified by the USPSTF as efficacious and cost-effective are provided at unacceptably low rates, even to patients who regularly visit traditional primary care settings [44] .", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159]]], ["Many patients only receive acute episodic care in EDs.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["acute episodic care", "TREATMENT", 27, 46]]], ["Thus, EDs may be in a position to treat those patients with the greatest potential to benefit from preventive services.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["preventive services", "TREATMENT", 99, 118]]], ["It is perhaps important to clarify that classical primary preventive services are those delivered before onset of a condition, such as education and immunization.", [["immunization", "TREATMENT", 149, 161]]], ["Secondary prevention is targeted at high-risk individuals before they suffer the adverse consequences of their behaviors, such as counseling problem drinkers to cut down or those with risky sexual behaviors to use condoms to prevent HIV infection.", [["risky sexual behaviors", "DISEASE", 184, 206], ["HIV infection", "DISEASE", 233, 246], ["HIV", "ORGANISM", 233, 236], ["HIV", "SPECIES", 233, 236], ["HIV", "SPECIES", 233, 236], ["condoms", "TREATMENT", 214, 221], ["HIV infection", "PROBLEM", 233, 246], ["infection", "OBSERVATION", 237, 246]]], ["Tertiary preventive care is targeted at halting progression of clinically apparent conditions, eg, advising individuals with heart disease to quit smoking or referring substance abusers for treatment.", [["heart", "ANATOMY", 125, 130], ["heart disease", "DISEASE", 125, 138], ["smoking", "CHEMICAL", 147, 154], ["heart", "ORGAN", 125, 130], ["Tertiary preventive care", "TREATMENT", 0, 24], ["clinically apparent conditions", "PROBLEM", 63, 93], ["heart disease", "PROBLEM", 125, 138], ["treatment", "TREATMENT", 190, 199], ["heart", "ANATOMY", 125, 130], ["disease", "OBSERVATION", 131, 138]]], ["A relatively young specialty, EM has been defined by unscheduled acute care and crisis management, an emphasis that is reflected in the scope of residency curriculum.", [["unscheduled acute care", "TREATMENT", 53, 75], ["crisis management", "TREATMENT", 80, 97]]], ["Emergency physicians in training have little exposure to the assessment of patient psychosocial or behavioral health risks or skills in motivational interviewing.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["the assessment", "TEST", 57, 71]]], ["While recognizing the health burden of unhealthy behaviors, even strong advocates for ED prevention recognize that screening and intervention of any kind has been difficult in the ED.", [["unhealthy behaviors", "DISEASE", 39, 58], ["ED prevention", "TREATMENT", 86, 99], ["screening", "TEST", 115, 124], ["intervention", "TREATMENT", 129, 141]]], ["Moreover, the EDs that treat the most vulnerable patients are the most stressed.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["High-volume public hospital EDs with long waits, limited budgets, and insufficient staff, do not have the resources to add to their scope of practice.Preventive services in the EDAs emergency medicine has matured, there has been more focus on the public health implications of being a ''safety net'' provider for more than 40 million uninsured Americans.", [["volume", "OBSERVATION_MODIFIER", 5, 11]]], ["In the past 10 years, there has been increasing recognition of the potential role of EDs in injury surveillance and population-based public health strategies [2] , including the need to address the behavioral health risks that put individuals and their communities at risk of adverse health outcomes.Preventive services in the EDIn 1998, the Society of Academic Emergency Medicine's (SAEM) Board of Directors directed the SAEM Public Health Task Force (PHTF) to develop recommendations for prevention, screening, and counseling activities to be conducted in emergency departments.", [["injury surveillance", "TEST", 92, 111], ["screening", "TEST", 502, 511], ["increasing", "OBSERVATION_MODIFIER", 37, 47]]], ["They used a systematic approach to collect evidence from published clinical research and to judge the quality of individual studies.", [["a systematic approach", "TREATMENT", 10, 31], ["individual studies", "TEST", 113, 131]]], ["Given the very few high-quality studies of preventive services in the ED setting, they also accepted high-quality studies from primary care, where there was evidence for feasibility of the intervention in the ED setting.", [["the intervention", "TREATMENT", 185, 201]]], ["Using this criterion, the PHTF identified only five preventive services with sufficient evidence of effectiveness to support a recommendation in the ED setting: alcohol screening and intervention, HIV screening and referral (in high-risk populations), hypertension screening and referral, pneumococcal vaccinations (age O 65), and smoking cessation counseling [45] .Preventive services in the EDWhile not fully addressed by the PHTF, episodes of trauma care are widely recognized as unique opportunities to identify injury risk factors and initiate interventions aimed at breaking the cycle of injury recidivism [46, 47] .", [["alcohol", "CHEMICAL", 161, 168], ["hypertension", "DISEASE", 252, 264], ["smoking", "CHEMICAL", 331, 338], ["trauma", "DISEASE", 446, 452], ["injury recidivism", "DISEASE", 594, 611], ["alcohol", "CHEMICAL", 161, 168], ["alcohol", "SIMPLE_CHEMICAL", 161, 168], ["HIV", "SPECIES", 197, 200], ["HIV", "SPECIES", 197, 200], ["pneumococcal", "SPECIES", 289, 301], ["alcohol screening", "TEST", 161, 178], ["intervention", "TREATMENT", 183, 195], ["HIV screening", "TEST", 197, 210], ["hypertension screening", "PROBLEM", 252, 274], ["pneumococcal vaccinations", "TREATMENT", 289, 314], ["trauma care", "TREATMENT", 446, 457], ["injury risk factors", "PROBLEM", 516, 535], ["interventions", "TREATMENT", 549, 562], ["injury recidivism", "PROBLEM", 594, 611], ["hypertension", "OBSERVATION", 252, 264]]], ["Although emergency physicians and nurses have been increasingly involved in injury control and prevention efforts, the ED remains a clinical setting where the primary focus is treatment of the physical manifestations of emergency medical conditions.", [["injury control", "TREATMENT", 76, 90]]], ["Screening for underlying injury risk factors and counseling and other forms of risk reduction are not consistently performed and often neglected [25] .", [["underlying injury risk factors", "PROBLEM", 14, 44], ["counseling", "TREATMENT", 49, 59], ["risk reduction", "PROBLEM", 79, 93]]], ["To reduce injury morbidity and mortality, it may be imperative to capitalize on the opportunities that the ED presents for injury prevention [48] .", [["injury morbidity", "PROBLEM", 10, 26], ["injury prevention", "TREATMENT", 123, 140], ["injury", "OBSERVATION_MODIFIER", 10, 16], ["morbidity", "OBSERVATION", 17, 26]]], ["Moreover, attention to injury epidemiology will help in the development and evaluation of intervention programs.", [["evaluation", "TEST", 76, 86], ["intervention programs", "TREATMENT", 90, 111]]], ["ED-based injury surveillance will need to be strengthened and integrated into local, state, and national prevention strategies.Preventive services in the EDSome have advocated that screening all ED patients for injury risk behaviors, such as intoxicated driving and seatbelt use, should become the routine practice [47, 49, 50] .", [["injury risk behaviors", "DISEASE", 211, 232], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["based injury surveillance", "PROBLEM", 3, 28], ["national prevention strategies", "TREATMENT", 96, 126], ["screening", "TEST", 181, 190], ["injury risk behaviors", "PROBLEM", 211, 232], ["injury", "OBSERVATION", 9, 15]]], ["One of the most controversial questions is whether emergency physicians should screen all women for intimate partner violence (IPV).", [["intimate partner violence", "DISEASE", 100, 125], ["women", "ORGANISM", 90, 95], ["women", "SPECIES", 90, 95]]], ["Recognizing that intimate partner violence is a major cause of morbidity and mortality, medical organizations [51, 52] and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) recommended that all EDs implement protocols for screening and intervention of this high-risk group [53] .", [["intimate partner violence", "DISEASE", 17, 42], ["morbidity", "PROBLEM", 63, 72], ["screening", "TEST", 246, 255], ["intervention", "TREATMENT", 260, 272], ["Joint", "ANATOMY", 127, 132]]], ["However, most articles from the ED setting have reported on the system's failure to identify IPV and the barriers involved in universal screening [54, 55] .", [["the system's failure", "PROBLEM", 60, 80], ["universal screening", "TEST", 126, 145]]], ["The feasibility issues combined with a lack of an evidence-basis that IPV screening in a health care setting leads to a reduction in morbidity and mortality [56] have resulted in general discouragement regarding universal screening for IPV [57] .", [["The feasibility issues", "PROBLEM", 0, 22], ["IPV screening", "TEST", 70, 83], ["a reduction in morbidity", "TREATMENT", 118, 142], ["universal screening", "TEST", 212, 231]]], ["Currently, the USPSTF and others suggest that we should not engage in any screening or intervention that lacks an evidence basis [58] .", [["any screening", "TEST", 70, 83], ["intervention", "TREATMENT", 87, 99]]], ["While IPV screening is a low-risk, low-cost procedure with reliable screening tools [59] , time spent on screening or counseling for non-evidence-based conditions is costly and infringes on other physician tasks of proven benefit [60] .", [["IPV screening", "TEST", 6, 19], ["low-cost procedure", "TREATMENT", 35, 53], ["reliable screening tools", "TEST", 59, 83], ["screening", "TEST", 105, 114]]], ["Studying the effectiveness of ED-based interventions will require careful consideration of particular outcomes and valid measurements of these outcomes.Preventive services in the EDClearly there are knowledge gaps that need to be addressed before evidence-based recommendations can be made in favor of screening for health risks in the ED setting.", [["ED-based interventions", "TREATMENT", 30, 52]]], ["One of these gaps is a lack of well-defined, desirable, and measurable outcomes related to the screening process itself.", [["gaps", "OBSERVATION", 13, 17], ["lack of well-defined", "OBSERVATION_MODIFIER", 23, 43], ["desirable", "OBSERVATION_MODIFIER", 45, 54]]], ["For example, any understanding of the value of identifying IPV in a health care setting is confounded by the psychosocial and biological complexity of violence.", [["violence", "DISEASE", 151, 159]]], ["Using ''incidence of violence'' as an outcome measure for the effect of a brief intervention in health care setting involves measuring the behavioral outcomes of a third party, something that is not necessarily under the control of either the physician or the patient.", [["patient", "ORGANISM", 260, 267], ["patient", "SPECIES", 260, 267], ["a brief intervention", "TREATMENT", 72, 92]]], ["Establishing a direct link between physician screening and incidence of violence is not feasible under that condition.Preventive services in the EDThe most appropriate outcomes for evaluating screening interventions in a health care setting may involve measuring the direct effect of screening on the outcomes of care.", [["violence", "DISEASE", 72, 80], ["physician screening", "TEST", 35, 54], ["screening interventions", "TREATMENT", 192, 215]]], ["For example, information about abuse histories may influence assessment and treatment of other health problems.", [["influence assessment", "TEST", 51, 71], ["other health problems", "PROBLEM", 89, 110]]], ["Nonetheless, it is time to expand the vision of potential outcomes to be measured from screening and counseling interventions in a health care setting, including identification of patient-desired outcomes.", [["patient", "ORGANISM", 180, 187], ["patient", "SPECIES", 180, 187], ["screening", "TEST", 87, 96], ["counseling interventions", "TREATMENT", 101, 125]]], ["One example from the substance abuse literature might be to measure the impact of an ED intervention on a patient's stage of readiness to change the risky health behavior [61] .", [["substance abuse", "DISEASE", 21, 36], ["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["an ED intervention", "TREATMENT", 82, 100]]], ["Another way to conceptualize ED screening for adverse health behaviors would be to think of ED screening as just one component of an overall public health strategy to influence health behaviors.", [["ED screening", "TEST", 29, 41], ["adverse health behaviors", "PROBLEM", 46, 70], ["ED screening", "TEST", 92, 104]]], ["Acknowledging that this is the case means that we must also evaluate the value of ED interventions in proportion to other population-based strategies such as public service announcements and other educational interventions.Future research on providing preventative care in the EDThere are several arguments to support expanding our research in the area of prevention.", [["ED interventions", "TREATMENT", 82, 98], ["educational interventions", "TREATMENT", 197, 222], ["preventative care", "TREATMENT", 252, 269]]], ["First, EDs are already doing a significant amount of prevention, screening, and counseling.", [["screening", "TEST", 65, 74]]], ["Most emergency physicians order tetanus immunizations for patients with lacerations.", [["tetanus", "DISEASE", 32, 39], ["lacerations", "DISEASE", 72, 83], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["tetanus immunizations", "TREATMENT", 32, 53], ["lacerations", "PROBLEM", 72, 83], ["lacerations", "OBSERVATION", 72, 83]]], ["Perhaps it would make more sense to immunize the large numbers of patients at risk for more common infections such as pneumococcal pneumonia and influenza, as both of these immunizations have been shown to be effective and feasible in the ED setting [62] .", [["infections", "DISEASE", 99, 109], ["pneumococcal pneumonia", "DISEASE", 118, 140], ["influenza", "DISEASE", 145, 154], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["pneumococcal", "SPECIES", 118, 130], ["more common infections", "PROBLEM", 87, 109], ["pneumococcal pneumonia", "PROBLEM", 118, 140], ["influenza", "PROBLEM", 145, 154], ["these immunizations", "TREATMENT", 167, 186], ["large", "OBSERVATION_MODIFIER", 49, 54], ["infections", "OBSERVATION", 99, 109], ["pneumococcal", "OBSERVATION_MODIFIER", 118, 130], ["pneumonia", "OBSERVATION", 131, 140]]], ["A fruitful area of research would be to identify effective, efficient methods of how the ED staff might provide such advice and to identify if it is indeed helpful and linked to desired outcomes [63] .Future research on providing preventative care in the EDSecond, to the extent that EDs serve as ''safety nets'' treating patients without other sources of care, we are the only potential source of prevention services for a highly vulnerable portion of the US population.", [["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 322, 330], ["preventative care", "TREATMENT", 230, 247]]], ["Over 40 million uninsured Americans have limited access to medical care outside of the ED.", [["medical care", "TREATMENT", 59, 71]]], ["These Americans are particularly likely to have unmet needs for prevention services.", [["prevention services", "TREATMENT", 64, 83]]], ["Smokers, drinkers, drug users, and motor vehicle crash victims presenting to the ED could benefit the most from behavioral interventions.", [["Smokers", "SPECIES", 0, 7], ["behavioral interventions", "TREATMENT", 112, 136]]], ["Homeless people at risk for tuberculosis and patients with sexually transmitted diseases in need of HIV counseling and testing commonly use the ED for health care.", [["tuberculosis", "DISEASE", 28, 40], ["sexually transmitted diseases", "DISEASE", 59, 88], ["people", "ORGANISM", 9, 15], ["patients", "ORGANISM", 45, 53], ["HIV", "ORGANISM", 100, 103], ["people", "SPECIES", 9, 15], ["patients", "SPECIES", 45, 53], ["HIV", "SPECIES", 100, 103], ["tuberculosis", "PROBLEM", 28, 40], ["sexually transmitted diseases", "PROBLEM", 59, 88], ["HIV counseling", "TREATMENT", 100, 114], ["tuberculosis", "OBSERVATION", 28, 40]]], ["ED physicians are frequently the only health care providers for these patients.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["Many of our patients may not receive prevention services at all if they do not receive them in the ED [66] .Future research on providing preventative care in the EDThird, it is likely that unmet preventive health needs will result in ED visits for more serious problems.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["prevention services", "TREATMENT", 37, 56], ["preventative care", "TREATMENT", 137, 154], ["more serious problems", "PROBLEM", 248, 269]]], ["A retrospective review by Stack and colleagues [67] found that 55% of their patients admitted with pneumococcal bacteremia had been seen in the ED an average of 3.4 times during the 72 months before their bacteremic episode; 88% of those patients were at high risk for pneumococcal disease by CDC criteria and 10% of them died during their admission.", [["pneumococcal bacteremia", "DISEASE", 99, 122], ["pneumococcal disease", "DISEASE", 269, 289], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 238, 246], ["pneumococcal", "SPECIES", 99, 111], ["pneumococcal", "SPECIES", 269, 281], ["pneumococcal bacteremia", "PROBLEM", 99, 122], ["their bacteremic episode", "PROBLEM", 199, 223], ["pneumococcal disease", "PROBLEM", 269, 289], ["pneumococcal", "OBSERVATION_MODIFIER", 99, 111], ["bacteremia", "OBSERVATION", 112, 122], ["pneumococcal disease", "OBSERVATION", 269, 289]]], ["A large multisite study of ED patients by Lowenstein and colleagues [68] found very high prevalence rates of injury-prone behaviors as well as risk factors for chronic disease.", [["injury-prone behaviors", "DISEASE", 109, 131], ["chronic disease", "DISEASE", 160, 175], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["A large multisite study", "TEST", 0, 23], ["injury", "PROBLEM", 109, 115], ["prone behaviors", "PROBLEM", 116, 131], ["chronic disease", "PROBLEM", 160, 175], ["large", "OBSERVATION_MODIFIER", 2, 7], ["injury", "OBSERVATION", 109, 115], ["chronic", "OBSERVATION_MODIFIER", 160, 167], ["disease", "OBSERVATION", 168, 175]]], ["High proportions of these patients were deficient in recommended preventive services.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["preventive services", "TREATMENT", 65, 84]]], ["This was true even among the patients with access to primary care.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["primary care", "TREATMENT", 53, 65]]], ["It has long been acknowledged that ED visits are frequently the result of a failure of prevention and that public health problems such as substance abuse, sexually transmitted disease (STD) treatment, and violence have placed a major burden on EDs.", [["substance abuse", "DISEASE", 138, 153], ["sexually transmitted disease", "DISEASE", 155, 183], ["STD", "DISEASE", 185, 188], ["violence", "DISEASE", 205, 213], ["public health problems", "PROBLEM", 107, 129], ["sexually transmitted disease", "PROBLEM", 155, 183], ["treatment", "TREATMENT", 190, 199]]], ["One area of future research is to document the extent and costs of these patients recycling back to the ED if there is no attempt at intervention.Future research on providing preventative care in the EDLast, patients in the ED may experience a ''teachable moment.''", [["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 208, 216], ["intervention", "TREATMENT", 133, 145], ["preventative care", "TREATMENT", 175, 192], ["extent", "OBSERVATION_MODIFIER", 47, 53]]], ["The ED patient treated for an injury following a motor vehicle collision may be more receptive to advice about seatbelts than he was a month earlier in his internist's office.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["an injury", "PROBLEM", 27, 36], ["injury", "OBSERVATION", 30, 36]]], ["The teenager with an STD may be more receptive to safe-sex counseling than she was in a high school lecture the week before.", [["STD", "DISEASE", 21, 24]]], ["There is evidence that ED patients have both a need and a desire for preventive services to be initiated in the ED setting [69] .", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["preventive services", "TREATMENT", 69, 88]]], ["There is some evidence that ED interventions targeted at high-risk populations can be very effective [63, 70] .", [["ED interventions", "TREATMENT", 28, 44]]], ["Parents trained about adolescent suicide risks during an ED visit for an adolescent behavior problem were four times more likely to take steps to limit their child's access to guns and prescription drugs than parents without the training [71] .", [["an adolescent behavior problem", "PROBLEM", 70, 100]]], ["However, the hypothesis that the ED visit is a ''teachable moment'' has yet to be rigorously tested.Future research on providing preventative care in the EDThere are also reasons not to provide preventive services in the ED.", [["preventative care", "TREATMENT", 129, 146]]], ["The EDs that treat the most vulnerable patients (where prevention, screening, and counseling activities should be focused) are the most stressed.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["screening", "TEST", 67, 76]]], ["High-volume public hospital EDs with long waits, limited budgets, and insufficient staff do not have the resources to add to their scope of practice.", [["volume", "OBSERVATION_MODIFIER", 5, 11]]], ["In these settings, coordinating follow-up for screening lab test results, determining what immunizations a patient has had previously, and so forth, may render many preventive and screening services much more difficult and potentially less effective than in primary care settings.", [["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["screening lab test", "TEST", 46, 64], ["immunizations", "TREATMENT", 91, 104]]], ["The worse scenario would be if the provision of preventive services detracted from our ability to provide critical care.", [["preventive services", "TREATMENT", 48, 67]]], ["So perhaps the appropriate research questions are not should we be doing prevention, but what prevention should we be doing, what resources do we need to do to perform these services, and how well does it work?Future research on providing preventative care in the EDPolicy-relevant research on health services systems, social welfare, and social determinants of health Current and future EM public health researchers wishing to engage in policy-relevant research will need to take a broad ''big picture'' approach to studying health.", [["preventative care", "TREATMENT", 239, 256]]], ["They will need to reach outside the clinic walls and consider the opportunity costs of our current high-priced high-tech health system and finally study the social determinants of health itself.Future research on providing preventative care in the EDResearch on the quality of emergency medical care: addressing the quality chiasmFuture research on providing preventative care in the EDThe Institute of Medicine (IOM) outlined six aims to improve the quality of care in the United States [72] .", [["preventative care", "TREATMENT", 223, 240], ["preventative care", "TREATMENT", 359, 376]]], ["They suggest identifying whether ED care is effective (''based on the use of systematically acquired evidence to determine whether an intervention, such as a preventive service, diagnostic test, or therapy, produces better outcomes than alternativesdincluding the alternative of doing nothing'') [72, 74] , efficient (avoids the waste of equipment, supplies, money, ideas, or energy) [72] , timely (able to avoid delays caused by patient, provider, or system factors), safe (''when patients [can] avoid injury from the care that is intended to help them'') [72, 75] , patient-centered (care that promotes patient involvement in medical decision making and helps care providers ''in attending to their patients' physical and emotional needs, and maintaining or improving their quality of life'') [72] , and equitable (free of bias).", [["patient", "ORGANISM", 430, 437], ["patients", "ORGANISM", 482, 490], ["patient", "ORGANISM", 568, 575], ["patient", "ORGANISM", 605, 612], ["patients", "ORGANISM", 701, 709], ["patient", "SPECIES", 430, 437], ["patients", "SPECIES", 482, 490], ["patient", "SPECIES", 568, 575], ["patient", "SPECIES", 605, 612], ["patients", "SPECIES", 701, 709], ["diagnostic test", "TEST", 178, 193], ["therapy", "TREATMENT", 198, 205], ["injury", "PROBLEM", 503, 509]]], ["To identify opportunities for research within each of these six quality domains, the authors classify current research into four research steps that build upon each other: (1) evidence does not exist and there is a need to generate rigorous research studies, (2) evidence exits but there is a need for synthesis of existing evidence into guidelines and quality measures, (3) there are existing evidence-based clinical guidelines and measures and a need for assessment of the quality of clinical practice compared with evidence-based guidelines and quality measures, and (4) there is a need to design and evaluate new interventions to improve clinical quality of care.EM public health research on health disparitiesAs an important part of the safety net for vulnerable populations, the ED is ideally positioned to conduct studies on health disparities [76] .", [["rigorous research studies", "TEST", 232, 257], ["synthesis", "TREATMENT", 302, 311], ["assessment", "TEST", 457, 467], ["new interventions", "TREATMENT", 613, 630]]], ["Multiple studies have demonstrated inequities in the delivery of health services attributable to gender, race, and age [77] [78] [79] .", [["Multiple studies", "TEST", 0, 16]]], ["There is a need, however, for investigation into the causes of these differences and interventions to correct the disparities.", [["interventions", "TREATMENT", 85, 98]]], ["While most emergency physicians agree that the same high quality of care should be available to all patients, prior research suggests that this may not always be the case [80] .", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108]]], ["For instance, African Americans and Hispanics are less likely to receive analgesics for painful conditions [81] .", [["analgesics", "TREATMENT", 73, 83], ["painful conditions", "PROBLEM", 88, 106]]], ["When inequities in care are documented, there is need for investigation into the patient and provider factors that may contribute to differences so that interventions to close these gaps can be designed and evaluated.", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["interventions", "TREATMENT", 153, 166]]], ["As an example, we can explore the influence of time pressure and complex cognitive tasks on medical decision making to see if bias exists in the treatment of critical conditions (eg, chest pain, respiratory failure, end-of-life care, pain management) in need of immediate assessment and treatment.", [["chest", "ANATOMY", 183, 188], ["respiratory", "ANATOMY", 195, 206], ["chest pain", "DISEASE", 183, 193], ["respiratory failure", "DISEASE", 195, 214], ["pain", "DISEASE", 234, 238], ["chest", "ORGANISM_SUBDIVISION", 183, 188], ["critical conditions", "PROBLEM", 158, 177], ["chest pain", "PROBLEM", 183, 193], ["respiratory failure", "PROBLEM", 195, 214], ["end-of-life care", "TREATMENT", 216, 232], ["pain management", "TREATMENT", 234, 249], ["immediate assessment", "TEST", 262, 282], ["treatment", "TREATMENT", 287, 296], ["chest", "ANATOMY", 183, 188], ["respiratory", "ANATOMY", 195, 206], ["failure", "OBSERVATION", 207, 214]]], ["It has been suggested that these conditions increase the likelihood that providers will use stereotypes or prejudice as they provide clinical care [80] .", [["these conditions", "PROBLEM", 27, 43]]], ["In its position as ''a window on the safety net'' and as ''the last hole that patients fall through in the fraying health care safety net,'' EDs can monitor the performance of the entire system [82] .", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["position", "OBSERVATION_MODIFIER", 7, 15]]], ["We see the patients who ''fall through the cracks,'' and can study where those patients come from, where they get resources, and who provides their primary care.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 79, 87]]], ["We can learn what patients want, how they use the system, and how nonhealth factors affect their choices [82] .", [["patients", "ORGANISM", 18, 26], ["nonhealth factors", "PROTEIN", 66, 83], ["patients", "SPECIES", 18, 26]]], ["Since the late 1990s, we have been living in an era of failed health care reform where cost containment strategies have created additional nonprice barriers to care.", [["cost containment strategies", "TREATMENT", 87, 114]]], ["While earlier legislative initiatives such as EMTALA and the prudent layperson standard provided important safeguards for managed care plan enrollees and the larger community, many emergency providers eventually came to resent the legislation as an unfunded federal mandate for universal access to health care via emergency departments [14] .", [["EMTALA", "TREATMENT", 46, 52]]], ["The resultant combination of regulatory and fiscal pressures on hospitals resulted in increasingly stressed and crowded conditions in many EDs [3] .", [["regulatory and fiscal pressures on hospitals", "TREATMENT", 29, 73], ["increasingly stressed and crowded conditions", "PROBLEM", 86, 130], ["fiscal pressures", "OBSERVATION", 44, 60], ["crowded conditions", "OBSERVATION", 112, 130]]], ["Regulatory extensions of EMTALA have held health systems liable for providing not only emergency care, but also any needed care.", [["EMTALA", "PROTEIN", 25, 31]]], ["With decreases in reimbursement for the care of publicly insured patients, the ED has become a medical-legal and financial liability for many hospital systems, as the primary portal of entrance for uninsured and publicly insured patients who compete with privately insured patients for scarce inpatient beds [15] .ED crowdingSeveral recent national reports find that this competition for inpatient beds has contributed to ED crowding and prolonged wait times to see an ED physician [84, 85] .", [["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 273, 281], ["ED crowding", "PROBLEM", 422, 433], ["decreases", "OBSERVATION_MODIFIER", 5, 14]]], ["EM research began to focus on the implications and patient outcomes associated with the failing safety net [86] [87] [88] .", [["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58]]], ["A March 2003 report from the US General Accounting Office (GAO) found that measures of ED crowding varied widely across hospitals and communities, with hospitals in urban areas (with populations greater than 2.5 million) and cities with greater proportions of uninsured people experiencing the most severe crowding conditions [84] .", [["people", "ORGANISM", 270, 276], ["people", "SPECIES", 270, 276], ["ED crowding", "PROBLEM", 87, 98], ["the most severe crowding conditions", "PROBLEM", 290, 325], ["most severe", "OBSERVATION_MODIFIER", 294, 305], ["crowding", "OBSERVATION", 306, 314]]], ["The National Hospital and Ambulatory Medical Care Survey (NHAMCS) found average 2001 ED waiting times for nonurgent conditions had increased 33% in a 3-year period [89] .", [["nonurgent conditions", "TEST", 106, 126]]], ["The current widespread occurrence of long waiting times for hospital beds, ambulance diversion, and high percentages of patients leaving EDs without being seen calls into question the amount of progress being made toward the Healthy People 2010 objective 1-10, which is to ''reduce the proportion of persons who delay or have difficulty in getting emergency medical care'' [90] .", [["patients", "ORGANISM", 120, 128], ["persons", "ORGANISM", 300, 307], ["patients", "SPECIES", 120, 128], ["People", "SPECIES", 233, 239], ["persons", "SPECIES", 300, 307], ["hospital beds", "TREATMENT", 60, 73], ["ambulance diversion", "TREATMENT", 75, 94], ["widespread", "OBSERVATION_MODIFIER", 12, 22]]], ["In addition, an overburdened emergency care system cannot be expected to adequately serve the country's need for emergent care, public health, or surveillance.", [["emergent care", "TREATMENT", 113, 126], ["surveillance", "TEST", 146, 158]]], ["The terrorist attack on September 11, 2001 , further called attention to the need for coordinated community responses to disasters and the role of EM in mass casualty intervention.", [["casualty intervention", "TREATMENT", 158, 179]]], ["However, many emergency physicians point out that the current capacity of the emergency response system is already exceeded on a daily basis.ED crowdingA recent analysis of the National Health Interview Survey (NHIS) found that a substantial number of adults report delay or difficulty in accessing needed emergency care.", [["adults", "ORGANISM", 252, 258], ["emergency care", "TREATMENT", 306, 320], ["substantial", "OBSERVATION_MODIFIER", 230, 241]]], ["Moreover, there appear to be significant disparities in rates of problems encountered by adults seeking emergency medical care, with younger, lower income, uninsured patients, and those reporting poorer health being at greatest risk of experiencing delays or difficulty [91] .", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["appear to be", "UNCERTAINTY", 16, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["disparities", "OBSERVATION", 41, 52]]], ["Further work will be necessary to assess the impact of access barriers on actual health outcomes.Future research on ED crowdingAlthough ED crowding as a concept has a lot of ''face validity,'' uniform definitions or valid measures of the problem are currently lacking.", [["''face validity", "PROBLEM", 174, 189], ["the problem", "PROBLEM", 234, 245]]], ["More importantly, the causal links between crowded conditions and adverse patient outcomes have not been well established.", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["crowded conditions", "PROBLEM", 43, 61]]], ["Asplin and colleagues [92] focused this discussion on the larger supply and demand mismatches in the health care system.", [["demand mismatches", "OBSERVATION", 76, 93]]], ["They point out that ED crowding is the end result of a cascade of system characteristics that adversely affect the supply of and demand for emergency care.", [["ED crowding", "PROBLEM", 20, 31], ["emergency care", "TREATMENT", 140, 154]]], ["To find solutions, the entire delivery system must be examined using reliable methods to describe, measure, and monitor system capacity.", [["the entire delivery system", "TREATMENT", 19, 45]]], ["Therefore, they have proposed a conceptual framework to explain ED crowding that includes input, throughput, and output factors [92] .", [["ED crowding", "PROBLEM", 64, 75], ["output factors", "TEST", 113, 127]]], ["Use of such a conceptual model can highlight specific areas of study to identify the places where the system is failing.Future research on ED crowdingThe importance of methodological rigor in EM public health research Future EM public health research requires a higher degree of methodological rigor.", [["ED crowding", "TEST", 139, 150], ["methodological rigor", "PROBLEM", 168, 188], ["methodological rigor", "PROBLEM", 279, 299]]], ["For example, health promotion research should go beyond prevalence studies to design new interventions, follow morbidity and mortality, and document the health consequences of lack of access to preventive care.", [["prevalence studies", "TEST", 56, 74], ["new interventions", "TREATMENT", 85, 102], ["preventive care", "TREATMENT", 194, 209]]], ["However, descriptive studies of previously undescribed phenomena will continue to be important.", [["descriptive studies", "TEST", 9, 28], ["previously undescribed phenomena", "PROBLEM", 32, 64]]], ["With its wealth of patient stories, EM lends itself well to rigorous qualitative researchda methodological approach that has yet to be adequately developed in this setting.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26]]], ["Studies of interventions should ideally use randomized designs and minimize selection bias by using systematic rather than convenience samples.", [["interventions", "TREATMENT", 11, 24], ["randomized designs", "TREATMENT", 44, 62], ["selection bias", "TEST", 76, 90], ["convenience samples", "TEST", 123, 142]]], ["When experimental design and randomization are not feasible, the analysis for comorbidity and confounders should be controlled so that our nonexperimental studies have more validity.", [["randomization", "TREATMENT", 29, 42], ["the analysis", "TEST", 61, 73], ["comorbidity", "PROBLEM", 78, 89], ["our nonexperimental studies", "TEST", 135, 162]]], ["For example, the disciplines of economics, sociology, and anthropology can provide new perspectives on the culture of emergency medicine and the communities we serve.", [["the culture", "TEST", 103, 114], ["emergency medicine", "TREATMENT", 118, 136]]], ["A greater depth of understanding of the problems we are seeing is needed.", [["the problems", "PROBLEM", 36, 48], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["depth", "OBSERVATION_MODIFIER", 10, 15]]], ["Geographic Information Systems analysis along with census measures of poverty and race can help identify and provide a picture of health disparities.Future research on ED crowdingLast, the focus of EM public health research needs to reach out beyond the clinic walls to the surrounding neighborhoods and community members.", [["Geographic Information Systems analysis", "TEST", 0, 39]]], ["Involvement in community-based participatory research will improve the understanding of patient barriers to healthy behavior and the role that family members, religion, social support, and neighborhood factors play in health.SummaryWith more than 110 million patient visits annually, EDs can provide information on the health care needs of a diverse population and serve as a unique research laboratory for studying the functioning of the health care system.", [["patient", "ORGANISM", 88, 95], ["patient", "ORGANISM", 259, 266], ["patient", "SPECIES", 88, 95], ["patient", "SPECIES", 259, 266]]], ["Much of past EM public health research has focused on three large areas, all of which continue to have major relevance as topics of public health research: access to systems of care; the identification of the unmet medical and behavioral health needs of ED populations and the potential for meeting these needs during an ED visit; and the need for surveillance for infectious diseases, behavioral health risks, and injuries.", [["infectious diseases", "DISEASE", 365, 384], ["injuries", "DISEASE", 415, 423], ["infectious diseases", "PROBLEM", 365, 384], ["injuries", "PROBLEM", 415, 423]]], ["Fulfilling this function includes conducting rigorous research studies to monitor and ensure that the public's needs are met, as well as continuing to advocate for high-quality universal health care for all Americans.", [["conducting rigorous research studies", "TEST", 34, 70]]]], "PMC7267627": [["BackgroundThe current COVID\u201019 pandemic, caused by a novel coronavirus (SARS\u2010CoV\u20102), poses a number of dilemmas for the investigation of thrombocytopenia and the management of patients with ITP.BackgroundThis includes consideration of the advantages and disadvantages of standard therapeutic options for new or relapsed acute ITP, as well as recognition of the challenges posed to the management of ITP patients due to both bleeding and thrombotic risks seen in patients hospitalised with COVID\u201019 infection.", [["coronavirus", "DISEASE", 59, 70], ["SARS", "DISEASE", 72, 76], ["thrombocytopenia", "DISEASE", 137, 153], ["ITP", "DISEASE", 190, 193], ["ITP", "DISEASE", 326, 329], ["ITP", "DISEASE", 399, 402], ["bleeding", "DISEASE", 424, 432], ["thrombotic", "DISEASE", 437, 447], ["infection", "DISEASE", 498, 507], ["coronavirus", "ORGANISM", 59, 70], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 403, 411], ["patients", "ORGANISM", 462, 470], ["coronavirus", "SPECIES", 59, 70], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 403, 411], ["patients", "SPECIES", 462, 470], ["pandemic", "PROBLEM", 31, 39], ["a novel coronavirus", "PROBLEM", 51, 70], ["thrombocytopenia", "PROBLEM", 137, 153], ["the management", "TREATMENT", 158, 172], ["ITP", "PROBLEM", 190, 193], ["standard therapeutic options", "TREATMENT", 271, 299], ["relapsed acute ITP", "PROBLEM", 311, 329], ["the management", "TREATMENT", 381, 395], ["ITP patients", "TREATMENT", 399, 411], ["both bleeding", "PROBLEM", 419, 432], ["thrombotic risks", "PROBLEM", 437, 453], ["COVID\u201019 infection", "PROBLEM", 489, 507], ["thrombocytopenia", "OBSERVATION", 137, 153], ["ITP", "OBSERVATION", 190, 193], ["acute", "OBSERVATION_MODIFIER", 320, 325], ["ITP", "OBSERVATION", 326, 329], ["bleeding", "OBSERVATION", 424, 432], ["thrombotic", "OBSERVATION", 437, 447], ["infection", "OBSERVATION", 498, 507]]], ["Furthermore, patients are often unclear about the extent of required self\u2010isolation procedures.Recommendation ::: Thrombocytopenia and COVID\u201019", [["Thrombocytopenia", "DISEASE", 114, 130], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["self\u2010isolation procedures", "TREATMENT", 69, 94], ["Thrombocytopenia", "PROBLEM", 114, 130], ["COVID\u2010", "TEST", 135, 141]]]], "7bc58a6f36cf62a7d4e064bb18edab126936718d": [["Mice infected with the JHM strain of mouse hepatitis virus (JHMV), a neurotropic coronavirus, develop acute and chronic diseases of the central nervous system.", [["central nervous system", "ANATOMY", 136, 158], ["mouse hepatitis virus", "DISEASE", 37, 58], ["neurotropic coronavirus", "DISEASE", 69, 92], ["chronic diseases of the central nervous system", "DISEASE", 112, 158], ["Mice", "ORGANISM", 0, 4], ["JHM strain", "ORGANISM", 23, 33], ["mouse hepatitis virus", "ORGANISM", 37, 58], ["JHMV", "ORGANISM", 60, 64], ["neurotropic coronavirus", "ORGANISM", 69, 92], ["central nervous system", "ANATOMICAL_SYSTEM", 136, 158], ["Mice", "SPECIES", 0, 4], ["mouse", "SPECIES", 37, 42], ["hepatitis virus", "SPECIES", 43, 58], ["neurotropic coronavirus", "SPECIES", 69, 92], ["mouse hepatitis virus", "SPECIES", 37, 58], ["JHMV", "SPECIES", 60, 64], ["neurotropic coronavirus", "SPECIES", 69, 92], ["mouse hepatitis virus", "PROBLEM", 37, 58], ["a neurotropic coronavirus", "PROBLEM", 67, 92], ["acute and chronic diseases of the central nervous system", "PROBLEM", 102, 158], ["mouse hepatitis virus", "OBSERVATION", 37, 58], ["neurotropic coronavirus", "OBSERVATION", 69, 92], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["chronic", "OBSERVATION_MODIFIER", 112, 119], ["diseases", "OBSERVATION", 120, 128], ["central", "ANATOMY_MODIFIER", 136, 143], ["nervous system", "ANATOMY", 144, 158]]], ["The JHMV-infected mouse is most often studied as a model of chronic demyelination because it has similarities to the disease observed in humans with multiple sclerosis.", [["chronic demyelination", "DISEASE", 60, 81], ["multiple sclerosis", "DISEASE", 149, 167], ["JHMV", "GENE_OR_GENE_PRODUCT", 4, 8], ["mouse", "ORGANISM", 18, 23], ["humans", "ORGANISM", 137, 143], ["mouse", "SPECIES", 18, 23], ["humans", "SPECIES", 137, 143], ["mouse", "SPECIES", 18, 23], ["humans", "SPECIES", 137, 143], ["chronic demyelination", "PROBLEM", 60, 81], ["the disease", "PROBLEM", 113, 124], ["multiple sclerosis", "PROBLEM", 149, 167], ["infected mouse", "OBSERVATION", 9, 23], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["demyelination", "OBSERVATION", 68, 81], ["disease", "OBSERVATION", 117, 124], ["multiple", "OBSERVATION_MODIFIER", 149, 157], ["sclerosis", "OBSERVATION", 158, 167]]], ["1, 2 Myelin destruction in these animals occurs as a direct consequence of virus clearance and is largely immune-mediated because it does not occur to a significant extent in mice lacking T or B cells (lethally irradiated mice, mice with severe combined immunodeficiency, or mice lacking recombination activation enzyme gene 1", [["B cells", "ANATOMY", 193, 200], ["immunodeficiency", "DISEASE", 254, 270], ["Myelin", "GENE_OR_GENE_PRODUCT", 5, 11], ["mice", "ORGANISM", 175, 179], ["T", "CELL", 188, 189], ["B cells", "CELL", 193, 200], ["lethally irradiated mice", "ORGANISM", 202, 226], ["mice", "ORGANISM", 228, 232], ["mice", "ORGANISM", 275, 279], ["T or B cells", "CELL_TYPE", 188, 200], ["recombination activation enzyme gene 1", "DNA", 288, 326], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 222, 226], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 275, 279], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 222, 226], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 275, 279], ["2 Myelin destruction", "PROBLEM", 3, 23], ["virus clearance", "PROBLEM", 75, 90], ["severe combined immunodeficiency", "PROBLEM", 238, 270], ["Myelin", "OBSERVATION_MODIFIER", 5, 11], ["destruction", "OBSERVATION", 12, 23], ["significant", "OBSERVATION_MODIFIER", 153, 164], ["extent", "OBSERVATION_MODIFIER", 165, 171]]]], "PMC7340925": [], "b6186a1e47c78d4495e64dc98a007ecda4df554e": [["IntroductionVentilator-associated pneumonia (VAP) is the second most common cause of antibiotic use on the neonatal intensive care unit (NICU) [1] .", [["Ventilator-associated pneumonia", "DISEASE", 12, 43], ["VAP", "DISEASE", 45, 48], ["pneumonia", "PROBLEM", 34, 43], ["VAP", "PROBLEM", 45, 48], ["pneumonia", "OBSERVATION", 34, 43], ["antibiotic", "OBSERVATION", 85, 95]]], ["VAP is associated with higher incidence of bronchopulmonary dysplasia, prolonged mechanical ventilation and hospital stay [2] .IntroductionDefinition of VAP is challenging in neonates with no international consensus [3] .", [["bronchopulmonary dysplasia", "ANATOMY", 43, 69], ["VAP", "DISEASE", 0, 3], ["bronchopulmonary dysplasia", "DISEASE", 43, 69], ["VAP", "DISEASE", 153, 156], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 43, 69], ["VAP", "PROBLEM", 0, 3], ["bronchopulmonary dysplasia", "PROBLEM", 43, 69], ["prolonged mechanical ventilation", "TREATMENT", 71, 103], ["VAP", "PROBLEM", 153, 156], ["associated with", "UNCERTAINTY", 7, 22], ["higher", "OBSERVATION_MODIFIER", 23, 29], ["bronchopulmonary", "ANATOMY", 43, 59], ["dysplasia", "OBSERVATION", 60, 69], ["prolonged", "OBSERVATION_MODIFIER", 71, 80], ["mechanical ventilation", "OBSERVATION", 81, 103], ["VAP", "OBSERVATION", 153, 156]]], ["In adults, VAP is generally defined as a nosocomial lower airway infection in intubated patients with onset after more than 48 h of invasive mechanical ventilation [4] .", [["lower airway", "ANATOMY", 52, 64], ["VAP", "DISEASE", 11, 14], ["airway infection", "DISEASE", 58, 74], ["lower airway", "ORGANISM_SUBDIVISION", 52, 64], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["VAP", "PROBLEM", 11, 14], ["a nosocomial lower airway infection", "PROBLEM", 39, 74], ["invasive mechanical ventilation", "TREATMENT", 132, 163], ["VAP", "OBSERVATION", 11, 14], ["airway", "ANATOMY", 58, 64], ["infection", "OBSERVATION", 65, 74]]], ["In neonates, frequently applied definitions from Centres for Disease Control and Prevention (CDC) and European Centre for Disease Prevention and Control (ECDC) are difficult to apply mainly due to the absence of specific clinical and laboratory findings.", [["Disease Control", "TREATMENT", 61, 76], ["Disease Prevention", "TREATMENT", 122, 140]]], ["However, comparison of agreement between four diagnostic criteria showed only moderate agreement [5] .IntroductionCDC and ECDC criteria require chest X-ray changes as one of the main criteria for VAP diagnosis.", [["VAP", "DISEASE", 196, 199], ["four diagnostic criteria", "TEST", 41, 65], ["chest X-ray changes", "TEST", 144, 163], ["VAP diagnosis", "PROBLEM", 196, 209], ["chest", "ANATOMY", 144, 149], ["VAP", "OBSERVATION", 196, 199]]], ["However, interpreting radiographic changes in patients with underlying lung pathology and on mechanical ventilation can be challenging and comorbidities such as chronic lung disease (CLD) can obscure radiographic evidence of VAP [6, 7] .", [["lung", "ANATOMY", 71, 75], ["lung", "ANATOMY", 169, 173], ["chronic lung disease", "DISEASE", 161, 181], ["CLD", "DISEASE", 183, 186], ["VAP", "DISEASE", 225, 228], ["patients", "ORGANISM", 46, 54], ["lung", "ORGAN", 71, 75], ["lung", "ORGAN", 169, 173], ["patients", "SPECIES", 46, 54], ["interpreting radiographic changes", "PROBLEM", 9, 42], ["underlying lung pathology", "PROBLEM", 60, 85], ["mechanical ventilation", "TREATMENT", 93, 115], ["comorbidities", "PROBLEM", 139, 152], ["chronic lung disease (CLD", "PROBLEM", 161, 186], ["VAP", "PROBLEM", 225, 228], ["lung", "ANATOMY", 71, 75], ["pathology", "OBSERVATION", 76, 85], ["mechanical ventilation", "OBSERVATION", 93, 115], ["chronic", "OBSERVATION_MODIFIER", 161, 168], ["lung", "ANATOMY", 169, 173], ["disease", "OBSERVATION", 174, 181], ["VAP", "OBSERVATION", 225, 228]]], ["Reliability of chest X-ray interpretation has been shown to be low for neonatal VAP [5] .IntroductionLung ultrasound (LU) is increasingly used in neonates to diagnose lung pathologies [8] [9] [10] [11] .", [["chest", "ANATOMY", 15, 20], ["lung", "ANATOMY", 167, 171], ["VAP", "DISEASE", 80, 83], ["chest", "ORGAN", 15, 20], ["neonates", "ORGANISM", 146, 154], ["lung", "ORGAN", 167, 171], ["chest X-ray interpretation", "TEST", 15, 41], ["neonatal VAP", "PROBLEM", 71, 83], ["IntroductionLung ultrasound", "TEST", 89, 116], ["diagnose lung pathologies", "PROBLEM", 158, 183], ["chest", "ANATOMY", 15, 20], ["lung", "ANATOMY", 167, 171]]], ["LU has been shown to be equivalent to chest X-ray for diagnosis of respiratory distress syndrome in infants [8, 9] and is highly accurate for the diagnosis of pneumonia in children [10, 11] .", [["respiratory", "ANATOMY", 67, 78], ["respiratory distress syndrome", "DISEASE", 67, 96], ["pneumonia", "DISEASE", 159, 168], ["infants", "ORGANISM", 100, 107], ["children", "ORGANISM", 172, 180], ["infants", "SPECIES", 100, 107], ["children", "SPECIES", 172, 180], ["chest X-ray", "TEST", 38, 49], ["respiratory distress syndrome", "PROBLEM", 67, 96], ["pneumonia", "PROBLEM", 159, 168], ["chest", "ANATOMY", 38, 43], ["respiratory", "ANATOMY", 67, 78], ["distress", "OBSERVATION", 79, 87], ["pneumonia", "OBSERVATION", 159, 168]]], ["Multiparameter systematic approach for diagnosis and monitoring of VAP with clinical, laboratory, microbiological and LU data has recently been proposed in adults [12] .", [["VAP", "DISEASE", 67, 70], ["VAP", "PROBLEM", 67, 70], ["LU data", "TEST", 118, 125]]], ["However, it has never been evaluated for diagnosis of VAP in neonates, especially in preterm infants with underlying CLD.IntroductionOur aim was to define clinical, laboratory, microbiological, chest X-ray and LU characteristics of VAP in our population and propose a multiparameter score for VAP diagnosis in neonates.MethodsThis quality improvement project was part of the preimplementation phase of a bundle of care aiming at reducing the number of VAP episodes and antibiotics use in our level III NICU at the Evelina London Children's Hospital, London (UK).", [["VAP", "DISEASE", 54, 57], ["CLD", "DISEASE", 117, 120], ["VAP", "DISEASE", 232, 235], ["VAP", "DISEASE", 293, 296], ["VAP", "DISEASE", 452, 455], ["neonates", "ORGANISM", 61, 69], ["infants", "ORGANISM", 93, 100], ["neonates", "ORGANISM", 310, 318], ["infants", "SPECIES", 93, 100], ["VAP in neonates", "PROBLEM", 54, 69], ["underlying CLD", "PROBLEM", 106, 120], ["chest X-ray", "TEST", 194, 205], ["VAP", "PROBLEM", 232, 235], ["a multiparameter score", "TEST", 266, 288], ["VAP diagnosis in neonates", "PROBLEM", 293, 318], ["a bundle of care", "TREATMENT", 402, 418], ["VAP episodes", "PROBLEM", 452, 464], ["antibiotics", "TREATMENT", 469, 480], ["VAP", "OBSERVATION", 54, 57], ["CLD", "OBSERVATION", 117, 120], ["chest", "ANATOMY", 194, 199], ["VAP", "OBSERVATION", 232, 235], ["VAP episodes", "OBSERVATION", 452, 464]]], ["Infants with suspected VAP were prospectively identified between March 25, 2018 , and May 25, 2019, by the attending medical team led by the NICU consultant using the a modified version of the previously published \"NICU Lucerne\" definition [5] of ventilation for more than 48 h and new start or change of antibiotic therapy due to worsening ventilation requirements (increased FiO2 by > 20%, increased pCO 2 or ventilation demand) and at least one of the following: (i) clinical deterioration (temperature instability defined as axilla temperature of > 37.5\u00b0C or < 36.5\u00b0C that was deemed not to be due to environmental factors by the attending medical team, tachycardia, hypotension, increased frequency of episodes with bradycardias and/or desaturations), (ii) new or worsening opacity, consolidation or pleural effusion on chest X-ray, (iii) changes of tracheal secretions, (iv) abnormal laboratory parameters (C-reactive protein (CRP) > 10 mg/l, leucocytosis (white cell count > 20 \u00d7 10 9 /l) or leucopenia (white cell count < 5 \u00d7 10 9 /l)).", [["axilla", "ANATOMY", 529, 535], ["pleural", "ANATOMY", 805, 812], ["tracheal secretions", "ANATOMY", 855, 874], ["white cell", "ANATOMY", 963, 973], ["white cell", "ANATOMY", 1011, 1021], ["VAP", "DISEASE", 23, 26], ["tachycardia", "DISEASE", 658, 669], ["hypotension", "DISEASE", 671, 682], ["bradycardias", "DISEASE", 721, 733], ["desaturations", "DISEASE", 741, 754], ["opacity", "DISEASE", 779, 786], ["pleural effusion", "DISEASE", 805, 821], ["leucocytosis", "DISEASE", 949, 961], ["leucopenia", "DISEASE", 999, 1009], ["pleural", "ORGAN", 805, 812], ["tracheal secretions", "MULTI-TISSUE_STRUCTURE", 855, 874], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 913, 931], ["CRP", "GENE_OR_GENE_PRODUCT", 933, 936], ["white cell", "CELL", 963, 973], ["white cell", "CELL", 1011, 1021], ["C-reactive protein", "PROTEIN", 913, 931], ["CRP", "PROTEIN", 933, 936], ["Infants", "SPECIES", 0, 7], ["suspected VAP", "PROBLEM", 13, 26], ["ventilation", "TREATMENT", 247, 258], ["antibiotic therapy", "TREATMENT", 305, 323], ["worsening ventilation requirements", "PROBLEM", 331, 365], ["increased FiO2", "TREATMENT", 367, 381], ["increased pCO", "TREATMENT", 392, 405], ["ventilation demand", "TREATMENT", 411, 429], ["clinical deterioration (temperature instability", "PROBLEM", 470, 517], ["axilla temperature", "TEST", 529, 547], ["tachycardia", "PROBLEM", 658, 669], ["hypotension", "PROBLEM", 671, 682], ["bradycardias", "PROBLEM", 721, 733], ["desaturations", "PROBLEM", 741, 754], ["new or worsening opacity", "PROBLEM", 762, 786], ["consolidation", "PROBLEM", 788, 801], ["pleural effusion", "PROBLEM", 805, 821], ["chest X-ray", "TEST", 825, 836], ["tracheal secretions", "PROBLEM", 855, 874], ["abnormal laboratory parameters", "PROBLEM", 881, 911], ["C-reactive protein", "TEST", 913, 931], ["CRP", "TEST", 933, 936], ["leucocytosis", "PROBLEM", 949, 961], ["white cell count", "TEST", 963, 979], ["leucopenia", "PROBLEM", 999, 1009], ["white cell count", "TEST", 1011, 1027], ["VAP", "OBSERVATION", 23, 26], ["worsening", "OBSERVATION_MODIFIER", 331, 340], ["ventilation requirements", "OBSERVATION", 341, 365], ["axilla", "ANATOMY", 529, 535], ["hypotension", "OBSERVATION", 671, 682], ["new", "OBSERVATION_MODIFIER", 762, 765], ["worsening", "OBSERVATION_MODIFIER", 769, 778], ["opacity", "OBSERVATION", 779, 786], ["consolidation", "OBSERVATION", 788, 801], ["pleural", "ANATOMY", 805, 812], ["effusion", "OBSERVATION", 813, 821], ["chest", "ANATOMY", 825, 830], ["tracheal", "ANATOMY", 855, 863], ["secretions", "OBSERVATION", 864, 874], ["leucocytosis", "OBSERVATION", 949, 961], ["leucopenia", "OBSERVATION", 999, 1009]]], ["Confirmed VAP was defined according to the above criteria plus isolation of a pathogenic microorganism in the airway aspirate.MethodsDemographic, clinical, laboratory and microbiology data were collected from electronic patient records (BadgerNet\u00ae, Electronic Patient Records).", [["airway aspirate", "ANATOMY", 110, 125], ["VAP", "DISEASE", 10, 13], ["airway aspirate", "MULTI-TISSUE_STRUCTURE", 110, 125], ["patient", "ORGANISM", 220, 227], ["patient", "SPECIES", 220, 227], ["VAP", "PROBLEM", 10, 13], ["a pathogenic microorganism in the airway aspirate", "PROBLEM", 76, 125], ["microbiology data", "TEST", 171, 188], ["VAP", "OBSERVATION", 10, 13], ["pathogenic", "OBSERVATION_MODIFIER", 78, 88], ["microorganism", "OBSERVATION", 89, 102], ["airway", "ANATOMY", 110, 116], ["aspirate", "OBSERVATION", 117, 125]]], ["Demographic data were collected on gestational age at birth and corrected age at VAP diagnosis, birth weight and actual weight.", [["VAP", "DISEASE", 81, 84], ["Demographic data", "TEST", 0, 16], ["VAP diagnosis", "TEST", 81, 94], ["birth weight", "TEST", 96, 108], ["actual weight", "TEST", 113, 126]]], ["Clinical data included type of and reason for respiratory support, presence of respiratory deterioration, temperature instability within 24 h of VAP diagnosis and change in the amount and/or characteristics of airway secretions as recorded in the medical notes.", [["respiratory", "ANATOMY", 46, 57], ["respiratory", "ANATOMY", 79, 90], ["airway secretions", "ANATOMY", 210, 227], ["respiratory deterioration", "DISEASE", 79, 104], ["VAP", "DISEASE", 145, 148], ["airway secretions", "MULTI-TISSUE_STRUCTURE", 210, 227], ["Clinical data", "TEST", 0, 13], ["respiratory support", "TREATMENT", 46, 65], ["respiratory deterioration", "PROBLEM", 79, 104], ["temperature instability", "PROBLEM", 106, 129], ["VAP diagnosis", "TEST", 145, 158], ["change in the amount", "PROBLEM", 163, 183], ["airway secretions", "PROBLEM", 210, 227], ["respiratory deterioration", "OBSERVATION", 79, 104], ["amount", "OBSERVATION_MODIFIER", 177, 183], ["airway", "ANATOMY", 210, 216], ["secretions", "OBSERVATION", 217, 227]]], ["Clinical data on risk factors known to be associated with VAP were also collected including number of intubation episodes, length of respiratory support with positive pressure ventilation and number of antibiotic courses.", [["respiratory", "ANATOMY", 133, 144], ["VAP", "DISEASE", 58, 61], ["risk factors", "PROBLEM", 17, 29], ["VAP", "PROBLEM", 58, 61], ["intubation episodes", "TREATMENT", 102, 121], ["respiratory support", "TREATMENT", 133, 152], ["positive pressure ventilation", "TREATMENT", 158, 187], ["antibiotic courses", "TREATMENT", 202, 220], ["pressure ventilation", "OBSERVATION", 167, 187]]], ["Laboratory data included CRP and white cell count at the time of VAP diagnosis and within the next 48 h.", [["white cell", "ANATOMY", 33, 43], ["VAP", "DISEASE", 65, 68], ["CRP", "GENE_OR_GENE_PRODUCT", 25, 28], ["white cell", "CELL", 33, 43], ["CRP", "PROTEIN", 25, 28], ["Laboratory data", "TEST", 0, 15], ["CRP", "TEST", 25, 28], ["white cell count", "TEST", 33, 49], ["VAP diagnosis", "TEST", 65, 78], ["white cell", "OBSERVATION_MODIFIER", 33, 43]]], ["We collected semi-quantitative microbiology results and data on culture and sensitivity profile of pathogens that grew in the airway secretions.MethodsWe also applied the definition of Paediatric Ventilator-Associated Events (Ped-VAE), including Ventilator-Associated Condition (Ped-VAC), Infectious VAC (Ped-IVAC) and Possible Ventilator-Associated Pneumonia (Ped-PVAP) [13] to all cases to assess whether our definition for neonatal VAP were consistent with Ped-VAE, Ped-VAC, Ped-IVAC and/or Ped-PVAP.MethodsChest X-rays acquired as part of routine clinical care and stored on the Patient Archiving and Communication System were reported by the attending consultant radiologist.", [["airway secretions", "ANATOMY", 126, 143], ["Pneumonia", "DISEASE", 350, 359], ["VAP", "DISEASE", 435, 438], ["airway secretions", "MULTI-TISSUE_STRUCTURE", 126, 143], ["culture", "TEST", 64, 71], ["sensitivity profile", "TEST", 76, 95], ["pathogens", "PROBLEM", 99, 108], ["the airway secretions", "PROBLEM", 122, 143], ["MethodsWe", "TREATMENT", 144, 153], ["Paediatric Ventilator", "TREATMENT", 185, 206], ["Ventilator", "TREATMENT", 246, 256], ["Associated Condition", "PROBLEM", 257, 277], ["Ped-VAC)", "TREATMENT", 279, 287], ["Infectious VAC (Ped-IVAC)", "TREATMENT", 289, 314], ["Ventilator", "TREATMENT", 328, 338], ["Pneumonia", "PROBLEM", 350, 359], ["neonatal VAP", "PROBLEM", 426, 438], ["Ped-VAE", "PROBLEM", 460, 467], ["Ped-VAC", "TREATMENT", 469, 476], ["Ped-IVAC", "TREATMENT", 478, 486], ["Ped-PVAP", "TREATMENT", 494, 502], ["MethodsChest X-rays", "TEST", 503, 522], ["airway", "ANATOMY", 126, 132], ["secretions", "OBSERVATION", 133, 143], ["Infectious VAC", "OBSERVATION", 289, 303], ["Possible", "UNCERTAINTY", 319, 327], ["Pneumonia", "OBSERVATION", 350, 359], ["Chest", "ANATOMY", 510, 515]]], ["Reports were retrospectively reviewed by a neonatal consultant (VMP) to determine whether based on the CDC, ECDC, Lucerne and Dutch NICU definitions [14] of VAP, the following criteria were met: new emergence or worsening of consolidation, infiltration, ple ur al e f f us io n o r pre s enc e o f cav i t at i on or pneumatocele.", [["VAP", "DISEASE", 157, 160], ["VAP", "PROBLEM", 157, 160], ["consolidation", "PROBLEM", 225, 238], ["infiltration", "PROBLEM", 240, 252], ["pneumatocele", "PROBLEM", 317, 329], ["new", "OBSERVATION_MODIFIER", 195, 198], ["worsening", "OBSERVATION_MODIFIER", 212, 221], ["consolidation", "OBSERVATION", 225, 238], ["infiltration", "OBSERVATION", 240, 252], ["pneumatocele", "OBSERVATION", 317, 329]]], ["Using the diagnosis on the radiological report, episodes were dichotomized based on whether the chest X-ray report was suggestive of VAP.MethodsAdditionally, LU scans were done within 24 h of VAP diagnosis as part of routine clinical care.", [["VAP", "DISEASE", 133, 136], ["VAP", "DISEASE", 192, 195], ["episodes", "PROBLEM", 48, 56], ["the chest X-ray", "TEST", 92, 107], ["VAP", "PROBLEM", 133, 136], ["LU scans", "TEST", 158, 166], ["VAP diagnosis", "TEST", 192, 205], ["routine clinical care", "TREATMENT", 217, 238], ["chest", "ANATOMY", 96, 101], ["suggestive of", "UNCERTAINTY", 119, 132], ["VAP", "OBSERVATION", 133, 136]]], ["LU scans were performed by trained members of the attending neonatal medical team using a GE Logiqe ultrasound machine (GE Healthcare\u00ae) with a L10-22 linear probe.", [["L10-22 linear probe", "DNA", 143, 162], ["LU scans", "TEST", 0, 8], ["a GE Logiqe ultrasound machine", "TREATMENT", 88, 118], ["a L10-22 linear probe", "TREATMENT", 141, 162]]], ["The probe was held perpendicular to the ribs.", [["ribs", "ANATOMY", 40, 44], ["ribs", "ORGAN", 40, 44], ["The probe", "TREATMENT", 0, 9], ["ribs", "ANATOMY", 40, 44]]], ["For each hemithorax, three areas were defined by the anterior and posterior axillary lines (anterior, axillary and posterior).", [["hemithorax", "ANATOMY", 9, 19], ["anterior", "ANATOMY", 53, 61], ["axillary lines", "ANATOMY", 76, 90], ["anterior", "ANATOMY", 92, 100], ["axillary", "ANATOMY", 102, 110], ["hemithorax", "ORGAN", 9, 19], ["anterior", "MULTI-TISSUE_STRUCTURE", 53, 61], ["anterior", "MULTI-TISSUE_STRUCTURE", 92, 100], ["axillary", "MULTI-TISSUE_STRUCTURE", 102, 110], ["each hemithorax", "PROBLEM", 4, 19], ["hemithorax", "ANATOMY", 9, 19], ["three", "OBSERVATION_MODIFIER", 21, 26], ["areas", "OBSERVATION_MODIFIER", 27, 32], ["anterior", "ANATOMY_MODIFIER", 53, 61], ["posterior", "ANATOMY_MODIFIER", 66, 75], ["axillary", "ANATOMY", 76, 84], ["lines", "ANATOMY_MODIFIER", 85, 90], ["anterior", "ANATOMY_MODIFIER", 92, 100], ["axillary", "ANATOMY", 102, 110], ["posterior", "ANATOMY_MODIFIER", 115, 124]]], ["Anterior and posterior areas were divided into superior and inferior regions.", [["Anterior", "ANATOMY", 0, 8], ["posterior areas", "ANATOMY", 13, 28], ["superior", "ANATOMY", 47, 55], ["inferior regions", "ANATOMY", 60, 76], ["Anterior", "MULTI-TISSUE_STRUCTURE", 0, 8], ["Anterior and posterior areas", "PROBLEM", 0, 28], ["posterior", "ANATOMY_MODIFIER", 13, 22], ["superior", "ANATOMY_MODIFIER", 47, 55], ["inferior", "ANATOMY_MODIFIER", 60, 68], ["regions", "ANATOMY_MODIFIER", 69, 76]]], ["At least nine standard views were acquired including right anterior apex and base, right axilla, right posterior apex and base, left anterior apex, left axilla, left posterior apex and base.", [["right anterior apex", "ANATOMY", 53, 72], ["base", "ANATOMY", 77, 81], ["right axilla", "ANATOMY", 83, 95], ["right posterior apex", "ANATOMY", 97, 117], ["base", "ANATOMY", 122, 126], ["left anterior apex", "ANATOMY", 128, 146], ["left axilla", "ANATOMY", 148, 159], ["left posterior apex", "ANATOMY", 161, 180], ["anterior apex", "MULTI-TISSUE_STRUCTURE", 59, 72], ["axilla", "MULTI-TISSUE_STRUCTURE", 89, 95], ["posterior apex", "MULTI-TISSUE_STRUCTURE", 103, 117], ["anterior apex", "MULTI-TISSUE_STRUCTURE", 133, 146], ["axilla", "MULTI-TISSUE_STRUCTURE", 153, 159], ["posterior apex", "MULTI-TISSUE_STRUCTURE", 166, 180], ["nine standard views", "TEST", 9, 28], ["right", "ANATOMY_MODIFIER", 53, 58], ["anterior", "ANATOMY_MODIFIER", 59, 67], ["apex", "ANATOMY_MODIFIER", 68, 72], ["base", "ANATOMY_MODIFIER", 77, 81], ["right", "ANATOMY_MODIFIER", 83, 88], ["axilla", "ANATOMY", 89, 95], ["right", "ANATOMY_MODIFIER", 97, 102], ["posterior", "ANATOMY_MODIFIER", 103, 112], ["apex", "ANATOMY_MODIFIER", 113, 117], ["base", "ANATOMY_MODIFIER", 122, 126], ["left", "ANATOMY_MODIFIER", 128, 132], ["anterior", "ANATOMY_MODIFIER", 133, 141], ["apex", "ANATOMY_MODIFIER", 142, 146], ["left", "ANATOMY_MODIFIER", 148, 152], ["axilla", "ANATOMY", 153, 159], ["left", "ANATOMY_MODIFIER", 161, 165], ["posterior", "ANATOMY_MODIFIER", 166, 175], ["apex", "ANATOMY_MODIFIER", 176, 180], ["base", "ANATOMY_MODIFIER", 185, 189]]], ["A short clip was recorded in each view, downloaded anonymised and reviewed retrospectively offline by two neonatal consultants, NT and VMP with 1.5 and 6 years of experience respectively in performing and interpreting LU in neonates.", [["neonates", "ORGANISM", 224, 232], ["A short clip", "TREATMENT", 0, 12], ["short", "OBSERVATION_MODIFIER", 2, 7]]], ["In each view, the following parameters were assessed: aspect of the pleural line (presence of pleural sliding, thickness and regularity of the pleural line), presence of A-lines and B-lines, presence of consolidations and their characteristics (presence of static and/or dynamic air bronchograms, size and location in terms of translobar/non-translobar) and presence of pleural effusion.", [["pleural line", "ANATOMY", 68, 80], ["pleural", "ANATOMY", 94, 101], ["pleural line", "ANATOMY", 143, 155], ["B-lines", "ANATOMY", 182, 189], ["translobar", "ANATOMY", 327, 337], ["translobar", "ANATOMY", 342, 352], ["pleural effusion", "ANATOMY", 370, 386], ["pleural effusion", "DISEASE", 370, 386], ["pleural line", "CELL", 68, 80], ["pleural", "MULTI-TISSUE_STRUCTURE", 94, 101], ["B-lines", "CELL", 182, 189], ["pleural effusion", "CANCER", 370, 386], ["B-lines", "CELL_LINE", 182, 189], ["the pleural line", "TREATMENT", 64, 80], ["pleural sliding, thickness and regularity of the pleural line", "TREATMENT", 94, 155], ["A-lines", "TREATMENT", 170, 177], ["B-lines", "TREATMENT", 182, 189], ["consolidations", "PROBLEM", 203, 217], ["static and/or dynamic air bronchograms", "PROBLEM", 257, 295], ["translobar/non-translobar)", "PROBLEM", 327, 353], ["pleural effusion", "PROBLEM", 370, 386], ["pleural", "ANATOMY", 68, 75], ["line", "OBSERVATION", 76, 80], ["pleural", "ANATOMY", 94, 101], ["sliding", "OBSERVATION", 102, 109], ["regularity", "OBSERVATION_MODIFIER", 125, 135], ["pleural", "ANATOMY", 143, 150], ["line", "OBSERVATION", 151, 155], ["B", "OBSERVATION_MODIFIER", 182, 183], ["-lines", "OBSERVATION", 183, 189], ["consolidations", "OBSERVATION", 203, 217], ["static", "OBSERVATION_MODIFIER", 257, 263], ["air bronchograms", "OBSERVATION", 279, 295], ["size", "OBSERVATION_MODIFIER", 297, 301], ["non-translobar", "OBSERVATION_MODIFIER", 338, 352], ["pleural", "ANATOMY", 370, 377], ["effusion", "OBSERVATION", 378, 386]]], ["Translobar consolidation was defined as tissue-like image of the lung reflecting a loss of aeration with a regular inner limit (opposed visceral pleura).", [["tissue", "ANATOMY", 40, 46], ["lung", "ANATOMY", 65, 69], ["visceral pleura", "ANATOMY", 136, 151], ["tissue", "TISSUE", 40, 46], ["lung", "ORGAN", 65, 69], ["visceral pleura", "MULTI-TISSUE_STRUCTURE", 136, 151], ["Translobar consolidation", "PROBLEM", 0, 24], ["a loss of aeration", "PROBLEM", 81, 99], ["consolidation", "OBSERVATION", 11, 24], ["tissue", "OBSERVATION_MODIFIER", 40, 46], ["lung", "ANATOMY", 65, 69], ["loss", "OBSERVATION_MODIFIER", 83, 87], ["aeration", "OBSERVATION_MODIFIER", 91, 99], ["regular", "OBSERVATION_MODIFIER", 107, 114], ["inner limit", "OBSERVATION_MODIFIER", 115, 126], ["visceral", "ANATOMY_MODIFIER", 136, 144], ["pleura", "ANATOMY", 145, 151]]], ["Non-translobar consolidation was defined as a tissue-like image limited by irregular \"shredded\" border as the non-aerated lung is in continuity with the aerated lung.", [["tissue", "ANATOMY", 46, 52], ["lung", "ANATOMY", 122, 126], ["lung", "ANATOMY", 161, 165], ["tissue", "TISSUE", 46, 52], ["lung", "ORGAN", 122, 126], ["lung", "ORGAN", 161, 165], ["Non-translobar consolidation", "PROBLEM", 0, 28], ["irregular \"shredded\" border", "PROBLEM", 75, 102], ["consolidation", "OBSERVATION", 15, 28], ["irregular", "OBSERVATION_MODIFIER", 75, 84], ["\"", "OBSERVATION_MODIFIER", 85, 86], ["shredded", "OBSERVATION", 86, 94], ["border", "ANATOMY_MODIFIER", 96, 102], ["non-aerated", "ANATOMY_MODIFIER", 110, 121], ["lung", "ANATOMY", 122, 126], ["aerated", "OBSERVATION", 153, 160], ["lung", "ANATOMY", 161, 165]]], ["When a consolidation was found, in some patients, it was assessed whether the consolidated area could be re-opened if indicated and possible by patient positioning and/or by increasing the mean airway pressure.", [["airway", "ANATOMY", 194, 200], ["patients", "ORGANISM", 40, 48], ["patient", "ORGANISM", 144, 151], ["airway", "MULTI-TISSUE_STRUCTURE", 194, 200], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 144, 151], ["a consolidation", "PROBLEM", 5, 20], ["the mean airway pressure", "TEST", 185, 209], ["consolidation", "OBSERVATION", 7, 20], ["consolidated", "OBSERVATION", 78, 90], ["mean airway pressure", "OBSERVATION", 189, 209]]], ["For positioning, the consolidated area was positioned upward.", [["consolidated", "OBSERVATION_MODIFIER", 21, 33], ["area", "OBSERVATION_MODIFIER", 34, 38], ["upward", "OBSERVATION_MODIFIER", 54, 60]]], ["For example, if a large consolidation was found in the posterior views, the patient was positioned prone for at least 1 h and the LU was repeated subsequently to assess re-opening of the consolidated area.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["a large consolidation", "PROBLEM", 16, 37], ["large", "OBSERVATION_MODIFIER", 18, 23], ["consolidation", "OBSERVATION", 24, 37], ["posterior", "ANATOMY_MODIFIER", 55, 64], ["consolidated", "OBSERVATION", 187, 199]]], ["Increasing mean airway pressure was achieved by stepwise increments of the positive end expiratory pressure and the peak inspiratory pressure, with close pressurevolume curve monitoring on the ventilator to detect overdistension [15] .MethodsBased on pathophysiological significance clinical, radiology and microbiology parameters [12] were identified and a scoring system for VAP diagnosis (multiparameter VAP score) was built post-hoc (Table 1) .", [["airway", "ANATOMY", 16, 22], ["overdistension", "DISEASE", 214, 228], ["VAP", "DISEASE", 377, 380], ["airway", "MULTI-TISSUE_STRUCTURE", 16, 22], ["Increasing mean airway pressure", "TEST", 0, 31], ["the positive end expiratory pressure", "TEST", 71, 107], ["the peak inspiratory pressure", "TEST", 112, 141], ["close pressurevolume curve monitoring", "TEST", 148, 185], ["the ventilator", "TREATMENT", 189, 203], ["overdistension", "PROBLEM", 214, 228], ["VAP diagnosis", "TEST", 377, 390], ["multiparameter VAP score", "TEST", 392, 416], ["mean airway pressure", "OBSERVATION", 11, 31], ["expiratory pressure", "OBSERVATION", 88, 107], ["inspiratory pressure", "OBSERVATION", 121, 141], ["overdistension", "OBSERVATION", 214, 228]]], ["Clinical signs included respiratory deterioration, temperature instability and changes to airway secretions.", [["respiratory", "ANATOMY", 24, 35], ["airway", "ANATOMY", 90, 96], ["respiratory deterioration", "DISEASE", 24, 49], ["Clinical signs", "TEST", 0, 14], ["respiratory deterioration", "PROBLEM", 24, 49], ["temperature instability", "PROBLEM", 51, 74], ["changes to airway secretions", "PROBLEM", 79, 107], ["respiratory deterioration", "OBSERVATION", 24, 49], ["airway", "ANATOMY", 90, 96], ["secretions", "OBSERVATION", 97, 107]]], ["In terms of radiological signs, for the purposes of scoring, on LU consolidations (> 0.5 cm depth), areas with linear/ arborescent dynamic bronchograms and pleural effusion were included.", [["pleural effusion", "ANATOMY", 156, 172], ["pleural effusion", "DISEASE", 156, 172], ["pleural effusion", "CANCER", 156, 172], ["radiological signs", "TEST", 12, 30], ["LU consolidations", "PROBLEM", 64, 81], ["linear/ arborescent dynamic bronchograms", "PROBLEM", 111, 151], ["pleural effusion", "PROBLEM", 156, 172], ["consolidations", "OBSERVATION", 67, 81], ["linear", "OBSERVATION_MODIFIER", 111, 117], ["arborescent", "OBSERVATION_MODIFIER", 119, 130], ["dynamic", "OBSERVATION_MODIFIER", 131, 138], ["bronchograms", "OBSERVATION", 139, 151], ["pleural", "ANATOMY", 156, 163], ["effusion", "OBSERVATION", 164, 172]]], ["The VAP score was calculated on Day 1 when antibiotics were started or changed and on Day 3 when microbiology result was available and antibiotic therapy was reviewed.", [["VAP", "DISEASE", 4, 7], ["The VAP score", "TEST", 0, 13], ["antibiotics", "TREATMENT", 43, 54], ["antibiotic therapy", "TREATMENT", 135, 153], ["VAP", "OBSERVATION", 4, 7]]], ["To assess the clinical value of LU, the multiparameter VAP score was computed with and without LU findings on Day 1 and Day 3.MethodsA group of infants who received positive pressure respiratory support for at least 48 h and underwent LU scanning because of respiratory deterioration but did not have a VAP diagnosis was identified.", [["respiratory", "ANATOMY", 258, 269], ["respiratory deterioration", "DISEASE", 258, 283], ["VAP", "DISEASE", 303, 306], ["infants", "ORGANISM", 144, 151], ["infants", "SPECIES", 144, 151], ["the multiparameter VAP score", "TEST", 36, 64], ["positive pressure respiratory support", "TREATMENT", 165, 202], ["LU scanning", "TEST", 235, 246], ["respiratory deterioration", "PROBLEM", 258, 283], ["a VAP diagnosis", "PROBLEM", 301, 316], ["respiratory support", "OBSERVATION", 183, 202], ["respiratory", "ANATOMY", 258, 269], ["deterioration", "OBSERVATION", 270, 283], ["VAP", "OBSERVATION", 303, 306]]], ["Data were similarly collected and VAP scores calculated.MethodsData was also collected on presence of chronic pulmonary insufficiency of prematurity (CPIP), defined as respiratory morbidity after preterm birth during the birth hospitalization and through infancy and childhood [16] , and CLD, defined according to National Institute of Health Consensus definition [17] and death.Statistical analysisStatistical analyses were performed with IBM SPSS statistics 25.0 (SPSS Inc., Chicago, IL, USA).", [["pulmonary", "ANATOMY", 110, 119], ["respiratory", "ANATOMY", 168, 179], ["chronic pulmonary insufficiency of prematurity", "DISEASE", 102, 148], ["CPIP", "DISEASE", 150, 154], ["preterm birth", "DISEASE", 196, 209], ["CLD", "DISEASE", 288, 291], ["death", "DISEASE", 373, 378], ["pulmonary", "ORGAN", 110, 119], ["VAP scores", "TEST", 34, 44], ["MethodsData", "TEST", 56, 67], ["chronic pulmonary insufficiency", "PROBLEM", 102, 133], ["prematurity", "PROBLEM", 137, 148], ["CLD", "PROBLEM", 288, 291], ["Statistical analysisStatistical analyses", "TEST", 379, 419], ["IBM SPSS statistics", "TEST", 440, 459], ["SPSS Inc.", "TEST", 466, 475], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["pulmonary", "ANATOMY", 110, 119], ["insufficiency", "OBSERVATION", 120, 133], ["prematurity", "OBSERVATION", 137, 148]]], ["Distribution of continuous variables was determined.", [["continuous variables", "OBSERVATION", 16, 36]]], ["Independent samples t-test was used for comparison of normally distributed variables and non-parametric tests for independent samples for variables where the distribution significantly deviated from normal.", [["Independent samples t-test", "TEST", 0, 26], ["normally distributed variables", "PROBLEM", 54, 84], ["non-parametric tests", "TEST", 89, 109], ["independent samples", "TEST", 114, 133], ["normal", "OBSERVATION", 199, 205]]], ["Categorical variables were compared with Chi-square test.", [["Categorical variables", "TEST", 0, 21], ["Chi-square test", "TEST", 41, 56]]], ["Continuous variables were reported as mean (standard deviation) or median (interquartile range) if normally or nonnormally distributed, respectively.", [["nonnormally", "OBSERVATION_MODIFIER", 111, 122], ["distributed", "OBSERVATION_MODIFIER", 123, 134]]], ["Categorical variables were reported as number (%).", [["Categorical variables", "TEST", 0, 21]]], ["Statistical significance was assumed at p < 0.05.Statistical analysisPredictive values with 95% confidence intervals (CI) were calculated from 2 \u00d7 2 contingency tables, and area under the receiver operating characteristic curve (AUC) was determined.", [["Statistical analysisPredictive values", "TEST", 49, 86], ["CI", "TEST", 118, 120], ["AUC", "TEST", 229, 232]]], ["Multiple AUCs were computed to assess the predictive value of different approaches: clinical information only on Day 1, clinical information on Day 1 and chest X-ray, clinical information on Day 1 and LU, clinical information on Day 1 and microbiology result on Day 3 and finally clinical information on Day 1, microbiology result on Day 3 and LU.", [["Multiple AUCs", "TEST", 0, 13], ["chest X-ray", "TEST", 154, 165], ["chest", "ANATOMY", 154, 159]]], ["MedCalc was used to compute Youden's J index for each AUC and to compare the AUCs between them [18] .Statistical analysisIncidence of VAP was established over 1000 ventilator days.", [["VAP", "DISEASE", 134, 137], ["MedCalc", "TREATMENT", 0, 7], ["each AUC", "TEST", 49, 57], ["Statistical analysis", "TEST", 101, 121], ["VAP", "PROBLEM", 134, 137], ["VAP", "OBSERVATION", 134, 137]]], ["The number of ventilator days was determined during the study period using data recorded in BadgerNet\u00ae Electronic Patient Records.Statistical analysisInterclass correlation coefficient was calculated using SPSS to establish concordance between the two experts who reviewed the LU.Patients' characteristics and outcomeWe identified 54 VAP episodes in 28 infants.", [["VAP", "DISEASE", 334, 337], ["Patients", "ORGANISM", 280, 288], ["infants", "ORGANISM", 353, 360], ["Patients", "SPECIES", 280, 288], ["infants", "SPECIES", 353, 360], ["Statistical analysis", "TEST", 130, 150], ["54 VAP episodes", "PROBLEM", 331, 346], ["ventilator days", "OBSERVATION", 14, 29]]], ["Fourteen infants had multiple VAP episodes and the mean number of relapses was 1.5 (standard deviation 1.6).", [["VAP", "DISEASE", 30, 33], ["infants", "ORGANISM", 9, 16], ["infants", "SPECIES", 9, 16], ["multiple VAP episodes", "PROBLEM", 21, 42], ["relapses", "PROBLEM", 66, 74], ["multiple", "OBSERVATION_MODIFIER", 21, 29], ["VAP", "OBSERVATION", 30, 33]]], ["Incidence of VAP was 10.47/1000 ventilator days.", [["VAP", "DISEASE", 13, 16], ["VAP", "PROBLEM", 13, 16], ["VAP", "OBSERVATION", 13, 16]]], ["LU was not done in 20 episodes and chest X-ray in three.", [["chest X-ray", "TEST", 35, 46], ["chest", "ANATOMY", 35, 40]]], ["Therefore, we report 31 VAP episodes in 21 patients, who underwent LU and chest X-ray as part of their routine clinical care.", [["VAP", "DISEASE", 24, 27], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["31 VAP episodes", "PROBLEM", 21, 36], ["LU and chest X-ray", "TEST", 67, 85], ["their routine clinical care", "TREATMENT", 97, 124], ["chest", "ANATOMY", 74, 79]]], ["The clinical characteristics were not significantly different between the episodes that were excluded and those that are included in the analysis.", [["the analysis", "TEST", 133, 145], ["significantly different", "OBSERVATION_MODIFIER", 38, 61]]], ["Nine episodes of respiratory deterioration that were deemed not to be due to VAP were identified in 8 patients.", [["respiratory", "ANATOMY", 17, 28], ["respiratory deterioration", "DISEASE", 17, 42], ["VAP", "DISEASE", 77, 80], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["respiratory deterioration", "PROBLEM", 17, 42], ["VAP", "PROBLEM", 77, 80], ["respiratory deterioration", "OBSERVATION", 17, 42], ["VAP", "OBSERVATION", 77, 80]]], ["However, in three episodes no chest X-ray was done.", [["chest X-ray", "TEST", 30, 41], ["chest", "ANATOMY", 30, 35]]], ["Therefore, six episodes of respiratory deterioration in five patients were included that were not considered VAP.", [["respiratory", "ANATOMY", 27, 38], ["respiratory deterioration", "DISEASE", 27, 52], ["VAP", "DISEASE", 109, 112], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["respiratory deterioration", "PROBLEM", 27, 52], ["VAP", "PROBLEM", 109, 112], ["respiratory deterioration", "OBSERVATION", 27, 52]]], ["Flow diagram of the episodes is shown in Fig. 1 .Patients' characteristics and outcomeIn the VAP group, infants were on high frequency oscillation ventilation (HFOV) in 11 episodes.", [["VAP", "DISEASE", 93, 96], ["Patients", "ORGANISM", 49, 57], ["infants", "ORGANISM", 104, 111], ["Patients", "SPECIES", 49, 57], ["infants", "SPECIES", 104, 111], ["Flow diagram", "TEST", 0, 12], ["the episodes", "PROBLEM", 16, 28], ["high frequency oscillation ventilation", "TREATMENT", 120, 158]]], ["In five of these cases, the respiratory support was escalated from conventional assist control volume guarantee to HFOV at the time of respiratory deterioration.", [["respiratory", "ANATOMY", 28, 39], ["respiratory", "ANATOMY", 135, 146], ["respiratory deterioration", "DISEASE", 135, 160], ["the respiratory support", "TREATMENT", 24, 47], ["conventional assist control volume guarantee", "TREATMENT", 67, 111], ["HFOV", "TREATMENT", 115, 119], ["respiratory deterioration", "PROBLEM", 135, 160], ["respiratory support", "OBSERVATION", 28, 47], ["respiratory deterioration", "OBSERVATION", 135, 160]]], ["In one case, the infant was changed from HFOV to conventional ventilation.", [["infant", "ORGANISM", 17, 23], ["infant", "SPECIES", 17, 23], ["HFOV", "TREATMENT", 41, 45], ["conventional ventilation", "TREATMENT", 49, 73]]], ["In 18 cases, the infants were on conventional assist control volume guarantee ventilation.", [["infants", "ORGANISM", 17, 24], ["infants", "SPECIES", 17, 24], ["conventional assist control volume guarantee ventilation", "TREATMENT", 33, 89]]], ["In two episodes, the patients were on synchronized nasal intermittent positive pressure ventilation.", [["nasal", "ANATOMY", 51, 56], ["patients", "ORGANISM", 21, 29], ["nasal", "ORGANISM_SUBDIVISION", 51, 56], ["patients", "SPECIES", 21, 29], ["synchronized nasal intermittent positive pressure ventilation", "TREATMENT", 38, 99], ["positive", "OBSERVATION", 70, 78], ["pressure ventilation", "OBSERVATION", 79, 99]]], ["Both of them were intubated at the time of respiratory deterioration.", [["respiratory", "ANATOMY", 43, 54], ["respiratory deterioration", "DISEASE", 43, 68], ["intubated", "TREATMENT", 18, 27], ["respiratory deterioration", "PROBLEM", 43, 68], ["respiratory", "ANATOMY", 43, 54], ["deterioration", "OBSERVATION", 55, 68]]], ["In the no-VAP group, the patients were on conventional ventilation in three episodes and on HFOV in two episodes.", [["no-VAP", "CANCER", 7, 13], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["conventional ventilation", "TREATMENT", 42, 66], ["HFOV", "TREATMENT", 92, 96]]], ["In one episode, the patient was on synchronized nasal intermittent positive pressure ventilation.Patients' characteristics and outcomeMain reasons for mechanical ventilation were respiratory distress syndrome (n = 8) [19] , neonatal ARDS (n = 4 pulmonary haemorrhages, n = 1 congenital pneumonia n = 1 necrotizing enterocolitis) [20] , sepsis-induced respiratory failure (n = 5) and pulmonary hypoplasia associated with oligohydramnios sequence (n = 2).", [["nasal", "ANATOMY", 48, 53], ["respiratory", "ANATOMY", 179, 190], ["pulmonary", "ANATOMY", 245, 254], ["respiratory", "ANATOMY", 351, 362], ["pulmonary", "ANATOMY", 383, 392], ["respiratory distress syndrome", "DISEASE", 179, 208], ["ARDS", "DISEASE", 233, 237], ["pulmonary haemorrhages", "DISEASE", 245, 267], ["congenital pneumonia", "DISEASE", 275, 295], ["necrotizing enterocolitis", "DISEASE", 302, 327], ["sepsis", "DISEASE", 336, 342], ["respiratory failure", "DISEASE", 351, 370], ["pulmonary hypoplasia", "DISEASE", 383, 403], ["oligohydramnios", "DISEASE", 420, 435], ["patient", "ORGANISM", 20, 27], ["nasal", "ORGANISM_SUBDIVISION", 48, 53], ["Patients", "ORGANISM", 97, 105], ["pulmonary", "ORGAN", 245, 254], ["pulmonary", "ORGAN", 383, 392], ["patient", "SPECIES", 20, 27], ["Patients", "SPECIES", 97, 105], ["synchronized nasal intermittent positive pressure ventilation", "TREATMENT", 35, 96], ["mechanical ventilation", "TREATMENT", 151, 173], ["respiratory distress syndrome", "PROBLEM", 179, 208], ["neonatal ARDS (n = 4 pulmonary haemorrhages", "PROBLEM", 224, 267], ["congenital pneumonia n", "PROBLEM", 275, 297], ["1 necrotizing enterocolitis", "PROBLEM", 300, 327], ["sepsis", "PROBLEM", 336, 342], ["respiratory failure", "PROBLEM", 351, 370], ["pulmonary hypoplasia", "PROBLEM", 383, 403], ["oligohydramnios sequence", "PROBLEM", 420, 444], ["positive", "OBSERVATION", 67, 75], ["pressure ventilation", "OBSERVATION", 76, 96], ["mechanical ventilation", "OBSERVATION", 151, 173], ["respiratory distress", "OBSERVATION", 179, 199], ["ARDS", "OBSERVATION", 233, 237], ["pulmonary", "ANATOMY", 245, 254], ["haemorrhages", "OBSERVATION", 255, 267], ["pneumonia", "OBSERVATION", 286, 295], ["necrotizing", "OBSERVATION_MODIFIER", 302, 313], ["enterocolitis", "OBSERVATION", 314, 327], ["sepsis", "OBSERVATION", 336, 342], ["respiratory", "ANATOMY", 351, 362], ["failure", "OBSERVATION", 363, 370], ["pulmonary", "ANATOMY", 383, 392], ["hypoplasia", "OBSERVATION", 393, 403], ["oligohydramnios", "OBSERVATION", 420, 435]]], ["The patient who was born at term had trachea-oesophageal atresia associated with Trisomy 18.", [["trachea", "ANATOMY", 37, 44], ["oesophageal", "ANATOMY", 45, 56], ["trachea-oesophageal atresia", "DISEASE", 37, 64], ["Trisomy 18", "DISEASE", 81, 91], ["patient", "ORGANISM", 4, 11], ["trachea-oesophageal atresia", "PATHOLOGICAL_FORMATION", 37, 64], ["patient", "SPECIES", 4, 11], ["trachea", "PROBLEM", 37, 44], ["oesophageal atresia", "PROBLEM", 45, 64], ["Trisomy 18", "PROBLEM", 81, 91], ["trachea", "ANATOMY", 37, 44], ["oesophageal", "ANATOMY", 45, 56], ["atresia", "OBSERVATION", 57, 64], ["Trisomy 18", "OBSERVATION", 81, 91]]], ["In the no-VAP group, the main reasons for mechanical ventilation were respiratory distress syndrome (n = 2), sepsis induced respiratory failure (n = 2), congenital pneumonia (n = 1) and neonatal ARDS related to necrotizing enterocolitis (n = 1).Patients' characteristics and outcomeAll but one infant in the VAP group had evolving CPIP at time of first VAP episode [16] .", [["respiratory", "ANATOMY", 70, 81], ["respiratory", "ANATOMY", 124, 135], ["respiratory distress syndrome", "DISEASE", 70, 99], ["sepsis", "DISEASE", 109, 115], ["respiratory failure", "DISEASE", 124, 143], ["congenital pneumonia", "DISEASE", 153, 173], ["ARDS", "DISEASE", 195, 199], ["necrotizing enterocolitis", "DISEASE", 211, 236], ["VAP", "DISEASE", 308, 311], ["CPIP", "DISEASE", 331, 335], ["VAP", "DISEASE", 353, 356], ["no-VAP", "CANCER", 7, 13], ["Patients", "ORGANISM", 245, 253], ["infant", "ORGANISM", 294, 300], ["Patients", "SPECIES", 245, 253], ["infant", "SPECIES", 294, 300], ["mechanical ventilation", "TREATMENT", 42, 64], ["respiratory distress syndrome", "PROBLEM", 70, 99], ["sepsis induced respiratory failure", "PROBLEM", 109, 143], ["congenital pneumonia", "PROBLEM", 153, 173], ["neonatal ARDS", "PROBLEM", 186, 199], ["necrotizing enterocolitis", "PROBLEM", 211, 236], ["first VAP episode", "PROBLEM", 347, 364], ["main", "OBSERVATION_MODIFIER", 25, 29], ["mechanical ventilation", "OBSERVATION", 42, 64], ["respiratory distress", "OBSERVATION", 70, 90], ["sepsis", "OBSERVATION", 109, 115], ["respiratory failure", "OBSERVATION", 124, 143], ["congenital", "OBSERVATION_MODIFIER", 153, 163], ["pneumonia", "OBSERVATION", 164, 173], ["ARDS", "OBSERVATION", 195, 199], ["necrotizing", "OBSERVATION_MODIFIER", 211, 222], ["enterocolitis", "OBSERVATION", 223, 236]]], ["Out of 21 patients 5 died.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Of the surviving infants, all had CLD at 36 weeks.", [["CLD", "DISEASE", 34, 37], ["infants", "ORGANISM", 17, 24], ["infants", "SPECIES", 17, 24], ["CLD", "PROBLEM", 34, 37]]], ["In the no-VAP group, all five patients developed CPIP.", [["CPIP", "DISEASE", 49, 53], ["no-VAP", "CANCER", 7, 13], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["CPIP", "PROBLEM", 49, 53], ["CPIP", "OBSERVATION", 49, 53]]], ["Two of them died and the rest developed CLD at 36 weeks.", [["CLD", "DISEASE", 40, 43], ["CLD", "PROBLEM", 40, 43]]], ["Of note, all episodes were consistent with Ped-VAE.", [["all episodes", "PROBLEM", 9, 21], ["Ped-VAE", "PROBLEM", 43, 50], ["consistent with", "UNCERTAINTY", 27, 42], ["Ped-VAE", "OBSERVATION", 43, 50]]], ["In the VAP group, two episodes, where the white cell count and temperature were within normal range, were consistent with Ped-VAC and the rest of the episodes with Ped-PVAP.", [["white cell", "ANATOMY", 42, 52], ["VAP", "DISEASE", 7, 10], ["Ped-PVAP", "DISEASE", 164, 172], ["white cell", "CELL", 42, 52], ["the white cell count", "TEST", 38, 58], ["temperature", "TEST", 63, 74], ["Ped-VAC", "TREATMENT", 122, 129], ["Ped-PVAP", "TREATMENT", 164, 172], ["VAP", "OBSERVATION", 7, 10], ["consistent with", "UNCERTAINTY", 106, 121], ["Ped-VAC", "OBSERVATION", 122, 129]]], ["In the no-VAP group, two episodes were classified as Ped-VAC.Patients' characteristics and outcomeBasic clinical characteristics of patients are shown in Table 2 .", [["no-VAP", "CANCER", 7, 13], ["Patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 132, 140], ["Patients", "SPECIES", 61, 69], ["patients", "SPECIES", 132, 140], ["Ped-VAC", "TREATMENT", 53, 60], ["Ped-VAC", "OBSERVATION", 53, 60]]], ["Clinical and laboratory data at the time of respiratory deterioration are shown in Table 3 .Clinical, laboratory and microbiology resultsAll patients had respiratory deterioration.", [["respiratory", "ANATOMY", 44, 55], ["respiratory", "ANATOMY", 154, 165], ["respiratory deterioration", "DISEASE", 44, 69], ["respiratory deterioration", "DISEASE", 154, 179], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["laboratory data", "TEST", 13, 28], ["respiratory deterioration", "PROBLEM", 44, 69], ["respiratory deterioration", "PROBLEM", 154, 179], ["respiratory", "ANATOMY", 154, 165], ["deterioration", "OBSERVATION", 166, 179]]], ["FiO 2 increased by more than 10% in 6 VAP episodes (19.3%) and by more than 20% in 20 episodes (64.5%).", [["VAP", "DISEASE", 38, 41], ["FiO 2", "GENE_OR_GENE_PRODUCT", 0, 5], ["FiO", "TEST", 0, 3], ["6 VAP episodes", "PROBLEM", 36, 50]]], ["Temperature instability was reported in 23 episodes (74.2%).", [["Temperature instability", "PROBLEM", 0, 23], ["instability", "OBSERVATION", 12, 23]]], ["Changes to airway secretions, described as change in colour, amount and/or thickness that required more frequent suctioning were reported in all cases but one.", [["airway", "ANATOMY", 11, 17], ["airway secretions", "MULTI-TISSUE_STRUCTURE", 11, 28], ["Changes to airway secretions", "PROBLEM", 0, 28], ["change in colour, amount and/or thickness", "PROBLEM", 43, 84], ["more frequent suctioning", "TREATMENT", 99, 123], ["airway", "ANATOMY", 11, 17], ["secretions", "OBSERVATION", 18, 28], ["change", "OBSERVATION_MODIFIER", 43, 49], ["colour", "OBSERVATION_MODIFIER", 53, 59], ["amount", "OBSERVATION_MODIFIER", 61, 67]]], ["Leucocytosis at time of deterioration occurred in 6 (19.3%), whereas leukopenia in two (6.5%) episodes.", [["Leucocytosis", "DISEASE", 0, 12], ["leukopenia", "DISEASE", 69, 79], ["Leucocytosis", "PROBLEM", 0, 12], ["deterioration", "PROBLEM", 24, 37], ["leukopenia", "PROBLEM", 69, 79], ["episodes", "PROBLEM", 94, 102], ["deterioration", "OBSERVATION", 24, 37], ["leukopenia", "OBSERVATION", 69, 79]]], ["CRP at time of deterioration was above 10 mg/l in 11 (35.4%) cases.", [["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["CRP", "PROTEIN", 0, 3], ["CRP", "TEST", 0, 3]]], ["There was no difference in white cell count (p = 0.27) or CRP (p = 0.18) taken at respiratory deterioration and repeated within 48 h.Clinical, laboratory and microbiology resultsOne episode was defined as suspected and 30 as confirmed VAP.", [["white cell", "ANATOMY", 27, 37], ["respiratory", "ANATOMY", 82, 93], ["respiratory deterioration", "DISEASE", 82, 107], ["VAP", "DISEASE", 235, 238], ["white cell", "CELL", 27, 37], ["CRP", "GENE_OR_GENE_PRODUCT", 58, 61], ["CRP", "PROTEIN", 58, 61], ["white cell count", "TEST", 27, 43], ["p", "TEST", 45, 46], ["CRP", "TEST", 58, 61], ["p", "TEST", 63, 64], ["VAP", "PROBLEM", 235, 238], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["VAP", "OBSERVATION", 235, 238]]], ["The patient whose microbiology culture of airway secretion showed no growth was already on antibiotics for 48 h prior to onset of suspected VAP.", [["airway", "ANATOMY", 42, 48], ["VAP", "DISEASE", 140, 143], ["patient", "ORGANISM", 4, 11], ["airway", "MULTI-TISSUE_STRUCTURE", 42, 48], ["patient", "SPECIES", 4, 11], ["The patient whose microbiology culture", "TEST", 0, 38], ["airway secretion", "TEST", 42, 58], ["antibiotics", "TREATMENT", 91, 102], ["VAP", "PROBLEM", 140, 143], ["airway", "ANATOMY", 42, 48], ["no", "UNCERTAINTY", 66, 68], ["VAP", "OBSERVATION", 140, 143]]], ["Microorganisms isolated from airway secretions are reported in Table 4 .", [["airway secretions", "ANATOMY", 29, 46], ["airway secretions", "MULTI-TISSUE_STRUCTURE", 29, 46], ["Microorganisms", "PROBLEM", 0, 14], ["airway secretions", "PROBLEM", 29, 46], ["airway", "ANATOMY", 29, 35], ["secretions", "OBSERVATION", 36, 46]]], ["Of note, in three episodes more than one bacterium was isolated.", [["one bacterium", "PROBLEM", 37, 50]]], ["Blood culture was positive in 3 episodes (Escherichia coli n = 1, Klebsiella pneumoniae n = 1, Staphylococcus aureus n = 1).Chest X-rayChest X-ray was performed at the time of respiratory deterioration in 31 episodes in the VAP and in 6 episodes in the no-VAP group.", [["Blood culture", "ANATOMY", 0, 13], ["respiratory", "ANATOMY", 176, 187], ["Klebsiella pneumoniae", "DISEASE", 66, 87], ["Staphylococcus aureus", "DISEASE", 95, 116], ["respiratory deterioration", "DISEASE", 176, 201], ["VAP", "DISEASE", 224, 227], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Escherichia coli n = 1", "ORGANISM", 42, 64], ["Klebsiella pneumoniae n = 1", "ORGANISM", 66, 93], ["Staphylococcus aureus", "ORGANISM", 95, 116], ["no-VAP", "CANCER", 253, 259], ["Escherichia coli", "SPECIES", 42, 58], ["Klebsiella pneumoniae", "SPECIES", 66, 87], ["Staphylococcus aureus", "SPECIES", 95, 116], ["Escherichia coli", "SPECIES", 42, 58], ["Klebsiella pneumoniae", "SPECIES", 66, 87], ["Staphylococcus aureus n = 1", "SPECIES", 95, 122], ["Blood culture", "TEST", 0, 13], ["Escherichia coli n", "PROBLEM", 42, 60], ["Klebsiella pneumoniae n", "PROBLEM", 66, 89], ["Staphylococcus aureus n", "PROBLEM", 95, 118], ["Chest X-rayChest X-ray", "TEST", 124, 146], ["respiratory deterioration", "PROBLEM", 176, 201], ["the VAP", "PROBLEM", 220, 227], ["Escherichia coli", "OBSERVATION", 42, 58], ["respiratory", "ANATOMY", 176, 187], ["deterioration", "OBSERVATION", 188, 201], ["VAP", "OBSERVATION", 224, 227]]], ["Only 20 (64.5%) episodes met radiological criteria for VAP, exhibiting new appearance or worsening consolidations (n = 4 (12.9%)) and/or opacities (n = 15 (48.4%)) on chest X-ray.", [["chest", "ANATOMY", 167, 172], ["VAP", "DISEASE", 55, 58], ["consolidations", "DISEASE", 99, 113], ["opacities", "DISEASE", 137, 146], ["VAP", "PROBLEM", 55, 58], ["worsening consolidations", "PROBLEM", 89, 113], ["opacities", "PROBLEM", 137, 146], ["chest X-ray", "TEST", 167, 178], ["new", "OBSERVATION_MODIFIER", 71, 74], ["worsening", "OBSERVATION_MODIFIER", 89, 98], ["consolidations", "OBSERVATION", 99, 113], ["opacities", "OBSERVATION", 137, 146], ["chest", "ANATOMY", 167, 172]]], ["Two chest X-rays (33.3%) in the no-VAP group were described as worsening opacity (Table 5 ).Lung ultrasoundLU was available for 31 VAP and 6 no-VAP episodes.", [["Lung", "ANATOMY", 92, 96], ["opacity", "DISEASE", 73, 80], ["VAP", "DISEASE", 131, 134], ["VAP", "DISEASE", 144, 147], ["no-VAP", "CANCER", 32, 38], ["Lung", "ORGAN", 92, 96], ["Two chest X-rays", "TEST", 0, 16], ["worsening opacity", "PROBLEM", 63, 80], ["Lung ultrasoundLU", "TEST", 92, 109], ["VAP", "TEST", 131, 134], ["VAP episodes", "PROBLEM", 144, 156], ["chest", "ANATOMY", 4, 9], ["worsening", "OBSERVATION_MODIFIER", 63, 72], ["opacity", "OBSERVATION", 73, 80]]], ["The agreement in LU scoring was high between the two experts with an interclass correlation coefficient of 0.899 (95% CI 0.80-0.95).Lung ultrasoundIn both the VAP and no-VAP groups, all patients had disseminated lung rockets in all lung fields (anterior, axillary and posterior).", [["Lung", "ANATOMY", 132, 136], ["lung", "ANATOMY", 212, 216], ["lung", "ANATOMY", 232, 236], ["anterior", "ANATOMY", 245, 253], ["axillary", "ANATOMY", 255, 263], ["VAP", "DISEASE", 159, 162], ["Lung", "ORGAN", 132, 136], ["patients", "ORGANISM", 186, 194], ["lung", "ORGAN", 212, 216], ["lung", "ORGAN", 232, 236], ["anterior", "MULTI-TISSUE_STRUCTURE", 245, 253], ["axillary", "MULTI-TISSUE_STRUCTURE", 255, 263], ["patients", "SPECIES", 186, 194], ["LU scoring", "TEST", 17, 27], ["CI", "TEST", 118, 120], ["Lung ultrasound", "TEST", 132, 147], ["disseminated lung rockets in all lung fields", "PROBLEM", 199, 243], ["VAP", "OBSERVATION", 159, 162], ["disseminated", "OBSERVATION_MODIFIER", 199, 211], ["lung", "ANATOMY", 212, 216], ["rockets", "OBSERVATION", 217, 224], ["all", "ANATOMY_MODIFIER", 228, 231], ["lung", "ANATOMY", 232, 236], ["fields", "ANATOMY_MODIFIER", 237, 243], ["anterior", "ANATOMY_MODIFIER", 245, 253], ["axillary", "ANATOMY", 255, 263], ["posterior", "ANATOMY_MODIFIER", 268, 277]]], ["In the VAP group, there were 2 main groups of consolidations based on size, < 0.2 cm and > 0.5 cm (Online Resource 1).", [["VAP", "DISEASE", 7, 10], ["consolidations", "PROBLEM", 46, 60], ["size", "TEST", 70, 74], ["VAP", "OBSERVATION", 7, 10], ["main", "OBSERVATION_MODIFIER", 31, 35], ["groups", "OBSERVATION_MODIFIER", 36, 42], ["consolidations", "OBSERVATION", 46, 60], ["size", "OBSERVATION_MODIFIER", 70, 74], ["< 0.2 cm", "OBSERVATION_MODIFIER", 76, 84]]], ["In all VAP episodes, there was at least one consolidation > 0.5 cm and in 70.9% there were 2 (22/31).", [["VAP", "DISEASE", 7, 10], ["all VAP episodes", "PROBLEM", 3, 19], ["one consolidation", "PROBLEM", 40, 57], ["all", "OBSERVATION_MODIFIER", 3, 6], ["VAP episodes", "OBSERVATION", 7, 19], ["least", "OBSERVATION_MODIFIER", 34, 39], ["one", "OBSERVATION_MODIFIER", 40, 43], ["consolidation", "OBSERVATION", 44, 57], ["0.5 cm", "OBSERVATION_MODIFIER", 60, 66]]], ["Non-translobar consolidations were found in all episodes and both translobar and non-translobar consolidations in 7.", [["translobar", "ANATOMY", 66, 76], ["consolidations", "DISEASE", 96, 110], ["Non-translobar consolidations", "PROBLEM", 0, 29], ["both translobar and non-translobar consolidations", "PROBLEM", 61, 110], ["consolidations", "OBSERVATION", 15, 29], ["all", "OBSERVATION_MODIFIER", 44, 47], ["episodes", "OBSERVATION_MODIFIER", 48, 56], ["both", "OBSERVATION_MODIFIER", 61, 65], ["translobar", "OBSERVATION_MODIFIER", 66, 76], ["non-translobar", "OBSERVATION_MODIFIER", 81, 95], ["consolidations", "OBSERVATION", 96, 110]]], ["Mean size of the non-translobar consolidation was 1.5 cm (range: 0.8-2.75).", [["the non-translobar consolidation", "PROBLEM", 13, 45], ["size", "OBSERVATION_MODIFIER", 5, 9], ["non-translobar", "OBSERVATION_MODIFIER", 17, 31], ["consolidation", "OBSERVATION", 32, 45], ["1.5 cm", "OBSERVATION_MODIFIER", 50, 56]]], ["These were mainly seen posteriorly.", [["posteriorly", "ANATOMY_MODIFIER", 23, 34]]], ["Consolidations <0.2 cm were mainly located anteriorly (Online Resource 2).", [["Consolidations", "PROBLEM", 0, 14], ["0.2 cm", "OBSERVATION_MODIFIER", 16, 22], ["anteriorly", "ANATOMY_MODIFIER", 43, 53]]], ["Static bronchograms were present in all episodes, linear/arborescent dynamic bronchograms (Online Resource 3) in 23 and pleural effusion in 3 ( Table 5 ).", [["pleural effusion", "ANATOMY", 120, 136], ["pleural effusion", "DISEASE", 120, 136], ["pleural effusion", "CANCER", 120, 136], ["Static bronchograms", "TEST", 0, 19], ["linear/arborescent dynamic bronchograms", "PROBLEM", 50, 89], ["pleural effusion", "PROBLEM", 120, 136], ["bronchograms", "OBSERVATION", 7, 19], ["linear", "OBSERVATION_MODIFIER", 50, 56], ["dynamic bronchograms", "OBSERVATION", 69, 89], ["pleural", "ANATOMY", 120, 127], ["effusion", "OBSERVATION", 128, 136]]], ["Re-opening of the consolidated area was attempted in 11 episodes.", [["the consolidated area", "PROBLEM", 14, 35], ["consolidated", "OBSERVATION_MODIFIER", 18, 30], ["area", "OBSERVATION_MODIFIER", 31, 35]]], ["The consolidated area was completely re-opened in 3 episodes (Online Resource 4 and 5).Lung ultrasoundLU was performed at the end of antibiotic treatment in 12 episodes.", [["Lung", "ANATOMY", 87, 91], ["Lung", "ORGAN", 87, 91], ["Lung ultrasoundLU", "TEST", 87, 104], ["antibiotic treatment", "TREATMENT", 133, 153], ["consolidated", "OBSERVATION_MODIFIER", 4, 16], ["area", "OBSERVATION_MODIFIER", 17, 21], ["completely", "OBSERVATION_MODIFIER", 26, 36], ["re-opened", "OBSERVATION_MODIFIER", 37, 46], ["3 episodes", "OBSERVATION_MODIFIER", 50, 60]]], ["In 6 episodes, persisting consolidations suggestive of VAP were seen and all of these patients had a relapse within the next month.", [["VAP", "DISEASE", 55, 58], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["persisting consolidations", "PROBLEM", 15, 40], ["VAP", "PROBLEM", 55, 58], ["persisting", "OBSERVATION_MODIFIER", 15, 25], ["consolidations", "OBSERVATION", 26, 40], ["suggestive of", "UNCERTAINTY", 41, 54], ["VAP", "OBSERVATION", 55, 58]]], ["Among the 6 patients without LU findings suggestive of VAP at end of antibiotic treatment, only 1 relapsed within the next month.", [["VAP", "DISEASE", 55, 58], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["LU findings", "TEST", 29, 40], ["VAP", "PROBLEM", 55, 58], ["antibiotic treatment", "TREATMENT", 69, 89], ["suggestive of", "UNCERTAINTY", 41, 54], ["VAP", "OBSERVATION", 55, 58]]], ["In the no-VAP group, consolidations < 0.2 cm were present in all episodes.", [["no-VAP", "CANCER", 7, 13], ["consolidations", "PROBLEM", 21, 35], ["consolidations", "OBSERVATION", 21, 35], ["0.2 cm", "OBSERVATION_MODIFIER", 38, 44], ["all episodes", "OBSERVATION_MODIFIER", 61, 73]]], ["In four episodes, the consolidations were > 0.5 cm.", [["the consolidations", "PROBLEM", 18, 36], ["four", "OBSERVATION_MODIFIER", 3, 7], ["episodes", "OBSERVATION_MODIFIER", 8, 16], ["consolidations", "OBSERVATION", 22, 36], ["> 0.5 cm", "OBSERVATION_MODIFIER", 42, 50]]], ["Mean size of the non-translobar consolidations was 1.8 cm (range 1-2 cm).", [["non-translobar consolidations", "ANATOMY", 17, 46], ["the non-translobar consolidations", "PROBLEM", 13, 46], ["size", "OBSERVATION_MODIFIER", 5, 9], ["non-translobar", "OBSERVATION_MODIFIER", 17, 31], ["consolidations", "OBSERVATION", 32, 46], ["1.8 cm", "OBSERVATION_MODIFIER", 51, 57], ["2 cm", "OBSERVATION_MODIFIER", 67, 71]]], ["Static bronchograms were seen in all but one episode.", [["Static bronchograms", "TEST", 0, 19], ["bronchograms", "OBSERVATION", 7, 19]]], ["This one episode was consistent with segmental atelectasis (Online Resource 6).", [["atelectasis", "DISEASE", 47, 58], ["segmental atelectasis", "PROBLEM", 37, 58], ["consistent with", "UNCERTAINTY", 21, 36], ["segmental", "ANATOMY_MODIFIER", 37, 46], ["atelectasis", "OBSERVATION", 47, 58]]], ["Pleural effusion was not found in any of the patients, who did not have VAP.", [["Pleural", "ANATOMY", 0, 7], ["Pleural effusion", "DISEASE", 0, 16], ["VAP", "DISEASE", 72, 75], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["Pleural effusion", "PROBLEM", 0, 16], ["VAP", "PROBLEM", 72, 75], ["effusion", "OBSERVATION", 8, 16], ["VAP", "OBSERVATION", 72, 75]]], ["Reopening of the consolidated area was attempted in two episodes and was successful in infants without VAP.", [["VAP", "DISEASE", 103, 106], ["infants", "ORGANISM", 87, 94], ["infants", "SPECIES", 87, 94], ["the consolidated area", "PROBLEM", 13, 34], ["VAP", "PROBLEM", 103, 106], ["consolidated", "OBSERVATION_MODIFIER", 17, 29], ["area", "OBSERVATION_MODIFIER", 30, 34]]], ["Chest X-ray and LU findings are shown in Table 5 .VAP scorePredictive values of different approaches as described in the Methods were calculated and are shown in Table 6 .", [["Chest X-ray", "TEST", 0, 11], ["LU findings", "TEST", 16, 27]]], ["A multiparameter VAP score of > 4 on Day 1 and > 5 on Day 3 gave the highest sensitivity (0.94) with AUC of 0.91 (standard error (SE) 0.06, 95% CI 0.8-1.00, p = 0.002) and 0.97 (SE 0.03, 95% CI 0.92-1.00, p = 0.0003), respectively (Fig. 2) .", [["A multiparameter VAP score", "TEST", 0, 26], ["AUC", "TEST", 101, 104], ["CI", "TEST", 144, 146], ["p", "TEST", 157, 158], ["SE", "TEST", 178, 180], ["CI", "TEST", 191, 193], ["p", "TEST", 205, 206], ["VAP", "OBSERVATION", 17, 20]]], ["Sensitivity and AUC showed that adding LU to clinical information improves the predictive value as opposed to combining clinical information with chest X-ray (Table 6) .", [["Sensitivity", "TEST", 0, 11], ["AUC", "TEST", 16, 19], ["chest X-ray", "TEST", 146, 157], ["chest", "ANATOMY", 146, 151]]], ["AUCs were compared, and following correction for multiple comparisons, no significant difference was found between them.DiscussionWe demonstrated that adding LU to clinical information could be an alternative to chest X-Ray to diagnose VAP in neonates.", [["VAP", "DISEASE", 236, 239], ["neonates", "ORGANISM", 243, 251], ["AUCs", "TEST", 0, 4], ["chest X-Ray", "TEST", 212, 223], ["VAP in neonates", "PROBLEM", 236, 251], ["chest", "ANATOMY", 212, 217]]], ["As there is no widely accepted consensus regarding definition of neonatal VAP, we have also introduced a multiparameter score comprising clinical, laboratory, microbiological and LU data that showed high predictive values for VAP diagnosis in neonates with underlying lung pathology.DiscussionChest X-Ray has been the gold standard imaging method for diagnosing chest infection in paediatric patients, and it is a mandatory criterion in the most often applied VAP definitions, such as the CDC guidelines for infants \u2264 1 year and the ECDC criteria [5] .", [["lung", "ANATOMY", 268, 272], ["chest", "ANATOMY", 362, 367], ["VAP", "DISEASE", 74, 77], ["VAP", "DISEASE", 226, 229], ["chest infection", "DISEASE", 362, 377], ["neonates", "ORGANISM", 243, 251], ["lung", "ORGAN", 268, 272], ["chest", "ORGANISM_SUBDIVISION", 362, 367], ["patients", "ORGANISM", 392, 400], ["patients", "SPECIES", 392, 400], ["infants", "SPECIES", 508, 515], ["neonatal VAP", "PROBLEM", 65, 77], ["a multiparameter score", "TEST", 103, 125], ["LU data", "TEST", 179, 186], ["high predictive values", "PROBLEM", 199, 221], ["VAP diagnosis in neonates", "PROBLEM", 226, 251], ["underlying lung pathology", "PROBLEM", 257, 282], ["chest infection", "PROBLEM", 362, 377], ["VAP definitions", "PROBLEM", 460, 475], ["no", "UNCERTAINTY", 12, 14], ["VAP", "OBSERVATION", 74, 77], ["lung", "ANATOMY", 268, 272], ["pathology", "OBSERVATION", 273, 282], ["chest", "ANATOMY", 362, 367], ["infection", "OBSERVATION", 368, 377]]], ["However, challenges in interpreting radiographic changes in patients with underlying lung pathology, like infants with CLD have been previously reported [5] [6] [7] and inter-rater reliability of chest X-ray interpretation was shown to be poor in this context [5] .", [["lung", "ANATOMY", 85, 89], ["CLD", "DISEASE", 119, 122], ["patients", "ORGANISM", 60, 68], ["lung", "ORGAN", 85, 89], ["infants", "ORGANISM", 106, 113], ["patients", "SPECIES", 60, 68], ["infants", "SPECIES", 106, 113], ["underlying lung pathology", "PROBLEM", 74, 99], ["CLD", "PROBLEM", 119, 122], ["inter-rater reliability", "TEST", 169, 192], ["chest X-ray interpretation", "TEST", 196, 222], ["lung", "ANATOMY", 85, 89], ["pathology", "OBSERVATION", 90, 99], ["chest", "ANATOMY", 196, 201]]], ["In our series, only 64.5% of episodes met radiological criteria for VAP diagnosis based on chest X-ray.", [["VAP", "DISEASE", 68, 71], ["VAP diagnosis", "PROBLEM", 68, 81], ["chest X-ray", "TEST", 91, 102], ["chest", "ANATOMY", 91, 96]]], ["Subpleural consolidation, consolidations > 1 cm, dynamic bronchogram, focal B-lines, pleural line abnormalities and pleural effusion have been shown to be characteristics of community-acquired pneumonia in hospitalized children with high specificity in suspected pneumonia [10, 11, 21, 22] .", [["Subpleural", "ANATOMY", 0, 10], ["focal B-lines", "ANATOMY", 70, 83], ["pleural line", "ANATOMY", 85, 97], ["pleural effusion", "ANATOMY", 116, 132], ["pleural line abnormalities", "DISEASE", 85, 111], ["pleural effusion", "DISEASE", 116, 132], ["pneumonia", "DISEASE", 193, 202], ["pneumonia", "DISEASE", 263, 272], ["B-lines", "CELL", 76, 83], ["pleural line", "CELL", 85, 97], ["pleural effusion", "CANCER", 116, 132], ["children", "ORGANISM", 219, 227], ["children", "SPECIES", 219, 227], ["Subpleural consolidation", "PROBLEM", 0, 24], ["consolidations", "PROBLEM", 26, 40], ["dynamic bronchogram", "TEST", 49, 68], ["focal B-lines", "PROBLEM", 70, 83], ["pleural line abnormalities", "PROBLEM", 85, 111], ["pleural effusion", "PROBLEM", 116, 132], ["community-acquired pneumonia", "PROBLEM", 174, 202], ["suspected pneumonia", "PROBLEM", 253, 272], ["consolidation", "OBSERVATION", 11, 24], ["consolidations", "OBSERVATION", 26, 40], ["1 cm", "OBSERVATION_MODIFIER", 43, 47], ["bronchogram", "OBSERVATION_MODIFIER", 57, 68], ["focal", "OBSERVATION_MODIFIER", 70, 75], ["B", "OBSERVATION_MODIFIER", 76, 77], ["-lines", "OBSERVATION", 77, 83], ["pleural", "ANATOMY", 85, 92], ["line", "OBSERVATION", 93, 97], ["pleural", "ANATOMY", 116, 123], ["effusion", "OBSERVATION", 124, 132], ["pneumonia", "OBSERVATION", 193, 202], ["pneumonia", "OBSERVATION", 263, 272]]], ["In adult VAP, subpleural consolidation and dynamic arborescent/linear airbronchogram had high positive predictive values [23] .", [["subpleural", "ANATOMY", 14, 24], ["VAP", "DISEASE", 9, 12], ["subpleural", "MULTI-TISSUE_STRUCTURE", 14, 24], ["adult VAP", "PROBLEM", 3, 12], ["subpleural consolidation", "PROBLEM", 14, 38], ["dynamic arborescent/linear airbronchogram", "TEST", 43, 84], ["high positive predictive values", "PROBLEM", 89, 120], ["adult", "OBSERVATION_MODIFIER", 3, 8], ["VAP", "OBSERVATION", 9, 12], ["subpleural", "ANATOMY", 14, 24], ["consolidation", "OBSERVATION", 25, 38], ["dynamic", "OBSERVATION_MODIFIER", 43, 50], ["linear", "OBSERVATION_MODIFIER", 63, 69]]], ["Of all the LU findings described in paediatric patients and adults, sub-pleural consolidations were also present in all our patients who did not have VAP and were thus not considered to be suggestive of VAP diagnosis.", [["pleural", "ANATOMY", 72, 79], ["VAP", "DISEASE", 150, 153], ["VAP", "DISEASE", 203, 206], ["LU", "CANCER", 11, 13], ["patients", "ORGANISM", 47, 55], ["pleural", "PATHOLOGICAL_FORMATION", 72, 79], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 124, 132], ["sub-pleural consolidations", "PROBLEM", 68, 94], ["VAP", "PROBLEM", 150, 153], ["VAP diagnosis", "PROBLEM", 203, 216], ["sub", "OBSERVATION_MODIFIER", 68, 71], ["pleural", "ANATOMY", 72, 79], ["consolidations", "OBSERVATION", 80, 94], ["VAP", "OBSERVATION", 150, 153], ["suggestive of", "UNCERTAINTY", 189, 202], ["VAP", "OBSERVATION", 203, 206]]], ["All patients in both VAP and no-VAP groups had diffuse lung rockets, related to the underlying lung pathology.", [["lung", "ANATOMY", 55, 59], ["lung", "ANATOMY", 95, 99], ["VAP", "DISEASE", 21, 24], ["lung rockets", "DISEASE", 55, 67], ["patients", "ORGANISM", 4, 12], ["lung", "ORGAN", 55, 59], ["lung", "ORGAN", 95, 99], ["patients", "SPECIES", 4, 12], ["diffuse lung rockets", "PROBLEM", 47, 67], ["the underlying lung pathology", "PROBLEM", 80, 109], ["VAP", "OBSERVATION", 21, 24], ["diffuse", "OBSERVATION_MODIFIER", 47, 54], ["lung", "ANATOMY", 55, 59], ["rockets", "OBSERVATION", 60, 67], ["lung", "ANATOMY", 95, 99], ["pathology", "OBSERVATION", 100, 109]]], ["We therefore excluded focal Blines from our score.", [["focal Blines", "PROBLEM", 22, 34], ["focal", "OBSERVATION_MODIFIER", 22, 27], ["Blines", "OBSERVATION", 28, 34]]], ["The LU findings that were suggestive of VAP in our patient population were consolidations > 0.5 cm accompanied by linear/arborescent dynamic bronchograms and/or associated with pleural effusion.", [["pleural", "ANATOMY", 177, 184], ["VAP", "DISEASE", 40, 43], ["pleural effusion", "DISEASE", 177, 193], ["LU", "CANCER", 4, 6], ["patient", "ORGANISM", 51, 58], ["pleural", "ORGAN", 177, 184], ["patient", "SPECIES", 51, 58], ["VAP", "PROBLEM", 40, 43], ["consolidations", "PROBLEM", 75, 89], ["linear/arborescent dynamic bronchograms", "PROBLEM", 114, 153], ["pleural effusion", "PROBLEM", 177, 193], ["suggestive of", "UNCERTAINTY", 26, 39], ["VAP", "OBSERVATION", 40, 43], ["consolidations", "OBSERVATION", 75, 89], ["0.5 cm", "OBSERVATION_MODIFIER", 92, 98], ["linear", "OBSERVATION_MODIFIER", 114, 120], ["arborescent", "OBSERVATION_MODIFIER", 121, 132], ["dynamic bronchograms", "OBSERVATION", 133, 153], ["pleural", "ANATOMY", 177, 184], ["effusion", "OBSERVATION", 185, 193]]], ["All LU in the VAP group showed large consolidations, which could either be atelectasis, collapse in dependant areas or VAP.", [["VAP", "DISEASE", 14, 17], ["atelectasis", "DISEASE", 75, 86], ["VAP", "DISEASE", 119, 122], ["the VAP group", "TEST", 10, 23], ["large consolidations", "PROBLEM", 31, 51], ["atelectasis", "PROBLEM", 75, 86], ["collapse in dependant areas", "PROBLEM", 88, 115], ["VAP", "PROBLEM", 119, 122], ["large", "OBSERVATION_MODIFIER", 31, 36], ["consolidations", "OBSERVATION", 37, 51], ["could either be", "UNCERTAINTY", 59, 74], ["atelectasis", "OBSERVATION", 75, 86], ["collapse", "OBSERVATION", 88, 96], ["dependant", "OBSERVATION_MODIFIER", 100, 109], ["areas", "OBSERVATION_MODIFIER", 110, 115], ["VAP", "OBSERVATION", 119, 122]]], ["Atelectasis could easily be recognized as a well limited area of consolidation with absent or very rare static bronchograms.", [["Atelectasis", "DISEASE", 0, 11], ["Atelectasis", "PROBLEM", 0, 11], ["consolidation", "PROBLEM", 65, 78], ["very rare static bronchograms", "PROBLEM", 94, 123], ["limited", "OBSERVATION_MODIFIER", 49, 56], ["area", "OBSERVATION_MODIFIER", 57, 61], ["consolidation", "OBSERVATION", 65, 78], ["very", "OBSERVATION_MODIFIER", 94, 98], ["rare", "OBSERVATION_MODIFIER", 99, 103], ["static", "OBSERVATION_MODIFIER", 104, 110], ["bronchograms", "OBSERVATION", 111, 123]]], ["Most challenging part of the assessment was to differentiate between areas of collapse and infection.", [["infection", "DISEASE", 91, 100], ["the assessment", "TEST", 25, 39], ["collapse", "PROBLEM", 78, 86], ["infection", "PROBLEM", 91, 100], ["collapse", "OBSERVATION", 78, 86], ["infection", "OBSERVATION", 91, 100]]], ["Linear/arborescent dynamic bronchograms have been shown to be highly specific for pneumonia but identifying such changes in neonates with respiratory rates as high as 60/min and small tidal volumes could be challenging.", [["respiratory", "ANATOMY", 138, 149], ["pneumonia", "DISEASE", 82, 91], ["neonates", "ORGANISM", 124, 132], ["Linear/arborescent dynamic bronchograms", "PROBLEM", 0, 39], ["pneumonia", "PROBLEM", 82, 91], ["such changes in neonates", "PROBLEM", 108, 132], ["respiratory rates", "TEST", 138, 155], ["small tidal volumes", "PROBLEM", 178, 197], ["dynamic bronchograms", "OBSERVATION", 19, 39], ["pneumonia", "OBSERVATION", 82, 91], ["small", "OBSERVATION_MODIFIER", 178, 183], ["tidal volumes", "OBSERVATION", 184, 197]]], ["Of note, identifying dynamic bronchograms was the only disagreement between the two experts in our cohort.", [["dynamic bronchograms", "PROBLEM", 21, 41], ["dynamic bronchograms", "OBSERVATION", 21, 41]]], ["Surprisingly, two infants in the no-VAP group had consolidations with linear dynamic bronchograms.", [["infants", "ORGANISM", 18, 25], ["no-VAP", "CANCER", 33, 39], ["infants", "SPECIES", 18, 25], ["consolidations", "PROBLEM", 50, 64], ["linear dynamic bronchograms", "PROBLEM", 70, 97], ["consolidations", "OBSERVATION", 50, 64], ["linear", "OBSERVATION_MODIFIER", 70, 76], ["dynamic bronchograms", "OBSERVATION", 77, 97]]], ["Thus, specificity of linear/arborescent dynamic bronchograms in the collapsed dependant areas of infants with CLD needs further study.", [["CLD", "DISEASE", 110, 113], ["infants", "ORGANISM", 97, 104], ["infants", "SPECIES", 97, 104], ["linear/arborescent dynamic bronchograms", "PROBLEM", 21, 60], ["the collapsed dependant areas", "PROBLEM", 64, 93], ["CLD", "PROBLEM", 110, 113], ["further study", "TEST", 120, 133], ["linear", "OBSERVATION_MODIFIER", 21, 27], ["dynamic bronchograms", "OBSERVATION", 40, 60], ["collapsed", "OBSERVATION_MODIFIER", 68, 77], ["dependant", "OBSERVATION_MODIFIER", 78, 87], ["areas", "OBSERVATION_MODIFIER", 88, 93], ["CLD", "OBSERVATION", 110, 113]]], ["Punctiform dynamic bronchograms were identified in consolidations > 0.5 cm in both groups.", [["Punctiform dynamic bronchograms", "PROBLEM", 0, 31], ["consolidations", "PROBLEM", 51, 65], ["dynamic bronchograms", "OBSERVATION", 11, 31], ["consolidations", "OBSERVATION", 51, 65], ["0.5 cm", "OBSERVATION_MODIFIER", 68, 74]]], ["However, these are not specific to pneumonia [23] , rather a sign of de-recruitment.", [["pneumonia", "DISEASE", 35, 44], ["pneumonia", "PROBLEM", 35, 44], ["de-recruitment", "PROBLEM", 69, 83], ["pneumonia", "OBSERVATION", 35, 44]]], ["Recruitment of consolidated areas was another criterion to differentiate between collapsed areas and VAP.", [["VAP", "DISEASE", 101, 104], ["collapsed areas", "PROBLEM", 81, 96], ["VAP", "PROBLEM", 101, 104], ["consolidated", "OBSERVATION_MODIFIER", 15, 27], ["areas", "OBSERVATION_MODIFIER", 28, 33], ["collapsed", "OBSERVATION_MODIFIER", 81, 90], ["areas", "OBSERVATION", 91, 96], ["VAP", "OBSERVATION", 101, 104]]], ["We hypothesised that when a consolidation cannot be completely recruited either by positioning of the infant or by recruitment airway manoeuvres, this would be suggestive of VAP.", [["airway", "ANATOMY", 127, 133], ["VAP", "DISEASE", 174, 177], ["airway", "MULTI-TISSUE_STRUCTURE", 127, 133], ["a consolidation", "PROBLEM", 26, 41], ["recruitment airway manoeuvres", "TREATMENT", 115, 144], ["VAP", "PROBLEM", 174, 177], ["consolidation", "OBSERVATION", 28, 41], ["airway", "ANATOMY", 127, 133], ["suggestive of", "UNCERTAINTY", 160, 173], ["VAP", "OBSERVATION", 174, 177]]], ["Most patients in the VAP group had consolidations that partially re-opened, changing from a consolidated area to white lungs following recruitment manoeuvres.", [["lungs", "ANATOMY", 119, 124], ["VAP", "DISEASE", 21, 24], ["patients", "ORGANISM", 5, 13], ["lungs", "ORGAN", 119, 124], ["patients", "SPECIES", 5, 13], ["consolidations", "PROBLEM", 35, 49], ["recruitment manoeuvres", "TREATMENT", 135, 157], ["VAP", "OBSERVATION", 21, 24], ["consolidations", "OBSERVATION", 35, 49], ["consolidated", "OBSERVATION_MODIFIER", 92, 104], ["area", "OBSERVATION_MODIFIER", 105, 109], ["white", "OBSERVATION_MODIFIER", 113, 118], ["lungs", "ANATOMY", 119, 124], ["recruitment manoeuvres", "OBSERVATION", 135, 157]]], ["Partial re-opening may be related to the presence of collapsed areas around areas of infection.", [["infection", "DISEASE", 85, 94], ["Partial re-opening", "PROBLEM", 0, 18], ["collapsed areas", "PROBLEM", 53, 68], ["infection", "PROBLEM", 85, 94], ["may be related to", "UNCERTAINTY", 19, 36], ["collapsed", "OBSERVATION_MODIFIER", 53, 62], ["areas", "OBSERVATION_MODIFIER", 63, 68], ["areas", "OBSERVATION_MODIFIER", 76, 81], ["infection", "OBSERVATION", 85, 94]]], ["All consolidations in the control group were possible to recruit.DiscussionLU to monitor recovery following VAP and efficacy of antibiotics was previously studied [24] .", [["VAP", "DISEASE", 108, 111], ["All consolidations", "PROBLEM", 0, 18], ["VAP", "PROBLEM", 108, 111], ["antibiotics", "TREATMENT", 128, 139], ["consolidations", "OBSERVATION", 4, 18]]], ["In our cohort, all patients (6/12) who had persisting consolidation suggestive of quantify the global loss of aeration has been proposed in adult VAP patients.", [["VAP", "DISEASE", 146, 149], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 150, 158], ["persisting consolidation", "PROBLEM", 43, 67], ["the global loss of aeration", "PROBLEM", 91, 118], ["consolidation", "OBSERVATION", 54, 67], ["suggestive of", "UNCERTAINTY", 68, 81], ["global", "OBSERVATION_MODIFIER", 95, 101], ["loss", "OBSERVATION", 102, 106], ["aeration", "OBSERVATION_MODIFIER", 110, 118]]], ["Its modification in days showed a significant correlation with re-aeration as assessed by quantitative CT scan (rho = 0.85) when computed after 7 days of antibiotics [25] .", [["quantitative CT scan", "TEST", 90, 110], ["rho", "TEST", 112, 115], ["antibiotics", "TREATMENT", 154, 165]]], ["LU to monitor response to antibiotics treatment in neonates should be investigated further as optimal duration for treatment is currently unknown.", [["neonates", "ORGANISM", 51, 59], ["antibiotics treatment", "TREATMENT", 26, 47], ["neonates", "TREATMENT", 51, 59], ["treatment", "TREATMENT", 115, 124]]], ["Fig. 2 Area under the receiver operating curve for multiparameter ventilatorassociated pneumonia score CXR chest X-ray, D day, LUS lung ultrasound Despite LU being a promising tool to aid VAP diagnosis, similar to other neonatal respiratory pathologies [26] , there is no single highly specific marker of VAP in neonates.", [["lung", "ANATOMY", 131, 135], ["respiratory", "ANATOMY", 229, 240], ["pneumonia", "DISEASE", 87, 96], ["VAP", "DISEASE", 188, 191], ["respiratory pathologies", "DISEASE", 229, 252], ["VAP", "DISEASE", 305, 308], ["lung", "ORGAN", 131, 135], ["neonates", "ORGANISM", 312, 320], ["operating curve", "TEST", 31, 46], ["multiparameter ventilatorassociated pneumonia score", "TEST", 51, 102], ["CXR chest X-ray", "TEST", 103, 118], ["LUS lung ultrasound", "TEST", 127, 146], ["other neonatal respiratory pathologies", "PROBLEM", 214, 252], ["VAP in neonates", "PROBLEM", 305, 320], ["pneumonia", "OBSERVATION", 87, 96], ["chest", "ANATOMY", 107, 112], ["lung", "ANATOMY", 131, 135], ["no", "UNCERTAINTY", 269, 271], ["VAP", "OBSERVATION", 305, 308]]], ["Clinical and laboratory findings have been shown to be nonspecific [3, 25] .", [["nonspecific", "OBSERVATION_MODIFIER", 55, 66]]], ["In our series, only 26% of infants had abnormal white cell count and only 41.8% had increased CRP.", [["white cell", "ANATOMY", 48, 58], ["abnormal white cell count", "DISEASE", 39, 64], ["infants", "ORGANISM", 27, 34], ["white cell", "CELL", 48, 58], ["CRP", "GENE_OR_GENE_PRODUCT", 94, 97], ["CRP", "PROTEIN", 94, 97], ["infants", "SPECIES", 27, 34], ["abnormal white cell count", "PROBLEM", 39, 64], ["increased CRP", "PROBLEM", 84, 97], ["white cell", "OBSERVATION_MODIFIER", 48, 58], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["CRP", "OBSERVATION", 94, 97]]], ["Other markers, such as procalcitonin have no positive impact on the accuracy of clinical and ultrasound-based scores for VAP diagnosis [27] .", [["VAP", "DISEASE", 121, 124], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 23, 36], ["procalcitonin", "PROTEIN", 23, 36], ["Other markers", "TEST", 0, 13], ["procalcitonin", "TEST", 23, 36], ["ultrasound", "TEST", 93, 103], ["VAP diagnosis", "TEST", 121, 134]]], ["Microbiological samples cannot guide early decisions on starting antibiotics.", [["samples", "ANATOMY", 16, 23], ["Microbiological samples", "TEST", 0, 23], ["starting antibiotics", "TREATMENT", 56, 76]]], ["A multiparameter systematic approach for diagnosis and monitoring of VAP with clinical, laboratory, microbiological and LU data is essential.", [["VAP", "DISEASE", 69, 72], ["VAP", "PROBLEM", 69, 72], ["LU data", "TEST", 120, 127]]], ["A multiparameter score has recently shown to have greater specificity and sensitivity than clinical signs alone in adults [12] .", [["A multiparameter score", "TEST", 0, 22], ["clinical signs", "TEST", 91, 105]]], ["To our knowledge, this is the first time that a multiparameter score combining clinical, microbiological and LU characteristics has been studied in neonates.", [["neonates", "ORGANISM", 148, 156], ["a multiparameter score", "TEST", 46, 68]]], ["Furthermore, sensitivity, specificity and AUC showed that predictive values increased when LU was included in the multiparameter VAP score.DiscussionIncidence of VAP in our NICU was 10.47/1000 ventilator days, which is in line with published incidence of 2.7-11.8/ 1000 ventilator days in developed countries [5] .", [["VAP", "DISEASE", 129, 132], ["VAP", "DISEASE", 162, 165], ["sensitivity", "TEST", 13, 24], ["specificity", "TEST", 26, 37], ["AUC", "TEST", 42, 45], ["predictive values", "TEST", 58, 75], ["the multiparameter VAP score", "TEST", 110, 138], ["VAP", "PROBLEM", 162, 165], ["VAP", "OBSERVATION", 162, 165]]], ["Recent studies have reported lower incidence of VAP after implementation of VAP prevention bundles that combined antimicrobial stewardship and infection control measures, such as hand hygiene, isolation guidelines, handling and disinfection of patient care equipment, instruments and devices and use of personnel protective equipment [5, 28, 29] .", [["hand", "ANATOMY", 179, 183], ["VAP", "DISEASE", 48, 51], ["VAP", "DISEASE", 76, 79], ["infection", "DISEASE", 143, 152], ["hand", "ORGANISM_SUBDIVISION", 179, 183], ["patient", "ORGANISM", 244, 251], ["patient", "SPECIES", 244, 251], ["Recent studies", "TEST", 0, 14], ["VAP", "PROBLEM", 48, 51], ["VAP prevention bundles", "TREATMENT", 76, 98], ["antimicrobial stewardship", "TREATMENT", 113, 138], ["infection control measures", "TREATMENT", 143, 169], ["hand hygiene", "TREATMENT", 179, 191], ["isolation guidelines", "TREATMENT", 193, 213], ["patient care equipment", "TREATMENT", 244, 266], ["instruments and devices", "TREATMENT", 268, 291], ["personnel protective equipment", "TREATMENT", 303, 333], ["lower", "OBSERVATION_MODIFIER", 29, 34], ["VAP", "OBSERVATION", 48, 51], ["infection", "OBSERVATION", 143, 152]]], ["This reduction had a significant impact on antibiotic use.DiscussionThe main limitation of our cohort is its small sample size.", [["This reduction", "TREATMENT", 0, 14], ["antibiotic use", "TREATMENT", 43, 57], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["impact", "OBSERVATION_MODIFIER", 33, 39], ["main", "OBSERVATION_MODIFIER", 72, 76], ["limitation", "OBSERVATION_MODIFIER", 77, 87], ["small", "OBSERVATION_MODIFIER", 109, 114], ["sample", "OBSERVATION_MODIFIER", 115, 121], ["size", "OBSERVATION_MODIFIER", 122, 126]]], ["As a result, it was not possible to undertake multivariate analysis adjusting for cofounders.", [["multivariate analysis", "TEST", 46, 67], ["cofounders", "PROBLEM", 82, 92]]], ["Also, there is a mismatch between the size of the group of patients with and without VAP.", [["VAP", "DISEASE", 85, 88], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["VAP", "PROBLEM", 85, 88], ["mismatch", "OBSERVATION", 17, 25], ["size", "OBSERVATION_MODIFIER", 38, 42], ["without", "UNCERTAINTY", 77, 84], ["VAP", "OBSERVATION", 85, 88]]], ["We prospectively identified patients over a 14 months period during the pre-implementation phase of a VAP prevention care bundle.", [["VAP", "DISEASE", 102, 105], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["a VAP prevention care bundle", "TREATMENT", 100, 128]]], ["However, some potentially eligible patients might have been inevitably missed in context of non-trial settings.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["non-trial settings", "TREATMENT", 92, 110]]], ["Recruitment manoeuvre, although a dynamic and important element to explore further, was attempted only in a small number of episodes.DiscussionIn summary, LU is a potential diagnostic tool in neonatal VAP.", [["VAP", "DISEASE", 201, 204], ["Recruitment manoeuvre", "TREATMENT", 0, 21], ["neonatal VAP", "PROBLEM", 192, 204], ["small", "OBSERVATION_MODIFIER", 108, 113], ["VAP", "OBSERVATION", 201, 204]]], ["Compared with CXR, we found LU to be more useful to differentiate areas of atelectasis from areas of de-recruitment or areas of pneumonia, to assess the effect of positioning and recruitment manoeuvres on large consolidations and potentially to monitor evolution of consolidations following antibiotic treatment.", [["atelectasis", "DISEASE", 75, 86], ["pneumonia", "DISEASE", 128, 137], ["CXR", "PROTEIN", 14, 17], ["CXR", "TEST", 14, 17], ["atelectasis", "PROBLEM", 75, 86], ["de-recruitment", "PROBLEM", 101, 115], ["pneumonia", "PROBLEM", 128, 137], ["recruitment manoeuvres", "TREATMENT", 179, 201], ["large consolidations", "PROBLEM", 205, 225], ["consolidations", "PROBLEM", 266, 280], ["antibiotic treatment", "TREATMENT", 291, 311], ["atelectasis", "OBSERVATION", 75, 86], ["areas", "OBSERVATION_MODIFIER", 92, 97], ["areas", "OBSERVATION_MODIFIER", 119, 124], ["pneumonia", "OBSERVATION", 128, 137], ["large", "OBSERVATION_MODIFIER", 205, 210], ["consolidations", "OBSERVATION", 211, 225], ["consolidations", "OBSERVATION", 266, 280]]], ["However, this needs to be explored further in larger studies.", [["larger studies", "TEST", 46, 60]]], ["While the proposed multiparameter VAP score, incorporating LU findings, showed promising predictive values for diagnosis of VAP in neonates with underlying CLD, it needs further testing in larger patient populations under prospective, multi-centre clinical trial settings.", [["VAP", "DISEASE", 124, 127], ["CLD", "DISEASE", 156, 159], ["neonates", "ORGANISM", 131, 139], ["patient", "ORGANISM", 196, 203], ["patient", "SPECIES", 196, 203], ["the proposed multiparameter VAP score", "TEST", 6, 43], ["VAP in neonates", "PROBLEM", 124, 139], ["underlying CLD", "PROBLEM", 145, 159], ["further testing", "TEST", 170, 185], ["VAP", "OBSERVATION", 124, 127], ["CLD", "OBSERVATION", 156, 159]]]], "b1ea896cc7cf0af2906bb82b046788695e5d0d2d": [["INTRODUCTIONThe last decade has seen rapid advances in diagnostic tools and novel therapies as a result of basic research in fi elds as diverse as genomics, drug discovery, information science, imaging, and nanotechnologies ( Mankoff et al., 2004 ; Reece, 2006 ) .", [["diagnostic tools", "TEST", 55, 71], ["novel therapies", "TREATMENT", 76, 91], ["imaging", "TEST", 194, 201], ["rapid", "OBSERVATION_MODIFIER", 37, 42]]], ["These areas of advancing knowledge are changing the practice of modern medicine.", [["modern medicine", "TREATMENT", 64, 79]]], ["However, their uptake in the health care setting is often slow and haphazard ( Graham et al., 2006 ; Kerner, 2006 ) .INTRODUCTIONIt is clear that new knowledge and clever technologies are not enough to improve patient care.", [["patient", "ORGANISM", 210, 217], ["patient", "SPECIES", 210, 217]]], ["Basic discoveries must be linked to insights surrounding the development, delivery, deployment, and application of new information or techniques in health care for translation to successfully occur.", [["delivery", "TREATMENT", 74, 82], ["deployment", "TREATMENT", 84, 94]]], ["The study of translating knowledge in health care or \"translational medicine \" has been characterized in many ways, but one defi nition is that efforts to fi nd cures for affected individuals are complemented by the pursuit to understand human diseases and their complexities ( Mankoff et al., 2004 ) .", [["human", "ORGANISM", 238, 243], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 238, 243], ["The study", "TEST", 0, 9], ["affected individuals", "PROBLEM", 171, 191]]], ["Within this idealized framework, advances in basic research are properly tested in the clinical setting, then knowledge gained is both fed back to basic researchers and effi ciently translated into new therapeutic strategies to treat, cure or prevent disease ( Marincola, 2003 ; Sonntag, 2005 ) .INTRODUCTIONHowever, gaps in translation and the provision of new knowledge in the health care setting (so-called \"translational gaps\") do occur.", [["new therapeutic strategies", "TREATMENT", 198, 224], ["disease", "PROBLEM", 251, 258]]], ["They can adversely impact the quality of medical care, decrease patient safety, and escalate costs.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["medical care", "TREATMENT", 41, 53]]], ["An example of an important topic in translational medicine is the estimated 30-45% of all patients who do not receive medical care according to the best scientifi c evidence.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["medical care", "TREATMENT", 118, 130]]], ["In fact, it has been reported that 20-25% of medical care currently provided is either unnecessary or potentially harmful ( Graham et al., 2006 ) .INTRODUCTIONEfforts to close these translational gaps have focused in large part on the perceived obstacles and challenges in translating basic research into viable diagnostic and therapeutic strategies.", [["medical care", "TREATMENT", 45, 57], ["therapeutic strategies", "TREATMENT", 327, 349]]], ["These include: communication and education between researchers from diverse fi elds, institutional support for translational research activities, regulatory hurdles, the high cost of developing diagnostics and novel therapeutics, the need for bioinformatics and complex data handling capabilities, adapting new technologies to high-throughput automation, intellectual property and licensing protection, and the willingness to move away from standard therapies and embrace new paradigms for diagnostic and therapeutic strategies ( Horig and Pullman, 2004 ; Horig et al., 2005 ; Humes, 2005 ; Marincola, 2003 ; Reece, 2006 ; Tsongalis, 2005 ) .INTRODUCTIONThere is a need to recognize the key role of technological innovation in closing translational gaps in medicine as compared to incremental improvements with current practice.", [["diverse fi elds", "TREATMENT", 68, 83], ["institutional support", "TREATMENT", 85, 106], ["novel therapeutics", "TREATMENT", 210, 228], ["licensing protection", "TREATMENT", 381, 401], ["standard therapies", "TREATMENT", 441, 459], ["current practice", "TREATMENT", 811, 827]]], ["There may be no area where this is more clearly demonstrated than in translational diagnostics, a fi eld driven by innovation ( Ratner, 2006 ) .", [["may be no", "UNCERTAINTY", 6, 15]]], ["The implementation of genomics and other innovative diagnostics for personalized medicine requires the translation of a vast array of technologies and therapeutic strategies from basic science to clinical application.", [["personalized medicine", "TREATMENT", 68, 89], ["therapeutic strategies", "TREATMENT", 151, 173], ["clinical application", "TREATMENT", 196, 216]]], ["Delivery of these diagnostics to patients requires physician and patient education, as well as evidence-based demonstration of effi cacy for healthcare uptake, payment, and regulatory approval.INTRODUCTIONHow have some of these challenges been addressed?", [["patients", "ORGANISM", 33, 41], ["patient", "ORGANISM", 65, 72], ["patients", "SPECIES", 33, 41], ["patient", "SPECIES", 65, 72], ["these diagnostics", "TEST", 12, 29]]], ["In the United States, the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) then began initiatives to identify, fi nance, and develop translational research programs.", [["Drug Administration", "TREATMENT", 79, 98], ["translational research programs", "TREATMENT", 163, 194]]], ["Roadmap initiatives sought to improve the development and availability of modern scientifi c tools and information resources, foster novel methods of research collaboration, and enhance the nation's clinical research enterprise.", [["Roadmap initiatives", "TREATMENT", 0, 19]]], ["The NIH funded the fi rst 12 Clinical and Translational Science Awards (CTSAs) in 2006 for academic centers conducting projects on translational research ( NCRR, 2006 ) ; additional centers are being named in subsequent years.INTRODUCTIONThe FDA plays a key regulatory role in medical practice and has promoted translational medicine.", [["translational medicine", "TREATMENT", 311, 333]]], ["The FDA's Critical Path Initiative, subtitled \"Stagnation to Innovation, \" identifi ed key areas for development: better evaluation tools -Biomarkers and Disease Models; streamlining clinical trials; harnessing bioinformatics; moving manufacturing into the 21st century; and products to address urgent public health needs and at-risk populations ( FDA, 2006a ) .", [["better evaluation tools", "TEST", 114, 137], ["Disease Models", "PROBLEM", 154, 168]]], ["As the role of diagnostics continues to evolve, examining translational diagnostics from the view of the largest providers of labbased tests, the national reference laboratories, will be important.", [["translational diagnostics", "TEST", 58, 83], ["labbased tests", "TEST", 126, 140]]], ["Reference labs translate everything from \"home brew \" technologies (also called laboratory-developed tests) licensed directly from academic institutions, to FDA-approved kits purchased from manufacturers, and sophisticated in vitro diagnostic multivariate index assays (IVDMIAs) used to generate patient specifi c risk data ( FDA, 2006d ) .", [["patient", "ORGANISM", 296, 303], ["patient", "SPECIES", 296, 303], ["Reference labs", "TEST", 0, 14]]], ["They provide complex data analysis of laboratory tests, educate both physicians and patients, and in this and other ways spearhead the uptake of new diagnostic technologies.INTRODUCTIONWith this in mind, this chapter will focus on translational diagnostics in the context of genomic and personalized medicine and on the practical lessons learned from bringing innovative diagnostics to market at larger reference laboratories.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["laboratory tests", "TEST", 38, 54], ["translational diagnostics", "TEST", 231, 256]]], ["The large national labs in the United States -including Quest Diagnostics, Laboratory Corporation of America Holdings, Sonic Healthcare, Genzyme, Mayo Clinic, Associated Regional University Pathology (ARUP), and others -provide about 50% of all lab testing delivered in this country and complete several million assays a day in support of patient care.", [["patient", "ORGANISM", 339, 346], ["patient", "SPECIES", 339, 346], ["all lab testing", "TEST", 241, 256], ["patient care", "TREATMENT", 339, 351], ["large", "OBSERVATION_MODIFIER", 4, 9]]], ["The potential for translational diagnostics in cancer, infectious disease, and other health care sectors will also be discussed.NOVEL DIAGNOSTICSThe goal of translational diagnostics is to provide improved diagnostic procedures leading to more effi cacious therapies and improved medical outcomes.", [["cancer", "ANATOMY", 47, 53], ["cancer", "DISEASE", 47, 53], ["infectious disease", "DISEASE", 55, 73], ["cancer", "CANCER", 47, 53], ["translational diagnostics in cancer", "PROBLEM", 18, 53], ["translational diagnostics", "TEST", 157, 182], ["diagnostic procedures", "TREATMENT", 206, 227], ["effi cacious therapies", "TREATMENT", 244, 266], ["potential for", "UNCERTAINTY", 4, 17], ["cancer", "OBSERVATION", 47, 53]]], ["Early laboratory medicine consisted primarily of the direct examination of tissue or the analysis of simple analytes in blood.", [["tissue", "ANATOMY", 75, 81], ["blood", "ANATOMY", 120, 125], ["tissue", "TISSUE", 75, 81], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["the direct examination", "TEST", 49, 71], ["the analysis", "TEST", 85, 97], ["simple analytes in blood", "PROBLEM", 101, 125]]], ["Molecular biology techniques such as positional DNA cloning, DNA sequencing and nucleic acid hybridization assays led to early molecular diagnostics.", [["nucleic acid", "CHEMICAL", 80, 92], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["positional DNA cloning", "TREATMENT", 37, 59], ["DNA sequencing", "TEST", 61, 75], ["nucleic acid hybridization assays", "TEST", 80, 113], ["early molecular diagnostics", "TEST", 121, 148]]], ["Southern blot hybridization assays were used to detect gene deletions in Duchenne muscular dystrophy, repeat expansions in fragile X syndrome, and gene rearrangements diagnostic for B-and T-cell lymphoma ( Tsongalis and Silverman, 2006 ) .", [["Duchenne muscular dystrophy", "ANATOMY", 73, 100], ["B-", "ANATOMY", 182, 184], ["T-cell lymphoma", "ANATOMY", 188, 203], ["Duchenne muscular dystrophy", "DISEASE", 73, 100], ["fragile X syndrome", "DISEASE", 123, 141], ["T-cell lymphoma", "DISEASE", 188, 203], ["B-", "CANCER", 182, 184], ["T-cell lymphoma", "CANCER", 188, 203], ["Southern blot hybridization assays", "TEST", 0, 34], ["gene deletions", "PROBLEM", 55, 69], ["Duchenne muscular dystrophy", "PROBLEM", 73, 100], ["repeat expansions", "PROBLEM", 102, 119], ["fragile X syndrome", "PROBLEM", 123, 141], ["gene rearrangements diagnostic", "TEST", 147, 177], ["B", "TEST", 182, 183], ["T-cell lymphoma", "PROBLEM", 188, 203], ["Duchenne muscular dystrophy", "OBSERVATION", 73, 100], ["fragile X syndrome", "OBSERVATION_MODIFIER", 123, 141], ["cell lymphoma", "OBSERVATION", 190, 203]]], ["The fi rst molecular diagnostic products to reach the market included tests for the detection of viral RNA or DNA, genetic tests for single gene diseases, and tests to determine risk for developing certain cancers, such as breast or colon cancer.", [["cancers", "ANATOMY", 206, 213], ["breast", "ANATOMY", 223, 229], ["colon cancer", "ANATOMY", 233, 245], ["cancers", "DISEASE", 206, 213], ["breast or colon cancer", "DISEASE", 223, 245], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["cancers", "CANCER", 206, 213], ["breast", "CANCER", 223, 229], ["colon cancer", "CANCER", 233, 245], ["viral RNA", "RNA", 97, 106], ["tests", "TEST", 70, 75], ["the detection", "TEST", 80, 93], ["viral RNA", "PROBLEM", 97, 106], ["DNA", "PROBLEM", 110, 113], ["genetic tests", "TEST", 115, 128], ["single gene diseases", "PROBLEM", 133, 153], ["tests", "TEST", 159, 164], ["developing certain cancers", "PROBLEM", 187, 213], ["breast or colon cancer", "PROBLEM", 223, 245], ["cancers", "OBSERVATION", 206, 213], ["breast", "ANATOMY", 223, 229], ["colon", "ANATOMY", 233, 238], ["cancer", "OBSERVATION", 239, 245]]], ["Many of the new diagnostic technologies entering the clinical laboratory are part of an evolution from nucleic acid amplifi cation technologies for use in amplifying, identifying, and sequencing target single gene sequences towards a systems biology approach which looks at the expression of multiple genes in response to a variety of stimuli and conditions such as infectious disease, drug therapy, and cancer ( Billings and Brown, 2004 ) .", [["cancer", "ANATOMY", 404, 410], ["nucleic acid", "CHEMICAL", 103, 115], ["infectious disease", "DISEASE", 366, 384], ["cancer", "DISEASE", 404, 410], ["cancer", "CANCER", 404, 410], ["nucleic acid amplifi cation technologies", "TREATMENT", 103, 143], ["infectious disease", "PROBLEM", 366, 384], ["drug therapy", "TREATMENT", 386, 398], ["cancer", "PROBLEM", 404, 410], ["new", "OBSERVATION_MODIFIER", 12, 15]]], ["Systems biology is often used as a synonym for functional genomics, a description of the genomic and epigenomic infl uences on a trait and interactions with environmental variants (see Chapter 6).New Diagnostic TechnologiesTo understand translational diagnostics and the gaps that currently exist in the movement of knowledge, it is necessary to understand what technological innovations and potential applications are coming forth ( Table 31 .1 ).MicroarraysMicroarray technology typically involves tethering numerous probes to a solid substrate.", [["translational diagnostics", "TEST", 237, 262], ["a solid substrate", "PROBLEM", 529, 546]]], ["For DNA microarrays, the probes usually consist of small oligonucleotides or complementary DNAs (cDNAs).", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["complementary DNAs", "DNA", 77, 95], ["cDNAs", "DNA", 97, 102], ["DNA microarrays", "TEST", 4, 19], ["the probes", "TEST", 21, 31], ["small oligonucleotides", "TREATMENT", 51, 73], ["small", "OBSERVATION_MODIFIER", 51, 56], ["oligonucleotides", "OBSERVATION", 57, 73]]], ["DNA targets, commonly in the form of fl uorescently labeled cDNA or genomic DNA fragments, are then hybridized to the probe.", [["fragments", "ANATOMY", 80, 89], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["cDNA", "CELLULAR_COMPONENT", 60, 64], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["DNA targets", "DNA", 0, 11], ["fl uorescently labeled cDNA", "DNA", 37, 64], ["genomic DNA fragments", "DNA", 68, 89], ["DNA targets", "PROBLEM", 0, 11], ["fl uorescently labeled cDNA", "PROBLEM", 37, 64], ["genomic DNA fragments", "PROBLEM", 68, 89], ["genomic", "OBSERVATION", 68, 75], ["DNA fragments", "OBSERVATION", 76, 89]]], ["Detection of a fl uorescent signal from directly labeled nucleic acid or protein samples is the most common microarray detection method ( Tefferi et al., 2002 ) .", [["nucleic acid", "CHEMICAL", 57, 69], ["nucleic acid", "SIMPLE_CHEMICAL", 57, 69], ["a fl uorescent signal", "TEST", 13, 34], ["labeled nucleic acid", "TEST", 49, 69], ["protein samples", "TEST", 73, 88]]], ["DNA microarray technology provides data on DNA sequence variation (mutations and polymorphisms) and gene expression levels (see Chapters 8, 9, and 13) .MicroarraysGene expression profi les can identify upregulated and downregulated genes, which are then targets for novel therapeutics. cDNA arrays have also been used to classify pathological subgroups of specifi c disorders.", [["specifi c disorders", "DISEASE", 356, 375], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["downregulated genes", "DNA", 218, 237], ["cDNA arrays", "DNA", 286, 297], ["DNA microarray technology", "TEST", 0, 25], ["DNA sequence variation", "TEST", 43, 65], ["mutations and polymorphisms)", "PROBLEM", 67, 95], ["gene expression levels", "TEST", 100, 122], ["MicroarraysGene expression profi les", "TREATMENT", 152, 188], ["novel therapeutics", "TREATMENT", 266, 284], ["cDNA arrays", "TEST", 286, 297], ["specifi c disorders", "PROBLEM", 356, 375], ["downregulated genes", "OBSERVATION", 218, 237]]], ["When polymorphisms are identifi ed, genomic DNA targets are probed with oligonucleotides which defi ne allelic differences.", [["DNA", "CELLULAR_COMPONENT", 44, 47], ["genomic DNA targets", "DNA", 36, 55], ["polymorphisms", "PROBLEM", 5, 18], ["genomic DNA targets", "PROBLEM", 36, 55], ["oligonucleotides", "TREATMENT", 72, 88], ["allelic differences", "OBSERVATION", 103, 122]]], ["Recent advances in microarray technology involve the use of liquid-phase or microparticle-based arrays.", [["microarray technology", "TREATMENT", 19, 40], ["liquid-phase", "TREATMENT", 60, 72], ["microparticle-based arrays", "TREATMENT", 76, 102]]], ["One example would be bead-based multiplexing, which allows multiple analytes to be assayed in the same well.", [["multiple analytes", "TREATMENT", 59, 76], ["bead", "OBSERVATION", 21, 25]]], ["Molecular diagnostic applications of microarray technology include cancer diagnosis, typing, and prognosis; infectious disease identifi cation, biodefense applications, and pharmacogenomics ( Petrik, 2006 ) .MicroarraysAnother application of array technology is array comparative genome hybridization.", [["cancer", "ANATOMY", 67, 73], ["cancer", "DISEASE", 67, 73], ["cancer", "CANCER", 67, 73], ["cation", "SIMPLE_CHEMICAL", 136, 142], ["microarray technology", "TREATMENT", 37, 58], ["array technology", "TREATMENT", 242, 258], ["cancer", "OBSERVATION", 67, 73]]], ["This is a powerful technique that detects high-level amplifi cation and homozygous deletions in small genomic regions.", [["cation", "SIMPLE_CHEMICAL", 61, 67], ["small genomic regions", "DNA", 96, 117], ["a powerful technique", "TEST", 8, 28], ["high-level amplifi cation", "TREATMENT", 42, 67], ["homozygous deletions in small genomic regions", "PROBLEM", 72, 117], ["high", "OBSERVATION_MODIFIER", 42, 46], ["homozygous deletions", "OBSERVATION", 72, 92], ["small", "OBSERVATION_MODIFIER", 96, 101], ["genomic regions", "OBSERVATION", 102, 117]]], ["Array technology has been used to detect highresolution copy number changes in breast, renal, and bladder cancer ( Gabriele et al., 2006 ; Petrik, 2006 ) .", [["breast", "ANATOMY", 79, 85], ["renal", "ANATOMY", 87, 92], ["bladder cancer", "ANATOMY", 98, 112], ["breast, renal, and bladder cancer", "DISEASE", 79, 112], ["breast", "CANCER", 79, 85], ["renal", "CANCER", 87, 92], ["bladder cancer", "CANCER", 98, 112], ["Array technology", "TEST", 0, 16], ["highresolution copy number changes in breast, renal, and bladder cancer", "PROBLEM", 41, 112], ["breast", "ANATOMY", 79, 85], ["renal", "ANATOMY", 87, 92], ["bladder", "ANATOMY", 98, 105], ["cancer", "OBSERVATION", 106, 112]]], ["Using the genomic clone sequence data, this technique can lead quickly to the identifi cation and cloning of genes associated with disease for use in diagnostics and targeted therapeutics.", [["cation", "SIMPLE_CHEMICAL", 87, 93], ["genomic clone sequence", "DNA", 10, 32], ["the genomic clone sequence data", "TEST", 6, 37], ["this technique", "TREATMENT", 39, 53], ["the identifi cation", "TREATMENT", 74, 93], ["disease", "PROBLEM", 131, 138]]], ["Array technology promises to revolutionize the fi eld of medical cytogenetics by providing molecular karyotyping without the need to culture cells or stain chromosomes for visualization (see Chapter 9).ProteomicsProteomics seeks to understand the structure, function, and expression of all proteins encoded by a given genome (see Chapter 14).", [["cells", "ANATOMY", 141, 146], ["chromosomes", "ANATOMY", 156, 167], ["cells", "CELL", 141, 146], ["chromosomes", "CELLULAR_COMPONENT", 156, 167], ["stain chromosomes", "DNA", 150, 167], ["medical cytogenetics", "TEST", 57, 77], ["molecular karyotyping", "TEST", 91, 112], ["culture cells", "TEST", 133, 146], ["stain chromosomes", "TEST", 150, 167], ["visualization", "TEST", 172, 185], ["ProteomicsProteomics", "TEST", 202, 222]]], ["The human genome project identifi ed approximately 25,000 human genes.", [["human", "ORGANISM", 4, 9], ["human", "ORGANISM", 58, 63], ["human genome", "DNA", 4, 16], ["25,000 human genes", "DNA", 51, 69], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 58, 63]]], ["However, it is estimated that the number of protein products is 10-30 times higher due to alternative splicing and post-translational modifi cation of gene products ( Petrik, 2006) .", [["protein products", "PROTEIN", 44, 60], ["gene products", "PROTEIN", 151, 164], ["alternative splicing", "TREATMENT", 90, 110], ["post-translational modifi cation of gene products", "TREATMENT", 115, 164]]], ["Proteomics also encompasses protein expression profi les as a function of age, state, and environment.", [["protein expression", "OBSERVATION", 28, 46]]], ["The basic technique of proteomics is the separation of proteins from a biological sample by various separation technologies (2-D PAGE, liquid chromatography, affi nity capture) followed by detection of proteins peptide fragments by technologies such as peptide fi ngerprinting by mass spectrometry, protein arrays, or antibody arrays ( Rice et al., 2006) .", [["sample", "ANATOMY", 82, 88], ["liquid chromatography", "TREATMENT", 135, 156], ["affi nity capture", "TREATMENT", 158, 175], ["proteins peptide fragments", "PROBLEM", 202, 228], ["peptide fi ngerprinting", "TREATMENT", 253, 276], ["mass spectrometry", "TEST", 280, 297], ["protein arrays", "TEST", 299, 313], ["antibody arrays", "TEST", 318, 333]]], ["Proteomic analysis based on mass spectrometry may be better suited for the identifi cation of useful protein biomarkers, while technologies such as automated chip technology using protein arrays may have higher clinical diagnostic utility.", [["Proteomic analysis", "TEST", 0, 18], ["mass spectrometry", "TEST", 28, 45], ["useful protein biomarkers", "TEST", 94, 119], ["protein arrays", "TREATMENT", 180, 194]]], ["Protein arrays use protein probes that in solution retain the ability to interact specifi cally with other proteins or molecules.", [["Protein arrays", "TREATMENT", 0, 14], ["protein probes", "TREATMENT", 19, 33]]], ["Protein arrays can be used to identify protein-protein interactions, enzyme-substrate interactions, and antibody-antigen interactions.GlycomicsGlycosylation is a critically important post-translational modifi cation of cellular proteins.", [["cellular", "ANATOMY", 219, 227], ["antibody-antigen", "GENE_OR_GENE_PRODUCT", 104, 120], ["cellular", "CELL", 219, 227], ["enzyme", "PROTEIN", 69, 75], ["cellular proteins", "PROTEIN", 219, 236], ["Protein arrays", "TEST", 0, 14], ["protein", "TEST", 39, 46], ["enzyme", "TEST", 69, 75], ["antibody", "TEST", 104, 112], ["GlycomicsGlycosylation", "TREATMENT", 134, 156], ["translational modifi cation", "TREATMENT", 188, 215], ["cellular proteins", "PROBLEM", 219, 236], ["cellular proteins", "OBSERVATION", 219, 236]]], ["Glycan moieties are involved in a wide variety of intracellular, cell-cell, and cell-matrix recognition events.", [["intracellular", "ANATOMY", 50, 63], ["cell", "ANATOMY", 65, 69], ["cell", "ANATOMY", 70, 74], ["cell", "ANATOMY", 80, 84], ["matrix", "ANATOMY", 85, 91], ["Glycan", "CHEMICAL", 0, 6], ["Glycan", "SIMPLE_CHEMICAL", 0, 6], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["cell", "CELL", 65, 69], ["cell", "CELL", 70, 74], ["cell", "CELL", 80, 84], ["matrix", "CELLULAR_COMPONENT", 85, 91], ["Glycan moieties", "PROBLEM", 0, 15]]], ["Glycomics is the study of the glycans produced by humans and their role in protein function in health and disease (Morrelle and Michalski, 2005 ) .", [["humans", "ORGANISM", 50, 56], ["humans", "SPECIES", 50, 56], ["humans", "SPECIES", 50, 56], ["the study", "TEST", 13, 22]]], ["Early technologies used separation methodologies and mass spectrometry analyses that were similar to proteomic methods.", [["separation methodologies", "TREATMENT", 24, 48], ["mass spectrometry analyses", "TEST", 53, 79]]], ["New approaches are being developed for clinical applications and include such technologies as microcapillary chromatography, lectin affi nity chromatography, and carbohydrate microarray and mass spectrometry ( Miyamoto, 2006) .", [["carbohydrate", "CHEMICAL", 162, 174], ["lectin", "PROTEIN", 125, 131], ["such technologies", "TEST", 73, 90], ["microcapillary chromatography", "TEST", 94, 123], ["lectin affi nity chromatography", "TEST", 125, 156], ["carbohydrate microarray", "TEST", 162, 185], ["mass spectrometry", "TEST", 190, 207]]], ["Glycan analysis has contributed to drug discovery, clinical assays, and basic research into the underlying biology of cancer.", [["cancer", "ANATOMY", 118, 124], ["cancer", "DISEASE", 118, 124], ["cancer", "CANCER", 118, 124], ["Glycan analysis", "TEST", 0, 15], ["clinical assays", "TEST", 51, 66], ["cancer", "PROBLEM", 118, 124], ["cancer", "OBSERVATION", 118, 124]]], ["However, its greatest promise will be to enhance genomic and proteomic analysis of clinical samples to determine the effects of the genetic, environmental, lifestyle, and nutritional state of patients on their health status.EpigeneticsEpigenetics involves the study of heritable changes in gene function that occur without a change in DNA sequence (see Chapter 1).", [["samples", "ANATOMY", 92, 99], ["samples", "CANCER", 92, 99], ["patients", "ORGANISM", 192, 200], ["DNA", "CELLULAR_COMPONENT", 335, 338], ["DNA sequence", "DNA", 335, 347], ["patients", "SPECIES", 192, 200], ["proteomic analysis", "TEST", 61, 79], ["clinical samples", "TEST", 83, 99], ["the study", "TEST", 256, 265], ["heritable changes in gene function", "PROBLEM", 269, 303], ["a change in DNA sequence", "PROBLEM", 323, 347]]], ["Epigenetic mechanisms include DNA methylation, histone acetylation, and RNA interference (see Chapters 5 and 11).", [["DNA", "CELLULAR_COMPONENT", 30, 33], ["histone", "GENE_OR_GENE_PRODUCT", 47, 54], ["histone", "PROTEIN", 47, 54], ["Epigenetic mechanisms", "PROBLEM", 0, 21], ["DNA methylation", "PROBLEM", 30, 45], ["histone acetylation", "TREATMENT", 47, 66], ["RNA interference", "PROBLEM", 72, 88]]], ["Some neuropsychiatric and rheumatologic diseases and cancers may affect both the genotype and epigenotype.", [["cancers", "ANATOMY", 53, 60], ["neuropsychiatric and rheumatologic diseases", "DISEASE", 5, 48], ["cancers", "DISEASE", 53, 60], ["cancers", "CANCER", 53, 60], ["Some neuropsychiatric and rheumatologic diseases", "PROBLEM", 0, 48], ["cancers", "PROBLEM", 53, 60], ["neuropsychiatric", "OBSERVATION_MODIFIER", 5, 21], ["rheumatologic diseases", "OBSERVATION", 26, 48], ["cancers", "OBSERVATION", 53, 60]]], ["Small interfering RNAs (siRNAs) can induce specifi c post-transcriptional gene silencing in mammalian systems and hold great promise as therapeutic agents.", [["Small interfering RNAs", "GENE_OR_GENE_PRODUCT", 0, 22], ["specifi c", "GENE_OR_GENE_PRODUCT", 43, 52], ["Small interfering RNAs", "RNA", 0, 22], ["siRNAs", "RNA", 24, 30], ["Small interfering RNAs (siRNAs)", "PROBLEM", 0, 31], ["therapeutic agents", "TREATMENT", 136, 154], ["interfering RNAs", "OBSERVATION", 6, 22]]], ["Diagnostic assays will have to be developed to analyze the effectiveness of these new therapies.", [["Diagnostic assays", "TEST", 0, 17], ["these new therapies", "TREATMENT", 76, 95]]], ["Cancer cells are known to undergo changes in 5-methylcytosine distribution including hypomethylation and hypermethylation of promoter CpG islands, which are associated with tumor-suppressor genes (Esteller, 2002 ) .", [["Cancer cells", "ANATOMY", 0, 12], ["tumor", "ANATOMY", 173, 178], ["Cancer", "DISEASE", 0, 6], ["5-methylcytosine", "CHEMICAL", 45, 61], ["tumor", "DISEASE", 173, 178], ["5-methylcytosine", "CHEMICAL", 45, 61], ["Cancer cells", "CELL", 0, 12], ["5-methylcytosine", "SIMPLE_CHEMICAL", 45, 61], ["tumor", "CANCER", 173, 178], ["Cancer cells", "CELL_TYPE", 0, 12], ["promoter CpG islands", "DNA", 125, 145], ["tumor-suppressor genes", "DNA", 173, 195], ["Cancer cells", "PROBLEM", 0, 12], ["hypomethylation and hypermethylation of promoter CpG islands", "PROBLEM", 85, 145], ["tumor-suppressor genes", "PROBLEM", 173, 195], ["promoter CpG islands", "OBSERVATION", 125, 145], ["tumor", "OBSERVATION", 173, 178], ["suppressor genes", "OBSERVATION", 179, 195]]], ["An integrated analysis of the epigenetic state of cancer cells can involve DNA methylation, transcription factor binding analysis, and histone acetylation analysis.", [["cancer cells", "ANATOMY", 50, 62], ["cancer", "DISEASE", 50, 56], ["cancer cells", "CELL", 50, 62], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["histone", "GENE_OR_GENE_PRODUCT", 135, 142], ["cancer cells", "CELL_TYPE", 50, 62], ["transcription factor", "PROTEIN", 92, 112], ["histone", "PROTEIN", 135, 142], ["An integrated analysis", "TEST", 0, 22], ["cancer cells", "PROBLEM", 50, 62], ["DNA methylation", "TREATMENT", 75, 90], ["transcription factor binding analysis", "TEST", 92, 129], ["histone acetylation analysis", "TEST", 135, 163], ["cancer cells", "OBSERVATION", 50, 62]]], ["Treatments being evaluated include histone deacetylase inhibitors and DNA methyltransferase inhibitors.", [["histone deacetylase", "GENE_OR_GENE_PRODUCT", 35, 54], ["DNA methyltransferase", "GENE_OR_GENE_PRODUCT", 70, 91], ["histone deacetylase", "PROTEIN", 35, 54], ["DNA methyltransferase", "PROTEIN", 70, 91], ["Treatments", "TREATMENT", 0, 10], ["histone deacetylase inhibitors", "TREATMENT", 35, 65], ["DNA methyltransferase inhibitors", "TREATMENT", 70, 102]]], ["DNA methylation patterns are being developed as diagnostic biomarkers for detection and risk assessment ( Laird, 2005 ) (see Chapter 11).Biological ImagingBiological imaging has begun to play an increasingly important role in the early detection and staging of disease (see Chapter 43).", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA methylation patterns", "PROBLEM", 0, 24], ["diagnostic biomarkers", "TEST", 48, 69], ["risk assessment", "TEST", 88, 103], ["Biological Imaging", "TEST", 137, 155], ["Biological imaging", "TEST", 155, 173], ["disease", "PROBLEM", 261, 268]]], ["Recent advances in imaging include multislice computer tomography (CT) and whole-body magnetic resonance imaging (MRI) to provide earlier detection and more accurate determination of the extent of disease ( Schwaiger and Peschel, 2006 ) .", [["imaging", "TEST", 19, 26], ["multislice computer tomography", "TEST", 35, 65], ["CT", "TEST", 67, 69], ["whole-body magnetic resonance imaging", "TEST", 75, 112], ["MRI", "TEST", 114, 117], ["earlier detection", "TEST", 130, 147], ["disease", "PROBLEM", 197, 204], ["disease", "OBSERVATION", 197, 204]]], ["Tracer techniques in combination with positron emission tomography (PET) have aided in discriminating between normal and tumor tissues.", [["tumor tissues", "ANATOMY", 121, 134], ["tumor", "DISEASE", 121, 126], ["tumor tissues", "TISSUE", 121, 134], ["Tracer techniques", "TREATMENT", 0, 17], ["positron emission tomography", "TEST", 38, 66], ["normal", "OBSERVATION", 110, 116], ["tumor tissues", "OBSERVATION", 121, 134]]], ["Such molecular imaging technologies seek to visualize biological processes and molecular binding sites.", [["molecular binding sites", "PROTEIN", 79, 102], ["Such molecular imaging technologies", "TEST", 0, 35], ["molecular binding sites", "PROBLEM", 79, 102], ["binding sites", "OBSERVATION", 89, 102]]], ["New advances such as PET-CT provide qualitative and quantitative assessment of tumor tissue.", [["tumor tissue", "ANATOMY", 79, 91], ["tumor", "DISEASE", 79, 84], ["tumor tissue", "TISSUE", 79, 91], ["PET-CT", "TEST", 21, 27], ["quantitative assessment", "TEST", 52, 75], ["tumor tissue", "PROBLEM", 79, 91], ["tumor tissue", "OBSERVATION", 79, 91]]], ["Taken together with other molecular diagnostic methods, biological imaging should aid in disease detection, be predictive of therapeutic effi cacy, and provide markers for disease treatments.NanotechnologyThe near future of nanobiosensing envisions a merger of molecular diagnostic technology with nanotechnology to produce nanobiosensors capable of detecting biological processes at the molecular level with continuous operation in real time ( see Chapter 51 and Demidov, 2004 ) .", [["biological imaging", "TEST", 56, 74], ["disease detection", "TEST", 89, 106], ["therapeutic effi cacy", "TREATMENT", 125, 146], ["disease treatments", "TREATMENT", 172, 190], ["continuous operation", "TREATMENT", 409, 429]]], ["Molecular beacons comprised of both nucleic acid probes and self-reporting optical transducers should be capable of providing feedback for monitoring therapeutic intervention or for periodic checkup.", [["nucleic acid", "CHEMICAL", 36, 48], ["Molecular beacons", "PROBLEM", 0, 17], ["both nucleic acid probes", "PROBLEM", 31, 55], ["optical transducers", "TREATMENT", 75, 94], ["therapeutic intervention", "TREATMENT", 150, 174], ["periodic checkup", "TEST", 182, 198]]], ["Nanoparticlebased molecular detection is being used currently to develop multiplexed molecular recognition arrays and label free ways to quantify specifi c binding events ( Ming- Cheng Cheng et al., 2006) .", [["specifi c", "GENE_OR_GENE_PRODUCT", 146, 155], ["Nanoparticlebased molecular detection", "TREATMENT", 0, 37]]], ["Quantum dot nanocrystals provides a nearly unlimited range of sharply defi ned color indicators that can be tagged to biomolecules of interest and provide long-lived, sensitive probes.", [["Quantum dot nanocrystals", "TREATMENT", 0, 24]]], ["Nanodevices using microfl uidic technologies may produce useful cancer, infectious diseases and other tests.", [["cancer", "ANATOMY", 64, 70], ["cancer", "DISEASE", 64, 70], ["infectious diseases", "DISEASE", 72, 91], ["cancer", "CANCER", 64, 70], ["Nanodevices", "TREATMENT", 0, 11], ["microfl uidic technologies", "TREATMENT", 18, 44], ["useful cancer", "PROBLEM", 57, 70], ["infectious diseases", "PROBLEM", 72, 91], ["other tests", "TEST", 96, 107], ["cancer", "OBSERVATION", 64, 70]]], ["These technologies will aid the continuing miniaturization of molecular diagnostic platforms; a necessary evolution if molecular diagnostics are to be expanded to point of care use and for system biology approaches that require the simultaneous detection of specifi c biological processes associated with disease.Infectious DiseaseFactors affecting disease progression and therapy management in infectious disease associated with viral, bacterial, fungal, and parasitic pathogens include rapid detection and identifi cation, quantifying pathogen burden, and pathogen genotyping ( NIH, 2002 ) .Infectious DiseaseAs with the Human Immunodefi ciency Virus (HIV), quantifying the viral load of a wide variety of viral pathogens is needed to monitor both the progression of the disease and the response to therapy.", [["infectious disease", "DISEASE", 395, 413], ["viral, bacterial, fungal, and parasitic pathogens", "DISEASE", 430, 479], ["Infectious DiseaseAs", "DISEASE", 593, 613], ["Immunodefi ciency Virus", "DISEASE", 629, 652], ["cation", "SIMPLE_CHEMICAL", 517, 523], ["Human", "ORGANISM", 623, 628], ["Immunodefi ciency Virus", "ORGANISM", 629, 652], ["HIV", "ORGANISM", 654, 657], ["Human", "SPECIES", 623, 628], ["Human Immunodefi ciency Virus", "SPECIES", 623, 652], ["HIV", "SPECIES", 654, 657], ["the simultaneous detection", "TEST", 228, 254], ["specifi c biological processes", "PROBLEM", 258, 288], ["disease", "PROBLEM", 305, 312], ["Infectious DiseaseFactors", "PROBLEM", 313, 338], ["disease progression", "PROBLEM", 349, 368], ["therapy management", "TREATMENT", 373, 391], ["infectious disease", "PROBLEM", 395, 413], ["viral, bacterial, fungal, and parasitic pathogens", "PROBLEM", 430, 479], ["rapid detection", "TEST", 488, 503], ["identifi cation", "PROBLEM", 508, 523], ["quantifying pathogen burden", "PROBLEM", 525, 552], ["pathogen genotyping", "TEST", 558, 577], ["the Human Immunodefi ciency Virus", "PROBLEM", 619, 652], ["HIV", "PROBLEM", 654, 657], ["the viral load", "PROBLEM", 672, 686], ["viral pathogens", "PROBLEM", 708, 723], ["the disease", "PROBLEM", 769, 780], ["therapy", "TREATMENT", 801, 808], ["viral load", "OBSERVATION", 676, 686], ["viral pathogens", "OBSERVATION", 708, 723], ["disease", "OBSERVATION", 773, 780]]], ["Pathogen genotyping is also essential in order to identify variants resistant to therapy, and to differentiate closely-related species or viral types.", [["Pathogen genotyping", "TEST", 0, 19], ["therapy", "TREATMENT", 81, 88], ["viral types", "PROBLEM", 138, 149], ["viral types", "OBSERVATION", 138, 149]]], ["Currently, the gold standard for pathogen detection is growth of the pathogen in culture.", [["pathogen detection", "TEST", 33, 51], ["the pathogen in culture", "PROBLEM", 65, 88]]], ["Diagnostic methods for viral detection consist primarily of immunological identifi cation of antibodies produced in response to viral infection.", [["viral infection", "DISEASE", 128, 143], ["antibodies", "PROTEIN", 93, 103], ["Diagnostic methods", "TEST", 0, 18], ["viral detection", "TEST", 23, 38], ["immunological identifi cation of antibodies", "TREATMENT", 60, 103], ["viral infection", "PROBLEM", 128, 143], ["viral infection", "OBSERVATION", 128, 143]]], ["Molecular diagnostics utilizing nucleic acid amplifi cation testing (NAAT) have been used for viral load monitoring and genotyping for HIV and screening for HIV1, hepatitis B and C (HBV, HCV), and West Nile virus (WNV) ( Paxton, 2004 ) .", [["nucleic acid", "CHEMICAL", 32, 44], ["hepatitis B", "DISEASE", 163, 174], ["HBV, HCV)", "DISEASE", 182, 191], ["HIV1", "ORGANISM", 157, 161], ["hepatitis B and C", "ORGANISM", 163, 180], ["HBV, HCV", "ORGANISM", 182, 190], ["West Nile virus", "ORGANISM", 197, 212], ["WNV", "ORGANISM", 214, 217], ["HIV", "SPECIES", 135, 138], ["West Nile virus", "SPECIES", 197, 212], ["HIV", "SPECIES", 135, 138], ["HIV1", "SPECIES", 157, 161], ["hepatitis B", "SPECIES", 163, 174], ["HBV", "SPECIES", 182, 185], ["HCV", "SPECIES", 187, 190], ["West Nile virus", "SPECIES", 197, 212], ["WNV", "SPECIES", 214, 217], ["Molecular diagnostics", "TEST", 0, 21], ["nucleic acid amplifi cation testing (NAAT)", "TREATMENT", 32, 74], ["viral load monitoring", "TEST", 94, 115], ["genotyping", "TEST", 120, 130], ["HIV", "PROBLEM", 135, 138], ["screening", "TEST", 143, 152], ["HIV1", "PROBLEM", 157, 161], ["hepatitis B and C", "PROBLEM", 163, 180], ["HBV", "PROBLEM", 182, 185], ["HCV", "PROBLEM", 187, 190], ["West Nile virus", "PROBLEM", 197, 212]]], ["In HIV and HCV there is a window between infection and detection of antibody production in which immunological methods fail to detect viral infection.", [["HIV and HCV", "DISEASE", 3, 14], ["infection", "DISEASE", 41, 50], ["viral infection", "DISEASE", 134, 149], ["HIV", "ORGANISM", 3, 6], ["HCV", "ORGANISM", 11, 14], ["HIV", "SPECIES", 3, 6], ["HIV", "SPECIES", 3, 6], ["HCV", "SPECIES", 11, 14], ["HIV", "PROBLEM", 3, 6], ["HCV", "PROBLEM", 11, 14], ["infection", "PROBLEM", 41, 50], ["antibody production", "PROBLEM", 68, 87], ["immunological methods", "TEST", 97, 118], ["viral infection", "PROBLEM", 134, 149], ["HCV", "OBSERVATION", 11, 14], ["infection", "OBSERVATION", 41, 50], ["viral", "OBSERVATION_MODIFIER", 134, 139], ["infection", "OBSERVATION", 140, 149]]], ["This is a very important issue for blood safety and for the identifi cation of acute infections which may account for a high percentage of new clinical cases.", [["blood", "ANATOMY", 35, 40], ["infections", "DISEASE", 85, 95], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["blood safety", "TREATMENT", 35, 47], ["acute infections", "PROBLEM", 79, 95], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["infections", "OBSERVATION", 85, 95], ["may account for", "UNCERTAINTY", 102, 117]]], ["NAAT testing has been implemented for blood screening and has been estimated to prevent about fi ve HIV-1 and 56 HCV infections per year.", [["blood", "ANATOMY", 38, 43], ["NAAT", "CHEMICAL", 0, 4], ["HCV infections", "DISEASE", 113, 127], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["HIV-1", "ORGANISM", 100, 105], ["HCV", "ORGANISM", 113, 116], ["NAAT", "PROTEIN", 0, 4], ["HIV-1", "SPECIES", 100, 105], ["HIV-1", "SPECIES", 100, 105], ["HCV", "SPECIES", 113, 116], ["NAAT testing", "TEST", 0, 12], ["blood screening", "TEST", 38, 53], ["HCV infections", "PROBLEM", 113, 127]]], ["Another advantage of NAAT testing lies with the fl exibility of the platform in the face of emerging infectious disease threats.", [["NAAT", "SIMPLE_CHEMICAL", 21, 25], ["NAAT testing", "TEST", 21, 33], ["emerging infectious disease threats", "PROBLEM", 92, 127], ["infectious", "OBSERVATION", 101, 111]]], ["When WNV became a public health concern in 2002, these platforms were converted for the detection and monitoring of WNV within 9 months.", [["WNV", "DISEASE", 5, 8], ["WNV", "DISEASE", 116, 119], ["WNV", "ORGANISM", 5, 8], ["WNV", "ORGANISM", 116, 119], ["WNV", "SPECIES", 5, 8], ["WNV", "SPECIES", 116, 119], ["the detection", "TEST", 84, 97], ["monitoring of WNV", "TEST", 102, 119]]], ["With the incorporation of DNA microarray technologies, rapid pathogen detection and genotyping may be accomplished simultaneously.", [["DNA", "CELLULAR_COMPONENT", 26, 29], ["DNA microarray technologies", "TREATMENT", 26, 53], ["rapid pathogen detection", "TEST", 55, 79], ["genotyping", "TEST", 84, 94]]], ["Recently, a protein microarray for Coronaviruses, including the severe acute respiratory syndrome (SARS) virus, has been tested and found to distinguish between SARS and other Corona viruses ( Zhu et al., 2006 ) .", [["acute respiratory syndrome (SARS) virus", "DISEASE", 71, 110], ["SARS", "DISEASE", 161, 165], ["Corona viruses", "ORGANISM", 176, 190], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 64, 110], ["a protein microarray", "TEST", 10, 30], ["Coronaviruses", "PROBLEM", 35, 48], ["the severe acute respiratory syndrome", "PROBLEM", 60, 97], ["SARS) virus", "PROBLEM", 99, 110], ["SARS", "PROBLEM", 161, 165], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory syndrome", "OBSERVATION", 77, 97], ["Corona viruses", "ANATOMY", 176, 190]]], ["Low-density microarray tests are being researched for use in subtyping infl uenza A and avian type H5N1.", [["avian type H5N1", "DISEASE", 88, 103], ["infl uenza A", "CANCER", 71, 83], ["avian type H5N1", "ORGANISM", 88, 103], ["avian type H5N1", "SPECIES", 88, 103], ["infl uenza A", "SPECIES", 71, 83], ["Low-density microarray tests", "PROBLEM", 0, 28], ["-density", "OBSERVATION_MODIFIER", 3, 11]]], ["These types of arrays may soon have clinical utility for monitoring infl uenza worldwide, developing vaccines, and eventually for point of care applications ( Mehlmann et al., 2007 ) .", [["developing vaccines", "TREATMENT", 90, 109]]], ["This last application is very important, as determining the presence of infl uenza on solely clinical grounds is very diffi cult due to poor specifi city and sensitivity of clinical fi ndings, the other pathogens that cause similar symptoms, and the infl uenza subtypes that cause different symptoms.", [["infl uenza", "ORGANISM", 72, 82], ["very diffi cult", "PROBLEM", 113, 128], ["poor specifi city", "PROBLEM", 136, 153], ["clinical fi ndings", "PROBLEM", 173, 191], ["the other pathogens", "PROBLEM", 193, 212], ["similar symptoms", "PROBLEM", 224, 240], ["the infl uenza subtypes", "PROBLEM", 246, 269], ["different symptoms", "PROBLEM", 281, 299]]], ["For example, up to 70% of patients with infl uenza symptoms are not infected with infl uenza virus, and up to 30% of those are due to Coronaviruses (Montalto, 2003 ; Brown, 2006 ) .", [["patients", "ORGANISM", 26, 34], ["infl uenza", "ORGANISM", 40, 50], ["infl uenza virus", "ORGANISM", 82, 98], ["patients", "SPECIES", 26, 34], ["infl uenza virus", "SPECIES", 82, 98], ["infl uenza symptoms", "PROBLEM", 40, 59], ["infl uenza virus", "PROBLEM", 82, 98], ["Coronaviruses", "PROBLEM", 134, 147], ["not", "UNCERTAINTY", 64, 67], ["infected", "OBSERVATION", 68, 76], ["Coronaviruses", "OBSERVATION", 134, 147]]], ["CombiMatrix has developed a DNA microarray to detect and type infl uenza strains and Tm Bioscience Corp. (now Luminex) has developed a major human respiratory virus array.", [["CombiMatrix", "CHEMICAL", 0, 11], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["human", "ORGANISM", 141, 146], ["human", "SPECIES", 141, 146], ["human respiratory virus", "SPECIES", 141, 164], ["a DNA microarray", "TEST", 26, 42], ["type infl uenza strains", "PROBLEM", 57, 80], ["a major human respiratory virus array", "PROBLEM", 133, 170], ["respiratory virus", "OBSERVATION", 147, 164]]], ["Molecular diagnostics can be utilized for sexually transmitted diseases such as Chlamydia trachomitis and Nisseria gonorrhea, as well as other bacterial pathogens such as Legionella pneumophilia (Legionnaire's disease), Borrelia burgdoreri (Lyme disease), Mycobacterium tuberculosis, and Bordetella pertussis and B. parapertussis (whooping cough).", [["sexually transmitted diseases", "DISEASE", 42, 71], ["Chlamydia trachomitis", "DISEASE", 80, 101], ["Nisseria gonorrhea", "DISEASE", 106, 124], ["Legionella pneumophilia", "DISEASE", 171, 194], ["Legionnaire's disease", "DISEASE", 196, 217], ["Borrelia burgdoreri", "DISEASE", 220, 239], ["Lyme disease", "DISEASE", 241, 253], ["Mycobacterium tuberculosis", "DISEASE", 256, 282], ["Bordetella pertussis", "DISEASE", 288, 308], ["B. parapertussis", "DISEASE", 313, 329], ["whooping cough", "DISEASE", 331, 345], ["Chlamydia trachomitis", "ORGANISM", 80, 101], ["Nisseria gonorrhea", "ORGANISM", 106, 124], ["Legionella pneumophilia", "ORGANISM", 171, 194], ["Legionnaire's disease", "ORGANISM", 196, 217], ["Borrelia burgdoreri", "ORGANISM", 220, 239], ["Lyme disease", "ORGANISM", 241, 253], ["Mycobacterium tuberculosis", "ORGANISM", 256, 282], ["Bordetella pertussis", "ORGANISM", 288, 308], ["B. parapertussis", "ORGANISM", 313, 329], ["Chlamydia trachomitis", "SPECIES", 80, 101], ["Legionella pneumophilia", "SPECIES", 171, 194], ["Borrelia burgdoreri", "SPECIES", 220, 239], ["Mycobacterium tuberculosis", "SPECIES", 256, 282], ["Bordetella pertussis", "SPECIES", 288, 308], ["B. parapertussis", "SPECIES", 313, 329], ["Chlamydia trachomitis", "SPECIES", 80, 101], ["Legionella pneumophilia", "SPECIES", 171, 194], ["Borrelia burgdoreri", "SPECIES", 220, 239], ["Mycobacterium tuberculosis", "SPECIES", 256, 282], ["Bordetella pertussis", "SPECIES", 288, 308], ["B. parapertussis", "SPECIES", 313, 329], ["Molecular diagnostics", "TEST", 0, 21], ["sexually transmitted diseases", "PROBLEM", 42, 71], ["Chlamydia trachomitis", "PROBLEM", 80, 101], ["Nisseria gonorrhea", "PROBLEM", 106, 124], ["other bacterial pathogens", "PROBLEM", 137, 162], ["Legionella pneumophilia", "PROBLEM", 171, 194], ["Legionnaire's disease)", "PROBLEM", 196, 218], ["Borrelia burgdoreri (Lyme disease)", "PROBLEM", 220, 254], ["Mycobacterium tuberculosis", "PROBLEM", 256, 282], ["Bordetella pertussis", "PROBLEM", 288, 308], ["B. parapertussis (whooping cough", "PROBLEM", 313, 345], ["Mycobacterium tuberculosis", "OBSERVATION", 256, 282]]], ["Despite effective vaccination programs, Bordetella pertussis remains an important and highly contagious disease due to the fact that newborns do not appear to gain passive maternal protection and vaccine-induced immunity is far less complete than expected.", [["Bordetella pertussis", "DISEASE", 40, 60], ["Bordetella pertussis", "ORGANISM", 40, 60], ["newborns", "ORGANISM", 133, 141], ["Bordetella pertussis", "SPECIES", 40, 60], ["Bordetella pertussis", "SPECIES", 40, 60], ["effective vaccination programs", "TREATMENT", 8, 38], ["Bordetella pertussis", "PROBLEM", 40, 60], ["highly contagious disease", "PROBLEM", 86, 111], ["passive maternal protection", "TREATMENT", 164, 191], ["vaccine", "TREATMENT", 196, 203]]], ["A real-time PCR assay that accurately detects and differentiates the DNA from both agents of pertussis syndromes has been developed ( Vincart et al., 2007) .", [["pertussis syndromes", "DISEASE", 93, 112], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["A real-time PCR assay", "TEST", 0, 21], ["the DNA", "PROBLEM", 65, 72], ["pertussis syndromes", "PROBLEM", 93, 112], ["pertussis syndromes", "OBSERVATION", 93, 112]]], ["This real-time PCR assay provides results within 24 h of sample receipt and provides clinicians with more timely and accurate information than that provided by culture, direct fl uorescence antibody, serological testing, or even conventional PCR methods.", [["sample", "ANATOMY", 57, 63], ["PCR assay", "TEST", 15, 24], ["culture", "TEST", 160, 167], ["direct fl uorescence antibody", "TEST", 169, 198], ["serological testing", "TEST", 200, 219]]], ["Additional applications include tissue product testing, bioterrorism monitoring, and characterization of host-pathogen interactions in the search for additional diagnostic biomarkers.OncologyStandard diagnostic procedures for human tumors use a combination of histopathology, special stains, immunohistology, radiology, and clinical data.", [["tissue", "ANATOMY", 32, 38], ["tumors", "ANATOMY", 232, 238], ["tumors", "DISEASE", 232, 238], ["tissue", "TISSUE", 32, 38], ["human", "ORGANISM", 226, 231], ["tumors", "CANCER", 232, 238], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["tissue product testing", "TEST", 32, 54], ["bioterrorism monitoring", "TEST", 56, 79], ["additional diagnostic biomarkers", "TEST", 150, 182], ["human tumors", "PROBLEM", 226, 238], ["special stains", "TEST", 276, 290], ["clinical data", "TEST", 324, 337], ["tumors", "OBSERVATION", 232, 238]]], ["Diagnostics derived in this manner provide data on tissue origin, tumor type, stage, and grade, along with information on completeness of surgical tumor removal ( Dietel and Sers, 2006 ) .", [["tissue", "ANATOMY", 51, 57], ["tumor", "ANATOMY", 66, 71], ["tumor", "ANATOMY", 147, 152], ["tumor", "DISEASE", 66, 71], ["tumor", "DISEASE", 147, 152], ["tissue", "TISSUE", 51, 57], ["tumor", "CANCER", 66, 71], ["tumor", "CANCER", 147, 152], ["tumor type, stage", "PROBLEM", 66, 83], ["surgical tumor removal", "TREATMENT", 138, 160], ["tumor", "OBSERVATION", 66, 71], ["surgical tumor", "OBSERVATION", 138, 152]]], ["However, these tests are neither sensitive nor specifi c enough to differentiate patients who will respond to treatment from those who will not.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["these tests", "TEST", 9, 20], ["treatment", "TREATMENT", 110, 119]]], ["The application of high-throughput DNA array technologies, which provide gene expression profi les, has revolutionized tumor diagnostics and led to the identifi cation of novel tumor subgroups for otherwise indistinguishable tumors ( Dietel and Sers, 2006 ) .", [["tumor", "ANATOMY", 119, 124], ["tumor", "ANATOMY", 177, 182], ["tumors", "ANATOMY", 225, 231], ["tumor", "DISEASE", 119, 124], ["tumor", "DISEASE", 177, 182], ["tumors", "DISEASE", 225, 231], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["tumor", "CANCER", 119, 124], ["tumor", "CANCER", 177, 182], ["tumors", "CANCER", 225, 231], ["high-throughput DNA array technologies", "TREATMENT", 19, 57], ["revolutionized tumor diagnostics", "TEST", 104, 136], ["the identifi cation", "TREATMENT", 148, 167], ["novel tumor subgroups", "PROBLEM", 171, 192], ["otherwise indistinguishable tumors", "PROBLEM", 197, 231], ["high", "OBSERVATION_MODIFIER", 19, 23], ["tumor", "OBSERVATION", 177, 182], ["tumors", "OBSERVATION", 225, 231]]], ["Researchers have also identifi ed genes the expression of which can be used to predict the metastatic potential of breast carcinomas.", [["breast carcinomas", "ANATOMY", 115, 132], ["breast carcinomas", "DISEASE", 115, 132], ["breast carcinomas", "CANCER", 115, 132], ["breast carcinomas", "PROBLEM", 115, 132], ["metastatic", "OBSERVATION_MODIFIER", 91, 101], ["breast", "ANATOMY", 115, 121], ["carcinomas", "OBSERVATION", 122, 132]]], ["In the future, technologies that take a systems approach will be needed to identify patients who will benefi t from novel therapies.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["a systems approach", "TREATMENT", 38, 56], ["novel therapies", "TREATMENT", 116, 131]]], ["These methods must be capable of detecting multiple oncogenic pathways in tumors both before and during therapy and they must be adaptable to routine clinical diagnostic testing.", [["tumors", "ANATOMY", 74, 80], ["tumors", "DISEASE", 74, 80], ["tumors", "CANCER", 74, 80], ["multiple oncogenic pathways in tumors", "PROBLEM", 43, 80], ["therapy", "TREATMENT", 104, 111], ["routine clinical diagnostic testing", "TEST", 142, 177], ["tumors", "OBSERVATION", 74, 80]]], ["Possible methods include: tissue microarrays; forward-phase protein microarrays, capable of simultaneously detecting multiple protein interactions with a single sample; and reverse-phase protein microarrays, capable of probing multiple analytes with specifi c antibodies ( Gulmann et al., 2006 ) .", [["tissue", "ANATOMY", 26, 32], ["sample", "ANATOMY", 161, 167], ["tissue", "TISSUE", 26, 32], ["specifi c antibodies", "GENE_OR_GENE_PRODUCT", 250, 270], ["specifi c antibodies", "PROTEIN", 250, 270], ["tissue microarrays", "TEST", 26, 44], ["forward-phase protein microarrays", "TEST", 46, 79], ["multiple protein interactions", "PROBLEM", 117, 146], ["a single sample", "TEST", 152, 167], ["reverse-phase protein microarrays", "TREATMENT", 173, 206], ["multiple analytes", "TEST", 227, 244], ["specifi c antibodies", "TREATMENT", 250, 270]]], ["These testing modalities may be applied to primary or metastatic tumor biopsies, or to 'blood biopsies' of rare circulating tumor cells.PharmacogenomicsUnderstanding the role of human genetic variation in disease susceptibility and in the selection and effi cacy of therapeutics is an essential component of optimizing care.", [["primary", "ANATOMY", 43, 50], ["metastatic tumor biopsies", "ANATOMY", 54, 79], ["blood", "ANATOMY", 88, 93], ["tumor cells", "ANATOMY", 124, 135], ["tumor", "DISEASE", 65, 70], ["tumor", "DISEASE", 124, 129], ["tumor biopsies", "CANCER", 65, 79], ["blood biopsies", "MULTI-TISSUE_STRUCTURE", 88, 102], ["circulating tumor cells", "CELL", 112, 135], ["human", "ORGANISM", 178, 183], ["circulating tumor cells", "CELL_TYPE", 112, 135], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["These testing modalities", "TEST", 0, 24], ["metastatic tumor biopsies", "TEST", 54, 79], ["'blood biopsies", "TEST", 87, 102], ["rare circulating tumor cells", "PROBLEM", 107, 135], ["disease susceptibility", "PROBLEM", 205, 227], ["metastatic", "OBSERVATION_MODIFIER", 54, 64], ["tumor", "OBSERVATION", 65, 70], ["rare", "OBSERVATION_MODIFIER", 107, 111], ["circulating", "OBSERVATION_MODIFIER", 112, 123], ["tumor cells", "OBSERVATION", 124, 135]]], ["Pharmacogenomics looks at the impact of patient genetic variation on response to therapeutics (see Chapter 27).", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["Sensitivity, toxicity, and resistance to medications at standard doses are prime examples of the effect of genotypic heterogeneity within the patient population.", [["toxicity", "DISEASE", 13, 21], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149], ["Sensitivity", "TEST", 0, 11], ["toxicity", "PROBLEM", 13, 21], ["medications", "TREATMENT", 41, 52], ["genotypic heterogeneity", "PROBLEM", 107, 130]]], ["Well known, clinically relevant examples include differential responses to warfarin, codeine, thiopurine antileukemic drugs, and succinylcholine.", [["warfarin", "CHEMICAL", 75, 83], ["codeine", "CHEMICAL", 85, 92], ["thiopurine", "CHEMICAL", 94, 104], ["succinylcholine", "CHEMICAL", 129, 144], ["warfarin", "CHEMICAL", 75, 83], ["codeine", "CHEMICAL", 85, 92], ["thiopurine", "CHEMICAL", 94, 104], ["succinylcholine", "CHEMICAL", 129, 144], ["warfarin", "SIMPLE_CHEMICAL", 75, 83], ["codeine", "SIMPLE_CHEMICAL", 85, 92], ["thiopurine", "SIMPLE_CHEMICAL", 94, 104], ["succinylcholine", "SIMPLE_CHEMICAL", 129, 144], ["warfarin", "TREATMENT", 75, 83], ["codeine", "TREATMENT", 85, 92], ["thiopurine antileukemic drugs", "TREATMENT", 94, 123], ["succinylcholine", "TREATMENT", 129, 144]]], ["Genetic differences in receptor structure and affi nity, drug metabolism, and drug transport systems are now known to play an important role in both differential responses to drug therapy and adverse drug reactions (ADRs).a) CYP450Adverse drug reactions result in 6.7% of hospitalizations and 0.32% of mortalities ( Montgomery and Louie, 2001 ) .", [["adverse drug reactions", "DISEASE", 192, 214], ["ADRs", "DISEASE", 216, 220], ["Genetic differences in receptor structure", "PROBLEM", 0, 41], ["drug metabolism", "PROBLEM", 57, 72], ["drug transport systems", "PROBLEM", 78, 100], ["drug therapy", "TREATMENT", 175, 187], ["adverse drug reactions", "PROBLEM", 192, 214], ["CYP450Adverse drug reactions", "PROBLEM", 225, 253]]], ["The genes most associated with ADR encode receptors, metabolic enzymes, and metabolite transport proteins, the same genes have been implicated in environmental toxin susceptibility and cancer predisposition.", [["cancer", "ANATOMY", 185, 191], ["ADR", "CHEMICAL", 31, 34], ["cancer predisposition", "DISEASE", 185, 206], ["ADR", "SIMPLE_CHEMICAL", 31, 34], ["cancer", "CANCER", 185, 191], ["metabolic enzymes", "PROTEIN", 53, 70], ["metabolite transport proteins", "PROTEIN", 76, 105], ["ADR encode receptors", "PROBLEM", 31, 51], ["metabolic enzymes", "TEST", 53, 70], ["metabolite transport proteins", "TEST", 76, 105], ["cancer predisposition", "PROBLEM", 185, 206], ["cancer", "OBSERVATION", 185, 191]]], ["Drug effi cacy is directly related to the binding of the drug molecule to cell surface receptors.", [["cell surface", "ANATOMY", 74, 86], ["cell", "CELL", 74, 78], ["cell surface receptors", "PROTEIN", 74, 96], ["Drug effi cacy", "PROBLEM", 0, 14]]], ["For example, it has been demonstrated that patients expressing high levels of beta-adrenergic receptors are more responsive to beta-agonists and antagonists.", [["patients", "ORGANISM", 43, 51], ["beta-adrenergic receptors", "GENE_OR_GENE_PRODUCT", 78, 103], ["beta-adrenergic receptors", "PROTEIN", 78, 103], ["patients", "SPECIES", 43, 51], ["high levels of beta-adrenergic receptors", "PROBLEM", 63, 103], ["beta-agonists", "TREATMENT", 127, 140], ["antagonists", "TREATMENT", 145, 156]]], ["Conversely, those expressing low levels of this receptor require higher-drug levels to achieve a comparable pharmacological effect.a) CYP450Once inside the cell, the drug is metabolized by a number of enzymes catalyzing alterations in the molecular structure of the therapeutic drug.", [["cell", "ANATOMY", 156, 160], ["CYP450Once", "CHEMICAL", 134, 144], ["CYP450Once", "SIMPLE_CHEMICAL", 134, 144], ["cell", "CELL", 156, 160], ["enzymes", "PROTEIN", 201, 208], ["this receptor", "TREATMENT", 43, 56], ["higher-drug levels", "TREATMENT", 65, 83], ["enzymes catalyzing alterations", "PROBLEM", 201, 231], ["cell", "OBSERVATION_MODIFIER", 156, 160], ["therapeutic drug", "OBSERVATION", 266, 282]]], ["Genetic variation in the genes encoding metabolic enzymes leads to differences in enzyme activity that can be characterized as extensive (standard dosage), intermediate (slower than extensive, altered dosage), poor (enzyme deficiency, do not treat with some drugs), and ultrarapid (break down drugs faster than extensive, no effect or reduced effectiveness from drug therapy).", [["metabolic enzymes", "PROTEIN", 40, 57], ["Genetic variation in the genes encoding metabolic enzymes", "PROBLEM", 0, 57], ["differences in enzyme activity", "PROBLEM", 67, 97], ["poor (enzyme deficiency", "PROBLEM", 210, 233], ["some drugs", "TREATMENT", 253, 263], ["ultrarapid (break down drugs", "TREATMENT", 270, 298], ["drug therapy", "TREATMENT", 362, 374], ["variation", "OBSERVATION_MODIFIER", 8, 17], ["extensive", "OBSERVATION_MODIFIER", 127, 136]]], ["One class of metabolic enzymes is the cytochrome P450 superfamily (CYP) that comprises more than 40 isozymes.", [["cytochrome P450", "GENE_OR_GENE_PRODUCT", 38, 53], ["CYP", "GENE_OR_GENE_PRODUCT", 67, 70], ["metabolic enzymes", "PROTEIN", 13, 30], ["cytochrome P450 superfamily", "PROTEIN", 38, 65], ["CYP", "PROTEIN", 67, 70], ["isozymes", "PROTEIN", 100, 108], ["metabolic enzymes", "TEST", 13, 30], ["metabolic enzymes", "OBSERVATION", 13, 30]]], ["These enzymes metabolize a large number of drugs, small molecules, mutagens, and carcinogens by modifying parent molecule functional groups.", [["These enzymes", "TEST", 0, 13], ["drugs", "TREATMENT", 43, 48], ["small molecules", "PROBLEM", 50, 65], ["mutagens", "TREATMENT", 67, 75], ["carcinogens", "TREATMENT", 81, 92], ["large", "OBSERVATION_MODIFIER", 27, 32], ["small molecules", "OBSERVATION", 50, 65]]], ["Polymorphisms in the gene CYP2D6 can result in a homozygous recessive inactive genotype that cannot convert codeine into the active metabolite morphine ( Rabinowitz and Poljak, 2003 ) .", [["codeine", "CHEMICAL", 108, 115], ["morphine", "CHEMICAL", 143, 151], ["Rabinowitz", "CHEMICAL", 154, 164], ["codeine", "CHEMICAL", 108, 115], ["morphine", "CHEMICAL", 143, 151], ["Rabinowitz", "CHEMICAL", 154, 164], ["CYP2D6", "GENE_OR_GENE_PRODUCT", 26, 32], ["codeine", "SIMPLE_CHEMICAL", 108, 115], ["morphine", "SIMPLE_CHEMICAL", 143, 151], ["Rabinowitz", "SIMPLE_CHEMICAL", 154, 164], ["CYP2D6", "DNA", 26, 32], ["Polymorphisms in the gene CYP2D6", "PROBLEM", 0, 32], ["a homozygous recessive inactive genotype", "PROBLEM", 47, 87], ["codeine", "TREATMENT", 108, 115], ["the active metabolite morphine", "TREATMENT", 121, 151]]], ["In 2005, the FDAapproved Roche Diagnostic's AmpliChip CYP450 test, a P450 molecular array which detects mutations in both the CYP2D6 and CYP2C19 genes, which contribute to the metabolism of about a quarter of all prescribed drugs.", [["P450", "GENE_OR_GENE_PRODUCT", 69, 73], ["CYP2D6", "GENE_OR_GENE_PRODUCT", 126, 132], ["CYP2C19", "GENE_OR_GENE_PRODUCT", 137, 144], ["FDAapproved Roche Diagnostic's AmpliChip CYP450 test", "DNA", 13, 65], ["CYP2D6 and CYP2C19 genes", "DNA", 126, 150], ["Diagnostic's AmpliChip CYP450 test", "TEST", 31, 65], ["a P450 molecular array", "TEST", 67, 89], ["mutations", "PROBLEM", 104, 113], ["all prescribed drugs", "TREATMENT", 209, 229]]], ["An example of the potential impact of CYP450 typing is illustrated by the drug warfarin which is metabolized by enzymes encoded by the gene CYP2C9.", [["warfarin", "CHEMICAL", 79, 87], ["warfarin", "CHEMICAL", 79, 87], ["CYP450", "GENE_OR_GENE_PRODUCT", 38, 44], ["warfarin", "SIMPLE_CHEMICAL", 79, 87], ["CYP2C9", "GENE_OR_GENE_PRODUCT", 140, 146], ["CYP450", "PROTEIN", 38, 44], ["CYP2C9", "DNA", 140, 146], ["CYP450 typing", "TEST", 38, 51], ["the drug warfarin", "TREATMENT", 70, 87], ["enzymes", "TEST", 112, 119]]], ["Polymorphisms in this gene infl uence warfarin dosing requirements and warfarin-associated bleeding ( Wittkowsky, 2002 ) .", [["warfarin", "CHEMICAL", 38, 46], ["warfarin", "CHEMICAL", 71, 79], ["bleeding", "DISEASE", 91, 99], ["warfarin", "CHEMICAL", 38, 46], ["warfarin", "CHEMICAL", 71, 79], ["warfarin", "SIMPLE_CHEMICAL", 38, 46], ["warfarin", "SIMPLE_CHEMICAL", 71, 79], ["Polymorphisms", "TREATMENT", 0, 13], ["this gene infl uence", "TREATMENT", 17, 37], ["warfarin dosing requirements", "TREATMENT", 38, 66], ["warfarin", "TREATMENT", 71, 79], ["associated bleeding", "PROBLEM", 80, 99], ["bleeding", "OBSERVATION", 91, 99]]], ["It has been demonstrated that the maintenance warfarin dose can be estimated from demographic, clinical, and pharmacogenetic factors ( Gage et al., 2004 ) .", [["warfarin", "CHEMICAL", 46, 54], ["warfarin", "CHEMICAL", 46, 54], ["warfarin", "SIMPLE_CHEMICAL", 46, 54], ["the maintenance warfarin dose", "TREATMENT", 30, 59]]], ["A second gene, VKORC1 , has been associated with the average weekly warfarin dose required to maintain patients at their desired anticoagulation target.", [["warfarin", "CHEMICAL", 68, 76], ["warfarin", "CHEMICAL", 68, 76], ["VKORC1", "GENE_OR_GENE_PRODUCT", 15, 21], ["warfarin", "SIMPLE_CHEMICAL", 68, 76], ["patients", "ORGANISM", 103, 111], ["VKORC1", "DNA", 15, 21], ["patients", "SPECIES", 103, 111], ["A second gene, VKORC1", "PROBLEM", 0, 21], ["the average weekly warfarin dose", "TREATMENT", 49, 81], ["VKORC1", "OBSERVATION", 15, 21]]], ["With more information it is expected that predictive models for warfarin dosing can be developed and help the more than one million patients which each year take warfarin at appropriate dosage to avoid thromboembolic events ( Li et al., 2006 ) .", [["warfarin", "CHEMICAL", 64, 72], ["warfarin", "CHEMICAL", 162, 170], ["thromboembolic", "DISEASE", 202, 216], ["warfarin", "CHEMICAL", 64, 72], ["warfarin", "CHEMICAL", 162, 170], ["warfarin", "SIMPLE_CHEMICAL", 64, 72], ["patients", "ORGANISM", 132, 140], ["warfarin", "SIMPLE_CHEMICAL", 162, 170], ["patients", "SPECIES", 132, 140], ["warfarin dosing", "TREATMENT", 64, 79], ["warfarin", "TREATMENT", 162, 170], ["thromboembolic events", "PROBLEM", 202, 223], ["thromboembolic", "OBSERVATION", 202, 216]]], ["Twelve percent of those users currently experience major bleeding episodes and death results in as many as 2%.b) HLA GenotypingAbacavir is a nucleoside analog that is a potent inhibitor of the HIV reverse transcriptase enzyme.", [["bleeding", "DISEASE", 57, 65], ["death", "DISEASE", 79, 84], ["Abacavir", "CHEMICAL", 127, 135], ["nucleoside", "CHEMICAL", 141, 151], ["Abacavir", "CHEMICAL", 127, 135], ["nucleoside", "CHEMICAL", 141, 151], ["Abacavir", "SIMPLE_CHEMICAL", 127, 135], ["nucleoside", "SIMPLE_CHEMICAL", 141, 151], ["HIV reverse transcriptase enzyme", "GENE_OR_GENE_PRODUCT", 193, 225], ["HIV reverse transcriptase enzyme", "PROTEIN", 193, 225], ["HIV", "SPECIES", 193, 196], ["major bleeding episodes", "PROBLEM", 51, 74], ["death", "PROBLEM", 79, 84], ["HLA GenotypingAbacavir", "TREATMENT", 113, 135], ["a nucleoside analog", "TREATMENT", 139, 158], ["a potent inhibitor", "TREATMENT", 167, 185]]], ["However, between 4-8% of patients develop hypersensitive reactions which can result in life threatening hypotension.", [["hypotension", "DISEASE", 104, 115], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["hypersensitive reactions", "PROBLEM", 42, 66], ["life threatening hypotension", "PROBLEM", 87, 115], ["hypersensitive reactions", "OBSERVATION", 42, 66]]], ["The possession of human leukocyte antigen (HLA) B5701 genotype screening has been shown to effectively reduce the incidence of abacavir hypersensitivity through the exclusion of patients positive for this allele from abacavir combination treatment ( Mallal et al., 2008 ) .", [["abacavir", "CHEMICAL", 127, 135], ["hypersensitivity", "DISEASE", 136, 152], ["abacavir", "CHEMICAL", 217, 225], ["abacavir", "CHEMICAL", 127, 135], ["abacavir", "CHEMICAL", 217, 225], ["human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 18, 41], ["HLA", "GENE_OR_GENE_PRODUCT", 43, 46], ["abacavir", "SIMPLE_CHEMICAL", 127, 135], ["patients", "ORGANISM", 178, 186], ["abacavir", "SIMPLE_CHEMICAL", 217, 225], ["allele", "DNA", 205, 211], ["human", "SPECIES", 18, 23], ["patients", "SPECIES", 178, 186], ["human", "SPECIES", 18, 23], ["human leukocyte antigen", "TEST", 18, 41], ["HLA", "TEST", 43, 46], ["genotype screening", "TEST", 54, 72], ["abacavir hypersensitivity", "PROBLEM", 127, 152], ["abacavir combination treatment", "TREATMENT", 217, 247], ["human leukocyte", "ANATOMY", 18, 33]]], ["Adoption of this pharmacogenomic test was impacted by drug safety issues and the demonstration of its cost-effectiveness (Hughes et al., 2004 ) .", [["this pharmacogenomic test", "TEST", 12, 37]]], ["Additional associations between specifi c HLA genotypes and life threatening ADRs include Allopurinol and HLA-B1502 ( Dainichi et al., 2007 ) .", [["ADRs", "DISEASE", 77, 81], ["Allopurinol", "CHEMICAL", 90, 101], ["Allopurinol", "CHEMICAL", 90, 101], ["specifi c HLA", "GENE_OR_GENE_PRODUCT", 32, 45], ["Allopurinol", "SIMPLE_CHEMICAL", 90, 101], ["specifi c HLA genotypes", "TREATMENT", 32, 55], ["life threatening ADRs", "PROBLEM", 60, 81], ["Allopurinol", "TREATMENT", 90, 101]]], ["In December, 2007, the FDA released guidelines calling for genetic testing of the HLA-B*1502 genotype prior to starting carbamazeprine therapy for patients with Asian ancestry ( FDA, 2007e ).c) Cancer PharmacogenomicsCancer pharmacogenomics impacts patient safety and therapeutic effi cacy and can be used to select treatment choice based on tumor genomics and patient genotype.", [["Cancer", "ANATOMY", 194, 200], ["tumor", "ANATOMY", 342, 347], ["carbamazeprine", "CHEMICAL", 120, 134], ["Cancer", "DISEASE", 194, 200], ["tumor", "DISEASE", 342, 347], ["carbamazeprine", "CHEMICAL", 120, 134], ["carbamazeprine", "SIMPLE_CHEMICAL", 120, 134], ["patients", "ORGANISM", 147, 155], ["Cancer", "CANCER", 194, 200], ["patient", "ORGANISM", 249, 256], ["tumor", "CANCER", 342, 347], ["patient", "ORGANISM", 361, 368], ["patients", "SPECIES", 147, 155], ["patient", "SPECIES", 249, 256], ["patient", "SPECIES", 361, 368], ["genetic testing", "TEST", 59, 74], ["carbamazeprine therapy", "TREATMENT", 120, 142], ["Cancer PharmacogenomicsCancer pharmacogenomics", "PROBLEM", 194, 240], ["therapeutic effi cacy", "TREATMENT", 268, 289], ["treatment choice", "TREATMENT", 316, 332], ["tumor genomics", "PROBLEM", 342, 356], ["tumor", "OBSERVATION", 342, 347]]], ["Methodologies such as molecular cytogenetics, somatic mutation detection, and gene expression profi ling have been used to examine genotypic differences in cancer tissue and in patient response to therapy.c) Cancer PharmacogenomicsChronic myelogenous leukemia (CML) is one of the most common forms of leukemia.", [["cancer tissue", "ANATOMY", 156, 169], ["Cancer PharmacogenomicsChronic myelogenous leukemia", "ANATOMY", 208, 259], ["CML", "ANATOMY", 261, 264], ["leukemia", "ANATOMY", 301, 309], ["cancer", "DISEASE", 156, 162], ["Cancer", "DISEASE", 208, 214], ["PharmacogenomicsChronic myelogenous leukemia", "DISEASE", 215, 259], ["CML", "DISEASE", 261, 264], ["leukemia", "DISEASE", 301, 309], ["cancer tissue", "TISSUE", 156, 169], ["patient", "ORGANISM", 177, 184], ["Cancer PharmacogenomicsChronic myelogenous leukemia", "CANCER", 208, 259], ["CML", "CANCER", 261, 264], ["leukemia", "CANCER", 301, 309], ["patient", "SPECIES", 177, 184], ["molecular cytogenetics", "TEST", 22, 44], ["somatic mutation detection", "TEST", 46, 72], ["gene expression profi ling", "TREATMENT", 78, 104], ["genotypic differences in cancer tissue", "PROBLEM", 131, 169], ["therapy", "TREATMENT", 197, 204], ["Cancer PharmacogenomicsChronic myelogenous leukemia", "PROBLEM", 208, 259], ["CML", "PROBLEM", 261, 264], ["leukemia", "PROBLEM", 301, 309], ["myelogenous leukemia", "OBSERVATION", 239, 259], ["CML", "OBSERVATION", 261, 264], ["most common", "OBSERVATION_MODIFIER", 280, 291], ["leukemia", "OBSERVATION", 301, 309]]], ["Most cases of CML result from a chromosome abnormality whereby DNA from chromosome 9, which contains most of the proto-oncogene c-abl , is translocated onto chromosome 22 within the breakpoint cluster region ( BCR) gene ( Billings and Brown, 2004 ) .", [["CML", "ANATOMY", 14, 17], ["chromosome", "ANATOMY", 32, 42], ["chromosome 9", "ANATOMY", 72, 84], ["chromosome 22", "ANATOMY", 157, 170], ["CML", "DISEASE", 14, 17], ["CML", "CANCER", 14, 17], ["chromosome", "CELLULAR_COMPONENT", 32, 42], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["chromosome 9", "CELLULAR_COMPONENT", 72, 84], ["c-abl", "GENE_OR_GENE_PRODUCT", 128, 133], ["chromosome 22", "CELLULAR_COMPONENT", 157, 170], ["BCR", "GENE_OR_GENE_PRODUCT", 210, 213], ["chromosome 9", "DNA", 72, 84], ["proto-oncogene c", "DNA", 113, 129], ["abl", "DNA", 130, 133], ["chromosome 22", "DNA", 157, 170], ["breakpoint cluster region ( BCR) gene", "DNA", 182, 219], ["CML result", "PROBLEM", 14, 24], ["a chromosome abnormality", "PROBLEM", 30, 54], ["DNA from chromosome", "TEST", 63, 82], ["CML", "OBSERVATION", 14, 17]]], ["This results in a gene fusion constitutive for expression of a protein with tyrosine kinase activity.", [["tyrosine", "CHEMICAL", 76, 84], ["tyrosine", "CHEMICAL", 76, 84], ["tyrosine", "AMINO_ACID", 76, 84], ["tyrosine kinase", "PROTEIN", 76, 91], ["a gene fusion constitutive", "TREATMENT", 16, 42], ["tyrosine kinase activity", "TREATMENT", 76, 100]]], ["This activity affects intracellular signaling pathways that result in unregulated cell proliferation.", [["intracellular", "ANATOMY", 22, 35], ["cell", "ANATOMY", 82, 86], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["cell", "CELL", 82, 86], ["intracellular signaling pathways", "PROBLEM", 22, 54], ["unregulated cell proliferation", "PROBLEM", 70, 100], ["unregulated cell proliferation", "OBSERVATION", 70, 100]]], ["Molecular diagnosis of CML utilizes quantitative PCR.", [["CML", "ANATOMY", 23, 26], ["CML", "DISEASE", 23, 26], ["CML", "CANCER", 23, 26], ["CML", "PROBLEM", 23, 26], ["quantitative PCR", "TEST", 36, 52], ["CML", "OBSERVATION", 23, 26]]], ["Fluorescence in situ hybridization (FISH) can also be used to visualize the translocated chromosomes.", [["chromosomes", "ANATOMY", 89, 100], ["chromosomes", "CELLULAR_COMPONENT", 89, 100], ["translocated chromosomes", "DNA", 76, 100], ["Fluorescence", "TREATMENT", 0, 12]]], ["The oral drug imatinib (Gleevec) was specifi cally designed as a selective inhibitor of the BCR-ABL tyrosine kinase and has demonstrated therapeutic superiority over conventional drug therapy.", [["oral", "ANATOMY", 4, 8], ["imatinib", "CHEMICAL", 14, 22], ["Gleevec", "CHEMICAL", 24, 31], ["tyrosine", "CHEMICAL", 100, 108], ["imatinib", "CHEMICAL", 14, 22], ["Gleevec", "CHEMICAL", 24, 31], ["tyrosine", "CHEMICAL", 100, 108], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["imatinib", "SIMPLE_CHEMICAL", 14, 22], ["Gleevec", "SIMPLE_CHEMICAL", 24, 31], ["BCR-ABL tyrosine kinase", "GENE_OR_GENE_PRODUCT", 92, 115], ["BCR-ABL tyrosine kinase", "PROTEIN", 92, 115], ["The oral drug imatinib (Gleevec", "TREATMENT", 0, 31], ["a selective inhibitor", "TREATMENT", 63, 84], ["the BCR", "TEST", 88, 95], ["ABL tyrosine kinase", "TREATMENT", 96, 115], ["conventional drug therapy", "TREATMENT", 166, 191]]], ["Molecular diagnostic testing can be used to monitor responsiveness to Gleevec or the development of therapeutic resistance.c) Cancer PharmacogenomicsHereditary nonpolyposis colorectal cancer (HNPCC) is the most common hereditary cause of colon cancer, accounting for about 2-5% of all colon cancer cases (see Chapter 73).c) Cancer PharmacogenomicsIt is caused by mutations in any of at least fi ve DNA mismatch repair genes, and DNA tests are available for the most common genes.", [["Cancer", "ANATOMY", 126, 132], ["nonpolyposis colorectal cancer", "ANATOMY", 160, 190], ["HNPCC", "ANATOMY", 192, 197], ["colon cancer", "ANATOMY", 238, 250], ["colon cancer", "ANATOMY", 285, 297], ["Cancer", "ANATOMY", 324, 330], ["Gleevec", "CHEMICAL", 70, 77], ["Cancer", "DISEASE", 126, 132], ["Hereditary nonpolyposis colorectal cancer", "DISEASE", 149, 190], ["HNPCC", "DISEASE", 192, 197], ["colon cancer", "DISEASE", 238, 250], ["colon cancer", "DISEASE", 285, 297], ["Cancer", "DISEASE", 324, 330], ["Gleevec", "CHEMICAL", 70, 77], ["Gleevec", "SIMPLE_CHEMICAL", 70, 77], ["Cancer", "CANCER", 126, 132], ["nonpolyposis colorectal cancer", "CANCER", 160, 190], ["HNPCC", "CANCER", 192, 197], ["colon cancer", "CANCER", 238, 250], ["colon cancer", "CANCER", 285, 297], ["Cancer", "CANCER", 324, 330], ["DNA", "CELLULAR_COMPONENT", 398, 401], ["DNA", "CELLULAR_COMPONENT", 429, 432], ["DNA mismatch repair genes", "DNA", 398, 423], ["Molecular diagnostic testing", "TEST", 0, 28], ["Gleevec", "TREATMENT", 70, 77], ["therapeutic resistance", "PROBLEM", 100, 122], ["Cancer Pharmacogenomics", "PROBLEM", 126, 149], ["Hereditary nonpolyposis colorectal cancer", "PROBLEM", 149, 190], ["HNPCC", "PROBLEM", 192, 197], ["colon cancer", "PROBLEM", 238, 250], ["all colon cancer cases", "PROBLEM", 281, 303], ["Cancer PharmacogenomicsIt", "PROBLEM", 324, 349], ["mutations", "PROBLEM", 363, 372], ["DNA mismatch repair genes", "TREATMENT", 398, 423], ["DNA tests", "TEST", 429, 438], ["nonpolyposis", "OBSERVATION_MODIFIER", 160, 172], ["colorectal cancer", "OBSERVATION", 173, 190], ["most common", "OBSERVATION_MODIFIER", 206, 217], ["colon", "ANATOMY", 238, 243], ["cancer", "OBSERVATION", 244, 250], ["colon", "ANATOMY", 285, 290], ["cancer", "OBSERVATION", 291, 297], ["mismatch repair", "OBSERVATION", 402, 417]]], ["The HNPCC syndrome predisposes a person to developing colon cancer at a young age.", [["colon cancer", "ANATOMY", 54, 66], ["HNPCC syndrome", "DISEASE", 4, 18], ["colon cancer", "DISEASE", 54, 66], ["colon cancer", "CANCER", 54, 66], ["person", "SPECIES", 33, 39], ["The HNPCC syndrome", "PROBLEM", 0, 18], ["colon cancer", "PROBLEM", 54, 66], ["HNPCC syndrome", "OBSERVATION", 4, 18], ["colon", "ANATOMY", 54, 59], ["cancer", "OBSERVATION", 60, 66]]], ["Presymptomatic and predispositional testing in families have been conducted.", [["Presymptomatic and predispositional testing", "PROBLEM", 0, 43]]], ["Since approximately 90% of tumors from HNPCC patients show microsatellite instability, testing for this phenomenon alone can be a good guide to the necessity for further molecular characterization.", [["tumors", "ANATOMY", 27, 33], ["tumors", "DISEASE", 27, 33], ["HNPCC", "DISEASE", 39, 44], ["microsatellite instability", "DISEASE", 59, 85], ["tumors", "CANCER", 27, 33], ["HNPCC", "CANCER", 39, 44], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["tumors", "PROBLEM", 27, 33], ["HNPCC", "PROBLEM", 39, 44], ["microsatellite instability", "PROBLEM", 59, 85], ["testing", "TEST", 87, 94], ["this phenomenon", "PROBLEM", 99, 114], ["further molecular characterization", "TEST", 162, 196], ["tumors", "OBSERVATION", 27, 33], ["microsatellite instability", "OBSERVATION", 59, 85]]], ["Gene sequencing can be used to identify the precise mutation.", [["Gene sequencing", "TREATMENT", 0, 15]]], ["Mutational data, along with DNA microsatellite instability testing results, can be used to identify fi rst-degree relatives with HNPCC.", [["HNPCC", "DISEASE", 129, 134], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["HNPCC", "CANCER", 129, 134], ["Mutational data", "TEST", 0, 15], ["DNA microsatellite instability testing", "PROBLEM", 28, 66], ["HNPCC", "PROBLEM", 129, 134]]], ["Once HNPCC has been implicated from clinical data, immunohistochemistry testing can be conducted on tumor tissue for confi rmation of diagnosis.", [["tumor tissue", "ANATOMY", 100, 112], ["HNPCC", "DISEASE", 5, 10], ["tumor", "DISEASE", 100, 105], ["HNPCC", "CANCER", 5, 10], ["tumor tissue", "TISSUE", 100, 112], ["HNPCC", "PROBLEM", 5, 10], ["clinical data", "TEST", 36, 49], ["immunohistochemistry testing", "TEST", 51, 79]]], ["In this way, members of families with HNPCC have a means to know if they need aggressive monitoring and treatment or not.c) Cancer PharmacogenomicsThiopurines, thioguanine, and mercaptopurine are commonly used anticancer therapeutics.", [["Cancer", "ANATOMY", 124, 130], ["anticancer", "ANATOMY", 210, 220], ["HNPCC", "DISEASE", 38, 43], ["Cancer", "DISEASE", 124, 130], ["Thiopurines", "CHEMICAL", 147, 158], ["thioguanine", "CHEMICAL", 160, 171], ["mercaptopurine", "CHEMICAL", 177, 191], ["Thiopurines", "CHEMICAL", 147, 158], ["thioguanine", "CHEMICAL", 160, 171], ["mercaptopurine", "CHEMICAL", 177, 191], ["HNPCC", "CANCER", 38, 43], ["Cancer", "CANCER", 124, 130], ["Thiopurines", "SIMPLE_CHEMICAL", 147, 158], ["thioguanine", "SIMPLE_CHEMICAL", 160, 171], ["mercaptopurine", "SIMPLE_CHEMICAL", 177, 191], ["anticancer", "CANCER", 210, 220], ["aggressive monitoring", "TREATMENT", 78, 99], ["treatment", "TREATMENT", 104, 113], ["Cancer Pharmacogenomics", "PROBLEM", 124, 147], ["Thiopurines", "TREATMENT", 147, 158], ["thioguanine", "TREATMENT", 160, 171], ["mercaptopurine", "TREATMENT", 177, 191], ["anticancer therapeutics", "TREATMENT", 210, 233]]], ["The thiopurine methyltransferase (TPMT) enzyme catalyses the methylation of thiopurines.", [["thiopurine", "CHEMICAL", 4, 14], ["thiopurines", "CHEMICAL", 76, 87], ["thiopurine", "CHEMICAL", 4, 14], ["thiopurines", "CHEMICAL", 76, 87], ["thiopurine methyltransferase", "GENE_OR_GENE_PRODUCT", 4, 32], ["TPMT", "GENE_OR_GENE_PRODUCT", 34, 38], ["thiopurines", "SIMPLE_CHEMICAL", 76, 87], ["thiopurine methyltransferase (TPMT) enzyme", "PROTEIN", 4, 46], ["The thiopurine methyltransferase (TPMT) enzyme catalyses", "TREATMENT", 0, 56], ["the methylation of thiopurines", "TREATMENT", 57, 87], ["thiopurine methyltransferase", "OBSERVATION", 4, 32]]], ["The TPMT gene is polymorphic, and one in 300 patients is defi cient in enzyme activity.", [["TPMT", "GENE_OR_GENE_PRODUCT", 4, 8], ["patients", "ORGANISM", 45, 53], ["TPMT gene", "DNA", 4, 13], ["patients", "SPECIES", 45, 53], ["TPMT", "OBSERVATION", 4, 8], ["polymorphic", "OBSERVATION_MODIFIER", 17, 28]]], ["At standard doses, this can lead to toxic accumulation of thiopurines, which can be fatal.", [["thiopurines", "CHEMICAL", 58, 69], ["thiopurines", "CHEMICAL", 58, 69], ["thiopurines", "SIMPLE_CHEMICAL", 58, 69], ["toxic accumulation of thiopurines", "PROBLEM", 36, 69], ["toxic", "OBSERVATION_MODIFIER", 36, 41]]], ["Three mutations account for the majority of mutant alleles, and genetic testing is available.", [["mutant alleles", "DNA", 44, 58], ["Three mutations", "PROBLEM", 0, 15], ["mutant alleles", "PROBLEM", 44, 58], ["genetic testing", "TEST", 64, 79]]], ["Children with leukemia who receive these medications are routinely screened for these defi ciency genes ( Billings and Brown, 2004 ) .c) Cancer PharmacogenomicsIn late 2005, the FDA-approved Third Wave Technologies ' Invader UGT1A1 molecular assay, which is used to identify patients who could experience adverse reactions to Camptosar (irinotecan), a colorectal chemotherapy drug ( Grebow, 2005 ) .", [["leukemia", "ANATOMY", 14, 22], ["Cancer", "ANATOMY", 137, 143], ["colorectal", "ANATOMY", 352, 362], ["leukemia", "DISEASE", 14, 22], ["Cancer", "DISEASE", 137, 143], ["Camptosar", "CHEMICAL", 326, 335], ["irinotecan", "CHEMICAL", 337, 347], ["Camptosar", "CHEMICAL", 326, 335], ["irinotecan", "CHEMICAL", 337, 347], ["Children", "ORGANISM", 0, 8], ["leukemia", "CANCER", 14, 22], ["UGT1A1", "GENE_OR_GENE_PRODUCT", 225, 231], ["patients", "ORGANISM", 275, 283], ["Camptosar", "SIMPLE_CHEMICAL", 326, 335], ["irinotecan", "SIMPLE_CHEMICAL", 337, 347], ["colorectal", "MULTI-TISSUE_STRUCTURE", 352, 362], ["defi ciency genes", "DNA", 86, 103], ["UGT1A1", "PROTEIN", 225, 231], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 275, 283], ["leukemia", "PROBLEM", 14, 22], ["these medications", "TREATMENT", 35, 52], ["Invader UGT1A1 molecular assay", "TEST", 217, 247], ["adverse reactions", "PROBLEM", 305, 322], ["Camptosar (irinotecan", "TREATMENT", 326, 347], ["a colorectal chemotherapy drug", "TREATMENT", 350, 380], ["leukemia", "OBSERVATION", 14, 22]]], ["The test detects mutations in the UGT1A1 gene, which produces a metabolizing enzyme active on the therapeutic.", [["UGT1A1", "GENE_OR_GENE_PRODUCT", 34, 40], ["UGT1A1 gene", "DNA", 34, 45], ["metabolizing enzyme", "PROTEIN", 64, 83], ["The test", "TEST", 0, 8], ["mutations in the UGT1A1 gene", "PROBLEM", 17, 45], ["a metabolizing enzyme", "TEST", 62, 83], ["active", "OBSERVATION_MODIFIER", 84, 90]]], ["This was one of the fi rst pharmacogonomic tests to be FDA approved for use as a companion diagnostic to a specifi c drug.c) Cancer PharmacogenomicsFinally, genetic testing to predict future disease risk based on an inherited germline mutation is also available.", [["Cancer", "ANATOMY", 125, 131], ["Cancer", "DISEASE", 125, 131], ["Cancer", "CANCER", 125, 131], ["Cancer", "PROBLEM", 125, 131], ["genetic testing", "TEST", 157, 172], ["disease risk", "PROBLEM", 191, 203], ["an inherited germline mutation", "PROBLEM", 213, 243], ["germline mutation", "OBSERVATION", 226, 243]]], ["The BRCA1/2 mutations are associated with a higher risk of breast and ovarian cancer.", [["breast", "ANATOMY", 59, 65], ["ovarian cancer", "ANATOMY", 70, 84], ["breast and ovarian cancer", "DISEASE", 59, 84], ["BRCA1", "GENE_OR_GENE_PRODUCT", 4, 9], ["2", "GENE_OR_GENE_PRODUCT", 10, 11], ["breast", "CANCER", 59, 65], ["ovarian cancer", "CANCER", 70, 84], ["BRCA1", "DNA", 4, 9], ["The BRCA1/2 mutations", "PROBLEM", 0, 21], ["breast and ovarian cancer", "PROBLEM", 59, 84], ["BRCA1", "OBSERVATION", 4, 9], ["breast", "ANATOMY", 59, 65], ["ovarian", "ANATOMY", 70, 77], ["cancer", "OBSERVATION", 78, 84]]], ["Approximately 60-80% of women with BRCA1/2 will develop breast cancer.", [["breast cancer", "ANATOMY", 56, 69], ["breast cancer", "DISEASE", 56, 69], ["women", "ORGANISM", 24, 29], ["BRCA1", "GENE_OR_GENE_PRODUCT", 35, 40], ["breast cancer", "CANCER", 56, 69], ["BRCA1", "DNA", 35, 40], ["women", "SPECIES", 24, 29], ["BRCA1/2", "PROBLEM", 35, 42], ["breast cancer", "PROBLEM", 56, 69], ["breast", "ANATOMY", 56, 62], ["cancer", "OBSERVATION", 63, 69]]], ["BRCA testing, the BRAC Analysis test, is expensive and provides information with limited therapeutic response.", [["BRCA testing", "TEST", 0, 12], ["the BRAC Analysis test", "TEST", 14, 36]]], ["Tests such as these can experience initial resistance among insurers to provide reimbursement ( Phillips et al., 2004 ) .Adoption of Pharmacogenomic TestingWhat are the factors that infl uence the uptake of pharmacogenomic diagnostic testing?", [["Tests", "TEST", 0, 5], ["Pharmacogenomic Testing", "TEST", 133, 156], ["pharmacogenomic diagnostic testing", "TEST", 207, 241]]], ["Clinical validity and utility need to be demonstrated and communicated to physicians and patients.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["Rapid, reliable, inexpensive, and easily interpretable molecular tests will increase the clinical use of these diagnostic tests ( Shah, 2004) .", [["these diagnostic tests", "TEST", 105, 127]]], ["This may limit the use of this technology to applications where there exists choice of treatments.", [["this technology", "TREATMENT", 26, 41], ["treatments", "TREATMENT", 87, 97]]], ["In addition, due to the screening nature of these tests, cost-effectiveness must be demonstrated (Flowers and Veenstra, 2004 ) .", [["these tests", "TEST", 44, 55], ["cost-effectiveness", "TREATMENT", 57, 75]]], ["Additional obstacles to the deployment of pharmacogenomic testing include obtaining reasonable reimbursement for testing, and the education of physicians and patients as to the value of tests and interpretation of the results.Examples of Translational DiagnosticsInvestigation of specifi c examples of translational diagnostics can reveal crucial issues and challenges faced as new methods enter health care.HIV Viral Load TestingPrior to the 1990s, therapeutics that truly impacted the course of viral diseases were not available.", [["viral diseases", "DISEASE", 497, 511], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["HIV", "SPECIES", 408, 411], ["HIV", "SPECIES", 408, 411], ["pharmacogenomic testing", "TEST", 42, 65], ["testing", "TEST", 113, 120], ["tests", "TEST", 186, 191], ["translational diagnostics", "TEST", 302, 327], ["crucial issues", "PROBLEM", 339, 353], ["HIV Viral Load TestingPrior", "TEST", 408, 435], ["therapeutics", "TREATMENT", 450, 462], ["viral diseases", "PROBLEM", 497, 511], ["viral diseases", "OBSERVATION", 497, 511]]], ["The symptoms could be affected, but there was no antibiotic equivalent for treating viral diseases.", [["viral diseases", "DISEASE", 84, 98], ["The symptoms", "PROBLEM", 0, 12], ["antibiotic equivalent", "TREATMENT", 49, 70], ["treating viral diseases", "PROBLEM", 75, 98]]], ["However, by the mid-1990s, pharmaceutical companies had a number of antiviral compounds; some specifi cally tailored to HIV, well into clinical trials and needed an accurate biomarker to analyze effectiveness of the new therapies.", [["HIV", "ORGANISM", 120, 123], ["HIV", "SPECIES", 120, 123], ["antiviral compounds", "TREATMENT", 68, 87], ["an accurate biomarker", "TEST", 162, 183], ["the new therapies", "TREATMENT", 212, 229]]], ["This convergence of therapeutics and diagnostics would lead to the birth of the theranostic , a diagnostic test linked to the application of specifi c therapies ( Warner, 2004 ) .", [["a diagnostic test", "TEST", 94, 111], ["specifi c therapies", "TREATMENT", 141, 160]]], ["In 1996, Roche Diagnostics began the Roche Amplicor\u00ae Access Program to provide two free baseline HIV viral load tests to anyone in the United States with HIV ( James, 1996 ) .", [["HIV", "SPECIES", 154, 157], ["HIV", "SPECIES", 97, 100], ["HIV", "SPECIES", 154, 157], ["the Roche Amplicor\u00ae Access Program", "TREATMENT", 33, 67], ["HIV viral load tests", "TEST", 97, 117]]], ["Reference laboratories helped execute this program, which began the successful uptake of HIV viral load testing in the marketplace.", [["HIV", "ORGANISM", 89, 92], ["HIV", "SPECIES", 89, 92], ["Reference laboratories", "TEST", 0, 22], ["HIV viral load testing", "TEST", 89, 111], ["HIV viral load", "OBSERVATION", 89, 103]]], ["As with traditional diagnostics, molecular diagnostic tests needed to demonstrate utility and performance before their adoption into practice.", [["traditional diagnostics", "TEST", 8, 31], ["molecular diagnostic tests", "TEST", 33, 59]]], ["First, there must be an unmet clinical need, which was clearly the case with HIV.", [["HIV", "ORGANISM", 77, 80], ["HIV", "SPECIES", 77, 80], ["HIV", "SPECIES", 77, 80], ["HIV", "PROBLEM", 77, 80]]], ["Secondly, with the development of antiviral therapies, HIV viral load testing provided information that resulted in a therapeutic action, and also provided the means to continually monitor the effi cacy of the treatment.", [["HIV", "ORGANISM", 55, 58], ["HIV", "SPECIES", 55, 58], ["HIV", "SPECIES", 55, 58], ["antiviral therapies", "TREATMENT", 34, 53], ["HIV viral load testing", "TEST", 55, 77], ["the treatment", "TREATMENT", 206, 219], ["antiviral therapies", "OBSERVATION", 34, 53]]], ["Without a therapeutic, the test would have provided information that would not have informed the treatment of HIV.HIV Viral Load TestingAdditional factors sped the uptake of HIV viral load testing.", [["HIV", "DISEASE", 110, 113], ["HIV", "ORGANISM", 110, 113], ["HIV", "ORGANISM", 174, 177], ["HIV", "SPECIES", 110, 113], ["HIV", "SPECIES", 114, 117], ["HIV", "SPECIES", 110, 113], ["HIV", "SPECIES", 114, 117], ["HIV", "SPECIES", 174, 177], ["HIV", "PROBLEM", 110, 113], ["HIV Viral Load TestingAdditional factors", "PROBLEM", 114, 154], ["the uptake", "TEST", 160, 170], ["HIV viral load testing", "TEST", 174, 196]]], ["Initial testing involved a relatively small group of highly focused clinicians.", [["Initial testing", "TEST", 0, 15]]], ["This made it much simpler to educate physicians in the use of the viral load test for the management of HIV.", [["HIV", "DISEASE", 104, 107], ["HIV", "ORGANISM", 104, 107], ["HIV", "SPECIES", 104, 107], ["HIV", "SPECIES", 104, 107], ["the viral load test", "TEST", 62, 81], ["the management", "TREATMENT", 86, 100], ["HIV", "PROBLEM", 104, 107]]], ["Highly motivated patients fueled demand for the test.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["the test", "TEST", 44, 52]]], ["The viral load test had a signifi cant role in early clinical trials of antiviral therapeutics and became an objective measurement tool, even before any protease inhibitors were approved for physician use.", [["The viral load test", "TEST", 0, 19], ["antiviral therapeutics", "TREATMENT", 72, 94], ["any protease inhibitors", "TREATMENT", 149, 172], ["viral load", "OBSERVATION", 4, 14]]], ["Publications on the antiviral therapeutics included the HIV viral load results.", [["HIV", "ORGANISM", 56, 59], ["HIV", "SPECIES", 56, 59], ["HIV", "SPECIES", 56, 59], ["the antiviral therapeutics", "TREATMENT", 16, 42], ["the HIV viral load", "TEST", 52, 70]]], ["Thought leaders who participated in the trials became early adopters of the test, even before the test was FDA approved.", [["the test", "TEST", 72, 80], ["the test", "TEST", 94, 102]]], ["The viral load test was put into a kit format and became FDA approved at approximately the same time as the fi rst protease inhibitors became available.", [["The viral load test", "TEST", 0, 19], ["the fi rst protease inhibitors", "TREATMENT", 104, 134], ["viral load", "OBSERVATION", 4, 14]]], ["Recommendations for viral load testing became part of standard guidelines for treating HIV infection ( Chesebro and Everett, 1998 ) .", [["HIV infection", "DISEASE", 87, 100], ["HIV", "ORGANISM", 87, 90], ["HIV", "SPECIES", 87, 90], ["HIV", "SPECIES", 87, 90], ["viral load testing", "TEST", 20, 38], ["HIV infection", "PROBLEM", 87, 100]]], ["The theranostic became tied to the use of the drug.", [["the drug", "TREATMENT", 42, 50]]], ["Roche's Amplicor Access Program led to rapid test utilization.", [["rapid test utilization", "TEST", 39, 61]]], ["HIV management requires relatively frequent monitoring, as often as four times per year.", [["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV management", "TREATMENT", 0, 14]]], ["Therefore, the test was not a \"one off \" test as in constitutional genetic testing.", [["the test", "TEST", 11, 19], ["test", "TEST", 41, 45], ["constitutional genetic testing", "TEST", 52, 82]]], ["HIV viral load testing also obtained its own CPT code, facilitating reimbursement.", [["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV viral load testing", "TEST", 0, 22]]], ["Additionally, the kit manufacturer, the national reference labs, patients, and doctors all worked to ensure that the test was reimbursed.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["the test", "TEST", 113, 121]]], ["These factors helped make HIV viral load testing cost effective and a foundation of HIV prevention efforts.", [["HIV", "ORGANISM", 26, 29], ["HIV", "SPECIES", 26, 29], ["HIV", "SPECIES", 84, 87], ["These factors", "PROBLEM", 0, 13], ["HIV viral load testing", "TEST", 26, 48], ["HIV prevention efforts", "TREATMENT", 84, 106]]], ["The combination of viral load testing and new therapeutics transformed HIV from a uniformly fatal disease to a chronic treatable disease.", [["HIV", "ORGANISM", 71, 74], ["HIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 71, 74], ["viral load testing", "TEST", 19, 37], ["HIV", "PROBLEM", 71, 74], ["a uniformly fatal disease", "PROBLEM", 80, 105], ["a chronic treatable disease", "PROBLEM", 109, 136], ["viral load", "OBSERVATION", 19, 29], ["uniformly", "OBSERVATION_MODIFIER", 82, 91], ["fatal disease", "OBSERVATION", 92, 105], ["chronic", "OBSERVATION_MODIFIER", 111, 118], ["treatable", "OBSERVATION_MODIFIER", 119, 128], ["disease", "OBSERVATION", 129, 136]]], ["Therefore, HIV has become a disease with an \"actionable \" result.", [["HIV", "ORGANISM", 11, 14], ["HIV", "SPECIES", 11, 14], ["HIV", "SPECIES", 11, 14], ["HIV", "PROBLEM", 11, 14], ["a disease", "PROBLEM", 26, 35], ["disease", "OBSERVATION", 28, 35]]], ["Recent Centers for Disease Control (CDC) recommendations now call for general population screening for HIV status.", [["HIV", "ORGANISM", 103, 106], ["HIV", "SPECIES", 103, 106], ["HIV", "SPECIES", 103, 106], ["general population screening", "TEST", 70, 98], ["HIV status", "PROBLEM", 103, 113]]], ["This example of translating a diagnostic into patient care was successful because so many of the hallmarks of successful diagnostic tests were in place.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["successful diagnostic tests", "TEST", 110, 137]]], ["There was an unmet clinical need, an actionable result was obtained from testing, the test was ultimately cost effective, high-throughput analysis became available, and reimbursement issues were rapidly resolved.Breast Cancer, HER2 Receptor Assay, and HerceptinSimilar to the convergence of HIV therapeutics and the need for HIV viral load assays, the development of the anti-cancer therapeutic Herceptin required a clinical laboratory test to determine Her2 receptor status ( Tsongalis and Silverman, 2006 ) .", [["Breast Cancer", "ANATOMY", 212, 225], ["Breast Cancer", "DISEASE", 212, 225], ["Herceptin", "CHEMICAL", 395, 404], ["Breast Cancer", "CANCER", 212, 225], ["HER2 Receptor", "GENE_OR_GENE_PRODUCT", 227, 240], ["HIV", "ORGANISM", 291, 294], ["HIV", "ORGANISM", 325, 328], ["Herceptin", "SIMPLE_CHEMICAL", 395, 404], ["Her2 receptor", "GENE_OR_GENE_PRODUCT", 454, 467], ["HER2", "PROTEIN", 227, 231], ["Her2", "PROTEIN", 454, 458], ["HIV", "SPECIES", 291, 294], ["HIV", "SPECIES", 325, 328], ["testing", "TEST", 73, 80], ["the test", "TEST", 82, 90], ["Breast Cancer", "PROBLEM", 212, 225], ["HER2 Receptor Assay", "TEST", 227, 246], ["HerceptinSimilar", "TREATMENT", 252, 268], ["HIV therapeutics", "TREATMENT", 291, 307], ["HIV viral load assays", "TEST", 325, 346], ["the anti-cancer therapeutic Herceptin", "TREATMENT", 367, 404], ["a clinical laboratory test", "TEST", 414, 440], ["Cancer", "OBSERVATION", 219, 225]]], ["Amplifi cation of the human epidermal growth factor receptor 2 gene ( HER2) in primary breast cancer carcinomas had been shown to correlate to poor clinical prognosis for breast cancer patients ( Ferretti et al., 2007 ) .", [["primary breast cancer carcinomas", "ANATOMY", 79, 111], ["breast cancer", "ANATOMY", 171, 184], ["breast cancer", "DISEASE", 87, 100], ["carcinomas", "DISEASE", 101, 111], ["breast cancer", "DISEASE", 171, 184], ["human epidermal growth factor receptor 2", "GENE_OR_GENE_PRODUCT", 22, 62], ["HER2", "GENE_OR_GENE_PRODUCT", 70, 74], ["breast cancer carcinomas", "CANCER", 87, 111], ["breast cancer", "CANCER", 171, 184], ["patients", "ORGANISM", 185, 193], ["human epidermal growth factor receptor 2 gene", "DNA", 22, 67], ["HER2", "PROTEIN", 70, 74], ["human", "SPECIES", 22, 27], ["patients", "SPECIES", 185, 193], ["human", "SPECIES", 22, 27], ["Amplifi cation", "TREATMENT", 0, 14], ["the human epidermal growth factor receptor", "TREATMENT", 18, 60], ["primary breast cancer carcinomas", "PROBLEM", 79, 111], ["breast cancer", "PROBLEM", 171, 184], ["breast", "ANATOMY", 87, 93], ["cancer", "OBSERVATION", 94, 100], ["breast", "ANATOMY", 171, 177], ["cancer", "OBSERVATION", 178, 184]]], ["The Her2/neu oncogene is active in 25-37% of breast cancers, and overexpression of the HER2 protein on cell surfaces was found to stimulate uncontrolled tumor growth.", [["breast cancers", "ANATOMY", 45, 59], ["cell surfaces", "ANATOMY", 103, 116], ["tumor", "ANATOMY", 153, 158], ["breast cancers", "DISEASE", 45, 59], ["tumor", "DISEASE", 153, 158], ["Her2", "GENE_OR_GENE_PRODUCT", 4, 8], ["neu", "GENE_OR_GENE_PRODUCT", 9, 12], ["breast cancers", "CANCER", 45, 59], ["HER2", "GENE_OR_GENE_PRODUCT", 87, 91], ["cell", "CELL", 103, 107], ["tumor", "CANCER", 153, 158], ["Her2/neu oncogene", "DNA", 4, 21], ["HER2 protein", "PROTEIN", 87, 99], ["The Her2/neu oncogene", "TEST", 0, 21], ["breast cancers", "PROBLEM", 45, 59], ["the HER2 protein", "PROBLEM", 83, 99], ["cell surfaces", "TREATMENT", 103, 116], ["uncontrolled tumor growth", "PROBLEM", 140, 165], ["active", "OBSERVATION_MODIFIER", 25, 31], ["breast", "ANATOMY", 45, 51], ["cancers", "OBSERVATION", 52, 59], ["uncontrolled", "OBSERVATION_MODIFIER", 140, 152], ["tumor", "OBSERVATION", 153, 158]]], ["Herceptin (trastuzumab) is a recombinant DNA-derived monoclonal antibody that binds with high affi nity and specifi city to the extracellular domain of the HER2 receptor and inhibits the proliferation of HER2 overexpressing tumor cells.", [["extracellular", "ANATOMY", 128, 141], ["HER2 overexpressing tumor cells", "ANATOMY", 204, 235], ["Herceptin", "CHEMICAL", 0, 9], ["trastuzumab", "CHEMICAL", 11, 22], ["tumor", "DISEASE", 224, 229], ["Herceptin", "CHEMICAL", 0, 9], ["Herceptin", "SIMPLE_CHEMICAL", 0, 9], ["trastuzumab", "SIMPLE_CHEMICAL", 11, 22], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 128, 141], ["HER2 receptor", "GENE_OR_GENE_PRODUCT", 156, 169], ["HER2", "GENE_OR_GENE_PRODUCT", 204, 208], ["tumor cells", "CELL", 224, 235], ["recombinant DNA-derived monoclonal antibody", "PROTEIN", 29, 72], ["affi nity", "PROTEIN", 94, 103], ["extracellular domain", "PROTEIN", 128, 148], ["HER2 receptor", "PROTEIN", 156, 169], ["HER2 overexpressing tumor cells", "CELL_TYPE", 204, 235], ["Herceptin (trastuzumab", "TREATMENT", 0, 22], ["a recombinant DNA", "PROBLEM", 27, 44], ["monoclonal antibody", "TEST", 53, 72], ["the HER2 receptor", "TREATMENT", 152, 169], ["HER2 overexpressing tumor cells", "PROBLEM", 204, 235], ["proliferation", "OBSERVATION_MODIFIER", 187, 200], ["HER2 overexpressing", "OBSERVATION", 204, 223], ["tumor cells", "OBSERVATION", 224, 235]]], ["Herceptin alone was associated with an objective response in 15% of extensively pretreated patients with metastatic breast cancer overexpressing HER2, and 26% of previously untreated patients ( McKeage and Perry, 2002 ) .", [["metastatic breast cancer", "ANATOMY", 105, 129], ["Herceptin", "CHEMICAL", 0, 9], ["breast cancer", "DISEASE", 116, 129], ["Herceptin", "SIMPLE_CHEMICAL", 0, 9], ["patients", "ORGANISM", 91, 99], ["breast cancer", "CANCER", 116, 129], ["HER2", "GENE_OR_GENE_PRODUCT", 145, 149], ["patients", "ORGANISM", 183, 191], ["HER2", "PROTEIN", 145, 149], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 183, 191], ["Herceptin", "TREATMENT", 0, 9], ["metastatic breast cancer", "PROBLEM", 105, 129], ["metastatic", "OBSERVATION_MODIFIER", 105, 115], ["breast", "ANATOMY", 116, 122], ["cancer", "OBSERVATION", 123, 129]]], ["Cardiac dysfunction occurred in 13% of patients receiving Herceptin and paclitaxel and in 4.7% of patients receiving only Herceptin.", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac dysfunction", "DISEASE", 0, 19], ["Herceptin", "CHEMICAL", 58, 67], ["paclitaxel", "CHEMICAL", 72, 82], ["Herceptin", "CHEMICAL", 122, 131], ["Herceptin", "CHEMICAL", 58, 67], ["paclitaxel", "CHEMICAL", 72, 82], ["Cardiac", "ORGAN", 0, 7], ["patients", "ORGANISM", 39, 47], ["Herceptin", "SIMPLE_CHEMICAL", 58, 67], ["paclitaxel", "SIMPLE_CHEMICAL", 72, 82], ["patients", "ORGANISM", 98, 106], ["Herceptin", "SIMPLE_CHEMICAL", 122, 131], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 98, 106], ["Cardiac dysfunction", "PROBLEM", 0, 19], ["Herceptin", "TREATMENT", 58, 67], ["paclitaxel", "TREATMENT", 72, 82], ["Herceptin", "TREATMENT", 122, 131], ["dysfunction", "OBSERVATION", 8, 19]]], ["Given the high cost of Herceptin therapy, the signifi cant side effects of Herceptin treatment for some patients, and the targeted nature of the therapeutic, it was necessary to restrict therapy to patients expected to respond to treatment.", [["Herceptin", "CHEMICAL", 23, 32], ["Herceptin", "CHEMICAL", 75, 84], ["Herceptin", "SIMPLE_CHEMICAL", 23, 32], ["Herceptin", "SIMPLE_CHEMICAL", 75, 84], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 198, 206], ["Herceptin therapy", "TREATMENT", 23, 40], ["Herceptin treatment", "TREATMENT", 75, 94], ["therapy", "TREATMENT", 187, 194], ["treatment", "TREATMENT", 230, 239]]], ["In 1998, the FDA approved both Herceptin and the HerCepTest for the treatment of metastatic breast cancer.", [["metastatic breast cancer", "ANATOMY", 81, 105], ["Herceptin", "CHEMICAL", 31, 40], ["HerCepTest", "CHEMICAL", 49, 59], ["breast cancer", "DISEASE", 92, 105], ["Herceptin", "SIMPLE_CHEMICAL", 31, 40], ["HerCepTest", "SIMPLE_CHEMICAL", 49, 59], ["metastatic breast cancer", "CANCER", 81, 105], ["both Herceptin", "TREATMENT", 26, 40], ["the HerCepTest", "TREATMENT", 45, 59], ["metastatic breast cancer", "PROBLEM", 81, 105], ["metastatic", "OBSERVATION_MODIFIER", 81, 91], ["breast", "ANATOMY", 92, 98], ["cancer", "OBSERVATION", 99, 105]]], ["HER2 protein is detected primarily by IHC or FISH methods.", [["HER2", "GENE_OR_GENE_PRODUCT", 0, 4], ["HER2 protein", "PROTEIN", 0, 12], ["HER2 protein", "TEST", 0, 12]]], ["HercepTest and PathVysion, a FISH assay for HER2 amplifi cation, are now used to select patients for Herceptin therapy.", [["Herceptin", "CHEMICAL", 101, 110], ["HER2", "GENE_OR_GENE_PRODUCT", 44, 48], ["patients", "ORGANISM", 88, 96], ["Herceptin", "SIMPLE_CHEMICAL", 101, 110], ["HER2", "PROTEIN", 44, 48], ["patients", "SPECIES", 88, 96], ["HercepTest", "TREATMENT", 0, 10], ["PathVysion", "TREATMENT", 15, 25], ["a FISH assay", "TEST", 27, 39], ["HER2 amplifi cation", "TREATMENT", 44, 63], ["Herceptin therapy", "TREATMENT", 101, 118]]], ["Uptake of diagnostic testing for HER2 receptor status was greatly accelerated due to safety issues associated with the therapy.", [["HER2 receptor", "GENE_OR_GENE_PRODUCT", 33, 46], ["HER2", "PROTEIN", 33, 37], ["diagnostic testing", "TEST", 10, 28], ["HER2 receptor status", "PROBLEM", 33, 53], ["safety issues", "PROBLEM", 85, 98], ["the therapy", "TREATMENT", 115, 126]]], ["Additionally, the assay did not require new tissue samples as in many cases archived samples in paraffi n blocks were already being sent to reference labs for estrogen and progesterone analysis, and physicians could merely check another box on the test order sheet.", [["tissue samples", "ANATOMY", 44, 58], ["samples", "ANATOMY", 85, 92], ["estrogen", "CHEMICAL", 159, 167], ["progesterone", "CHEMICAL", 172, 184], ["estrogen", "CHEMICAL", 159, 167], ["progesterone", "CHEMICAL", 172, 184], ["tissue samples", "CANCER", 44, 58], ["estrogen", "SIMPLE_CHEMICAL", 159, 167], ["progesterone", "SIMPLE_CHEMICAL", 172, 184], ["the assay", "TEST", 14, 23], ["new tissue samples", "TEST", 40, 58], ["paraffi n blocks", "TREATMENT", 96, 112], ["estrogen", "TEST", 159, 167], ["progesterone analysis", "TEST", 172, 193]]], ["Randomized clinical trials have recently demonstrated signifi cant differences in survival when comparing chemotherapy to chemotherapy plus Herceptin in women with HER2 overexpressing breast cancer in either the metastatic or adjuvant setting ( Ferretti et al., 2007) .", [["breast cancer", "ANATOMY", 184, 197], ["Herceptin", "CHEMICAL", 140, 149], ["breast cancer", "DISEASE", 184, 197], ["Herceptin", "SIMPLE_CHEMICAL", 140, 149], ["women", "ORGANISM", 153, 158], ["HER2", "GENE_OR_GENE_PRODUCT", 164, 168], ["breast cancer", "CANCER", 184, 197], ["HER2", "PROTEIN", 164, 168], ["women", "SPECIES", 153, 158], ["signifi cant differences", "PROBLEM", 54, 78], ["chemotherapy", "TREATMENT", 106, 118], ["chemotherapy", "TREATMENT", 122, 134], ["Herceptin", "TREATMENT", 140, 149], ["HER2 overexpressing breast cancer", "PROBLEM", 164, 197], ["breast", "ANATOMY", 184, 190], ["cancer", "OBSERVATION", 191, 197], ["metastatic", "OBSERVATION", 212, 222]]], ["Thus, what was once a prognosticator of poor outcome for the patient has become a predictive marker of response to therapy.", [["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["therapy", "TREATMENT", 115, 122]]], ["Unfortunately, a lack of concordance among detection techniques, different scoring systems used to determine HER2 status, and a lack of lab standardization and quality based on test experience have led to signifi cant variation in HER2 testing (Nelson, 2000 ) .", [["HER2", "GENE_OR_GENE_PRODUCT", 109, 113], ["HER2", "GENE_OR_GENE_PRODUCT", 231, 235], ["HER2", "PROTEIN", 109, 113], ["HER2", "PROTEIN", 231, 235], ["detection techniques", "TEST", 43, 63], ["lab standardization", "TEST", 136, 155], ["signifi cant variation", "PROBLEM", 205, 227], ["HER2 testing", "TEST", 231, 243]]], ["Recent CAP/ASCO guidelines, that include a testing algorithm, QA requirements, lab evaluations, and a scoring system, should help address these issues ( CAP/ASCO, 2007 ) .Cervical Cancer, HPV, and GardisilHuman papillomavirus (HPV) is the major cause of cervical cancer, a disease that kills more than 200,000 women worldwide each year ( Gottlieb, 2002 ) .", [["Cervical Cancer", "ANATOMY", 171, 186], ["cervical cancer", "ANATOMY", 254, 269], ["Cervical Cancer, HPV, and GardisilHuman papillomavirus (HPV)", "DISEASE", 171, 231], ["cervical cancer", "DISEASE", 254, 269], ["Cervical Cancer", "CANCER", 171, 186], ["HPV", "ORGANISM", 188, 191], ["GardisilHuman papillomavirus", "ORGANISM", 197, 225], ["HPV", "ORGANISM", 227, 230], ["cervical cancer", "CANCER", 254, 269], ["women", "ORGANISM", 310, 315], ["GardisilHuman papillomavirus", "SPECIES", 197, 225], ["women", "SPECIES", 310, 315], ["HPV", "SPECIES", 188, 191], ["GardisilHuman papillomavirus", "SPECIES", 197, 225], ["HPV", "SPECIES", 227, 230], ["a testing algorithm", "TEST", 41, 60], ["lab evaluations", "TEST", 79, 94], ["Cervical Cancer", "PROBLEM", 171, 186], ["HPV", "PROBLEM", 188, 191], ["GardisilHuman papillomavirus (HPV", "PROBLEM", 197, 230], ["cervical cancer", "PROBLEM", 254, 269], ["a disease", "PROBLEM", 271, 280], ["Cancer", "OBSERVATION", 180, 186], ["cervical", "ANATOMY", 254, 262], ["cancer", "OBSERVATION", 263, 269]]], ["In the United States more than 6 million new cases are reported annually and at least 20 million people in this country are already infected ( NIAID, 2006 ) .", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103], ["infected", "OBSERVATION", 132, 140]]], ["Approximately 40 of the 100 types of HPV virus can be sexually transmitted, but most rarely cause symptoms or disease.", [["HPV virus", "DISEASE", 37, 46], ["HPV virus", "ORGANISM", 37, 46], ["HPV virus", "SPECIES", 37, 46], ["HPV virus", "PROBLEM", 37, 46], ["symptoms", "PROBLEM", 98, 106], ["disease", "PROBLEM", 110, 117], ["disease", "OBSERVATION", 110, 117]]], ["Types 6 and 11 are low-cancer risk types that cause genital warts.", [["cancer", "ANATOMY", 23, 29], ["genital warts", "ANATOMY", 52, 65], ["low-cancer", "DISEASE", 19, 29], ["genital warts", "DISEASE", 52, 65], ["cancer", "CANCER", 23, 29], ["genital warts", "PATHOLOGICAL_FORMATION", 52, 65], ["low-cancer risk types", "PROBLEM", 19, 40], ["genital warts", "PROBLEM", 52, 65], ["cancer", "OBSERVATION", 23, 29], ["genital", "ANATOMY", 52, 59], ["warts", "OBSERVATION", 60, 65]]], ["Lowand high-risk types can cause the growth of abnormal cells which can be detected when a Pap test is done during a gynecologic exam.", [["cells", "ANATOMY", 56, 61], ["cells", "CELL", 56, 61], ["abnormal cells", "CELL_TYPE", 47, 61], ["abnormal cells", "PROBLEM", 47, 61], ["a Pap test", "TEST", 89, 99], ["a gynecologic exam", "TEST", 115, 133], ["risk types", "OBSERVATION_MODIFIER", 12, 22], ["growth", "OBSERVATION_MODIFIER", 37, 43], ["abnormal cells", "OBSERVATION", 47, 61]]], ["The Bethesda system divides the most common clearly abnormal Pap results into either: low-grade squamous intraepithelial lesions (LSILs) which are mild cell changes associated with HPV; high-grade squamous intraepithelial lesions (HSILs) which are precancerous cell changes which should be treated by a physician; and cancer.", [["low-grade squamous intraepithelial lesions", "ANATOMY", 86, 128], ["LSILs", "ANATOMY", 130, 135], ["cell", "ANATOMY", 152, 156], ["high-grade squamous intraepithelial lesions", "ANATOMY", 186, 229], ["HSILs", "ANATOMY", 231, 236], ["precancerous cell", "ANATOMY", 248, 265], ["cancer", "ANATOMY", 318, 324], ["squamous intraepithelial lesions", "DISEASE", 96, 128], ["LSILs", "DISEASE", 130, 135], ["squamous intraepithelial lesions", "DISEASE", 197, 229], ["HSILs", "DISEASE", 231, 236], ["cancer", "DISEASE", 318, 324], ["low-grade squamous intraepithelial lesions", "CANCER", 86, 128], ["LSILs", "CANCER", 130, 135], ["cell", "CELL", 152, 156], ["high-grade squamous intraepithelial lesions", "CANCER", 186, 229], ["HSILs", "CANCER", 231, 236], ["precancerous cell", "CELL", 248, 265], ["cancer", "CANCER", 318, 324], ["low-grade squamous intraepithelial lesions (LSILs)", "PROBLEM", 86, 136], ["mild cell changes", "PROBLEM", 147, 164], ["HPV", "PROBLEM", 181, 184], ["high-grade squamous intraepithelial lesions (HSILs)", "PROBLEM", 186, 237], ["precancerous cell changes", "PROBLEM", 248, 273], ["cancer", "PROBLEM", 318, 324], ["low", "OBSERVATION_MODIFIER", 86, 89], ["squamous", "OBSERVATION_MODIFIER", 96, 104], ["intraepithelial lesions", "OBSERVATION", 105, 128], ["mild", "OBSERVATION_MODIFIER", 147, 151], ["cell", "OBSERVATION", 152, 156], ["high", "OBSERVATION_MODIFIER", 186, 190], ["-grade", "OBSERVATION_MODIFIER", 190, 196], ["squamous", "OBSERVATION_MODIFIER", 197, 205], ["intraepithelial lesions", "OBSERVATION", 206, 229], ["precancerous cell", "OBSERVATION", 248, 265], ["cancer", "OBSERVATION", 318, 324]]], ["Clinicians managing a notcompletely-normal Pap result, known as ASCUS (atypical squamous cells of undetermined signifi cance), may benefi t from the additional information provided by HPV testing.Cervical Cancer, HPV, and GardisilIn 2000, the FDA-approved Digene Corporation's hc2 High-risk HPV DNA test for use in women with abnormal Pap test results.", [["squamous cells", "ANATOMY", 80, 94], ["Cervical Cancer", "ANATOMY", 196, 211], ["ASCUS", "DISEASE", 64, 69], ["Cervical Cancer", "DISEASE", 196, 211], ["squamous cells", "CELL", 80, 94], ["HPV", "ORGANISM", 184, 187], ["Cervical Cancer", "CANCER", 196, 211], ["HPV", "ORGANISM", 213, 216], ["hc2", "ORGANISM", 277, 280], ["HPV", "ORGANISM", 291, 294], ["women", "ORGANISM", 315, 320], ["atypical squamous cells", "CELL_TYPE", 71, 94], ["women", "SPECIES", 315, 320], ["HPV", "SPECIES", 291, 294], ["ASCUS (atypical squamous cells", "PROBLEM", 64, 94], ["HPV testing", "TEST", 184, 195], ["Cervical Cancer", "PROBLEM", 196, 211], ["HPV", "PROBLEM", 213, 216], ["HPV DNA test", "TEST", 291, 303], ["abnormal Pap test", "PROBLEM", 326, 343], ["squamous cells", "OBSERVATION", 80, 94], ["Cancer", "OBSERVATION", 205, 211]]], ["In 2003, the FDA expanded the use of HPV testing in conjunction with the Pap test for routine screening.", [["HPV", "ORGANISM", 37, 40], ["HPV", "SPECIES", 37, 40], ["HPV testing", "TEST", 37, 48], ["the Pap test", "TEST", 69, 81], ["routine screening", "TEST", 86, 103]]], ["The test uses hybrid capture technology to directly detect HPV virus DNA and the current system allows high-throughput testing.", [["HPV", "ORGANISM", 59, 62], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["HPV virus", "SPECIES", 59, 68], ["The test", "TEST", 0, 8], ["hybrid capture technology", "TREATMENT", 14, 39], ["HPV virus DNA", "PROBLEM", 59, 72], ["the current system", "TEST", 77, 95]]], ["A woman fi tting the appropriate clinical criteria with both a negative Pap and negative HPV DNA test has less than a one in one thousand chance of developing cervical cancer.", [["cervical cancer", "ANATOMY", 159, 174], ["cervical cancer", "DISEASE", 159, 174], ["woman", "ORGANISM", 2, 7], ["HPV", "ORGANISM", 89, 92], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["cervical cancer", "CANCER", 159, 174], ["woman", "SPECIES", 2, 7], ["HPV", "SPECIES", 89, 92], ["HPV DNA test", "TEST", 89, 101], ["developing cervical cancer", "PROBLEM", 148, 174], ["cervical", "ANATOMY", 159, 167], ["cancer", "OBSERVATION", 168, 174]]], ["In 2006, the FDA-approved Merck and Co's Gardisil, a recombinant vaccine which is designed to prevent the majority of HPV-related clinical diseases, those caused by HPV 6, 11, 16, and 18.", [["Co", "CHEMICAL", 36, 38], ["Gardisil", "CHEMICAL", 41, 49], ["Co", "CHEMICAL", 36, 38], ["Merck", "SIMPLE_CHEMICAL", 26, 31], ["Gardisil", "SIMPLE_CHEMICAL", 41, 49], ["HPV", "ORGANISM", 118, 121], ["Merck and Co's Gardisil", "TREATMENT", 26, 49], ["a recombinant vaccine", "TREATMENT", 51, 72], ["HPV", "PROBLEM", 118, 121], ["clinical diseases", "PROBLEM", 130, 147], ["HPV", "TEST", 165, 168]]], ["HPV types 16 and 18 account for approximately 70% of cases of cervical cancer, while HPV 6 and 11 cause approximately 90% of genital wart cases.", [["cervical cancer", "ANATOMY", 62, 77], ["genital wart", "ANATOMY", 125, 137], ["cervical cancer", "DISEASE", 62, 77], ["genital wart", "DISEASE", 125, 137], ["HPV", "ORGANISM", 0, 3], ["cervical cancer", "CANCER", 62, 77], ["HPV 6", "ORGANISM", 85, 90], ["genital wart", "CANCER", 125, 137], ["HPV types", "TEST", 0, 9], ["cervical cancer", "PROBLEM", 62, 77], ["HPV", "TEST", 85, 88], ["cervical", "ANATOMY", 62, 70], ["cancer", "OBSERVATION", 71, 77]]], ["In clinical studies, Gardasil prevented 100% of HPV 16-and 18-related cervical cancer in women not previously exposed to the relevant HPV types.", [["cervical cancer", "ANATOMY", 70, 85], ["Gardasil", "CHEMICAL", 21, 29], ["cervical cancer", "DISEASE", 70, 85], ["Gardasil", "CHEMICAL", 21, 29], ["Gardasil", "SIMPLE_CHEMICAL", 21, 29], ["HPV 16", "ORGANISM", 48, 54], ["cervical cancer", "CANCER", 70, 85], ["women", "ORGANISM", 89, 94], ["HPV", "ORGANISM", 134, 137], ["women", "SPECIES", 89, 94], ["HPV", "SPECIES", 48, 51], ["clinical studies", "TEST", 3, 19], ["Gardasil", "TREATMENT", 21, 29], ["HPV", "TEST", 48, 51], ["cervical cancer", "PROBLEM", 70, 85], ["cervical", "ANATOMY", 70, 78], ["cancer", "OBSERVATION", 79, 85], ["HPV", "OBSERVATION", 134, 137]]], ["These studies were conducted on 21,000 women ages 16-26 and the vaccine was nearly 100% effective in preventing precancerous lesions and genital warts.", [["precancerous lesions", "ANATOMY", 112, 132], ["genital warts", "ANATOMY", 137, 150], ["precancerous lesions", "DISEASE", 112, 132], ["genital warts", "DISEASE", 137, 150], ["women", "ORGANISM", 39, 44], ["precancerous lesions", "PATHOLOGICAL_FORMATION", 112, 132], ["genital warts", "PATHOLOGICAL_FORMATION", 137, 150], ["women", "SPECIES", 39, 44], ["These studies", "TEST", 0, 13], ["the vaccine", "TREATMENT", 60, 71], ["precancerous lesions", "PROBLEM", 112, 132], ["genital warts", "PROBLEM", 137, 150], ["precancerous", "OBSERVATION_MODIFIER", 112, 124], ["lesions", "OBSERVATION", 125, 132], ["genital", "ANATOMY", 137, 144], ["warts", "OBSERVATION", 145, 150]]], ["Gardisil was evaluated and approved in 6 months under the FDA's priority review process, a process for products with potential to provide signifi cant health benefi ts ( FDA, 2006f ) .", [["Gardisil", "CHEMICAL", 0, 8], ["Gardisil", "SIMPLE_CHEMICAL", 0, 8], ["Gardisil", "TREATMENT", 0, 8]]], ["On June 28, 2006 the CDC's Advisory Committee on Immunization Practices (ACIP) recommended that all females between the ages of 11-26 receive the HPV vaccine as part of routine primary care.Cervical Cancer, HPV, and GardisilHPV diagnostic tests expanded in utility from a test limited to abnormal Pap test results, to a diagnostic test that in conjunction with the Pap test is now standard of care for routine screening for women 30 years of age or older.", [["Cervical Cancer", "ANATOMY", 190, 205], ["Cancer", "DISEASE", 199, 205], ["HPV", "ORGANISM", 146, 149], ["Cervical Cancer", "CANCER", 190, 205], ["HPV", "ORGANISM", 207, 210], ["women", "ORGANISM", 424, 429], ["women", "SPECIES", 424, 429], ["HPV", "SPECIES", 146, 149], ["HPV", "SPECIES", 207, 210], ["GardisilHPV", "SPECIES", 216, 227], ["Immunization Practices (ACIP)", "TREATMENT", 49, 78], ["the HPV vaccine", "TREATMENT", 142, 157], ["routine primary care", "TREATMENT", 169, 189], ["Cervical Cancer", "PROBLEM", 190, 205], ["HPV", "PROBLEM", 207, 210], ["GardisilHPV diagnostic tests", "TEST", 216, 244], ["a test", "TEST", 270, 276], ["abnormal Pap test", "PROBLEM", 288, 305], ["a diagnostic test", "TEST", 318, 335], ["the Pap test", "TEST", 361, 373], ["routine screening", "TEST", 402, 419], ["Cancer", "OBSERVATION", 199, 205]]], ["The move to a liquid Pap test from previously common smear methods removed the need for additional sampling for HPV testing and the development of an effective vaccine bolstered the public awareness of HPV.", [["HPV", "ORGANISM", 112, 115], ["HPV", "ORGANISM", 202, 205], ["HPV", "SPECIES", 112, 115], ["HPV", "SPECIES", 202, 205], ["a liquid Pap test", "TEST", 12, 29], ["additional sampling", "TEST", 88, 107], ["HPV testing", "TEST", 112, 123], ["an effective vaccine", "TREATMENT", 147, 167]]], ["Technological innovations reducing sampling barriers and improving therapeutic options along with other factors aided the rapid uptake of HPV testing.CONCLUSIONS: TRANSLATIONAL CHALLENGES FOR INNOVATIVE DIAGNOSTICSDiagnostic tests are being developed at a rapid rate, and the technologies of diagnostic testing are expanding.", [["HPV", "ORGANISM", 138, 141], ["HPV", "SPECIES", 138, 141], ["Technological innovations", "TREATMENT", 0, 25], ["sampling barriers", "TREATMENT", 35, 52], ["improving therapeutic options", "TREATMENT", 57, 86], ["HPV testing", "TEST", 138, 149], ["INNOVATIVE DIAGNOSTICSDiagnostic tests", "TEST", 192, 230], ["diagnostic testing", "TEST", 292, 310]]], ["For example, early asymptomatic glaucoma testing was widely abandoned because early detection did not affect the outcome.", [["glaucoma", "ANATOMY", 32, 40], ["glaucoma", "DISEASE", 32, 40], ["early asymptomatic glaucoma testing", "PROBLEM", 13, 48], ["early", "OBSERVATION_MODIFIER", 13, 18], ["asymptomatic", "OBSERVATION_MODIFIER", 19, 31], ["glaucoma", "OBSERVATION", 32, 40]]], ["Other tests may not achieve the analytical performance characteristics required of a good diagnostic.", [["Other tests", "TEST", 0, 11]]], ["Assay sensitivity, specifi city, and predictive value must be high (Gaeta, 2005 ) .", [["Assay sensitivity", "TEST", 0, 17], ["predictive value", "TEST", 37, 53]]], ["For example, before microarray technology can be translated widely to diagnostic applications, problems with sensitivity and reproducibility will have to solved ( Petrik, 2006 ) .", [["sensitivity", "TEST", 109, 120]]], ["A rigorous evaluation of diagnostic tests prior to their introduction into clinical practice is the goal of the standards for the reporting of diagnostic accuracy (STARD) initiative ( Bossuyt et al., 2003 ) and evaluation of genomic applications in practice and prevention (EGAPP), a CDC project to establish an evidence-based process for assessing applications of genomic technology ( CDC and National Offi ce of Public Health Genomics, 2008 ).", [["A rigorous evaluation", "TEST", 0, 21], ["diagnostic tests", "TEST", 25, 41], ["diagnostic accuracy", "TEST", 143, 162], ["evaluation", "TEST", 211, 221], ["genomic applications", "TREATMENT", 225, 245], ["a CDC project", "TEST", 282, 295]]], ["Ultimately, the role of diagnostics in clinical care must be balanced with other tools available to the physician, such as patient history and physical exam (Halkin et al., 1997 ) .", [["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130], ["physical exam", "TEST", 143, 156]]], ["Additionally, technological advancements must produce an increase in effi cacy of treatment in excess of that produced by improving the delivery of older treatments ( Woolf and Johnson, 2005 ) .CONCLUSIONS: TRANSLATIONAL CHALLENGES FOR INNOVATIVE DIAGNOSTICSThe future of innovative diagnostics holds great promise for providing rapid identifi cation of disease susceptibility and status, for monitoring disease progress and therapeutic effi cacy, for reducing ADRs and speeding appropriate therapy selection, for the development of personalized medicine, and for optimizing disease prevention and cures.", [["ADRs", "DISEASE", 461, 465], ["treatment", "TREATMENT", 82, 91], ["older treatments", "TREATMENT", 148, 164], ["innovative diagnostics", "TEST", 272, 294], ["disease susceptibility", "PROBLEM", 354, 376], ["therapeutic effi cacy", "TREATMENT", 425, 446], ["reducing ADRs", "PROBLEM", 452, 465], ["speeding appropriate therapy selection", "TREATMENT", 470, 508], ["personalized medicine", "TREATMENT", 533, 554], ["optimizing disease prevention", "TREATMENT", 564, 593], ["increase", "OBSERVATION_MODIFIER", 57, 65]]], ["Diagnostic testing must address an unmet medical need, lead to an actionable event, and demonstrate its clinical utility.", [["Diagnostic testing", "TEST", 0, 18]]], ["These diagnostics must also demonstrate high specifi city, sensitivity, and predictive value.CONCLUSIONS: TRANSLATIONAL CHALLENGES FOR INNOVATIVE DIAGNOSTICSFor a novel diagnostic to be ultimately translated effectively, additional obstacles must also be overcome.", [["These diagnostics", "TEST", 0, 17], ["predictive value", "TEST", 76, 92], ["high", "OBSERVATION_MODIFIER", 40, 44]]], ["The diagnostic test must prove functional in the health care setting.", [["The diagnostic test", "TEST", 0, 19]]], ["For example, do new sample types need to be procured, or can the diagnostic test replace or add on to existing assays while retaining current sampling procedures?", [["the diagnostic test", "TEST", 61, 80], ["assays", "TEST", 111, 117], ["current sampling procedures", "TREATMENT", 134, 161]]], ["Will the clinical value of the test be clearly demonstrated to thought leaders, early adopters, patient advocacy groups, and other stakeholder; required for rapid uptake of the diagnostic?", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["the test", "TEST", 27, 35]]], ["The role of professional society guidelines, CMS coverage, technology review by the insurance industry, and regulators must be considered.", [["professional society guidelines", "TREATMENT", 12, 43]]], ["Will reimbursement issues delay the uptake and access of the test to a large sector of the patient population?", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["the test", "TEST", 57, 65]]], ["Are there patient safety issues, within specifi c treatments, that warrant rapid clinical uptake?", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["patient safety issues", "PROBLEM", 10, 31], ["specifi c treatments", "TREATMENT", 40, 60], ["rapid clinical uptake", "PROBLEM", 75, 96]]], ["How should a new diagnostic test best be used to optimize the healthcare benefi t, as a stand alone diagnostic, or linked to a treatment protocol (a companion diagnostic or theranostics)?", [["a new diagnostic test", "TEST", 11, 32], ["a treatment protocol", "TREATMENT", 125, 145]]], ["Finally, will new accurate and reliable diagnostic methods make the biases and inaccuracies that have characterized the practice of clinical medicine and patient reports a thing of the past?", [["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["clinical medicine", "TREATMENT", 132, 149]]], ["Closing the translational gaps highlighted by these issues and others requires research, its own knowledge translation, fi nancial support, and an awareness of the lessons learned from previously translated diagnostics (Table 31 .2 ).CONCLUSIONS: TRANSLATIONAL CHALLENGES FOR INNOVATIVE DIAGNOSTICSEven though diagnostics infl uence 60-70% of healthcare decision-making, they make up less than 5% of hospital costs and 1.6% of Medicare costs ( Nordhoff, 2005 ) .", [["fi nancial support", "TREATMENT", 120, 138], ["diagnostics", "TEST", 310, 321]]], ["In the next decade, new diagnostics are predicted to have an even greater impact on healthcare decision making by providing improved disease prediction and prognostication, and therapy guidance.", [["therapy guidance", "TREATMENT", 177, 193]]], ["Studies have found a 30-50% reduction in direct hospital and outpatient charges when changes in patient health status are accurately monitored.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["Studies", "TEST", 0, 7], ["changes in patient health status", "PROBLEM", 85, 117]]], ["Yet, diagnostic tests recommended as standard of care are underused 51% of the time ( Olsen, 2006 ) .", [["diagnostic tests", "TEST", 5, 21]]], ["Low compliance with diagnostics-based quality measures for diabetes, cardiovascular disease, colorectal cancer, and breast cancer can be linked to 34,000 avoidable deaths and $899 million in avoidable healthcare costs ( Olsen, 2006 ) .", [["cardiovascular", "ANATOMY", 69, 83], ["colorectal cancer", "ANATOMY", 93, 110], ["breast cancer", "ANATOMY", 116, 129], ["diabetes", "DISEASE", 59, 67], ["cardiovascular disease", "DISEASE", 69, 91], ["colorectal cancer", "DISEASE", 93, 110], ["breast cancer", "DISEASE", 116, 129], ["deaths", "DISEASE", 164, 170], ["cardiovascular", "ANATOMICAL_SYSTEM", 69, 83], ["colorectal cancer", "CANCER", 93, 110], ["breast cancer", "CANCER", 116, 129], ["diagnostics", "TEST", 20, 31], ["diabetes", "PROBLEM", 59, 67], ["cardiovascular disease", "PROBLEM", 69, 91], ["colorectal cancer", "PROBLEM", 93, 110], ["breast cancer", "PROBLEM", 116, 129], ["cardiovascular", "ANATOMY", 69, 83], ["disease", "OBSERVATION", 84, 91], ["colorectal", "ANATOMY", 93, 103], ["cancer", "OBSERVATION", 104, 110], ["breast", "ANATOMY", 116, 122], ["cancer", "OBSERVATION", 123, 129]]], ["Effi cient translation of new knowledge and technology is critical so that the promise of innovative diagnostics and personalized medicine can be realized.", [["personalized medicine", "TREATMENT", 117, 138], ["new", "OBSERVATION_MODIFIER", 26, 29]]]], "PMC7159270": [["In a double-blind, placebo-controlled trial, Sabine Meijvis and colleagues1 found clinical benefit of reduced length of hospital stay when dexamethasone was added to antibiotic treatment in immunocompetent patients with community-acquired pneumonia.", [["dexamethasone", "CHEMICAL", 139, 152], ["pneumonia", "DISEASE", 239, 248], ["dexamethasone", "CHEMICAL", 139, 152], ["dexamethasone", "SIMPLE_CHEMICAL", 139, 152], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["placebo", "TREATMENT", 19, 26], ["Sabine Meijvis", "TREATMENT", 45, 59], ["dexamethasone", "TREATMENT", 139, 152], ["antibiotic treatment", "TREATMENT", 166, 186], ["community-acquired pneumonia", "PROBLEM", 220, 248], ["pneumonia", "OBSERVATION", 239, 248]]], ["However, of the 304 recruited cases, most had bacterial infections such as Streptococcus pneumoniae, and only seven (2\u00b73%) were diagnosed as having influenza pneumonia (nine others [3\u00b70%] had mixed influenza-bacterial infections, mostly S pneumoniae).", [["bacterial infections", "DISEASE", 46, 66], ["Streptococcus pneumoniae", "DISEASE", 75, 99], ["influenza pneumonia", "DISEASE", 148, 167], ["influenza-bacterial infections", "DISEASE", 198, 228], ["Streptococcus pneumoniae", "ORGANISM", 75, 99], ["Streptococcus pneumoniae", "SPECIES", 75, 99], ["S pneumoniae", "SPECIES", 237, 249], ["Streptococcus pneumoniae", "SPECIES", 75, 99], ["S pneumoniae", "SPECIES", 237, 249], ["bacterial infections", "PROBLEM", 46, 66], ["Streptococcus pneumoniae", "PROBLEM", 75, 99], ["influenza pneumonia", "PROBLEM", 148, 167], ["mixed influenza", "PROBLEM", 192, 207], ["bacterial infections", "PROBLEM", 208, 228], ["S pneumoniae", "PROBLEM", 237, 249], ["infections", "OBSERVATION", 56, 66], ["Streptococcus pneumoniae", "OBSERVATION", 75, 99], ["influenza", "OBSERVATION_MODIFIER", 148, 157], ["pneumonia", "OBSERVATION", 158, 167], ["bacterial infections", "OBSERVATION", 208, 228]]], ["As such, the results cannot be generalised to community-acquired pneumonia with viral causes.", [["pneumonia", "DISEASE", 65, 74], ["pneumonia", "PROBLEM", 65, 74], ["viral causes", "PROBLEM", 80, 92], ["pneumonia", "OBSERVATION", 65, 74]]]], "019760388ec5fa9151add6cfe32178deda5433eb": [["IntroductionEukaryotic cellular and most viral messenger RNAs (mRNAs) are modified at their 5 0 termini with methylated cap structures, which promote stability and efficient translation [6, 9] .", [["cellular", "ANATOMY", 23, 31], ["cellular", "CELL", 23, 31], ["viral messenger RNAs", "RNA", 41, 61], ["mRNAs", "RNA", 63, 68], ["5 0 termini", "DNA", 92, 103], ["IntroductionEukaryotic cellular and most viral messenger RNAs (mRNAs)", "PROBLEM", 0, 69], ["methylated cap structures", "TREATMENT", 109, 134], ["most viral", "OBSERVATION_MODIFIER", 36, 46], ["messenger RNAs", "OBSERVATION", 47, 61], ["stability", "OBSERVATION_MODIFIER", 150, 159]]], ["Recent studies on selected viral methylated caps have revealed that cap structures may also have a function in cloaking viral messenger from sensors of the host cell innate immune response [5, 12, 16, 17, 34, 35] .", [["cap structures", "ANATOMY", 68, 82], ["cell", "ANATOMY", 161, 165], ["host cell", "CELL", 156, 165], ["Recent studies", "TEST", 0, 14], ["selected viral methylated caps", "TREATMENT", 18, 48], ["cap structures", "PROBLEM", 68, 82], ["host cell", "OBSERVATION", 156, 165]]], ["Most viral transcripts are characterized by a cap1 structure [ m7 GpppN 2m ] consisting of a 7-methylguanosine ( m7 G) linked by a 5 0 -5 0 triphosphate bond to the 5 0 end of the mRNA and the methylation of the 2 0 -OH group of the ribose of the first nucleotide.", [["7-methylguanosine", "CHEMICAL", 93, 110], ["5 0 -5 0 triphosphate", "CHEMICAL", 131, 152], ["ribose", "CHEMICAL", 233, 239], ["nucleotide", "CHEMICAL", 253, 263], ["7-methylguanosine", "CHEMICAL", 93, 110], ["m7 G", "CHEMICAL", 113, 117], ["5 0 -5 0 triphosphate", "CHEMICAL", 131, 152], ["2 0 -OH", "CHEMICAL", 212, 219], ["ribose", "CHEMICAL", 233, 239], ["nucleotide", "CHEMICAL", 253, 263], ["7-methylguanosine", "SIMPLE_CHEMICAL", 93, 110], ["m7 G", "SIMPLE_CHEMICAL", 113, 117], ["5 0 -5 0 triphosphate", "SIMPLE_CHEMICAL", 131, 152], ["2 0 -OH", "SIMPLE_CHEMICAL", 212, 219], ["ribose", "SIMPLE_CHEMICAL", 233, 239], ["viral transcripts", "RNA", 5, 22], ["cap1 structure", "PROTEIN", 46, 60], ["5 0 end", "RNA", 165, 172], ["mRNA", "RNA", 180, 184], ["a cap1 structure", "TEST", 44, 60]]], ["The cap structure is formed by an orchestrated series of reactions including the RNA triphosphatase, guanylyltransferase and the two methylase activities, viz., guanine-N7-methyltransferase (N7MTase) and nucleoside-2 0 -O-methyltransferase (2 0 -O MTase).", [["guanine", "CHEMICAL", 161, 168], ["nucleoside-2 0 -O", "CHEMICAL", 204, 221], ["guanine", "CHEMICAL", 161, 168], ["N7", "CHEMICAL", 169, 171], ["nucleoside", "CHEMICAL", 204, 214], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 101, 120], ["guanine-N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 161, 189], ["N7MTase", "SIMPLE_CHEMICAL", 191, 198], ["nucleoside-2 0 -O-methyltransferase", "SIMPLE_CHEMICAL", 204, 239], ["2 0 -O MTase", "SIMPLE_CHEMICAL", 241, 253], ["RNA triphosphatase", "PROTEIN", 81, 99], ["guanylyltransferase", "PROTEIN", 101, 120], ["guanine-N7-methyltransferase", "PROTEIN", 161, 189], ["N7MTase", "PROTEIN", 191, 198], ["nucleoside-2 0 -O-methyltransferase", "PROTEIN", 204, 239], ["O MTase", "PROTEIN", 246, 253], ["an orchestrated series of reactions", "PROBLEM", 31, 66], ["the RNA triphosphatase", "TEST", 77, 99], ["guanylyltransferase", "TREATMENT", 101, 120], ["the two methylase activities", "TREATMENT", 125, 153], ["guanine", "TREATMENT", 161, 168], ["N7-methyltransferase (N7MTase)", "TREATMENT", 169, 199], ["nucleoside", "TREATMENT", 204, 214], ["cap structure", "OBSERVATION_MODIFIER", 4, 17]]], ["Members of the Reoviridae, such as Bluetongue virus (BTV), encode specific viral proteins that are responsible for synthesizing the cap1 structures at the 5 0 termini of their RNA transcripts, similar to most eukaryotic and viral transcripts [23, 36] .", [["Reoviridae", "GENE_OR_GENE_PRODUCT", 15, 25], ["Bluetongue virus", "ORGANISM", 35, 51], ["BTV", "ORGANISM", 53, 56], ["cap1", "GENE_OR_GENE_PRODUCT", 132, 136], ["viral proteins", "PROTEIN", 75, 89], ["cap1 structures", "RNA", 132, 147], ["5 0 termini", "RNA", 155, 166], ["RNA transcripts", "RNA", 176, 191], ["eukaryotic and viral transcripts", "RNA", 209, 241], ["Bluetongue virus", "SPECIES", 35, 51], ["Bluetongue virus", "SPECIES", 35, 51], ["BTV", "SPECIES", 53, 56], ["the Reoviridae", "TREATMENT", 11, 25], ["Bluetongue virus", "PROBLEM", 35, 51], ["encode specific viral proteins", "PROBLEM", 59, 89], ["synthesizing the cap1 structures", "PROBLEM", 115, 147], ["viral proteins", "OBSERVATION", 75, 89]]], ["BTV VP4, a minor structural protein, alone catalyses the formation of cap1 structure and therefore possesses multiple catalytic activities [18, 23, 24] .", [["BTV", "ORGANISM", 0, 3], ["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["BTV VP4", "PROTEIN", 0, 7], ["minor structural protein", "PROTEIN", 11, 35], ["cap1 structure", "PROTEIN", 70, 84], ["BTV", "SPECIES", 0, 3], ["BTV VP4", "PROBLEM", 0, 7], ["a minor structural protein", "PROBLEM", 9, 35], ["cap1 structure", "PROBLEM", 70, 84], ["multiple catalytic activities", "PROBLEM", 109, 138], ["cap1 structure", "OBSERVATION", 70, 84], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["catalytic", "OBSERVATION_MODIFIER", 118, 127]]], ["VP4 forms a complex with the viral polymerase (VP1) and RNA helicase (VP6) proteins, this polymerase complex (PC) is closely associated with 10 segments of dsRNA genome [10, 21, 28] within the doublecapsid virion particle.", [["VP4", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP1", "GENE_OR_GENE_PRODUCT", 47, 50], ["VP6", "GENE_OR_GENE_PRODUCT", 70, 73], ["PC", "GENE_OR_GENE_PRODUCT", 110, 112], ["VP4", "PROTEIN", 0, 3], ["viral polymerase", "PROTEIN", 29, 45], ["VP1", "PROTEIN", 47, 50], ["RNA helicase (VP6) proteins", "PROTEIN", 56, 83], ["polymerase complex", "PROTEIN", 90, 108], ["PC", "PROTEIN", 110, 112], ["dsRNA genome", "DNA", 156, 168], ["the viral polymerase", "TEST", 25, 45], ["VP1", "TEST", 47, 50], ["RNA helicase (VP6) proteins", "TEST", 56, 83], ["this polymerase complex", "PROBLEM", 85, 108], ["10 segments of dsRNA genome", "PROBLEM", 141, 168], ["dsRNA genome", "OBSERVATION", 156, 168], ["virion particle", "OBSERVATION", 206, 221]]], ["The PC is located at the 5-fold axis of the inner capsid layer formed by a single protein, VP3, which in turn is enclosed by a second layer of VP7 protein.", [["inner capsid layer", "ANATOMY", 44, 62], ["PC", "CANCER", 4, 6], ["VP3", "GENE_OR_GENE_PRODUCT", 91, 94], ["VP7", "GENE_OR_GENE_PRODUCT", 143, 146], ["VP3", "PROTEIN", 91, 94], ["VP7 protein", "PROTEIN", 143, 154], ["a single protein, VP3", "TEST", 73, 94], ["PC", "OBSERVATION", 4, 6], ["5-", "OBSERVATION_MODIFIER", 25, 27], ["fold axis", "ANATOMY_MODIFIER", 27, 36], ["inner", "ANATOMY_MODIFIER", 44, 49], ["capsid", "ANATOMY_MODIFIER", 50, 56], ["layer", "ANATOMY_MODIFIER", 57, 62]]], ["This double-layered capsid or ''core'' is further enclosed by an outer capsid, composed of two proteins, VP2 and VP5, which are involved in virus attachment and entry into the host cells [27] .", [["cells", "ANATOMY", 181, 186], ["VP2", "GENE_OR_GENE_PRODUCT", 105, 108], ["VP5", "GENE_OR_GENE_PRODUCT", 113, 116], ["host cells", "CELL", 176, 186], ["outer capsid", "PROTEIN", 65, 77], ["VP2", "PROTEIN", 105, 108], ["VP5", "PROTEIN", 113, 116], ["host cells", "CELL_TYPE", 176, 186], ["This double-layered capsid or ''core", "TREATMENT", 0, 36], ["an outer capsid", "PROBLEM", 62, 77], ["VP2", "TEST", 105, 108], ["VP5", "TEST", 113, 116], ["virus attachment", "PROBLEM", 140, 156], ["outer capsid", "OBSERVATION_MODIFIER", 65, 77], ["host cells", "OBSERVATION", 176, 186]]], ["After cellular entry, the outer capsid is lost, releasing the core into the cytoplasm [11] where an active polymerase complex, which remains within the http N7MTase, guanine-N7-methyltransferase; m7G, 7-methylguanosine; m7, methyl group associated with m7G; PC, polymerase complex; BSR4, BHK-21 sub-clone expressing VP4; AdoMet, S-adenosyl methionine; VSV, vesicular stomatitis virus; WNV, West Nile virus; JEV, Japanese encephalitis virus unassembled core, synthesizes and extrudes new transcripts through pores situated at the core 5-fold axis [29] .", [["cellular", "ANATOMY", 6, 14], ["outer capsid", "ANATOMY", 26, 38], ["cytoplasm", "ANATOMY", 76, 85], ["guanine", "CHEMICAL", 166, 173], ["7-methylguanosine", "CHEMICAL", 201, 218], ["methyl", "CHEMICAL", 224, 230], ["AdoMet", "CHEMICAL", 321, 327], ["S-adenosyl methionine", "CHEMICAL", 329, 350], ["vesicular stomatitis virus", "DISEASE", 357, 383], ["Japanese encephalitis", "DISEASE", 412, 433], ["guanine", "CHEMICAL", 166, 173], ["N7", "CHEMICAL", 174, 176], ["7-methylguanosine", "CHEMICAL", 201, 218], ["m7", "CHEMICAL", 220, 222], ["methyl", "CHEMICAL", 224, 230], ["AdoMet", "CHEMICAL", 321, 327], ["S-adenosyl methionine", "CHEMICAL", 329, 350], ["cellular", "CELL", 6, 14], ["outer", "CELLULAR_COMPONENT", 26, 31], ["cytoplasm", "ORGANISM_SUBSTANCE", 76, 85], ["http", "GENE_OR_GENE_PRODUCT", 152, 156], ["guanine-N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 166, 194], ["m7G", "SIMPLE_CHEMICAL", 196, 199], ["7-methylguanosine", "SIMPLE_CHEMICAL", 201, 218], ["m7", "SIMPLE_CHEMICAL", 220, 222], ["methyl", "SIMPLE_CHEMICAL", 224, 230], ["m7G", "GENE_OR_GENE_PRODUCT", 253, 256], ["PC", "GENE_OR_GENE_PRODUCT", 258, 260], ["BSR4", "GENE_OR_GENE_PRODUCT", 282, 286], ["VP4", "GENE_OR_GENE_PRODUCT", 316, 319], ["AdoMet", "SIMPLE_CHEMICAL", 321, 327], ["S-adenosyl methionine", "SIMPLE_CHEMICAL", 329, 350], ["VSV,", "ORGANISM", 352, 356], ["vesicular stomatitis virus", "ORGANISM", 357, 383], ["WNV,", "ORGANISM", 385, 389], ["West Nile virus", "ORGANISM", 390, 405], ["JEV,", "ORGANISM", 407, 411], ["Japanese encephalitis virus", "ORGANISM", 412, 439], ["outer capsid", "PROTEIN", 26, 38], ["active polymerase complex", "PROTEIN", 100, 125], ["http N7MTase", "PROTEIN", 152, 164], ["guanine-N7-methyltransferase", "PROTEIN", 166, 194], ["m7G", "PROTEIN", 253, 256], ["PC", "PROTEIN", 258, 260], ["polymerase complex", "PROTEIN", 262, 280], ["BSR4", "PROTEIN", 282, 286], ["BHK", "PROTEIN", 288, 291], ["VP4", "PROTEIN", 316, 319], ["stomatitis virus", "SPECIES", 367, 383], ["West Nile virus", "SPECIES", 390, 405], ["Japanese encephalitis virus", "SPECIES", 412, 439], ["stomatitis virus", "SPECIES", 367, 383], ["WNV", "SPECIES", 385, 388], ["West Nile virus", "SPECIES", 390, 405], ["JEV", "SPECIES", 407, 410], ["Japanese encephalitis virus", "SPECIES", 412, 439], ["an active polymerase complex", "PROBLEM", 97, 125], ["guanine", "TEST", 166, 173], ["N7-methyltransferase", "TREATMENT", 174, 194], ["methylguanosine", "TREATMENT", 203, 218], ["PC, polymerase complex", "PROBLEM", 258, 280], ["BSR4", "TEST", 282, 286], ["BHK", "TEST", 288, 291], ["VP4", "TEST", 316, 319], ["AdoMet, S-adenosyl methionine", "TREATMENT", 321, 350], ["VSV", "PROBLEM", 352, 355], ["vesicular stomatitis virus", "PROBLEM", 357, 383], ["WNV", "PROBLEM", 385, 388], ["West Nile virus", "PROBLEM", 390, 405], ["JEV", "PROBLEM", 407, 410], ["Japanese encephalitis virus", "PROBLEM", 412, 439], ["extrudes new transcripts through pores", "TREATMENT", 474, 512], ["entry", "OBSERVATION_MODIFIER", 15, 20], ["active", "OBSERVATION_MODIFIER", 100, 106], ["vesicular stomatitis", "ANATOMY", 357, 377]]], ["The 2.5 \u00c5 X-ray crystallographic structure of VP4 showed that the protein has a unique structural organisation whereby each functional domain is arranged in sequential fashion to facilitate each catalytic activity required to form the cap structure of the newly synthesized transcripts [33] .", [["VP4", "GENE_OR_GENE_PRODUCT", 46, 49], ["VP4", "PROTEIN", 46, 49], ["cap structure", "PROTEIN", 235, 248], ["\u00c5 X-ray crystallographic structure of VP4", "TEST", 8, 49], ["the protein", "PROBLEM", 62, 73]]], ["Thus, VP4 offers an ideal model for characterizing each functional domain and determining their relative contributions to the virus replication cycle.IntroductionRecent studies of viral cap structures have revealed the importance of the 2 0 -O methylation in evading the host innate immune response to RNA viruses [39] .", [["VP4", "GENE_OR_GENE_PRODUCT", 6, 9], ["VP4", "PROTEIN", 6, 9], ["the virus replication cycle", "TREATMENT", 122, 149], ["IntroductionRecent studies", "TEST", 150, 176], ["viral cap structures", "PROBLEM", 180, 200], ["the 2 0 -O methylation", "TREATMENT", 233, 255], ["RNA viruses", "PROBLEM", 302, 313], ["viral cap", "OBSERVATION", 180, 189]]], ["Modification of the catalytic K-D-K-E tetrad within the domain has been demonstrated to render the virus replication deficient and mutations of key residues within the catalytic pocket affect the rate of methylation, which leads to attenuation [8, 13, 15] .", [["K-D-K-E", "CHEMICAL", 30, 37], ["catalytic K-D-K-E tetrad", "PROTEIN", 20, 44], ["catalytic pocket", "PROTEIN", 168, 184], ["the virus replication deficient", "PROBLEM", 95, 126], ["mutations of key residues", "PROBLEM", 131, 156], ["the catalytic pocket", "PROBLEM", 164, 184], ["catalytic", "OBSERVATION_MODIFIER", 168, 177], ["pocket", "OBSERVATION_MODIFIER", 178, 184], ["attenuation", "OBSERVATION_MODIFIER", 232, 243]]], ["In this report, we focused on the 2 0 -O MTase domain of VP4, which although possesses the consensus fold of the typical class I AdoMet-dependent methyltransferases and displays some structural similarities with Vaccinia virus VP39 and Dengue virus NS5 methyltransferase as well as containing some unique features, the precise roles of which are unclear.", [["AdoMet", "CHEMICAL", 129, 135], ["AdoMet", "CHEMICAL", 129, 135], ["VP4", "GENE_OR_GENE_PRODUCT", 57, 60], ["AdoMet", "SIMPLE_CHEMICAL", 129, 135], ["Vaccinia virus VP39", "ORGANISM", 212, 231], ["Dengue virus", "ORGANISM", 236, 248], ["NS5 methyltransferase", "GENE_OR_GENE_PRODUCT", 249, 270], ["O MTase domain", "PROTEIN", 39, 53], ["VP4", "PROTEIN", 57, 60], ["class I AdoMet-dependent methyltransferases", "PROTEIN", 121, 164], ["Dengue virus NS5 methyltransferase", "PROTEIN", 236, 270], ["Vaccinia virus", "SPECIES", 212, 226], ["Dengue virus NS5", "SPECIES", 236, 252], ["Vaccinia virus", "SPECIES", 212, 226], ["Dengue virus", "SPECIES", 236, 248], ["VP4", "PROBLEM", 57, 60], ["AdoMet-dependent methyltransferases", "TREATMENT", 129, 164], ["Vaccinia virus VP39", "TREATMENT", 212, 231], ["Dengue virus NS5 methyltransferase", "TREATMENT", 236, 270], ["Vaccinia virus", "OBSERVATION", 212, 226]]], ["We used structural information to identify key residues within VP4 2 0 -O MT and verified their importance employing a series of biochemical assays and the BTV reverse genetics system.", [["VP4 2 0 -O MT", "PROTEIN", 63, 76], ["BTV", "SPECIES", 156, 159], ["biochemical assays", "TEST", 129, 147]]], ["This is the first report to assign function to the putative 2 0 -O MT domain for the capping enzyme of any member of the Reoviridae.Virus stocks, cell linesBSR cells (BHK-21 sub-clone) were maintained in Dulbecco modified Eagle medium (DMEM, Sigma Aldrich) supplemented with 5% (v/v) fetal calf serum (FCS, Invitrogen).", [["cell linesBSR cells", "ANATOMY", 146, 165], ["BHK-21 sub-clone", "ANATOMY", 167, 183], ["fetal calf serum", "ANATOMY", 284, 300], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 121, 131], ["Virus", "ORGANISM", 132, 137], ["cell linesBSR cells", "CELL", 146, 165], ["BHK-21 sub-clone", "CELL", 167, 183], ["calf", "ORGANISM_SUBSTANCE", 290, 294], ["serum", "ORGANISM_SUBSTANCE", 295, 300], ["FCS", "ORGANISM_SUBSTANCE", 302, 305], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 307, 317], ["putative 2 0 -O MT domain", "PROTEIN", 51, 76], ["capping enzyme", "PROTEIN", 85, 99], ["Reoviridae", "PROTEIN", 121, 131], ["cell linesBSR cells", "CELL_LINE", 146, 165], ["BHK-21 sub-clone", "CELL_LINE", 167, 183], ["calf", "SPECIES", 290, 294], ["the capping enzyme", "TEST", 81, 99], ["the Reoviridae", "TREATMENT", 117, 131], ["Virus stocks", "TEST", 132, 144], ["cell linesBSR cells", "TEST", 146, 165], ["BHK", "TEST", 167, 170], ["fetal calf serum", "TEST", 284, 300], ["FCS", "TEST", 302, 305], ["cell linesBSR cells", "OBSERVATION", 146, 165], ["fetal calf", "ANATOMY", 284, 294]]], ["The stable BSR-VP4 (BSR expressing VP4; BSR4) cell line was grown in DMEM-5% FCS supplemented with 7.5 lg/ml of puromycin (Sigma Aldrich).", [["BSR4) cell line", "ANATOMY", 40, 55], ["puromycin", "CHEMICAL", 112, 121], ["puromycin", "CHEMICAL", 112, 121], ["BSR-VP4", "GENE_OR_GENE_PRODUCT", 11, 18], ["VP4", "GENE_OR_GENE_PRODUCT", 35, 38], ["FCS", "ORGANISM_SUBSTANCE", 77, 80], ["puromycin", "SIMPLE_CHEMICAL", 112, 121], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 123, 136], ["BSR-VP4 (BSR expressing VP4; BSR4) cell line", "CELL_LINE", 11, 55], ["VP4", "TEST", 15, 18], ["VP4", "TEST", 35, 38], ["cell line", "TREATMENT", 46, 55], ["DMEM", "TEST", 69, 73], ["puromycin", "TREATMENT", 112, 121], ["stable", "OBSERVATION_MODIFIER", 4, 10], ["BSR", "OBSERVATION_MODIFIER", 11, 14], ["cell line", "OBSERVATION", 46, 55]]], ["Cells and viruses were grown at 35\u00b0C in 5% CO 2 incubator.", [["Cells", "ANATOMY", 0, 5], ["CO 2", "CHEMICAL", 43, 47], ["Cells", "CELL", 0, 5], ["viruses", "PROBLEM", 10, 17], ["viruses", "OBSERVATION", 10, 17]]], ["BTV-1 wild-type (WT) and mutant virus stocks were propagated by infecting BSR cells at MOI of 0.5 and harvested when cytopathic effect (CPE) between 95% and 100% was evident.", [["BSR cells", "ANATOMY", 74, 83], ["BTV-1 wild-type (WT)", "ORGANISM", 0, 20], ["mutant virus", "ORGANISM", 25, 37], ["BSR cells", "CELL", 74, 83], ["BSR cells", "CELL_LINE", 74, 83], ["BTV", "TEST", 0, 3], ["mutant virus stocks", "PROBLEM", 25, 44], ["MOI", "TEST", 87, 90], ["cytopathic effect", "PROBLEM", 117, 134], ["CPE", "TEST", 136, 139], ["virus stocks", "OBSERVATION", 32, 44], ["cytopathic", "OBSERVATION_MODIFIER", 117, 127]]], ["Titres of viral stocks were obtained by either plaque assay and/or by TCID 50 /ml.", [["plaque", "ANATOMY", 47, 53], ["viral stocks", "TREATMENT", 10, 22], ["viral stocks", "OBSERVATION", 10, 22]]], ["Spodoptera frugiperda (Sf9) cells were grown in either Sf900 III (Gibco BRL) or InsectExpress (Lonza) media supplemented with 2% (v/v) fetal calf serum and incubated either in suspension or in monolayer cultures at 28\u00b0C. Recombinant Autographa californica nuclear polyhedrosis virus (AcNPV) that expressed either recombinant BTV-10 VP4 or mutated VP4 was propagated in Sf9 suspension culture.Generation of VP4 cell lineThe coding region of S4 (GenBank: FJ969722), VP4, was amplified and ligated into expression vector pCAG-Puro (pCAG-VP4).", [["Sf9) cells", "ANATOMY", 23, 33], ["fetal calf serum", "ANATOMY", 135, 151], ["monolayer cultures", "ANATOMY", 193, 211], ["cell line", "ANATOMY", 410, 419], ["BRL", "CHEMICAL", 72, 75], ["Spodoptera frugiperda", "ORGANISM", 0, 21], ["Sf9) cells", "CELL", 23, 33], ["fetal calf", "ORGANISM_SUBSTANCE", 135, 145], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["monolayer cultures", "CELL", 193, 211], ["Autographa californica nuclear polyhedrosis virus", "ORGANISM", 233, 282], ["AcNPV", "ORGANISM", 284, 289], ["BTV-10", "ORGANISM", 325, 331], ["VP4", "GENE_OR_GENE_PRODUCT", 332, 335], ["VP4", "GENE_OR_GENE_PRODUCT", 347, 350], ["VP4 cell line", "CELL", 406, 419], ["S4", "GENE_OR_GENE_PRODUCT", 440, 442], ["FJ969722", "GENE_OR_GENE_PRODUCT", 453, 461], ["VP4", "GENE_OR_GENE_PRODUCT", 464, 467], ["pCAG-Puro", "GENE_OR_GENE_PRODUCT", 518, 527], ["pCAG-VP4", "GENE_OR_GENE_PRODUCT", 529, 537], ["Spodoptera frugiperda (Sf9) cells", "CELL_LINE", 0, 33], ["Sf900 III", "CELL_LINE", 55, 64], ["monolayer cultures", "CELL_LINE", 193, 211], ["recombinant BTV-10 VP4 or mutated VP4", "DNA", 313, 350], ["Sf9 suspension culture", "CELL_LINE", 369, 391], ["VP4 cell line", "CELL_LINE", 406, 419], ["S4", "DNA", 440, 442], ["VP4", "DNA", 464, 467], ["pCAG", "DNA", 518, 522], ["Puro", "DNA", 523, 527], ["pCAG", "DNA", 529, 533], ["VP4", "DNA", 534, 537], ["Spodoptera frugiperda", "SPECIES", 0, 21], ["calf", "SPECIES", 141, 145], ["Autographa californica", "SPECIES", 233, 255], ["polyhedrosis virus", "SPECIES", 264, 282], ["Spodoptera frugiperda", "SPECIES", 0, 21], ["Autographa californica", "SPECIES", 233, 255], ["polyhedrosis virus", "SPECIES", 264, 282], ["AcNPV", "SPECIES", 284, 289], ["BTV-10", "SPECIES", 325, 331], ["Sf9", "SPECIES", 369, 372], ["Spodoptera frugiperda (Sf9) cells", "TREATMENT", 0, 33], ["InsectExpress (Lonza) media", "TREATMENT", 80, 107], ["fetal calf serum", "TEST", 135, 151], ["monolayer cultures", "TEST", 193, 211], ["Recombinant Autographa californica nuclear polyhedrosis virus", "PROBLEM", 221, 282], ["recombinant BTV", "TEST", 313, 328], ["VP4", "PROBLEM", 332, 335], ["mutated VP4", "PROBLEM", 339, 350], ["Sf9 suspension culture", "TEST", 369, 391], ["VP4 cell line", "TREATMENT", 406, 419], ["VP4", "TEST", 464, 467], ["calf", "ANATOMY", 141, 145], ["californica nuclear", "OBSERVATION", 244, 263], ["polyhedrosis virus", "OBSERVATION", 264, 282], ["VP4 cell line", "OBSERVATION", 406, 419], ["S4", "ANATOMY", 440, 442]]], ["BSR cells were transfected with the pCAG-VP4 plasmid using Lipofectamine2000 (Invitrogen) as per instruction.", [["BSR cells", "ANATOMY", 0, 9], ["Lipofectamine2000", "CHEMICAL", 59, 76], ["Lipofectamine2000", "CHEMICAL", 59, 76], ["BSR cells", "CELL", 0, 9], ["pCAG", "GENE_OR_GENE_PRODUCT", 36, 40], ["Lipofectamine2000", "SIMPLE_CHEMICAL", 59, 76], ["BSR cells", "CELL_LINE", 0, 9], ["pCAG-VP4 plasmid", "DNA", 36, 52], ["BSR cells", "TEST", 0, 9], ["the pCAG", "TEST", 32, 40], ["VP4 plasmid", "TREATMENT", 41, 52], ["Lipofectamine2000 (Invitrogen)", "TREATMENT", 59, 89]]], ["After transfection, cells with integrated copies of the expression vector were selected by the addition of 7.5 lg/ml of puromycin (Sigma).", [["cells", "ANATOMY", 20, 25], ["puromycin", "CHEMICAL", 120, 129], ["puromycin", "CHEMICAL", 120, 129], ["cells", "CELL", 20, 25], ["puromycin", "SIMPLE_CHEMICAL", 120, 129], ["expression vector", "DNA", 56, 73], ["the expression vector", "TREATMENT", 52, 73], ["puromycin", "TREATMENT", 120, 129]]], ["The surviving clones were tested for the expression level of VP4 by western immunoblot and the ability to grow virus.Mutagenesis reactionsSite-directed mutagenesis as previously described [37] was used to introduce site-specific mutations into the exact copy of BTV-1 S4 (pUCBTV1T7S4) and coding region of BTV-10 VP4 (pAcYM1VP4; GenBank: D00509).", [["clones", "ANATOMY", 14, 20], ["clones", "CELL", 14, 20], ["VP4", "GENE_OR_GENE_PRODUCT", 61, 64], ["BTV-1 S4", "GENE_OR_GENE_PRODUCT", 262, 270], ["pUCBTV1T7S4", "GENE_OR_GENE_PRODUCT", 272, 283], ["surviving clones", "CELL_LINE", 4, 20], ["VP4", "PROTEIN", 61, 64], ["BTV-1 S4", "DNA", 262, 270], ["pUCBTV1T7S4", "DNA", 272, 283], ["coding region", "DNA", 289, 302], ["BTV-10 VP4", "DNA", 306, 316], ["pAcYM1VP4", "DNA", 318, 327], ["BTV-1", "SPECIES", 262, 267], ["BTV-10 VP4", "SPECIES", 306, 316], ["The surviving clones", "PROBLEM", 0, 20], ["Mutagenesis reactions", "PROBLEM", 117, 138], ["BTV", "TEST", 262, 265], ["BTV", "TEST", 306, 309]]], ["Single mutations were introduced at the specific residues of the aspartic acid position 265 of VP4 to either a glutamic acid (D265E) or valine (D265V) and asparagine 311, tyrosine Y334 and arginine 367 residues to an alanine (A) referred to as N311A, Y334A and R367A.", [["aspartic acid", "CHEMICAL", 65, 78], ["glutamic acid", "CHEMICAL", 111, 124], ["D265E", "CHEMICAL", 126, 131], ["valine", "CHEMICAL", 136, 142], ["asparagine 311", "CHEMICAL", 155, 169], ["tyrosine", "CHEMICAL", 171, 179], ["arginine", "CHEMICAL", 189, 197], ["alanine", "CHEMICAL", 217, 224], ["aspartic acid", "CHEMICAL", 65, 78], ["glutamic acid", "CHEMICAL", 111, 124], ["valine", "CHEMICAL", 136, 142], ["asparagine", "CHEMICAL", 155, 165], ["tyrosine", "CHEMICAL", 171, 179], ["arginine", "CHEMICAL", 189, 197], ["alanine", "CHEMICAL", 217, 224], ["aspartic acid", "AMINO_ACID", 65, 78], ["VP4", "GENE_OR_GENE_PRODUCT", 95, 98], ["glutamic acid", "AMINO_ACID", 111, 124], ["D265E", "AMINO_ACID", 126, 131], ["valine", "AMINO_ACID", 136, 142], ["D265V", "AMINO_ACID", 144, 149], ["asparagine", "AMINO_ACID", 155, 165], ["311", "AMINO_ACID", 166, 169], ["tyrosine", "AMINO_ACID", 171, 179], ["Y334", "AMINO_ACID", 180, 184], ["arginine", "AMINO_ACID", 189, 197], ["367 residues", "AMINO_ACID", 198, 210], ["alanine", "AMINO_ACID", 217, 224], ["N311A", "GENE_OR_GENE_PRODUCT", 244, 249], ["aspartic acid position 265", "PROTEIN", 65, 91], ["VP4", "PROTEIN", 95, 98], ["N311A", "PROTEIN", 244, 249], ["Single mutations", "PROBLEM", 0, 16], ["the aspartic acid position", "TREATMENT", 61, 87], ["VP4", "TREATMENT", 95, 98], ["a glutamic acid (D265E)", "TREATMENT", 109, 132], ["valine (D265V)", "TREATMENT", 136, 150], ["asparagine", "TREATMENT", 155, 165], ["tyrosine Y334", "TREATMENT", 171, 184], ["arginine", "TREATMENT", 189, 197]]], ["A construct with the triple mutation, N311A/Y334/R367A (NYR) was also generated.Expression and purification of wild type and 2-OMT mutant VP4Baculovirus expressing VP4 with site specific mutation as described above were generated as described [38] .", [["2-OMT mutant VP4Baculovirus", "ORGANISM", 125, 152], ["VP4", "GENE_OR_GENE_PRODUCT", 164, 167], ["VP4Baculovirus", "PROTEIN", 138, 152], ["VP4", "PROTEIN", 164, 167], ["the triple mutation", "TEST", 17, 36], ["wild type and 2", "PROBLEM", 111, 126], ["OMT mutant VP4Baculovirus", "TREATMENT", 127, 152], ["site specific mutation", "PROBLEM", 173, 195]]], ["Briefly, pAcYM1VP4 with the mutations and Bacmid: 1629 were transfected into a monolayer of Sf9 using Genejuice (Novagen) as per manufacturer protocols.", [["monolayer", "ANATOMY", 79, 88], ["Sf9", "ANATOMY", 92, 95], ["pAcYM1VP4", "GENE_OR_GENE_PRODUCT", 9, 18], ["monolayer", "CELL", 79, 88], ["Sf9", "ORGANISM", 92, 95], ["Novagen", "GENE_OR_GENE_PRODUCT", 113, 120], ["pAcYM1VP4", "PROTEIN", 9, 18], ["Sf9", "CELL_LINE", 92, 95], ["Sf9", "SPECIES", 92, 95], ["Genejuice (Novagen)", "TREATMENT", 102, 121]]], ["After one round of virus amplification, plaque assay was performed and a number of virus isolates picked.", [["plaque", "ANATOMY", 40, 46], ["virus amplification", "TREATMENT", 19, 38], ["plaque assay", "TEST", 40, 52], ["virus isolates", "PROBLEM", 83, 97], ["virus", "OBSERVATION", 19, 24], ["plaque", "OBSERVATION", 40, 46]]], ["These plaque purified viruses were propagated and screened for VP4 expression.", [["plaque", "ANATOMY", 6, 12], ["VP4", "GENE_OR_GENE_PRODUCT", 63, 66], ["VP4", "PROTEIN", 63, 66], ["These plaque purified viruses", "PROBLEM", 0, 29], ["plaque", "OBSERVATION", 6, 12], ["viruses", "OBSERVATION", 22, 29]]], ["Recombinant protein VP4 was purified from Sf9 cells infected with AcNPV expressing recombinant VP4 or VP4 mutants as described [33] .", [["Sf9 cells", "ANATOMY", 42, 51], ["VP4", "GENE_OR_GENE_PRODUCT", 20, 23], ["Sf9 cells", "CELL", 42, 51], ["AcNPV", "GENE_OR_GENE_PRODUCT", 66, 71], ["VP4", "GENE_OR_GENE_PRODUCT", 95, 98], ["VP4", "GENE_OR_GENE_PRODUCT", 102, 105], ["Recombinant protein VP4", "PROTEIN", 0, 23], ["Sf9 cells", "CELL_LINE", 42, 51], ["AcNPV", "PROTEIN", 66, 71], ["recombinant VP4 or VP4 mutants", "PROTEIN", 83, 113], ["Sf9", "SPECIES", 42, 45], ["AcNPV", "SPECIES", 66, 71], ["Recombinant protein VP4", "PROBLEM", 0, 23], ["Sf9 cells", "PROBLEM", 42, 51], ["AcNPV", "TREATMENT", 66, 71], ["VP4 mutants", "PROBLEM", 102, 113]]], ["1 \u00c2 10 8 Sf9 were infected with recombinant baculovirus at MOI $ 5, cells were harvested at 68 h p.i and lysed in HNN buffer (50 mM Hepes pH 7.5, 300 mM NaCl, 0.5% NP40); and lysate was centrifuged and pellet suspended in HN buffer (50 mM Hepes pH 7.5, 1 M NaCl).", [["cells", "ANATOMY", 68, 73], ["lysate", "ANATOMY", 175, 181], ["NaCl", "CHEMICAL", 153, 157], ["NaCl", "CHEMICAL", 257, 261], ["NaCl", "CHEMICAL", 153, 157], ["NP40", "CHEMICAL", 164, 168], ["NaCl", "CHEMICAL", 257, 261], ["Sf9", "ORGANISM", 9, 12], ["baculovirus", "ORGANISM", 44, 55], ["cells", "CELL", 68, 73], ["lysate", "ORGANISM_SUBSTANCE", 175, 181], ["baculovirus", "SPECIES", 44, 55], ["recombinant baculovirus", "TREATMENT", 32, 55], ["Hepes pH", "TEST", 132, 140], ["300 mM NaCl", "TREATMENT", 146, 157], ["lysate", "TREATMENT", 175, 181], ["Hepes pH", "TEST", 239, 247]]], ["Supernatants were pooled and RNA precipitated with the addition of 0.1% polyethylenimine (PEI).", [["Supernatants", "ANATOMY", 0, 12], ["polyethylenimine", "CHEMICAL", 72, 88], ["PEI", "CHEMICAL", 90, 93], ["polyethylenimine", "CHEMICAL", 72, 88], ["PEI", "CHEMICAL", 90, 93], ["Supernatants", "CELL", 0, 12], ["polyethylenimine", "SIMPLE_CHEMICAL", 72, 88], ["PEI", "SIMPLE_CHEMICAL", 90, 93], ["RNA", "PROBLEM", 29, 32], ["0.1% polyethylenimine (PEI", "TREATMENT", 67, 93]]], ["VP4 was purified via size exclusion on a HiPrepS200 column.", [["VP4", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP4", "PROTEIN", 0, 3], ["VP4", "PROBLEM", 0, 3], ["a HiPrepS200 column", "TREATMENT", 39, 58], ["size", "OBSERVATION_MODIFIER", 21, 25], ["exclusion", "OBSERVATION", 26, 35]]], ["Fractions were collected and VP4 further purified using a heparin affinity column.", [["heparin", "CHEMICAL", 58, 65], ["Fractions", "ORGANISM_SUBSTANCE", 0, 9], ["VP4", "GENE_OR_GENE_PRODUCT", 29, 32], ["heparin", "SIMPLE_CHEMICAL", 58, 65], ["VP4", "PROTEIN", 29, 32], ["Fractions", "TEST", 0, 9], ["VP4", "TEST", 29, 32], ["a heparin affinity column", "TREATMENT", 56, 81]]], ["VP4 was eluted from the column using a 250 mM to 2 M NaCl gradient in 25 mM Hepes pH 7.5.Synthesis of T7 RNASynthesis of capped and uncapped BTV transcripts was as described previously [3, 19] .", [["NaCl", "CHEMICAL", 53, 57], ["NaCl", "CHEMICAL", 53, 57], ["VP4", "GENE_OR_GENE_PRODUCT", 0, 3], ["T7", "GENE_OR_GENE_PRODUCT", 102, 104], ["BTV", "ORGANISM", 141, 144], ["VP4", "PROTEIN", 0, 3], ["T7 RNASynthesis", "RNA", 102, 117], ["capped and uncapped BTV transcripts", "RNA", 121, 156], ["VP4", "TEST", 0, 3], ["NaCl gradient", "TEST", 53, 66], ["Hepes pH", "TEST", 76, 84], ["Synthesis of T7 RNASynthesis", "TREATMENT", 89, 117], ["uncapped BTV transcripts", "PROBLEM", 132, 156], ["column", "ANATOMY_MODIFIER", 24, 30], ["T7", "ANATOMY", 102, 104], ["uncapped", "OBSERVATION_MODIFIER", 132, 140], ["BTV transcripts", "OBSERVATION", 141, 156]]], ["Briefly, capped T7 transcripts were synthesized by using a mMESSAGE mMACHINE T7 Ultra Kit (Ambion), while uncapped T7 transcripts were synthesized by the RiboMAX Large-Scale RNA Production System T7 (Promega) according to the manufacturer's procedure. a 32 P-labelled RNA was synthesized using 2.5 mM GTP and 50 lCi a 32 P-GTP.", [["GTP", "CHEMICAL", 301, 304], ["32 P-GTP", "CHEMICAL", 318, 326], ["GTP", "CHEMICAL", 301, 304], ["GTP", "CHEMICAL", 323, 326], ["T7", "GENE_OR_GENE_PRODUCT", 16, 18], ["T7", "GENE_OR_GENE_PRODUCT", 115, 117], ["GTP", "SIMPLE_CHEMICAL", 301, 304], ["GTP", "SIMPLE_CHEMICAL", 323, 326], ["T7 transcripts", "RNA", 16, 30], ["T7 transcripts", "RNA", 115, 129], ["32 P-labelled RNA", "RNA", 254, 271], ["capped T7 transcripts", "TREATMENT", 9, 30], ["a mMESSAGE mMACHINE T7 Ultra Kit (Ambion)", "TREATMENT", 57, 98], ["the RiboMAX Large-Scale RNA Production System T7 (Promega)", "TREATMENT", 150, 208], ["the manufacturer's procedure", "TREATMENT", 222, 250], ["a 32 P-labelled RNA", "TREATMENT", 252, 271], ["2.5 mM GTP", "TREATMENT", 294, 304], ["T7", "ANATOMY", 16, 18]]], ["All RNA transcripts were dissolved in nuclease-free water and stored at \u00c080\u00b0C.Recovery and analysis of 2 0 -O MTase mutations in BTVMutant and WT BTV-1 viruses were rescued using a 2-step transfection protocol as previously described [19] .", [["WT BTV-1 viruses", "ORGANISM", 143, 159], ["RNA transcripts", "RNA", 4, 19], ["nuclease", "PROTEIN", 38, 46], ["BTV-1", "SPECIES", 146, 151], ["All RNA transcripts", "TREATMENT", 0, 19], ["analysis", "TEST", 91, 99], ["MTase mutations", "PROBLEM", 110, 125], ["WT BTV", "TEST", 143, 149], ["a 2-step transfection protocol", "TREATMENT", 179, 209], ["RNA transcripts", "OBSERVATION", 4, 19]]], ["Briefly, monolayers of either BSR or BSR4 were initially transfected with the plasmid constructs expressing the sub-core (VP1, VP3, VP4 and VP6) and non-structural (NS1 and NS2) proteins and after 12-18 h cells were transfected for a second time with a complete set of T7 derived BTV mRNAs.", [["monolayers", "ANATOMY", 9, 19], ["plasmid", "ANATOMY", 78, 85], ["cells", "ANATOMY", 205, 210], ["monolayers", "CELL", 9, 19], ["BSR4", "GENE_OR_GENE_PRODUCT", 37, 41], ["VP1", "GENE_OR_GENE_PRODUCT", 122, 125], ["VP3", "GENE_OR_GENE_PRODUCT", 127, 130], ["VP4", "GENE_OR_GENE_PRODUCT", 132, 135], ["VP6", "GENE_OR_GENE_PRODUCT", 140, 143], ["NS1", "GENE_OR_GENE_PRODUCT", 165, 168], ["cells", "CELL", 205, 210], ["BTV", "ORGANISM", 280, 283], ["BSR", "CELL_LINE", 30, 33], ["BSR4", "PROTEIN", 37, 41], ["plasmid constructs", "DNA", 78, 96], ["sub-core", "DNA", 112, 120], ["VP1", "DNA", 122, 125], ["VP3", "PROTEIN", 127, 130], ["VP4", "PROTEIN", 132, 135], ["VP6", "PROTEIN", 140, 143], ["non-structural (NS1 and NS2) proteins", "PROTEIN", 149, 186], ["T7 derived BTV mRNAs", "RNA", 269, 289], ["BTV", "SPECIES", 280, 283], ["the plasmid constructs", "TREATMENT", 74, 96], ["VP1", "TEST", 122, 125], ["VP3", "TEST", 127, 130], ["VP4", "TEST", 132, 135], ["VP6", "TEST", 140, 143], ["non-structural (NS1 and NS2) proteins", "TEST", 149, 186], ["T7", "ANATOMY", 269, 271], ["BTV mRNAs", "OBSERVATION", 280, 289]]], ["DNA and RNA transfections were performed in the presence of Lipofectamine2000 reagent (Invitrogen).Recovery and analysis of 2 0 -O MTase mutations in BTVFor the growth curves of the mutant or WT viruses, monolayers of BSR cells were infected at an MOI $ 0.1.", [["monolayers", "ANATOMY", 204, 214], ["BSR cells", "ANATOMY", 218, 227], ["Lipofectamine2000", "CHEMICAL", 60, 77], ["Lipofectamine2000", "CHEMICAL", 60, 77], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["Lipofectamine2000", "SIMPLE_CHEMICAL", 60, 77], ["Invitrogen", "SIMPLE_CHEMICAL", 87, 97], ["0 -O MTase", "SIMPLE_CHEMICAL", 126, 136], ["WT viruses", "ORGANISM", 192, 202], ["monolayers", "CELL", 204, 214], ["BSR cells", "CELL", 218, 227], ["BSR cells", "CELL_LINE", 218, 227], ["DNA", "PROBLEM", 0, 3], ["RNA transfections", "TEST", 8, 25], ["Lipofectamine2000 reagent", "TREATMENT", 60, 85], ["analysis", "TEST", 112, 120], ["MTase mutations", "PROBLEM", 131, 146], ["the growth curves", "TEST", 157, 174], ["WT viruses", "PROBLEM", 192, 202], ["BSR cells", "PROBLEM", 218, 227], ["RNA transfections", "OBSERVATION", 8, 25]]], ["Cells and supernatant were harvested at different times post-infection and disrupted by two freeze-thaw cycles; and the total titre was determined by plaque assay or TCID 50 /ml.Recovery and analysis of 2 0 -O MTase mutations in BTVThe dsRNA genome was extracted from virus infected cells as previously described [32] and analyzed on TBE agarose gel.", [["Cells", "ANATOMY", 0, 5], ["supernatant", "ANATOMY", 10, 21], ["plaque", "ANATOMY", 150, 156], ["cells", "ANATOMY", 283, 288], ["Cells", "CELL", 0, 5], ["cells", "CELL", 283, 288], ["agarose", "SIMPLE_CHEMICAL", 338, 345], ["BTVThe dsRNA genome", "DNA", 229, 248], ["virus infected cells", "CELL_TYPE", 268, 288], ["TBE", "SPECIES", 334, 337], ["supernatant", "TREATMENT", 10, 21], ["the total titre", "TREATMENT", 116, 131], ["analysis", "TEST", 191, 199], ["2 0 -O MTase mutations in BTVThe dsRNA genome", "TREATMENT", 203, 248], ["virus infected cells", "PROBLEM", 268, 288], ["TBE agarose gel", "TREATMENT", 334, 349]]], ["Purified dsRNAs were used as templates to reverse transcribe S4 to generate cDNA using SuperScript III (Invitrogen).", [["SuperScript III", "GENE_OR_GENE_PRODUCT", 87, 102], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 104, 114], ["cDNA", "DNA", 76, 80], ["SuperScript III", "DNA", 87, 102], ["Purified dsRNAs", "TREATMENT", 0, 15], ["SuperScript III (Invitrogen)", "TREATMENT", 87, 115], ["dsRNAs", "OBSERVATION", 9, 15]]], ["S4 was amplified using specific primers, using KOD polymerase.", [["S4", "GENE_OR_GENE_PRODUCT", 0, 2], ["KOD polymerase", "GENE_OR_GENE_PRODUCT", 47, 61], ["KOD polymerase", "PROTEIN", 47, 61], ["specific primers", "TREATMENT", 23, 39], ["KOD polymerase", "TREATMENT", 47, 61]]], ["PCR products were sequenced to ensure that the introduced mutations were stable and that there were no compensatory changes to the S4.Recovery and analysis of 2 0 -O MTase mutations in BTVExpression of viral proteins was monitored by western immunoblot using specific polyclonal antibodies that recognize either VP3 or NS1.", [["VP3", "GENE_OR_GENE_PRODUCT", 312, 315], ["NS1", "GENE_OR_GENE_PRODUCT", 319, 322], ["PCR products", "DNA", 0, 12], ["viral proteins", "PROTEIN", 202, 216], ["polyclonal antibodies", "PROTEIN", 268, 289], ["VP3", "PROTEIN", 312, 315], ["NS1", "PROTEIN", 319, 322], ["PCR products", "TREATMENT", 0, 12], ["compensatory changes", "PROBLEM", 103, 123], ["analysis", "TEST", 147, 155], ["MTase mutations", "PROBLEM", 166, 181], ["viral proteins", "PROBLEM", 202, 216], ["western immunoblot", "TEST", 234, 252], ["specific polyclonal antibodies", "TEST", 259, 289], ["VP3", "PROBLEM", 312, 315], ["NS1", "PROBLEM", 319, 322], ["stable", "OBSERVATION_MODIFIER", 73, 79], ["no", "UNCERTAINTY", 100, 102], ["compensatory changes", "OBSERVATION", 103, 123]]], ["Whole cell lysates and fractions were resolved on SDS-PAGE gels, and transferred to a nitrocellulose membrane (0.45 lm, Amersham) by the standard semi-dry transfer protocol.Recovery and analysis of 2 0 -O MTase mutations in BTVEach blot was developed with specific primary and secondary antibodies.Recovery and analysis of 2 0 -O MTase mutations in BTVA Renilla luciferase assay that detects the expression from BTV S10 (S10-Rluc) RNA reporter plasmid during virus infection was used to quantify the viral protein synthesis as established [2] .", [["cell lysates", "ANATOMY", 6, 18], ["fractions", "ANATOMY", 23, 32], ["membrane", "ANATOMY", 101, 109], ["infection", "DISEASE", 465, 474], ["nitrocellulose", "CHEMICAL", 86, 100], ["cell lysates", "ORGANISM_SUBSTANCE", 6, 18], ["membrane", "CELLULAR_COMPONENT", 101, 109], ["luciferase", "GENE_OR_GENE_PRODUCT", 362, 372], ["BTV S10", "GENE_OR_GENE_PRODUCT", 412, 419], ["S10-Rluc", "GENE_OR_GENE_PRODUCT", 421, 429], ["primary and secondary antibodies", "PROTEIN", 265, 297], ["luciferase", "PROTEIN", 362, 372], ["BTV S10 (S10-Rluc) RNA reporter plasmid", "DNA", 412, 451], ["BTV", "SPECIES", 412, 415], ["Whole cell lysates", "TEST", 0, 18], ["SDS", "TEST", 50, 53], ["a nitrocellulose membrane", "TREATMENT", 84, 109], ["analysis", "TEST", 186, 194], ["MTase mutations", "PROBLEM", 205, 220], ["BTVEach blot", "TEST", 224, 236], ["specific primary and secondary antibodies", "PROBLEM", 256, 297], ["analysis", "TEST", 311, 319], ["MTase mutations", "TEST", 330, 345], ["BTVA Renilla luciferase assay", "TEST", 349, 378], ["BTV S10 (S10-Rluc) RNA reporter plasmid during virus infection", "PROBLEM", 412, 474], ["the viral protein synthesis", "TREATMENT", 496, 523], ["cell lysates", "OBSERVATION", 6, 18], ["fractions", "OBSERVATION_MODIFIER", 23, 32], ["secondary antibodies", "OBSERVATION", 277, 297]]], ["In brief, BSR monolayer cells in 96 well plates were transfected with S10-Rluc RNA followed by infection with either BTV or NYR mutant virus at 12 h post-transfection.", [["monolayer cells", "ANATOMY", 14, 29], ["infection", "DISEASE", 95, 104], ["BSR monolayer cells", "CELL", 10, 29], ["Rluc", "GENE_OR_GENE_PRODUCT", 74, 78], ["BTV", "ORGANISM", 117, 120], ["NYR mutant virus", "ORGANISM", 124, 140], ["BSR monolayer cells", "CELL_LINE", 10, 29], ["S10", "PROTEIN", 70, 73], ["Rluc RNA", "RNA", 74, 82], ["BTV", "SPECIES", 117, 120], ["BSR monolayer cells", "TEST", 10, 29], ["Rluc RNA", "PROBLEM", 74, 82], ["infection", "PROBLEM", 95, 104], ["BTV", "PROBLEM", 117, 120], ["NYR mutant virus", "PROBLEM", 124, 140], ["infection", "OBSERVATION", 95, 104]]], ["Renilla luciferase activity was quantified at 12 h post infection using the Renilla Luciferase Assay System (Promega), according to the manufacturer's instructions.", [["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["luciferase", "PROTEIN", 8, 18], ["Renilla luciferase activity", "PROBLEM", 0, 27], ["infection", "PROBLEM", 56, 65], ["the Renilla Luciferase Assay System (Promega)", "TREATMENT", 72, 117], ["luciferase activity", "OBSERVATION", 8, 27]]], ["Each reaction was performed in triplicate and student t-test was used to determine significance.Autoguanylation of VP4To ensure that the mutations did not interfere with the structure of the mutant proteins, the stable interaction with VP4 capping enzyme and GMP moiety was undertaken according to Le Blois et al. [14] with the following modification: 2 lg of purified recombinant protein and 0.5 lCi/ll of a 32 P-GTP were used.Autoguanylation of VP4Reactions were performed in triplicate and data were analysed for significance using student t-test.Guanylyltransferase assaysGuanylyltransferase assays were performed as outlined by Martinez-Costas et al. [18] .", [["GMP", "CHEMICAL", 259, 262], ["GMP", "CHEMICAL", 259, 262], ["GTP", "CHEMICAL", 414, 417], ["VP4To", "GENE_OR_GENE_PRODUCT", 115, 120], ["VP4 capping enzyme", "GENE_OR_GENE_PRODUCT", 236, 254], ["GMP moiety", "SIMPLE_CHEMICAL", 259, 269], ["GTP", "SIMPLE_CHEMICAL", 414, 417], ["VP4Reactions", "GENE_OR_GENE_PRODUCT", 447, 459], ["Guanylyltransferase", "GENE_OR_GENE_PRODUCT", 550, 569], ["VP4To", "PROTEIN", 115, 120], ["mutant proteins", "PROTEIN", 191, 206], ["VP4 capping enzyme", "PROTEIN", 236, 254], ["purified recombinant protein", "PROTEIN", 360, 388], ["lCi", "PROTEIN", 397, 400], ["VP4Reactions", "DNA", 447, 459], ["Each reaction", "PROBLEM", 0, 13], ["student t-test", "TEST", 46, 60], ["the mutations", "PROBLEM", 133, 146], ["the mutant proteins", "PROBLEM", 187, 206], ["VP4 capping enzyme", "TREATMENT", 236, 254], ["GMP moiety", "TREATMENT", 259, 269], ["purified recombinant protein", "TREATMENT", 360, 388], ["a 32 P-GTP", "TREATMENT", 407, 417], ["VP4Reactions", "TREATMENT", 447, 459], ["student t-test", "TEST", 535, 549], ["Guanylyltransferase assaysGuanylyltransferase assays", "TEST", 550, 602], ["stable", "OBSERVATION_MODIFIER", 212, 218]]], ["A standard reaction consisted of 50 mM Tris HCl (pH 7.5), 9 mM MgCl 2 , 6 mM DTT, 10 mM AdoMet, 6 mM a 32 P-GTP (50 Ci/mmol), 2 lg of BTV S5 RNA transcripts as acceptor and $2 lg of purified VP4.", [["Tris HCl", "CHEMICAL", 39, 47], ["MgCl", "CHEMICAL", 63, 67], ["AdoMet", "CHEMICAL", 88, 94], ["32 P-GTP", "CHEMICAL", 103, 111], ["Tris HCl", "CHEMICAL", 39, 47], ["MgCl 2", "CHEMICAL", 63, 69], ["DTT", "CHEMICAL", 77, 80], ["AdoMet", "CHEMICAL", 88, 94], ["P-GTP", "CHEMICAL", 106, 111], ["Tris HCl", "SIMPLE_CHEMICAL", 39, 47], ["MgCl 2", "SIMPLE_CHEMICAL", 63, 69], ["DTT", "SIMPLE_CHEMICAL", 77, 80], ["AdoMet", "SIMPLE_CHEMICAL", 88, 94], ["GTP", "SIMPLE_CHEMICAL", 108, 111], ["BTV", "ORGANISM", 134, 137], ["VP4", "GENE_OR_GENE_PRODUCT", 191, 194], ["BTV S5 RNA transcripts", "RNA", 134, 156], ["VP4", "PROTEIN", 191, 194], ["BTV", "SPECIES", 134, 137], ["A standard reaction", "TEST", 0, 19], ["50 mM Tris HCl", "TREATMENT", 33, 47], ["pH", "TEST", 49, 51], ["MgCl", "TEST", 63, 67], ["DTT", "TEST", 77, 80], ["AdoMet", "TEST", 88, 94], ["GTP", "TEST", 108, 111]]], ["After incubation at 37\u00b0C for 2 h, RNA was extracted and analyzed by MOPS formaldehyde gel electrophoresis as described [4] followed by autoradiography.", [["MOPS formaldehyde", "CHEMICAL", 68, 85], ["formaldehyde", "CHEMICAL", 73, 85], ["formaldehyde", "SIMPLE_CHEMICAL", 73, 85], ["MOPS formaldehyde gel electrophoresis", "TREATMENT", 68, 105], ["autoradiography", "TEST", 135, 150]]], ["Reactions were performed in triplicate and data was analysed for significance using student t-test.Methyltransferase assayMethyl transfer from Ado[methyl-3 H]Met to T7 derived BTV ssRNAs were used to determine the ability of the methylase activity of mutant VP4.", [["assayMethyl", "CHEMICAL", 117, 128], ["Ado[methyl-3 H", "CHEMICAL", 143, 157], ["assayMethyl", "CHEMICAL", 117, 128], ["Ado[methyl-3 H]Met", "CHEMICAL", 143, 161], ["assayMethyl", "SIMPLE_CHEMICAL", 117, 128], ["Ado", "SIMPLE_CHEMICAL", 143, 146], ["methyl-3 H]Met", "SIMPLE_CHEMICAL", 147, 161], ["T7", "ORGANISM", 165, 167], ["BTV", "ORGANISM", 176, 179], ["VP4", "GENE_OR_GENE_PRODUCT", 258, 261], ["T7 derived BTV ssRNAs", "DNA", 165, 186], ["methylase", "PROTEIN", 229, 238], ["mutant VP4", "PROTEIN", 251, 261], ["BTV", "SPECIES", 176, 179], ["student t-test", "TEST", 84, 98], ["Methyltransferase assayMethyl transfer", "TREATMENT", 99, 137], ["Ado[methyl-3 H", "TREATMENT", 143, 157], ["Met to T7 derived BTV ssRNAs", "TREATMENT", 158, 186], ["mutant VP4", "PROBLEM", 251, 261]]], ["A standard reaction mixture contained 50 mM TrisHCl (pH 7.5), 9 mM MgCl 2 , 2 mM Ado[methyl-3 H]Met (87 Ci/mmol), 6 mM DTT, 1 lg of uncapped ssRNAs or 0.4 mM Cap analogue (GpppA, m7 GpppG; NEB) and 2 lg purified protein.", [["TrisHCl", "CHEMICAL", 44, 51], ["MgCl", "CHEMICAL", 67, 71], ["Ado", "CHEMICAL", 81, 84], ["methyl-3 H", "CHEMICAL", 85, 95], ["Met", "CHEMICAL", 96, 99], ["TrisHCl", "CHEMICAL", 44, 51], ["MgCl 2", "CHEMICAL", 67, 73], ["Ado[methyl-3 H]Met", "CHEMICAL", 81, 99], ["DTT", "CHEMICAL", 119, 122], ["TrisHCl", "SIMPLE_CHEMICAL", 44, 51], ["MgCl 2", "SIMPLE_CHEMICAL", 67, 73], ["Ado[methyl-3 H]Met", "SIMPLE_CHEMICAL", 81, 99], ["DTT", "SIMPLE_CHEMICAL", 119, 122], ["ssRNAs", "SIMPLE_CHEMICAL", 141, 147], ["Cap analogue", "SIMPLE_CHEMICAL", 158, 170], ["GpppA", "SIMPLE_CHEMICAL", 172, 177], ["NEB", "GENE_OR_GENE_PRODUCT", 189, 192], ["GpppA", "PROTEIN", 172, 177], ["NEB", "PROTEIN", 189, 192], ["lg purified protein", "PROTEIN", 200, 219], ["A standard reaction mixture", "TEST", 0, 27], ["pH", "TEST", 53, 55], ["MgCl", "TEST", 67, 71], ["Ado", "TEST", 81, 84], ["methyl", "TEST", 85, 91], ["Met", "TEST", 96, 99], ["Ci", "TEST", 104, 106], ["mM DTT", "TEST", 116, 122], ["ssRNAs", "TEST", 141, 147], ["Cap analogue", "TEST", 158, 170], ["GpppA", "TEST", 172, 177], ["NEB", "TEST", 189, 192]]], ["After incubation at 37\u00b0C for 2 h, the reaction mixtures were treated with proteinase K. RNA/cap analogues were purified by phenol:chloroform extraction and precipitated with cold ethanol.", [["phenol", "CHEMICAL", 123, 129], ["ethanol", "CHEMICAL", 179, 186], ["phenol", "CHEMICAL", 123, 129], ["chloroform", "CHEMICAL", 130, 140], ["ethanol", "CHEMICAL", 179, 186], ["phenol", "SIMPLE_CHEMICAL", 123, 129], ["chloroform", "SIMPLE_CHEMICAL", 130, 140], ["ethanol", "SIMPLE_CHEMICAL", 179, 186], ["proteinase", "PROTEIN", 74, 84], ["the reaction mixtures", "TREATMENT", 34, 55], ["proteinase K.", "TREATMENT", 74, 87], ["RNA/cap analogues", "TREATMENT", 88, 105], ["chloroform extraction", "TREATMENT", 130, 151], ["cold ethanol", "TREATMENT", 174, 186]]], ["Cap analogues were precipitated in 9 vol ice-cold ethanol.", [["ethanol", "CHEMICAL", 50, 57], ["ethanol", "CHEMICAL", 50, 57], ["Cap analogues", "SIMPLE_CHEMICAL", 0, 13], ["ethanol", "SIMPLE_CHEMICAL", 50, 57], ["Cap analogues", "PROBLEM", 0, 13]]], ["The transfer of the 3 H-methyl was determined using PerkinElmer 1450 microbeta.", [["H-methyl", "CHEMICAL", 22, 30], ["PerkinElmer 1450", "CHEMICAL", 52, 68], ["3 H-methyl", "CHEMICAL", 20, 30], ["3 H-methyl", "SIMPLE_CHEMICAL", 20, 30]]], ["As a negative control baculovirus infected cytosolic lysate was used, which was extracted from infected Sf9 cells using HNN buffer as described for VP4 recombinant proteins, treated with PEI and centrifuged to remove contaminating RNA and baculovirus particles.", [["cytosolic lysate", "ANATOMY", 43, 59], ["cells", "ANATOMY", 108, 113], ["PEI", "CHEMICAL", 187, 190], ["PEI", "CHEMICAL", 187, 190], ["baculovirus", "ORGANISM", 22, 33], ["cytosolic lysate", "ORGANISM_SUBSTANCE", 43, 59], ["Sf9 cells", "CELL", 104, 113], ["HNN", "SIMPLE_CHEMICAL", 120, 123], ["PEI", "SIMPLE_CHEMICAL", 187, 190], ["baculovirus", "ORGANISM", 239, 250], ["Sf9 cells", "CELL_LINE", 104, 113], ["VP4 recombinant proteins", "PROTEIN", 148, 172], ["contaminating RNA", "RNA", 217, 234], ["baculovirus", "SPECIES", 22, 33], ["Sf9", "SPECIES", 104, 107], ["baculovirus", "SPECIES", 239, 250], ["a negative control baculovirus infected cytosolic lysate", "PROBLEM", 3, 59], ["infected Sf9 cells", "TREATMENT", 95, 113], ["HNN buffer", "TREATMENT", 120, 130], ["VP4 recombinant proteins", "PROBLEM", 148, 172], ["PEI", "TREATMENT", 187, 190], ["contaminating RNA and baculovirus particles", "PROBLEM", 217, 260], ["cytosolic lysate", "OBSERVATION", 43, 59], ["infected Sf9 cells", "OBSERVATION", 95, 113]]], ["Reactions were performed in triplicate and data were analysed for significance using student t-test.In vitro capping assayTo examine the formation of cap structures by recombinant proteins in vitro, capping assay was performed using the standard methyltransferase assay as described [4] with the following modifications: 5 lg of recombinant protein, 0.5 lCi/ll a 32 P-GTP and 1 lg RNA.", [["GTP", "CHEMICAL", 368, 371], ["GTP", "SIMPLE_CHEMICAL", 368, 371], ["recombinant proteins", "PROTEIN", 168, 188], ["methyltransferase", "PROTEIN", 246, 263], ["recombinant protein", "PROTEIN", 329, 348], ["lCi", "PROTEIN", 354, 357], ["32 P-GTP and 1 lg RNA", "RNA", 363, 384], ["student t-test", "TEST", 85, 99], ["vitro capping assay", "TREATMENT", 103, 122], ["capping assay", "TEST", 199, 212], ["the standard methyltransferase assay", "TREATMENT", 233, 269], ["recombinant protein", "TEST", 329, 348], ["lCi", "TEST", 354, 357], ["GTP", "TEST", 368, 371], ["capping assay", "OBSERVATION", 109, 122], ["ll", "ANATOMY", 358, 360], ["lg RNA", "ANATOMY", 378, 384]]], ["After incubation for 2 h at 37\u00b0C, RNA was purified and digested with NucleaseP1 (Sigma) to release the cap structure.", [["NucleaseP1", "SIMPLE_CHEMICAL", 69, 79], ["NucleaseP1", "PROTEIN", 69, 79], ["NucleaseP1 (Sigma", "TREATMENT", 69, 86], ["cap structure", "OBSERVATION", 103, 116]]], ["Cap structures were resolved by thin layer chromatography (TLC) using PEI-cellulose plates (Millipore).", [["PEI-cellulose", "CHEMICAL", 70, 83], ["PEI", "CHEMICAL", 70, 73], ["thin layer chromatography", "TEST", 32, 57], ["PEI-cellulose plates", "TREATMENT", 70, 90]]], ["Reactions were performed in triplicate and ImageJ was used to quantify the intensity of the cap structures generated [30] .", [["ImageJ", "TEST", 43, 49]]], ["Data was analysed for significance using student t-test.m7-GTP sepharose interaction with recombinant proteinTo determine whether the mutations in 2 0 -O MT domain affected the binding to cap0, we performed m7-GTP pull-down assay.", [["GTP", "CHEMICAL", 59, 62], ["m7", "GENE_OR_GENE_PRODUCT", 56, 58], ["GTP", "SIMPLE_CHEMICAL", 59, 62], ["cap0", "GENE_OR_GENE_PRODUCT", 188, 192], ["m7-GTP", "GENE_OR_GENE_PRODUCT", 207, 213], ["m7", "PROTEIN", 56, 58], ["recombinant proteinTo", "PROTEIN", 90, 111], ["O MT domain", "PROTEIN", 152, 163], ["cap0", "PROTEIN", 188, 192], ["m7", "PROTEIN", 207, 209], ["student t-test", "TEST", 41, 55], ["GTP sepharose interaction", "TREATMENT", 59, 84], ["recombinant proteinTo", "TREATMENT", 90, 111], ["the mutations", "PROBLEM", 130, 143], ["GTP pull", "TEST", 210, 218]]], ["Purified recombinant protein was incubated with m7-GTP sepharose at 4\u00b0C for at least 4 h.", [["m7-GTP", "CHEMICAL", 48, 54], ["C", "SIMPLE_CHEMICAL", 70, 71], ["Purified recombinant protein", "PROTEIN", 0, 28], ["m7", "PROTEIN", 48, 50], ["Purified recombinant protein", "TEST", 0, 28]]], ["Samples were centrifuged at 500\u00c2g for 5 min, unbound fraction removed and washed the beads 3 times with binding buffer (50 mM TrisHCl pH 7.5, 300 mM NaCl, 0.5% NP40) supplemented with cold GTP to remove non-specific interactions.", [["Samples", "ANATOMY", 0, 7], ["NaCl", "CHEMICAL", 149, 153], ["GTP", "CHEMICAL", 189, 192], ["NaCl", "CHEMICAL", 149, 153], ["NP40", "CHEMICAL", 160, 164], ["GTP", "CHEMICAL", 189, 192], ["GTP", "SIMPLE_CHEMICAL", 189, 192], ["Samples", "TEST", 0, 7], ["unbound fraction", "TREATMENT", 45, 61], ["binding buffer", "TREATMENT", 104, 118], ["pH", "TEST", 134, 136], ["300 mM NaCl", "TREATMENT", 142, 153], ["cold GTP", "TREATMENT", 184, 192], ["non-specific interactions", "PROBLEM", 203, 228]]], ["Interacting proteins were eluted from the beads by the addition of SDS-PAGE sample buffer.", [["SDS", "CHEMICAL", 67, 70]]], ["Samples were resolved and analyzed by western immunoblot using VP4 polyclonal antibody.Expression and functional activities of recombinant VP4 mutant proteins targeting 2 0 -OMT domainThe 2.5 \u00c5 crystal structure of the 74 kDa BTV VP4 suggested that residues 175 to 377 encode a distinct 2 0 -O MT domain segregated from the other domains and is responsible for methylation of cap0 structure (Fig. 1) .", [["Samples", "ANATOMY", 0, 7], ["VP4", "GENE_OR_GENE_PRODUCT", 63, 66], ["VP4", "GENE_OR_GENE_PRODUCT", 139, 142], ["cap0", "GENE_OR_GENE_PRODUCT", 376, 380], ["VP4 polyclonal antibody", "PROTEIN", 63, 86], ["recombinant VP4 mutant proteins", "PROTEIN", 127, 158], ["2 0 -OMT domain", "PROTEIN", 169, 184], ["74 kDa BTV VP4", "PROTEIN", 219, 233], ["2 0 -O MT domain", "PROTEIN", 287, 303], ["cap0 structure", "PROTEIN", 376, 390], ["Samples", "TEST", 0, 7], ["western immunoblot", "TEST", 38, 56], ["VP4 polyclonal antibody", "TEST", 63, 86], ["recombinant VP4 mutant proteins targeting", "TREATMENT", 127, 168], ["kDa BTV VP4", "TEST", 222, 233], ["methylation of cap0 structure", "PROBLEM", 361, 390]]], ["Currently, there is no direct evidence available that this domain is indeed responsible for 2 0 -O MTase activity, although it includes putative signature catalytic residues, K178-D265-K306-E335, similar to the other catalytic motif of class I AdoMet-dependent methyltransferases ( Fig. 1; [33] ).", [["AdoMet", "CHEMICAL", 244, 250], ["AdoMet", "CHEMICAL", 244, 250], ["class I AdoMet-dependent methyltransferases", "GENE_OR_GENE_PRODUCT", 236, 279], ["MTase", "PROTEIN", 99, 104], ["K306", "PROTEIN", 185, 189], ["E335", "PROTEIN", 190, 194], ["catalytic motif", "PROTEIN", 217, 232], ["class I AdoMet-dependent methyltransferases", "PROTEIN", 236, 279], ["putative signature catalytic residues", "PROBLEM", 136, 173], ["K306", "TEST", 185, 189], ["AdoMet-dependent methyltransferases", "TREATMENT", 244, 279], ["no direct evidence", "UNCERTAINTY", 20, 38], ["catalytic residues", "OBSERVATION", 155, 173]]], ["Based on previous VP4 ligand binding data [33] and studies on other viruses, we hypothesized that aspartic acid 265 (D265) is critical for 2 0 -O MTase activity.", [["aspartic acid 265", "CHEMICAL", 98, 115], ["D265", "CHEMICAL", 117, 121], ["aspartic acid", "CHEMICAL", 98, 111], ["aspartic acid 265", "AMINO_ACID", 98, 115], ["D265", "AMINO_ACID", 117, 121], ["2 0 -O MTase", "GENE_OR_GENE_PRODUCT", 139, 151], ["VP4 ligand", "PROTEIN", 18, 28], ["MTase", "PROTEIN", 146, 151], ["previous VP4 ligand binding data", "TEST", 9, 41], ["other viruses", "PROBLEM", 62, 75], ["aspartic acid", "TEST", 98, 111]]], ["We focused on D265 rather than other catalytic residues as it is in proximate distance with the residues that bind S-adenosyl-L-homocysteine (SAH) and guanosine of the cap structure (Fig. 1 ).", [["S-adenosyl-L-homocysteine", "CHEMICAL", 115, 140], ["SAH", "DISEASE", 142, 145], ["guanosine", "CHEMICAL", 151, 160], ["S-adenosyl-L-homocysteine", "CHEMICAL", 115, 140], ["SAH", "CHEMICAL", 142, 145], ["guanosine", "CHEMICAL", 151, 160], ["D265", "SIMPLE_CHEMICAL", 14, 18], ["S-adenosyl-L-homocysteine", "SIMPLE_CHEMICAL", 115, 140], ["SAH", "SIMPLE_CHEMICAL", 142, 145], ["guanosine", "SIMPLE_CHEMICAL", 151, 160], ["cap structure", "PROTEIN", 168, 181], ["D265", "TREATMENT", 14, 18], ["other catalytic residues", "TREATMENT", 31, 55], ["S-adenosyl-L-homocysteine (SAH)", "TREATMENT", 115, 146], ["guanosine of the cap structure", "TREATMENT", 151, 181], ["cap", "OBSERVATION_MODIFIER", 168, 171]]], ["In addition, we identified a cluster of surface exposed amino acids N311, Y334 and R367 that are in close proximity to the guanosine in the ligand binding pocket ( Fig. 1 ; [33] ).", [["surface", "ANATOMY", 40, 47], ["amino acids", "CHEMICAL", 56, 67], ["guanosine", "CHEMICAL", 123, 132], ["amino acids", "CHEMICAL", 56, 67], ["Y334", "CHEMICAL", 74, 78], ["R367", "CHEMICAL", 83, 87], ["guanosine", "CHEMICAL", 123, 132], ["amino acids", "AMINO_ACID", 56, 67], ["N311", "AMINO_ACID", 68, 72], ["R367", "AMINO_ACID", 83, 87], ["guanosine", "SIMPLE_CHEMICAL", 123, 132], ["R367", "PROTEIN", 83, 87], ["ligand binding pocket", "PROTEIN", 140, 161], ["surface exposed amino acids", "TEST", 40, 67], ["ligand", "ANATOMY", 140, 146], ["binding pocket", "OBSERVATION", 147, 161]]], ["In particular, Y334 and possibly N311 are predicted to interact with guanine of the cap0 [33] , while R367 is believed to be responsible for recruiting the N7 cap ( Fig. 1 ; [33] ).", [["guanine", "CHEMICAL", 69, 76], ["guanine", "CHEMICAL", 69, 76], ["Y334", "GENE_OR_GENE_PRODUCT", 15, 19], ["N311", "GENE_OR_GENE_PRODUCT", 33, 37], ["guanine", "SIMPLE_CHEMICAL", 69, 76], ["R367", "GENE_OR_GENE_PRODUCT", 102, 106], ["N311", "PROTEIN", 33, 37], ["R367", "PROTEIN", 102, 106], ["N7 cap", "PROTEIN", 156, 162]]], ["Thus, these residues could be important in assisting the 2 0 -O MTase catalytic activity either through direct interaction with cap0 or by recruiting it within the catalytic domain.", [["cap0", "GENE_OR_GENE_PRODUCT", 128, 132], ["MTase", "PROTEIN", 64, 69], ["cap0", "PROTEIN", 128, 132], ["catalytic domain", "PROTEIN", 164, 180], ["cap0", "TREATMENT", 128, 132]]], ["Site-specific mutations into the coding region of VP4 were introduced to generate D265E and D265V to either conserve the charge or change the polarity of the residue.", [["VP4", "GENE_OR_GENE_PRODUCT", 50, 53], ["VP4", "DNA", 50, 53], ["D265E", "DNA", 82, 87], ["specific mutations", "PROBLEM", 5, 23], ["VP4", "TREATMENT", 50, 53], ["D265V", "TREATMENT", 92, 97], ["the residue", "PROBLEM", 154, 165]]], ["Similarly, residues N311, Y334 and R367 were mutated to an alanine either singly or in combination (NYR).", [["alanine", "CHEMICAL", 59, 66], ["alanine", "CHEMICAL", 59, 66], ["R367", "AMINO_ACID", 35, 39], ["alanine", "AMINO_ACID", 59, 66], ["an alanine", "TREATMENT", 56, 66]]], ["The mutated constructs were expressed using the baculovirus expression system and each protein was purified in soluble fraction indicating that the specific mutations, in particular, the surface exposed substitutions, have little or no effect on solubility (data not shown).Expression and functional activities of recombinant VP4 mutant proteins targeting 2 0 -OMT domainSince VP4 catalyzes all reactions of the cap methylation pathway in a sequential manner, it was necessary to ensure that mutations of any of the residues did not affect the upstream reactions.", [["surface", "ANATOMY", 187, 194], ["baculovirus", "ORGANISM", 48, 59], ["VP4", "GENE_OR_GENE_PRODUCT", 326, 329], ["VP4", "GENE_OR_GENE_PRODUCT", 377, 380], ["mutated constructs", "DNA", 4, 22], ["recombinant VP4 mutant proteins", "PROTEIN", 314, 345], ["VP4", "PROTEIN", 377, 380], ["baculovirus", "SPECIES", 48, 59], ["The mutated constructs", "PROBLEM", 0, 22], ["the baculovirus expression system", "TREATMENT", 44, 77], ["the specific mutations", "PROBLEM", 144, 166], ["recombinant VP4 mutant proteins", "TREATMENT", 314, 345], ["OMT domainSince VP4 catalyzes", "TREATMENT", 361, 390], ["the cap methylation pathway", "TREATMENT", 408, 435], ["the residues", "PROBLEM", 512, 524], ["the upstream reactions", "PROBLEM", 540, 562]]], ["Firstly, we analysed the GMP-VP4 complex formation by the mutant proteins to ensure the process of autoguanylation was retained.", [["GMP", "CHEMICAL", 25, 28], ["GMP-VP4", "GENE_OR_GENE_PRODUCT", 25, 32], ["VP4 complex", "PROTEIN", 29, 40], ["mutant proteins", "PROTEIN", 58, 73], ["the mutant proteins", "PROBLEM", 54, 73]]], ["The mutant proteins (D265E and D265V, N311A, Y334A, R367A and NYR) and VP4 WT were incubated with a 32 P-GTP for 30 min and products were analyzed by SDS-PAGE, followed by autoradiography.", [["GTP", "CHEMICAL", 105, 108], ["GTP", "CHEMICAL", 105, 108], ["GTP", "SIMPLE_CHEMICAL", 105, 108], ["mutant proteins", "PROTEIN", 4, 19], ["D265E", "PROTEIN", 21, 26], ["D265V", "PROTEIN", 31, 36], ["N311A", "PROTEIN", 38, 43], ["Y334A", "PROTEIN", 45, 50], ["R367A", "PROTEIN", 52, 57], ["NYR", "PROTEIN", 62, 65], ["VP4 WT", "PROTEIN", 71, 77], ["The mutant proteins", "TEST", 0, 19], ["D265V", "TREATMENT", 31, 36], ["N311A", "TEST", 38, 43], ["NYR", "TEST", 62, 65], ["VP4 WT", "TEST", 71, 77], ["autoradiography", "TEST", 172, 187]]], ["All recombinant mutant proteins exhibited formation of VP4-a 32 P-GMP intermediate complexes, albeit at variable amounts ( Fig. 2A) .", [["P-GMP", "CHEMICAL", 64, 69], ["VP4", "GENE_OR_GENE_PRODUCT", 55, 58], ["recombinant mutant proteins", "PROTEIN", 4, 31], ["VP4", "PROTEIN", 55, 58], ["32 P-GMP intermediate complexes", "PROTEIN", 61, 92], ["All recombinant mutant proteins", "TEST", 0, 31], ["VP4", "TEST", 55, 58], ["GMP intermediate complexes", "TREATMENT", 66, 92], ["intermediate complexes", "OBSERVATION_MODIFIER", 70, 92]]], ["There was some reduction ($4-20%) in GMP binding by all mutant proteins in comparison to WT VP4 but this was not significant.", [["GMP", "CHEMICAL", 37, 40], ["GMP", "CHEMICAL", 37, 40], ["GMP", "SIMPLE_CHEMICAL", 37, 40], ["VP4", "GENE_OR_GENE_PRODUCT", 92, 95], ["mutant proteins", "PROTEIN", 56, 71], ["WT VP4", "PROTEIN", 89, 95], ["some reduction", "PROBLEM", 10, 24], ["GMP binding", "PROBLEM", 37, 48], ["all mutant proteins", "PROBLEM", 52, 71], ["WT VP4", "TEST", 89, 95], ["reduction", "OBSERVATION_MODIFIER", 15, 24]]], ["A number of residues within VP4 have been shown to bind guanosine and phosphates including residues Y334 and D265 [33] .", [["guanosine", "CHEMICAL", 56, 65], ["phosphates", "CHEMICAL", 70, 80], ["guanosine", "CHEMICAL", 56, 65], ["phosphates", "CHEMICAL", 70, 80], ["VP4", "GENE_OR_GENE_PRODUCT", 28, 31], ["guanosine", "SIMPLE_CHEMICAL", 56, 65], ["phosphates", "SIMPLE_CHEMICAL", 70, 80], ["VP4", "PROTEIN", 28, 31], ["A number of residues within VP4", "PROBLEM", 0, 31], ["bind guanosine and phosphates including residues Y334", "TEST", 51, 104]]], ["Thus the reduction in autoguanylation observed by mutant proteins was likely due to disruption of specific guanosine interaction ( Fig. 2A) .", [["guanosine", "CHEMICAL", 107, 116], ["guanosine", "CHEMICAL", 107, 116], ["guanosine", "SIMPLE_CHEMICAL", 107, 116], ["mutant proteins", "PROTEIN", 50, 65], ["the reduction in autoguanylation", "PROBLEM", 5, 37], ["mutant proteins", "PROBLEM", 50, 65], ["specific guanosine interaction", "PROBLEM", 98, 128], ["reduction", "OBSERVATION_MODIFIER", 9, 18], ["likely due to", "UNCERTAINTY", 70, 83], ["guanosine interaction", "OBSERVATION", 107, 128]]], ["No complexes were detected in the control reactions either with baculovirus lysate or in absence of any VP4, confirming the specific interaction between VP4 and GMP ( Fig. 2A) .", [["GMP", "CHEMICAL", 161, 164], ["GMP", "CHEMICAL", 161, 164], ["baculovirus", "ORGANISM", 64, 75], ["VP4", "GENE_OR_GENE_PRODUCT", 104, 107], ["VP4", "GENE_OR_GENE_PRODUCT", 153, 156], ["GMP", "SIMPLE_CHEMICAL", 161, 164], ["VP4", "PROTEIN", 104, 107], ["VP4", "PROTEIN", 153, 156], ["GMP", "PROTEIN", 161, 164], ["Fig. 2A", "PROTEIN", 167, 174], ["baculovirus", "SPECIES", 64, 75], ["complexes", "PROBLEM", 3, 12], ["baculovirus lysate", "TREATMENT", 64, 82], ["any VP4", "PROBLEM", 100, 107], ["complexes", "OBSERVATION", 3, 12]]], ["Overall, the mutations did not result in a significant decrease in autoguanylation consistent with the unaltered structural integrity of each mutant VP4.Expression and functional activities of recombinant VP4 mutant proteins targeting 2 0 -OMT domainSince mutant proteins formed a stable covalent bond with GMP, we investigated whether the bound GMP could be transferred from VP4 to the 5 0 end of the ssRNAs to form the 'cap' structure i.e., the guanylyltransferase activity.", [["GMP", "CHEMICAL", 307, 310], ["GMP", "CHEMICAL", 346, 349], ["GMP", "CHEMICAL", 307, 310], ["GMP", "CHEMICAL", 346, 349], ["VP4", "GENE_OR_GENE_PRODUCT", 149, 152], ["VP4", "GENE_OR_GENE_PRODUCT", 205, 208], ["GMP", "SIMPLE_CHEMICAL", 307, 310], ["GMP", "SIMPLE_CHEMICAL", 346, 349], ["VP4", "GENE_OR_GENE_PRODUCT", 376, 379], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 402, 408], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 447, 466], ["mutant VP4", "PROTEIN", 142, 152], ["recombinant VP4 mutant proteins", "PROTEIN", 193, 224], ["2 0 -OMT domainSince mutant proteins", "PROTEIN", 235, 271], ["VP4", "PROTEIN", 376, 379], ["5 0 end", "DNA", 387, 394], ["ssRNAs", "PROTEIN", 402, 408], ["guanylyltransferase", "PROTEIN", 447, 466], ["a significant decrease in autoguanylation", "PROBLEM", 41, 82], ["recombinant VP4 mutant proteins targeting", "TEST", 193, 234], ["mutant proteins", "PROBLEM", 256, 271], ["the bound GMP", "PROBLEM", 336, 349], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["decrease", "OBSERVATION", 55, 63], ["stable", "OBSERVATION_MODIFIER", 281, 287], ["covalent bond", "OBSERVATION", 288, 301]]], ["All mutant recombinant proteins and WT VP4 were therefore incubated with unlabelled and uncapped T7 generated RNAs of one of the BTV segments (S5) in the presence of a 32 P-GTP for 2 h.", [["32 P-GTP", "CHEMICAL", 168, 176], ["GTP", "CHEMICAL", 173, 176], ["VP4", "GENE_OR_GENE_PRODUCT", 39, 42], ["GTP", "SIMPLE_CHEMICAL", 173, 176], ["mutant recombinant proteins", "PROTEIN", 4, 31], ["WT VP4", "PROTEIN", 36, 42], ["BTV", "SPECIES", 129, 132], ["WT VP4", "TEST", 36, 42], ["T7", "ANATOMY", 97, 99], ["BTV", "ANATOMY", 129, 132], ["segments", "ANATOMY_MODIFIER", 133, 141]]], ["The purified ssRNAs were analyzed by a denatured gel and a 32 P-labelled RNAs were detected.", [["ssRNAs", "GENE_OR_GENE_PRODUCT", 13, 19], ["ssRNAs", "PROTEIN", 13, 19], ["32 P-labelled RNAs", "RNA", 59, 77], ["a denatured gel", "TEST", 37, 52]]], ["All recombinant mutant proteins as well as control WT protein were able to generate a 32 P radio-labelled ssRNAs confirming that the GMP moiety (a 32 P-GMP) was transferred to the 5 0 ppG-RNA of the BTV ssRNA (Fig. 2B) .", [["GMP", "CHEMICAL", 133, 136], ["32 P-GMP", "CHEMICAL", 147, 155], ["GMP", "CHEMICAL", 133, 136], ["P-GMP", "CHEMICAL", 150, 155], ["GMP moiety", "SIMPLE_CHEMICAL", 133, 143], ["BTV", "ORGANISM", 199, 202], ["recombinant mutant proteins", "PROTEIN", 4, 31], ["WT protein", "PROTEIN", 51, 61], ["32 P radio-labelled ssRNAs", "PROTEIN", 86, 112], ["5 0 ppG-RNA", "RNA", 180, 191], ["BTV ssRNA", "DNA", 199, 208], ["BTV", "SPECIES", 199, 202], ["All recombinant mutant proteins", "PROBLEM", 0, 31], ["the GMP moiety", "TEST", 129, 143], ["the BTV ssRNA", "TREATMENT", 195, 208]]], ["N311A mutant protein catalyzed the capping of the ssRNA as efficiently as WT VP4.", [["N311A", "GENE_OR_GENE_PRODUCT", 0, 5], ["VP4", "GENE_OR_GENE_PRODUCT", 77, 80], ["N311A mutant protein", "PROTEIN", 0, 20], ["WT VP4", "PROTEIN", 74, 80], ["the ssRNA", "TREATMENT", 46, 55], ["ssRNA", "OBSERVATION", 50, 55]]], ["While mutations of the residues (Y334A, R367A and NYR) that are exposed at the VP4 surface and were predicted to interact with cap0, and D265 mutants were less efficient at transferring the GMP to the ssRNA (Fig. 2B) .", [["GMP", "CHEMICAL", 190, 193], ["GMP", "CHEMICAL", 190, 193], ["NYR", "GENE_OR_GENE_PRODUCT", 50, 53], ["VP4", "GENE_OR_GENE_PRODUCT", 79, 82], ["cap0", "GENE_OR_GENE_PRODUCT", 127, 131], ["D265", "GENE_OR_GENE_PRODUCT", 137, 141], ["GMP", "SIMPLE_CHEMICAL", 190, 193], ["NYR", "PROTEIN", 50, 53], ["VP4", "PROTEIN", 79, 82], ["cap0", "PROTEIN", 127, 131], ["D265 mutants", "PROTEIN", 137, 149], ["ssRNA", "DNA", 201, 206], ["the residues", "PROBLEM", 19, 31], ["cap0", "TREATMENT", 127, 131]]], ["The reduction in guanylyltransferase activity (5-20%) observed for these mutant proteins was the same as that observed for the GMP binding activity.", [["GMP", "CHEMICAL", 127, 130], ["GMP", "CHEMICAL", 127, 130], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 17, 36], ["GMP", "SIMPLE_CHEMICAL", 127, 130], ["guanylyltransferase", "PROTEIN", 17, 36], ["mutant proteins", "PROTEIN", 73, 88], ["The reduction in guanylyltransferase activity", "TREATMENT", 0, 45], ["these mutant proteins", "PROBLEM", 67, 88], ["the GMP binding activity", "TEST", 123, 147], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["activity", "OBSERVATION_MODIFIER", 37, 45], ["binding activity", "OBSERVATION", 131, 147]]], ["Reaction without VP4 did not generate any labelled ssRNAs (Fig. 2B) .", [["VP4", "GENE_OR_GENE_PRODUCT", 17, 20], ["VP4", "PROTEIN", 17, 20], ["ssRNAs", "PROTEIN", 51, 57], ["Fig. 2B", "PROTEIN", 59, 66], ["VP4", "PROBLEM", 17, 20]]], ["These results indicate that the function of the GTase domain was not significantly affected by the introduction of these mutations and structural integrity was maintained.Methylation of cap by VP4 mutant proteinsSince the mutations were specifically introduced into the 2 0 -O MT domain, to define its functional role, we examined if these mutations affected the catalytic ability of the VP4 to methylate the penultimate nucleotide of the 5 0 end of cap0.", [["nucleotide", "CHEMICAL", 421, 431], ["nucleotide", "CHEMICAL", 421, 431], ["GTase", "GENE_OR_GENE_PRODUCT", 48, 53], ["VP4", "GENE_OR_GENE_PRODUCT", 193, 196], ["VP4", "GENE_OR_GENE_PRODUCT", 388, 391], ["cap0", "GENE_OR_GENE_PRODUCT", 450, 454], ["GTase domain", "PROTEIN", 48, 60], ["VP4 mutant proteins", "PROTEIN", 193, 212], ["2 0 -O MT domain", "DNA", 270, 286], ["VP4", "PROTEIN", 388, 391], ["5 0 end", "DNA", 439, 446], ["cap0", "PROTEIN", 450, 454], ["the GTase domain", "PROBLEM", 44, 60], ["these mutations", "PROBLEM", 115, 130], ["Methylation of cap", "PROBLEM", 171, 189], ["these mutations", "PROBLEM", 334, 349]]], ["To investigate the effect of mutations at the putative catalytic tetrad on 2 0 -O MTase activity, recombinant D265E, D265V and WT VP4 proteins were incubated with cap0 analogue ( m7 GpppG) in the presence of Ado[methyl-3 H]Met for 2 h.", [["Ado", "CHEMICAL", 208, 211], ["methyl-3 H", "CHEMICAL", 212, 222], ["Met", "CHEMICAL", 223, 226], ["Ado[methyl-3 H]Met", "CHEMICAL", 208, 226], ["0 -O MTase", "GENE_OR_GENE_PRODUCT", 77, 87], ["VP4", "GENE_OR_GENE_PRODUCT", 130, 133], ["cap0 analogue", "SIMPLE_CHEMICAL", 163, 176], ["m7 GpppG", "SIMPLE_CHEMICAL", 179, 187], ["Ado", "SIMPLE_CHEMICAL", 208, 211], ["methyl-3 H]Met", "SIMPLE_CHEMICAL", 212, 226], ["MTase", "PROTEIN", 82, 87], ["recombinant D265E, D265V and WT VP4 proteins", "PROTEIN", 98, 142], ["mutations", "PROBLEM", 29, 38], ["D265V", "TREATMENT", 117, 122], ["WT VP4 proteins", "TREATMENT", 127, 142], ["Ado[methyl", "TREATMENT", 208, 218]]], ["The cap analogue was purified to remove the unincorporated Ado[methyl-3 H]Met and transfer of methyl-3 H was determined.", [["Ado", "CHEMICAL", 59, 62], ["methyl-3 H", "CHEMICAL", 63, 73], ["Met", "CHEMICAL", 74, 77], ["methyl-3 H", "CHEMICAL", 94, 104], ["Ado[methyl-3 H]Met", "CHEMICAL", 59, 77], ["methyl-3 H", "CHEMICAL", 94, 104], ["Ado", "SIMPLE_CHEMICAL", 59, 62], ["methyl-3 H]Met", "SIMPLE_CHEMICAL", 63, 77], ["methyl-3 H", "SIMPLE_CHEMICAL", 94, 104], ["The cap analogue", "TREATMENT", 0, 16], ["the unincorporated Ado[methyl", "TREATMENT", 40, 69]]], ["While the WT VP4 efficiently methylated the cap0 analogue, the two mutant proteins failed to methylate the cap0 analogue (Fig. 3A) .", [["VP4", "GENE_OR_GENE_PRODUCT", 13, 16], ["cap0", "GENE_OR_GENE_PRODUCT", 44, 48], ["WT VP4", "PROTEIN", 10, 16], ["mutant proteins", "PROTEIN", 67, 82], ["cap0", "PROTEIN", 107, 111], ["the WT VP4", "TREATMENT", 6, 16], ["methylated the cap0 analogue", "TREATMENT", 29, 57], ["the two mutant proteins", "PROBLEM", 59, 82]]], ["The values observed for D265E and D265V were equivalent to the two negative controls, with no significant differences observed between the two mutants (D265E, p < 0.1; D265V, p < 0.73; Fig. 3A ).", [["The values", "TEST", 0, 10], ["D265E", "TREATMENT", 24, 29], ["D265V", "TREATMENT", 34, 39], ["significant differences", "PROBLEM", 94, 117], ["p", "TEST", 159, 160]]], ["Our results demonstrated that only recombinant WT VP4 protein was able to methylate m7 GpppG while the mutation of D265 to either E or V abolished this catalytic function.", [["VP4", "GENE_OR_GENE_PRODUCT", 50, 53], ["m7 GpppG", "GENE_OR_GENE_PRODUCT", 84, 92], ["E or V", "GENE_OR_GENE_PRODUCT", 130, 136], ["recombinant WT VP4 protein", "PROTEIN", 35, 61], ["m7 GpppG", "PROTEIN", 84, 92], ["D265", "PROTEIN", 115, 119], ["E or V", "DNA", 130, 136], ["recombinant WT VP4 protein", "TREATMENT", 35, 61]]], ["To ensure that the catalytic activities of the 2 0 -O MT and N7MT domains of VP4 act independently, we performed the same reaction as above but substituted the cap0 analogue ( m7 GpppG) with an unmethylated cap analogue (GpppA); the later is not a natural substrate for VP4 as the 5 0 penultimate base for BTV transcript is a guanosine.", [["guanosine", "CHEMICAL", 326, 335], ["2 0 -O", "CHEMICAL", 47, 53], ["cap0", "CHEMICAL", 160, 164], ["guanosine", "CHEMICAL", 326, 335], ["2 0 -O MT", "SIMPLE_CHEMICAL", 47, 56], ["VP4", "GENE_OR_GENE_PRODUCT", 77, 80], ["cap0 analogue", "SIMPLE_CHEMICAL", 160, 173], ["m7 GpppG", "SIMPLE_CHEMICAL", 176, 184], ["GpppA", "SIMPLE_CHEMICAL", 221, 226], ["VP4", "GENE_OR_GENE_PRODUCT", 270, 273], ["BTV", "ORGANISM", 306, 309], ["guanosine", "SIMPLE_CHEMICAL", 326, 335], ["2 0 -O MT", "PROTEIN", 47, 56], ["N7MT domains", "PROTEIN", 61, 73], ["VP4", "PROTEIN", 77, 80], ["VP4", "PROTEIN", 270, 273], ["5 0 penultimate base", "RNA", 281, 301], ["BTV transcript", "RNA", 306, 320], ["BTV", "SPECIES", 306, 309], ["the cap0 analogue", "TREATMENT", 156, 173], ["an unmethylated cap analogue", "TREATMENT", 191, 219], ["VP4", "PROBLEM", 270, 273], ["BTV transcript", "TREATMENT", 306, 320], ["a guanosine", "TREATMENT", 324, 335]]], ["Both D265 mutant and WT VP4 proteins were able to methylate the GpppA cap analogue to generate m7 GpppA when compared with the cell lysate, indicating that the mutant proteins had retained the N7MT activity, albeit at reduced levels (Fig. 3B ).", [["cell lysate", "ANATOMY", 127, 138], ["D265 mutant", "ORGANISM", 5, 16], ["WT VP4", "ORGANISM", 21, 27], ["GpppA", "GENE_OR_GENE_PRODUCT", 64, 69], ["m7", "GENE_OR_GENE_PRODUCT", 95, 97], ["GpppA", "GENE_OR_GENE_PRODUCT", 98, 103], ["cell lysate", "CELL", 127, 138], ["N7MT", "GENE_OR_GENE_PRODUCT", 193, 197], ["D265 mutant", "PROTEIN", 5, 16], ["WT VP4 proteins", "PROTEIN", 21, 36], ["GpppA", "PROTEIN", 64, 69], ["m7 GpppA", "PROTEIN", 95, 103], ["mutant proteins", "PROTEIN", 160, 175], ["N7MT", "PROTEIN", 193, 197], ["WT VP4 proteins", "TREATMENT", 21, 36], ["the cell lysate", "TEST", 123, 138], ["the mutant proteins", "PROBLEM", 156, 175]]], ["This set of results demonstrated that the D265 residue within the K-D-K-E tetrad is essential for VP4 catalytic activity.", [["K", "CHEMICAL", 66, 67], ["D265", "CHEMICAL", 42, 46], ["VP4", "GENE_OR_GENE_PRODUCT", 98, 101], ["K-D-K-E tetrad", "DNA", 66, 80], ["VP4", "PROTEIN", 98, 101], ["the D265 residue", "PROBLEM", 38, 54], ["the K-D-K-E tetrad", "TREATMENT", 62, 80], ["VP4 catalytic activity", "PROBLEM", 98, 120], ["catalytic activity", "OBSERVATION", 102, 120]]], ["Further, these results may indicate that the 2 0 -O MT and N7MT catalytic domains act independently.Methylation of cap by VP4 mutant proteinsWhen the same in vitro assay was performed using cap0 analogue ( m7 GpppG) with cap0 binding pocket mutant proteins, each mutant still showed some 2 0 -O MTase activity.", [["2 0 -O", "CHEMICAL", 45, 51], ["0 -O MT", "SIMPLE_CHEMICAL", 47, 54], ["VP4", "GENE_OR_GENE_PRODUCT", 122, 125], ["cap0 analogue", "SIMPLE_CHEMICAL", 190, 203], ["m7 GpppG", "GENE_OR_GENE_PRODUCT", 206, 214], ["cap0", "GENE_OR_GENE_PRODUCT", 221, 225], ["0 -O MTase", "GENE_OR_GENE_PRODUCT", 290, 300], ["MT", "PROTEIN", 52, 54], ["N7MT catalytic domains", "PROTEIN", 59, 81], ["VP4 mutant proteins", "PROTEIN", 122, 141], ["cap0 binding pocket mutant proteins", "PROTEIN", 221, 256], ["MTase", "PROTEIN", 295, 300], ["Methylation of cap", "PROBLEM", 100, 118], ["vitro assay", "TEST", 158, 169], ["cap0 analogue", "TREATMENT", 190, 203], ["cap0 binding pocket mutant proteins", "PROBLEM", 221, 256]]], ["In particular, the single mutation of the residues Y334 or R367 did not affect the transfer of the methyl group to cap0 analogue ( m7 GpppG) (Fig. 4A) , while mutation at the residues N311 and NYR mutant protein had 2-fold reduction in the incorporation of Ado[methyl-3 H]Met (Fig. 4A ).", [["methyl", "CHEMICAL", 99, 105], ["Ado[methyl-3 H", "CHEMICAL", 257, 271], ["methyl", "CHEMICAL", 99, 105], ["cap0", "CHEMICAL", 115, 119], ["Ado[methyl-3 H]Met", "CHEMICAL", 257, 275], ["Y334", "AMINO_ACID", 51, 55], ["methyl", "SIMPLE_CHEMICAL", 99, 105], ["cap0 analogue", "SIMPLE_CHEMICAL", 115, 128], ["Fig. 4A", "GENE_OR_GENE_PRODUCT", 142, 149], ["Ado[methyl-3 H]Met", "SIMPLE_CHEMICAL", 257, 275], ["Fig. 4A", "SIMPLE_CHEMICAL", 277, 284], ["cap0", "PROTEIN", 115, 119], ["m7 GpppG", "PROTEIN", 131, 139], ["N311", "PROTEIN", 184, 188], ["NYR mutant protein", "PROTEIN", 193, 211], ["the methyl group to cap0 analogue", "TREATMENT", 95, 128], ["the residues", "TEST", 171, 183], ["NYR mutant protein", "PROBLEM", 193, 211], ["2-fold reduction", "TREATMENT", 216, 232], ["Ado[methyl", "TREATMENT", 257, 267]]], ["As these mutations were designed to disrupt the recruitment of the BTV transcripts with cap0 from the N7-MT domain, we used an uncapped BTV ssRNAs acceptor, instead of cap0 analogue, as it is representative of the reaction by VP4 that occurs within the core particle.", [["BTV", "ORGANISM", 67, 70], ["cap0", "GENE_OR_GENE_PRODUCT", 88, 92], ["cap0 analogue", "SIMPLE_CHEMICAL", 168, 181], ["VP4", "GENE_OR_GENE_PRODUCT", 226, 229], ["BTV transcripts", "RNA", 67, 82], ["cap0", "PROTEIN", 88, 92], ["N7-MT domain", "DNA", 102, 114], ["VP4", "PROTEIN", 226, 229], ["BTV", "SPECIES", 67, 70], ["cap0", "TREATMENT", 88, 92], ["an uncapped BTV ssRNAs acceptor", "TREATMENT", 124, 155], ["cap0 analogue", "TREATMENT", 168, 181], ["the reaction", "PROBLEM", 210, 222], ["VP4", "PROBLEM", 226, 229]]], ["Mutant and WT VP4 proteins, uncapped BTV ssRNAs and Ado[methyl-3 H]Met were incubated together, BTV ssRNAs were purified and amount of methyl-3 H transferred to an equivalent amount of ssRNAs was determined.", [["Ado", "CHEMICAL", 52, 55], ["methyl-3 H", "CHEMICAL", 56, 66], ["methyl-3", "CHEMICAL", 135, 143], ["H", "CHEMICAL", 144, 145], ["Ado[methyl-3 H]Met", "CHEMICAL", 52, 70], ["methyl-3", "CHEMICAL", 135, 143], ["VP4", "GENE_OR_GENE_PRODUCT", 14, 17], ["BTV", "ORGANISM", 37, 40], ["Ado", "SIMPLE_CHEMICAL", 52, 55], ["methyl-3 H]Met", "SIMPLE_CHEMICAL", 56, 70], ["BTV", "ORGANISM", 96, 99], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 100, 106], ["methyl-3", "SIMPLE_CHEMICAL", 135, 143], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 185, 191], ["Mutant and WT VP4 proteins", "PROTEIN", 0, 26], ["BTV ssRNAs", "PROTEIN", 37, 47], ["Ado[methyl-3 H]Met", "PROTEIN", 52, 70], ["BTV ssRNAs", "PROTEIN", 96, 106], ["ssRNAs", "PROTEIN", 185, 191], ["BTV", "SPECIES", 37, 40], ["BTV", "SPECIES", 96, 99], ["Mutant and WT VP4 proteins", "PROBLEM", 0, 26], ["Ado[methyl", "TREATMENT", 52, 62], ["BTV ssRNAs", "TEST", 96, 106], ["ssRNAs", "TREATMENT", 185, 191]]], ["All mutant proteins showed significant reduction in transferring methyl-3 H to the uncapped ssRNAs (Fig. 4B) .", [["methyl-3", "CHEMICAL", 65, 73], ["methyl-3", "CHEMICAL", 65, 73], ["methyl-3", "SIMPLE_CHEMICAL", 65, 73], ["mutant proteins", "PROTEIN", 4, 19], ["ssRNAs", "PROTEIN", 92, 98], ["All mutant proteins", "TEST", 0, 19], ["significant reduction", "PROBLEM", 27, 48], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["reduction", "OBSERVATION_MODIFIER", 39, 48]]], ["The data demonstrated that the mutation of the putative cap binding pocket retained 2-O MTase activity but the efficiency of formation of cap1 structure on ssRNAs acceptors, however, was hampered.", [["2-O", "CHEMICAL", 84, 87], ["2-O MTase", "GENE_OR_GENE_PRODUCT", 84, 93], ["cap1", "GENE_OR_GENE_PRODUCT", 138, 142], ["ssRNAs acceptors", "SIMPLE_CHEMICAL", 156, 172], ["O MTase", "PROTEIN", 86, 93], ["cap1 structure", "PROTEIN", 138, 152], ["The data", "TEST", 0, 8], ["the mutation", "PROBLEM", 27, 39], ["the putative cap binding pocket", "PROBLEM", 43, 74], ["cap1 structure", "PROBLEM", 138, 152], ["ssRNAs acceptors", "TREATMENT", 156, 172], ["pocket", "OBSERVATION_MODIFIER", 68, 74], ["cap1 structure", "OBSERVATION", 138, 152]]], ["These results supported that these residues are involved in the in vitro catalytic activity of VP4.Methylation of cap by VP4 mutant proteinsTo understand further the effect of mutant NYR on cap methylation, we investigated the kinetics of the same reaction.", [["VP4", "GENE_OR_GENE_PRODUCT", 95, 98], ["VP4", "GENE_OR_GENE_PRODUCT", 121, 124], ["NYR", "SIMPLE_CHEMICAL", 183, 186], ["VP4", "PROTEIN", 95, 98], ["VP4 mutant proteins", "PROTEIN", 121, 140], ["mutant NYR", "PROTEIN", 176, 186], ["these residues", "PROBLEM", 29, 43], ["Methylation of cap", "PROBLEM", 99, 117], ["cap methylation", "TREATMENT", 190, 205], ["the same reaction", "PROBLEM", 239, 256]]], ["NYR mutant and WT VP4 proteins were incubated with T7 derived ssRNAs in the presence of Ado[methyl-3 H]Met as described above and samples were analysed at 30 min intervals.", [["samples", "ANATOMY", 130, 137], ["Ado", "CHEMICAL", 88, 91], ["methyl-3 H", "CHEMICAL", 92, 102], ["Ado[methyl-3 H]Met", "CHEMICAL", 88, 106], ["NYR", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP4", "GENE_OR_GENE_PRODUCT", 18, 21], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 62, 68], ["Ado", "SIMPLE_CHEMICAL", 88, 91], ["methyl-3 H]Met", "SIMPLE_CHEMICAL", 92, 106], ["NYR mutant", "PROTEIN", 0, 10], ["WT VP4 proteins", "PROTEIN", 15, 30], ["WT VP4 proteins", "TEST", 15, 30], ["T7 derived ssRNAs", "PROBLEM", 51, 68], ["Ado[methyl", "TREATMENT", 88, 98]]], ["The cap methylation reaction to generate cap1 structure at the 5 0 termini of ssRNAs was severely delayed by the NYR mutant; 3 H-methyl labelled ssRNAs could be barely detected at 150 min time point (Fig. 4C) .", [["H", "CHEMICAL", 127, 128], ["3 H-methyl", "CHEMICAL", 125, 135], ["cap1", "GENE_OR_GENE_PRODUCT", 41, 45], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 78, 84], ["NYR", "GENE_OR_GENE_PRODUCT", 113, 116], ["3 H-methyl labelled ssRNAs", "SIMPLE_CHEMICAL", 125, 151], ["cap1 structure", "PROTEIN", 41, 55], ["ssRNAs", "PROTEIN", 78, 84], ["NYR mutant", "PROTEIN", 113, 123], ["H-methyl labelled ssRNAs", "PROTEIN", 127, 151], ["The cap methylation reaction", "PROBLEM", 0, 28], ["cap1 structure", "PROBLEM", 41, 55], ["severely delayed", "PROBLEM", 89, 105], ["-methyl labelled ssRNAs", "TEST", 128, 151], ["cap", "OBSERVATION_MODIFIER", 4, 7], ["methylation reaction", "OBSERVATION", 8, 28], ["cap1 structure", "OBSERVATION", 41, 55]]], ["In contrast, transfer of the methyl-3 H to the ssRNAs by WT VP4 at the same time point was at least a 100-fold higher than that of the mutant protein.", [["methyl-3 H", "CHEMICAL", 29, 39], ["methyl-3 H", "CHEMICAL", 29, 39], ["methyl-3 H", "SIMPLE_CHEMICAL", 29, 39], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 47, 53], ["WT VP4", "ORGANISM", 57, 63], ["ssRNAs", "DNA", 47, 53], ["WT VP4", "PROTEIN", 57, 63], ["mutant protein", "PROTEIN", 135, 149], ["WT VP4", "TEST", 57, 63]]], ["2 0 -O MTase activity was severely hampered by the substitution of NYR residues to alanine, as was also true when the m7 GpppG cap0 analogue was used as a substrate (data not shown).Methylation of cap by VP4 mutant proteinsOverall, our data identifies a key role of residue D265 within the catalytic tetrad to maintain 2 0 -O MT function of VP4.", [["alanine", "CHEMICAL", 83, 90], ["NYR", "CHEMICAL", 67, 70], ["alanine", "CHEMICAL", 83, 90], ["GpppG", "CHEMICAL", 121, 126], ["2 0 -O MTase", "SIMPLE_CHEMICAL", 0, 12], ["NYR", "SIMPLE_CHEMICAL", 67, 70], ["alanine", "AMINO_ACID", 83, 90], ["VP4", "GENE_OR_GENE_PRODUCT", 204, 207], ["D265", "AMINO_ACID", 274, 278], ["VP4", "GENE_OR_GENE_PRODUCT", 341, 344], ["MTase", "PROTEIN", 7, 12], ["VP4 mutant proteins", "PROTEIN", 204, 223], ["VP4", "PROTEIN", 341, 344], ["the substitution of NYR residues", "TREATMENT", 47, 79], ["alanine", "TEST", 83, 90], ["the m7 GpppG cap0 analogue", "TREATMENT", 114, 140], ["a substrate (data", "TEST", 153, 170], ["Methylation of cap", "PROBLEM", 182, 200], ["our data", "TEST", 232, 240], ["VP4", "PROBLEM", 341, 344], ["cap", "OBSERVATION_MODIFIER", 197, 200]]], ["Further, it highlights that the triple residues (N311, Y334 and R367) mutated in combination perturb the efficiency of catalytic activity of VP4 for cap1 formation at the 5 0 termini of the transcripts.Mutation of N311 is associated with decreased binding to m7 of cap0 structureThe decrease in methylation activity prompted us to further investigate if the reduced activity was due to perturbed interaction between VP4 and cap0 structure as hypothesized.", [["VP4", "GENE_OR_GENE_PRODUCT", 141, 144], ["cap1", "GENE_OR_GENE_PRODUCT", 149, 153], ["N311", "AMINO_ACID", 214, 218], ["cap0", "GENE_OR_GENE_PRODUCT", 265, 269], ["VP4", "GENE_OR_GENE_PRODUCT", 416, 419], ["cap0", "GENE_OR_GENE_PRODUCT", 424, 428], ["VP4", "PROTEIN", 141, 144], ["cap1", "PROTEIN", 149, 153], ["N311", "DNA", 214, 218], ["m7", "DNA", 259, 261], ["cap0 structure", "PROTEIN", 265, 279], ["VP4", "PROTEIN", 416, 419], ["cap0 structure", "PROTEIN", 424, 438], ["the triple residues", "PROBLEM", 28, 47], ["cap1 formation", "PROBLEM", 149, 163], ["Mutation of N311", "PROBLEM", 202, 218], ["decreased binding", "PROBLEM", 238, 255], ["The decrease in methylation activity", "PROBLEM", 279, 315], ["the reduced activity", "PROBLEM", 354, 374], ["perturbed interaction between VP4 and cap0 structure", "PROBLEM", 386, 438], ["triple residues", "OBSERVATION", 32, 47], ["decrease", "OBSERVATION_MODIFIER", 283, 291], ["methylation activity", "OBSERVATION", 295, 315]]], ["To this end a qualitative pull-down assay was used to examine whether the mutant VP4 proteins were able to interact with m7 of the cap1.", [["VP4", "GENE_OR_GENE_PRODUCT", 81, 84], ["m7", "GENE_OR_GENE_PRODUCT", 121, 123], ["cap1", "GENE_OR_GENE_PRODUCT", 131, 135], ["mutant VP4 proteins", "PROTEIN", 74, 93], ["m7", "PROTEIN", 121, 123], ["cap1", "PROTEIN", 131, 135], ["a qualitative pull-down assay", "TEST", 12, 41], ["the mutant VP4 proteins", "PROBLEM", 70, 93], ["the cap1", "TREATMENT", 127, 135]]], ["Each protein was incubated with m7-GTP linked to sepharose beads and washed in a solution containing excess GTP to reduce background and specific interaction with the guanosine.", [["m7-GTP", "CHEMICAL", 32, 38], ["GTP", "CHEMICAL", 108, 111], ["guanosine", "CHEMICAL", 167, 176], ["m7-GTP", "CHEMICAL", 32, 38], ["GTP", "CHEMICAL", 108, 111], ["guanosine", "CHEMICAL", 167, 176], ["m7-GTP", "SIMPLE_CHEMICAL", 32, 38], ["GTP", "SIMPLE_CHEMICAL", 108, 111], ["guanosine", "SIMPLE_CHEMICAL", 167, 176], ["m7", "PROTEIN", 32, 34], ["Each protein", "TEST", 0, 12], ["sepharose beads", "TREATMENT", 49, 64], ["a solution containing excess GTP", "TREATMENT", 79, 111], ["the guanosine", "TREATMENT", 163, 176]]], ["The bound VP4 was visualized by western analysis using anti-VP4 antibody.", [["VP4", "GENE_OR_GENE_PRODUCT", 10, 13], ["anti-VP4 antibody", "GENE_OR_GENE_PRODUCT", 55, 72], ["VP4", "PROTEIN", 10, 13], ["anti-VP4 antibody", "PROTEIN", 55, 72], ["The bound VP4", "PROBLEM", 0, 13], ["western analysis", "TEST", 32, 48], ["anti-VP4 antibody", "TREATMENT", 55, 72]]], ["Recombinant mutant proteins Y334A and R367 and VP4 WT protein were pulled-down by m7-GTP demonstrating that each protein interacted with the m7-GTP (Fig. 5) .", [["m7-GTP", "CHEMICAL", 82, 88], ["m7-GTP", "CHEMICAL", 82, 88], ["m7-GTP", "CHEMICAL", 141, 147], ["Y334A", "GENE_OR_GENE_PRODUCT", 28, 33], ["R367", "GENE_OR_GENE_PRODUCT", 38, 42], ["VP4 WT protein", "GENE_OR_GENE_PRODUCT", 47, 61], ["m7-GTP", "SIMPLE_CHEMICAL", 82, 88], ["m7-GTP", "GENE_OR_GENE_PRODUCT", 141, 147], ["Recombinant mutant proteins", "PROTEIN", 0, 27], ["Y334A", "PROTEIN", 28, 33], ["R367", "PROTEIN", 38, 42], ["VP4 WT protein", "PROTEIN", 47, 61], ["m7", "PROTEIN", 82, 84], ["m7", "PROTEIN", 141, 143], ["Recombinant mutant proteins", "TEST", 0, 27], ["VP4 WT protein", "TEST", 47, 61], ["each protein", "TEST", 108, 120]]], ["In contrast, the N311A and NYR mutants failed to interact with the m7-GTP as neither were detected in the pulled-down fraction (Fig. 5) .", [["GTP", "CHEMICAL", 70, 73], ["N311A", "GENE_OR_GENE_PRODUCT", 17, 22], ["NYR", "GENE_OR_GENE_PRODUCT", 27, 30], ["m7-GTP", "GENE_OR_GENE_PRODUCT", 67, 73], ["N311A", "PROTEIN", 17, 22], ["NYR mutants", "PROTEIN", 27, 38], ["m7", "PROTEIN", 67, 69]]], ["The results indicate that N311 amino acid most likely interacts with the methyl group of the cap0 within the catalytic domain of 2 0 -O MTase.2 0 -O MTase activity is essential for virus replicationTo investigate the importance of 2 0 -O MT activity on virus replication we examined the D265 mutants in the context of virus replication.", [["N311", "CHEMICAL", 26, 30], ["amino acid", "CHEMICAL", 31, 41], ["methyl", "CHEMICAL", 73, 79], ["amino acid", "CHEMICAL", 31, 41], ["methyl", "CHEMICAL", 73, 79], ["N311", "SIMPLE_CHEMICAL", 26, 30], ["amino acid", "AMINO_ACID", 31, 41], ["methyl", "SIMPLE_CHEMICAL", 73, 79], ["cap0", "GENE_OR_GENE_PRODUCT", 93, 97], ["2 0 -O MTase", "GENE_OR_GENE_PRODUCT", 129, 141], ["0 -O MTase", "GENE_OR_GENE_PRODUCT", 144, 154], ["0 -O MT", "SIMPLE_CHEMICAL", 233, 240], ["D265", "GENE_OR_GENE_PRODUCT", 287, 291], ["cap0", "PROTEIN", 93, 97], ["catalytic domain of 2 0 -O MTase", "PROTEIN", 109, 141], ["MTase", "PROTEIN", 149, 154], ["D265 mutants", "PROTEIN", 287, 299], ["N311 amino acid", "PROBLEM", 26, 41], ["the methyl group of the cap0", "TREATMENT", 69, 97], ["virus replication", "TREATMENT", 181, 198], ["virus replication", "TREATMENT", 253, 270], ["virus replication", "TREATMENT", 318, 335]]], ["To this end the D265E and D265V mutations were introduced into the S4 and BTV reverse genetics (RG) system used [3, 19] to recover mutant viruses in mammalian BSR cells, WT VP4 plasmid was excluded from the first transfection and replaced with mutant T7 S4 ssRNA.", [["BSR cells", "ANATOMY", 159, 168], ["D265E", "GENE_OR_GENE_PRODUCT", 16, 21], ["D265V", "GENE_OR_GENE_PRODUCT", 26, 31], ["mammalian BSR cells", "CELL", 149, 168], ["WT VP4", "ORGANISM", 170, 176], ["D265E and D265V mutations", "DNA", 16, 41], ["mammalian BSR cells", "CELL_LINE", 149, 168], ["WT VP4 plasmid", "DNA", 170, 184], ["mutant T7 S4 ssRNA", "DNA", 244, 262], ["D265V mutations", "TREATMENT", 26, 41], ["mutant viruses in mammalian BSR cells", "PROBLEM", 131, 168], ["WT VP4 plasmid", "TEST", 170, 184], ["mutant T7 S4 ssRNA", "PROBLEM", 244, 262], ["viruses", "OBSERVATION", 138, 145], ["BSR cells", "OBSERVATION", 159, 168], ["T7", "ANATOMY", 251, 253], ["S4 ssRNA", "OBSERVATION", 254, 262]]], ["In spite of several attempts, it was not possible to recover any virus, with either mutants of D265 in normal BSR cells, indicating that these substitution mutations were not tolerated and lethal for virus growth in mammalian cells (Fig. 6A) .2 0 -O MTase activity is essential for virus replicationIn order to determine if these two mutant viruses could be rescued when a native VP4 was provided in trans, a stable cell line (BSR4) constitutively expressing WT VP4 was generated.", [["BSR cells", "ANATOMY", 110, 119], ["mammalian cells", "ANATOMY", 216, 231], ["cell line", "ANATOMY", 416, 425], ["BSR cells", "CELL", 110, 119], ["mammalian cells", "CELL", 216, 231], ["0 -O MTase", "GENE_OR_GENE_PRODUCT", 245, 255], ["VP4", "GENE_OR_GENE_PRODUCT", 380, 383], ["cell line", "CELL", 416, 425], ["BSR4", "CELL", 427, 431], ["WT VP4", "ORGANISM", 459, 465], ["D265", "PROTEIN", 95, 99], ["normal BSR cells", "CELL_LINE", 103, 119], ["mammalian cells", "CELL_TYPE", 216, 231], ["MTase", "PROTEIN", 250, 255], ["VP4", "PROTEIN", 380, 383], ["stable cell line", "CELL_LINE", 409, 425], ["BSR4", "CELL_LINE", 427, 431], ["WT VP4", "PROTEIN", 459, 465], ["any virus", "PROBLEM", 61, 70], ["these substitution mutations", "PROBLEM", 137, 165], ["lethal", "TREATMENT", 189, 195], ["virus growth in mammalian cells", "PROBLEM", 200, 231], ["virus replication", "TREATMENT", 282, 299], ["these two mutant viruses", "PROBLEM", 324, 348], ["a native VP4", "PROBLEM", 371, 383], ["a stable cell line", "TREATMENT", 407, 425], ["normal BSR cells", "OBSERVATION", 103, 119], ["viruses", "OBSERVATION", 341, 348], ["stable", "OBSERVATION_MODIFIER", 409, 415], ["cell line", "OBSERVATION", 416, 425]]], ["The BSR4 cells were transfected with each mutant S4 transcripts together with 9 BTV-1 transcripts and monitored for CPE and plaque formation.", [["BSR4 cells", "ANATOMY", 4, 14], ["plaque", "ANATOMY", 124, 130], ["BSR4 cells", "CELL", 4, 14], ["BTV-1", "GENE_OR_GENE_PRODUCT", 80, 85], ["plaque", "PATHOLOGICAL_FORMATION", 124, 130], ["BSR4 cells", "CELL_LINE", 4, 14], ["mutant S4 transcripts", "PROTEIN", 42, 63], ["The BSR4 cells", "TEST", 0, 14], ["BTV", "TEST", 80, 83], ["CPE", "PROBLEM", 116, 119], ["plaque formation", "PROBLEM", 124, 140], ["BSR4 cells", "OBSERVATION", 4, 14], ["plaque", "OBSERVATION", 124, 130]]], ["Both mutant viruses were successfully rescued in the complementary cell line with plaque morphology similar to that of the WT BTV virus (Fig. 6A) .", [["cell line", "ANATOMY", 67, 76], ["plaque", "ANATOMY", 82, 88], ["mutant viruses", "ORGANISM", 5, 19], ["cell line", "CELL", 67, 76], ["plaque", "PATHOLOGICAL_FORMATION", 82, 88], ["WT BTV virus", "ORGANISM", 123, 135], ["Fig. 6A", "ORGANISM", 137, 144], ["complementary cell line", "CELL_LINE", 53, 76], ["BTV virus", "SPECIES", 126, 135], ["Both mutant viruses", "PROBLEM", 0, 19], ["plaque morphology", "PROBLEM", 82, 99], ["the WT BTV virus", "PROBLEM", 119, 135], ["mutant", "OBSERVATION_MODIFIER", 5, 11], ["viruses", "OBSERVATION", 12, 19], ["cell line", "OBSERVATION", 67, 76], ["plaque", "OBSERVATION", 82, 88]]], ["The disruption of the catalytic site could be compensated by the normal VP4 supplied in trans.", [["VP4", "GENE_OR_GENE_PRODUCT", 72, 75], ["catalytic site", "DNA", 22, 36], ["VP4", "PROTEIN", 72, 75], ["The disruption of the catalytic site", "PROBLEM", 0, 36], ["compensated", "OBSERVATION_MODIFIER", 46, 57], ["normal", "OBSERVATION", 65, 71], ["VP4", "OBSERVATION_MODIFIER", 72, 75]]], ["Further, viruses grown in the complementary BSR4 cells were used to infect both normal BSR and BSR4 in parallel, at an MOI $ 1 and viral structural and non-structural proteins (VP3 and NS1) synthesis were examined.", [["BSR4 cells", "ANATOMY", 44, 54], ["BSR4 cells", "CELL", 44, 54], ["BSR4", "GENE_OR_GENE_PRODUCT", 95, 99], ["VP3", "GENE_OR_GENE_PRODUCT", 177, 180], ["NS1", "GENE_OR_GENE_PRODUCT", 185, 188], ["BSR4 cells", "CELL_LINE", 44, 54], ["BSR4", "DNA", 95, 99], ["non-structural proteins", "PROTEIN", 152, 175], ["VP3", "PROTEIN", 177, 180], ["NS1", "PROTEIN", 185, 188], ["viruses", "PROBLEM", 9, 16], ["the complementary BSR4 cells", "PROBLEM", 26, 54], ["viral structural", "TEST", 131, 147], ["non-structural proteins", "TEST", 152, 175], ["VP3 and NS1) synthesis", "TEST", 177, 199], ["viruses", "OBSERVATION_MODIFIER", 9, 16], ["grown", "OBSERVATION_MODIFIER", 17, 22], ["BSR4 cells", "OBSERVATION", 44, 54], ["normal BSR", "OBSERVATION", 80, 90], ["non-structural proteins", "OBSERVATION", 152, 175]]], ["The expression of BTV proteins was detected in both cell lines at 24 h post infection indicating that the mutant viruses were able to infect and express the viral proteins in both cell lines (Fig. 6B) .", [["cell lines", "ANATOMY", 52, 62], ["cell lines", "ANATOMY", 180, 190], ["BTV", "ORGANISM", 18, 21], ["cell lines", "CELL", 52, 62], ["mutant viruses", "ORGANISM", 106, 120], ["cell lines", "CELL", 180, 190], ["Fig. 6B", "CELL", 192, 199], ["BTV proteins", "PROTEIN", 18, 30], ["cell lines", "CELL_LINE", 52, 62], ["viral proteins", "PROTEIN", 157, 171], ["cell lines", "CELL_LINE", 180, 190], ["BTV", "SPECIES", 18, 21], ["BTV proteins", "PROBLEM", 18, 30], ["infection", "PROBLEM", 76, 85], ["the mutant viruses", "PROBLEM", 102, 120], ["the viral proteins", "PROBLEM", 153, 171], ["BTV proteins", "OBSERVATION", 18, 30], ["cell lines", "OBSERVATION", 52, 62], ["viral proteins", "OBSERVATION", 157, 171], ["both cell lines", "OBSERVATION", 175, 190]]], ["Progeny mutant viruses grown in normal BSR cells failed to replicate further (data not shown).", [["BSR cells", "ANATOMY", 39, 48], ["Progeny mutant viruses", "ORGANISM", 0, 22], ["BSR cells", "CELL", 39, 48], ["normal BSR cells", "CELL_LINE", 32, 48], ["Progeny mutant viruses", "PROBLEM", 0, 22], ["viruses", "OBSERVATION_MODIFIER", 15, 22], ["grown", "OBSERVATION_MODIFIER", 23, 28], ["normal BSR cells", "OBSERVATION", 32, 48]]], ["The dsRNA genome of the mutant viruses were extracted from BSR4, infected cells, but not from normal cells, were purified and had a typical BTV genome profile indicating that there were no abnormal segments and genome replication was occurring (Fig. 6C) .Triple mutation within 2 0 -O MTase influence virus growthThe mutation of non-catalytic residues either singly or in combination indirectly affected 2 0 -O MTase activity in vitro, therefore, we investigated the biological significance of these residues on BTV replication.", [["cells", "ANATOMY", 74, 79], ["cells", "ANATOMY", 101, 106], ["mutant viruses", "ORGANISM", 24, 38], ["BSR4", "GENE_OR_GENE_PRODUCT", 59, 63], ["cells", "CELL", 74, 79], ["cells", "CELL", 101, 106], ["BTV", "ORGANISM", 140, 143], ["genome", "CELLULAR_COMPONENT", 211, 217], ["2 0 -O MTase", "GENE_OR_GENE_PRODUCT", 278, 290], ["0 -O MTase", "GENE_OR_GENE_PRODUCT", 406, 416], ["BTV", "ORGANISM", 512, 515], ["dsRNA genome", "DNA", 4, 16], ["BSR4, infected cells", "CELL_LINE", 59, 79], ["normal cells", "CELL_TYPE", 94, 106], ["BTV genome", "DNA", 140, 150], ["O MTase", "PROTEIN", 283, 290], ["MTase", "PROTEIN", 411, 416], ["BTV", "SPECIES", 140, 143], ["BTV", "SPECIES", 512, 515], ["the mutant viruses", "PROBLEM", 20, 38], ["BSR4", "PROBLEM", 59, 63], ["infected cells", "PROBLEM", 65, 79], ["abnormal segments", "PROBLEM", 189, 206], ["genome replication", "PROBLEM", 211, 229], ["Triple mutation", "PROBLEM", 255, 270], ["The mutation of non-catalytic residues", "PROBLEM", 313, 351], ["these residues", "PROBLEM", 494, 508], ["BTV replication", "TREATMENT", 512, 527], ["dsRNA genome", "OBSERVATION", 4, 16], ["mutant", "OBSERVATION_MODIFIER", 24, 30], ["viruses", "OBSERVATION", 31, 38], ["infected cells", "OBSERVATION", 65, 79], ["normal cells", "OBSERVATION", 94, 106], ["no", "UNCERTAINTY", 186, 188], ["abnormal", "OBSERVATION_MODIFIER", 189, 197], ["segments", "OBSERVATION_MODIFIER", 198, 206], ["genome replication", "OBSERVATION", 211, 229], ["non-catalytic residues", "OBSERVATION", 329, 351]]], ["The same mutations as described were introduced at each position (N311, Y334 or R367) either singly or in combination (NYR) into the S4 genomic clone and reverse genetics system used to recover each mutant virus.", [["clone", "CELL", 144, 149], ["N311", "DNA", 66, 70], ["NYR", "DNA", 119, 122], ["S4 genomic clone", "DNA", 133, 149], ["the S4 genomic clone", "PROBLEM", 129, 149], ["reverse genetics system", "PROBLEM", 154, 177], ["each mutant virus", "PROBLEM", 194, 211]]], ["Unlike the mutants of the catalytic residue (D265E or D265V), all other mutant viruses were recovered from normal BSR cells (Fig. 7A) .", [["BSR cells", "ANATOMY", 114, 123], ["BSR cells", "CELL", 114, 123], ["Fig. 7A", "CELL", 125, 132], ["catalytic residue", "PROTEIN", 26, 43], ["BSR cells", "CELL_LINE", 114, 123], ["the catalytic residue", "PROBLEM", 22, 43], ["all other mutant viruses", "PROBLEM", 62, 86], ["BSR cells", "OBSERVATION", 114, 123]]], ["The plaque morphology of the viruses with Y334A and R367A mutations were comparable to WT virus, while N311A and NYR mutation viruses exhibited smaller plaque sizes (Fig. 6A) .", [["plaque", "ANATOMY", 4, 10], ["plaque", "ANATOMY", 152, 158], ["plaque", "PATHOLOGICAL_FORMATION", 4, 10], ["Y334A", "GENE_OR_GENE_PRODUCT", 42, 47], ["R367A", "GENE_OR_GENE_PRODUCT", 52, 57], ["WT virus", "ORGANISM", 87, 95], ["N311A", "GENE_OR_GENE_PRODUCT", 103, 108], ["NYR", "GENE_OR_GENE_PRODUCT", 113, 116], ["plaque", "PATHOLOGICAL_FORMATION", 152, 158], ["the viruses", "PROBLEM", 25, 36], ["R367A mutations", "PROBLEM", 52, 67], ["WT virus", "TEST", 87, 95], ["N311A", "TEST", 103, 108], ["NYR mutation viruses", "PROBLEM", 113, 133], ["smaller plaque sizes", "PROBLEM", 144, 164], ["plaque", "OBSERVATION", 4, 10], ["viruses", "OBSERVATION", 29, 36], ["smaller", "OBSERVATION_MODIFIER", 144, 151], ["plaque", "OBSERVATION", 152, 158], ["sizes", "OBSERVATION_MODIFIER", 159, 164]]], ["Development of plaques was slowest in the virus with a triple mutation (NYR) taking up to 5 days p.i. to yield pinhead sized plaques (data not shown), significantly smaller than the normal plaque size of WT at 3 days p.i.", [["plaques", "ANATOMY", 15, 22], ["plaques", "ANATOMY", 125, 132], ["plaque", "ANATOMY", 189, 195], ["plaques", "PATHOLOGICAL_FORMATION", 15, 22], ["plaques", "PATHOLOGICAL_FORMATION", 125, 132], ["plaque", "PATHOLOGICAL_FORMATION", 189, 195], ["plaques", "PROBLEM", 15, 22], ["the virus", "PROBLEM", 38, 47], ["a triple mutation (NYR)", "TREATMENT", 53, 76], ["pinhead sized plaques", "PROBLEM", 111, 132], ["plaques", "OBSERVATION", 15, 22], ["slowest", "OBSERVATION_MODIFIER", 27, 34], ["sized", "OBSERVATION_MODIFIER", 119, 124], ["plaques", "OBSERVATION", 125, 132], ["significantly", "OBSERVATION_MODIFIER", 151, 164], ["smaller", "OBSERVATION_MODIFIER", 165, 172], ["normal", "OBSERVATION_MODIFIER", 182, 188], ["plaque", "OBSERVATION", 189, 195], ["size", "OBSERVATION_MODIFIER", 196, 200]]], ["Although, there was a distinct difference in the plaque size, sequence analysis of the genomic S4 segment of the mutant viruses after 10 passages demonstrated that the mutant viruses were stable.Triple mutation within 2 0 -O MTase influence virus growthThe differences in the development and size of the plaques of the mutant viruses were also reflected in the titres and growth kinetics monitored over 96 h (Fig. 7B) .", [["plaque", "ANATOMY", 49, 55], ["plaques", "ANATOMY", 304, 311], ["plaque", "PATHOLOGICAL_FORMATION", 49, 55], ["mutant viruses", "ORGANISM", 113, 127], ["mutant viruses", "ORGANISM", 168, 182], ["2 0 -O MTase", "GENE_OR_GENE_PRODUCT", 218, 230], ["mutant viruses", "ORGANISM", 319, 333], ["genomic S4 segment", "DNA", 87, 105], ["O MTase", "PROTEIN", 223, 230], ["a distinct difference in the plaque size", "PROBLEM", 20, 60], ["sequence analysis", "TEST", 62, 79], ["the mutant viruses", "PROBLEM", 109, 127], ["the mutant viruses", "PROBLEM", 164, 182], ["Triple mutation", "PROBLEM", 195, 210], ["the plaques", "PROBLEM", 300, 311], ["the mutant viruses", "PROBLEM", 315, 333], ["the titres and growth kinetics", "PROBLEM", 357, 387], ["distinct", "OBSERVATION_MODIFIER", 22, 30], ["difference", "OBSERVATION_MODIFIER", 31, 41], ["plaque", "OBSERVATION", 49, 55], ["size", "OBSERVATION_MODIFIER", 56, 60], ["S4", "ANATOMY_MODIFIER", 95, 97], ["segment", "ANATOMY_MODIFIER", 98, 105], ["mutant viruses", "OBSERVATION", 113, 127], ["viruses", "OBSERVATION", 175, 182], ["stable", "OBSERVATION_MODIFIER", 188, 194], ["size", "OBSERVATION_MODIFIER", 292, 296], ["plaques", "OBSERVATION", 304, 311], ["mutant viruses", "OBSERVATION", 319, 333]]], ["The Y334A mutant virus followed a growth pattern similar to that of the WT virus; similar titres were observed at all time-points measured indicating no apparent effect on virus replication.", [["Y334A", "GENE_OR_GENE_PRODUCT", 4, 9], ["WT virus", "ORGANISM", 72, 80], ["The Y334A mutant virus", "PROBLEM", 0, 22], ["a growth pattern", "PROBLEM", 32, 48], ["the WT virus", "PROBLEM", 68, 80], ["similar titres", "PROBLEM", 82, 96], ["virus replication", "TREATMENT", 172, 189], ["no apparent", "UNCERTAINTY", 150, 161], ["virus", "OBSERVATION", 172, 177]]], ["However, the other three mutant viruses, N311A, R367A and NYR, had titres lower than the WT virus (1-3.5 log 10 ), the R367A mutant virus titres were consistently 1 log 10 lower than WT at each time point.", [["mutant viruses", "ORGANISM", 25, 39], ["N311A", "GENE_OR_GENE_PRODUCT", 41, 46], ["NYR", "GENE_OR_GENE_PRODUCT", 58, 61], ["WT virus", "ORGANISM", 89, 97], ["R367A mutant virus", "ORGANISM", 119, 137], ["NYR", "TEST", 58, 61], ["titres", "TEST", 67, 73], ["the WT virus", "TEST", 85, 97], ["the R367A mutant virus titres", "TEST", 115, 144], ["viruses", "OBSERVATION", 32, 39]]], ["For the first 24 h p.i., the growth of the N311A followed a pattern similar to both the WT and Y334A mutant viruses in BSR cells.", [["BSR cells", "ANATOMY", 119, 128], ["Y334A", "GENE_OR_GENE_PRODUCT", 95, 100], ["BSR cells", "CELL", 119, 128], ["N311A", "DNA", 43, 48], ["BSR cells", "CELL_LINE", 119, 128], ["the WT", "TEST", 84, 90], ["mutant viruses in BSR cells", "PROBLEM", 101, 128], ["viruses", "OBSERVATION", 108, 115], ["BSR cells", "OBSERVATION", 119, 128]]], ["However, after 24 h p.i., the growth curve of the N311A mutant virus plateaued with titres between 1 log 10 to 1.5 log 10 lower than WT.", [["N311A mutant virus", "ORGANISM", 50, 68], ["the growth curve", "TEST", 26, 42], ["the N311A mutant virus", "TREATMENT", 46, 68], ["titres", "TEST", 84, 90]]], ["The growth of the NYR mutant virus within the first 24 h p.i. was slower than all three single mutant viruses and the WT and as observed with the N311A virus, growth curve plateaued after 24 h p.i.", [["NYR mutant virus", "ORGANISM", 18, 34], ["N311A virus", "ORGANISM", 146, 157], ["N311A virus", "SPECIES", 146, 157], ["the NYR mutant virus", "PROBLEM", 14, 34], ["the WT", "TEST", 114, 120], ["the N311A virus", "TREATMENT", 142, 157], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["viruses", "OBSERVATION", 102, 109]]], ["The NYR mutant virus consistently had titres of 2.5-3.5 log 10 lower than WT (Fig. 7B) .Triple mutation within 2 0 -O MTase influence virus growthAs NYR mutant virus replication showed the most drastic effect on replication in comparison to the WT virus, we examined the viral protein synthesis at different time points.", [["NYR mutant virus", "ORGANISM", 4, 20], ["2 0 -O MTase", "GENE_OR_GENE_PRODUCT", 111, 123], ["virus growthAs NYR mutant virus", "ORGANISM", 134, 165], ["WT virus", "ORGANISM", 245, 253], ["2 0 -O MTase", "DNA", 111, 123], ["viral protein", "PROTEIN", 271, 284], ["The NYR mutant virus", "PROBLEM", 0, 20], ["titres", "TEST", 38, 44], ["Triple mutation", "PROBLEM", 88, 103], ["mutant virus replication", "PROBLEM", 153, 177], ["the WT virus", "PROBLEM", 241, 253], ["the viral protein synthesis", "PROBLEM", 267, 294], ["virus", "OBSERVATION", 15, 20], ["most drastic", "OBSERVATION_MODIFIER", 189, 201], ["viral protein", "OBSERVATION", 271, 284]]], ["At 48 h p.i., both structural (e.g., VP3) and non-structural proteins (e.g., NS1) were detected in cell infected with the mutant virus although at levels lower than that of WT (Fig. 7C) , consistent with the low virus titres.", [["cell", "ANATOMY", 99, 103], ["VP3", "GENE_OR_GENE_PRODUCT", 37, 40], ["NS1", "GENE_OR_GENE_PRODUCT", 77, 80], ["cell", "CELL", 99, 103], ["mutant virus", "ORGANISM", 122, 134], ["VP3", "PROTEIN", 37, 40], ["non-structural proteins", "PROTEIN", 46, 69], ["NS1", "PROTEIN", 77, 80], ["VP3", "TEST", 37, 40], ["non-structural proteins", "TEST", 46, 69], ["NS1", "PROBLEM", 77, 80], ["the mutant virus", "PROBLEM", 118, 134], ["WT", "TEST", 173, 175], ["the low virus titres", "PROBLEM", 204, 224], ["non-structural proteins", "OBSERVATION", 46, 69], ["cell infected", "OBSERVATION", 99, 112], ["consistent with", "UNCERTAINTY", 188, 203], ["low virus titres", "OBSERVATION", 208, 224]]], ["In order to quantify the difference in protein expression between the NYR mutant and WT viruses, a more sensitive Renilla luciferase assay was undertaken [2] .", [["NYR", "GENE_OR_GENE_PRODUCT", 70, 73], ["WT viruses", "ORGANISM", 85, 95], ["luciferase", "GENE_OR_GENE_PRODUCT", 122, 132], ["NYR mutant", "PROTEIN", 70, 80], ["luciferase", "PROTEIN", 122, 132], ["the difference in protein expression between the NYR mutant and WT viruses", "PROBLEM", 21, 95], ["Renilla luciferase assay", "TEST", 114, 138]]], ["Cells were transfected with an S10-RLuc, an ssRNA that expresses Renilla luciferase under the regulation of BTV NS1, followed by infection with NYR mutant or WT BTV.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 129, 138], ["Cells", "CELL", 0, 5], ["S10", "GENE_OR_GENE_PRODUCT", 31, 34], ["RLuc", "GENE_OR_GENE_PRODUCT", 35, 39], ["Renilla", "GENE_OR_GENE_PRODUCT", 65, 72], ["luciferase", "GENE_OR_GENE_PRODUCT", 73, 83], ["BTV", "ORGANISM", 108, 111], ["NS1", "GENE_OR_GENE_PRODUCT", 112, 115], ["NYR", "GENE_OR_GENE_PRODUCT", 144, 147], ["WT BTV", "ORGANISM", 158, 164], ["S10", "DNA", 31, 34], ["RLuc", "DNA", 35, 39], ["luciferase", "PROTEIN", 73, 83], ["BTV NS1", "PROTEIN", 108, 115], ["NYR mutant", "PROTEIN", 144, 154], ["BTV", "SPECIES", 108, 111], ["BTV", "SPECIES", 161, 164], ["an ssRNA", "TREATMENT", 41, 49], ["Renilla luciferase", "TREATMENT", 65, 83], ["BTV NS1", "TREATMENT", 108, 115], ["infection", "PROBLEM", 129, 138], ["ssRNA", "OBSERVATION", 44, 49], ["Renilla luciferase", "OBSERVATION", 65, 83], ["infection", "OBSERVATION", 129, 138]]], ["Renilla luciferase production was quantified 12 h p.i (Fig. 7D) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["luciferase", "PROTEIN", 8, 18]]], ["In contrast to NYR mutant virus and control, Renilla luciferase activity was $4-fold higher in the WT BTV infected cells (Fig. 7D) .", [["cells", "ANATOMY", 115, 120], ["NYR mutant virus", "ORGANISM", 15, 31], ["Renilla", "ORGANISM", 45, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 53, 63], ["BTV", "ORGANISM", 102, 105], ["cells", "CELL", 115, 120], ["NYR", "PROTEIN", 15, 18], ["luciferase", "PROTEIN", 53, 63], ["WT BTV infected cells", "CELL_TYPE", 99, 120], ["BTV", "SPECIES", 102, 105], ["NYR mutant virus", "TREATMENT", 15, 31], ["Renilla luciferase activity", "TEST", 45, 72], ["the WT BTV infected cells", "PROBLEM", 95, 120], ["infected cells", "OBSERVATION", 106, 120]]], ["These results confirmed that the mutations affecting the growth of the viruses also perturb the viral protein production during early infection.DiscussionBTV VP4, unlike many other viral capping enzymes, possesses all the catalytic activities required for the generation of methylated cap structure at the 5 0 terminus of BTV transcripts.", [["infection", "DISEASE", 134, 143], ["VP4", "GENE_OR_GENE_PRODUCT", 158, 161], ["BTV", "ORGANISM", 322, 325], ["viral protein", "PROTEIN", 96, 109], ["VP4", "PROTEIN", 158, 161], ["viral capping enzymes", "PROTEIN", 181, 202], ["5 0 terminus", "PROTEIN", 306, 318], ["BTV transcripts", "RNA", 322, 337], ["BTV", "SPECIES", 322, 325], ["the mutations", "PROBLEM", 29, 42], ["the viruses", "PROBLEM", 67, 78], ["the viral protein production", "PROBLEM", 92, 120], ["early infection", "PROBLEM", 128, 143], ["VP4", "PROBLEM", 158, 161], ["viral capping enzymes", "TEST", 181, 202], ["methylated cap structure", "PROBLEM", 274, 298], ["growth", "OBSERVATION_MODIFIER", 57, 63], ["viruses", "OBSERVATION", 71, 78], ["viral protein production", "OBSERVATION", 96, 120], ["early", "OBSERVATION_MODIFIER", 128, 133], ["infection", "OBSERVATION", 134, 143], ["methylated cap", "OBSERVATION", 274, 288]]], ["Crystal structure of VP4 revealed that the protein consisted of four independent, discrete functional domains each with a discrete role in the capping pathway.", [["VP4", "GENE_OR_GENE_PRODUCT", 21, 24], ["VP4", "PROTEIN", 21, 24], ["Crystal structure of VP4", "TEST", 0, 24], ["the protein", "TEST", 39, 50], ["the capping pathway", "TREATMENT", 139, 158], ["four independent", "OBSERVATION_MODIFIER", 64, 80], ["discrete", "OBSERVATION_MODIFIER", 82, 90], ["functional", "OBSERVATION", 91, 101]]], ["The putative 2 0 -O MTase domain which is were detected using monospecific polyclonal antibodies; aVP3 or aNS1 respectively.", [["aVP3", "GENE_OR_GENE_PRODUCT", 98, 102], ["aNS1", "GENE_OR_GENE_PRODUCT", 106, 110], ["putative 2 0 -O MTase domain", "DNA", 4, 32], ["monospecific polyclonal antibodies", "PROTEIN", 62, 96], ["aVP3", "PROTEIN", 98, 102], ["aNS1", "PROTEIN", 106, 110], ["O MTase domain", "TEST", 18, 32], ["monospecific polyclonal antibodies", "TEST", 62, 96]]], ["As a loading control, cellular protein b-actin was detected using aActin antibody responsible for the last catalytic reaction of the cap structure, is attached via a small linker to the other upstream enzymatic domains including kinase-like, GT and N7-MT that are responsible for the upstream reactions of pathway.", [["cellular", "ANATOMY", 22, 30], ["cellular", "CELL", 22, 30], ["b-actin", "GENE_OR_GENE_PRODUCT", 39, 46], ["aActin antibody", "GENE_OR_GENE_PRODUCT", 66, 81], ["GT", "GENE_OR_GENE_PRODUCT", 242, 244], ["N7-MT", "GENE_OR_GENE_PRODUCT", 249, 254], ["cellular protein b-actin", "PROTEIN", 22, 46], ["aActin antibody", "PROTEIN", 66, 81], ["cap structure", "PROTEIN", 133, 146], ["upstream enzymatic domains", "PROTEIN", 192, 218], ["kinase", "PROTEIN", 229, 235], ["GT", "PROTEIN", 242, 244], ["N7", "PROTEIN", 249, 251], ["MT", "PROTEIN", 252, 254], ["a loading control", "TREATMENT", 3, 20], ["cellular protein b-actin", "TEST", 22, 46], ["aActin antibody", "TEST", 66, 81], ["the last catalytic reaction of the cap structure", "PROBLEM", 98, 146], ["a small linker", "TREATMENT", 164, 178], ["kinase", "TEST", 229, 235], ["GT", "TEST", 242, 244], ["cap structure", "OBSERVATION", 133, 146], ["small linker", "OBSERVATION", 166, 178]]], ["The highly ordered structure of VP4 highlighted the importance of synthesizing BTV cap in a sequential manner.", [["VP4", "GENE_OR_GENE_PRODUCT", 32, 35], ["BTV", "ORGANISM", 79, 82], ["VP4", "PROTEIN", 32, 35], ["BTV cap", "PROTEIN", 79, 86], ["synthesizing BTV cap", "TREATMENT", 66, 86], ["BTV cap", "OBSERVATION", 79, 86]]], ["To date no functions have been assigned to any domain of VP4 and the purpose of this report was to obtain structure-based biochemical evidence for function focussing mainly on the 2 0 -O MTase domain by generating a series of targeted mutations in the recombinant VP4 as well as in the replicating viral genome.DiscussionThe mutations in VP4 2 0 -O MTase domain were designed to target a key catalytic residue and the residues of the cap0 binding pocket (Fig. 1 ) that ideally would not influence the functions of the other domains.", [["VP4", "GENE_OR_GENE_PRODUCT", 57, 60], ["VP4", "GENE_OR_GENE_PRODUCT", 264, 267], ["VP4 2 0 -O MTase", "GENE_OR_GENE_PRODUCT", 338, 354], ["VP4", "PROTEIN", 57, 60], ["2 0 -O MTase domain", "PROTEIN", 180, 199], ["recombinant VP4", "PROTEIN", 252, 267], ["replicating viral genome", "DNA", 286, 310], ["VP4 2 0 -O MTase domain", "PROTEIN", 338, 361], ["cap0 binding pocket", "PROTEIN", 434, 453], ["targeted mutations", "PROBLEM", 226, 244], ["the recombinant VP4", "TREATMENT", 248, 267], ["a key catalytic residue", "PROBLEM", 386, 409], ["the cap0 binding pocket", "PROBLEM", 430, 453], ["viral genome", "OBSERVATION", 298, 310]]], ["We initially ensured that the substitution mutations did not adversely hamper the upstream activity of the other domains and that the domains acted discretely as predicted.", [["the substitution mutations", "PROBLEM", 26, 52]]], ["Since autoguanylation and guanylyltransferase reactions are the basis for all the downstream catalytic activities of VP4 and essential for initiating the cap methylation pathway, any interruption of these reactions would prevent the methylation of the transcripts.", [["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 26, 45], ["VP4", "GENE_OR_GENE_PRODUCT", 117, 120], ["VP4", "PROTEIN", 117, 120], ["guanylyltransferase reactions", "PROBLEM", 26, 55], ["VP4", "PROBLEM", 117, 120], ["the cap methylation pathway", "TREATMENT", 150, 177], ["these reactions", "PROBLEM", 199, 214]]], ["When examined in vitro, the mutations in either the catalytic K-D-K-E tetrad or surrounding residues were still capable of the upstream catalytic activities including autoguanylation and guanylyltransferase highlighting that the activities of these domains are most likely to be separate from 2 0 -O MT domain.", [["K", "CHEMICAL", 62, 63], ["guanylyltransferase", "SIMPLE_CHEMICAL", 187, 206], ["catalytic K", "PROTEIN", 52, 63], ["guanylyltransferase", "PROTEIN", 187, 206], ["O MT domain", "PROTEIN", 298, 309], ["the mutations", "PROBLEM", 24, 37], ["surrounding residues", "PROBLEM", 80, 100], ["autoguanylation", "TREATMENT", 167, 182], ["guanylyltransferase", "TREATMENT", 187, 206], ["most likely", "UNCERTAINTY", 261, 272]]], ["The slight decrease in the formation of a stable GMP-VP4 complex exhibited by the single substitution mutation D265 (K-D-K-E) and Y334 (one of the three residues in cap binding pocket) supported the crystal ligand binding data, indicating that the substitutions might have disrupted the interaction with the penultimate 5 0 guanosine of the transcript and G0 base of GTP, respectively.", [["GMP", "CHEMICAL", 49, 52], ["guanosine", "CHEMICAL", 324, 333], ["GTP", "CHEMICAL", 367, 370], ["GMP", "CHEMICAL", 49, 52], ["guanosine", "CHEMICAL", 324, 333], ["GTP", "CHEMICAL", 367, 370], ["GMP-VP4", "GENE_OR_GENE_PRODUCT", 49, 56], ["K-D-K-E", "GENE_OR_GENE_PRODUCT", 117, 124], ["Y334", "AMINO_ACID", 130, 134], ["GTP", "SIMPLE_CHEMICAL", 367, 370], ["GMP", "PROTEIN", 49, 52], ["VP4 complex", "PROTEIN", 53, 64], ["cap binding pocket", "PROTEIN", 165, 183], ["The slight decrease", "PROBLEM", 0, 19], ["a stable GMP-VP4 complex", "PROBLEM", 40, 64], ["the single substitution mutation", "TEST", 78, 110], ["K-D", "TEST", 117, 120], ["the three residues in cap binding pocket", "TREATMENT", 143, 183], ["the crystal ligand binding data", "TEST", 195, 226], ["the substitutions", "PROBLEM", 244, 261], ["slight", "OBSERVATION_MODIFIER", 4, 10], ["decrease", "OBSERVATION_MODIFIER", 11, 19], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["VP4 complex", "OBSERVATION_MODIFIER", 53, 64], ["base", "ANATOMY_MODIFIER", 359, 363]]], ["Unlike the single site specific mutations introduced into rotavirus VP3 that abolished autoguanylation [22] , single and triple amino acid substitution within BTV VP4 did not disrupt other proposed sites of GMP interaction, suggesting that the structural integrity of the protein was maintained.DiscussionAlthough the mutation of the D265 did not affect autoguanylation and guanylyltransferase activity in vitro, the 2 0 -OMTase activity was completely abolished.", [["amino acid", "CHEMICAL", 128, 138], ["GMP", "CHEMICAL", 207, 210], ["amino acid", "CHEMICAL", 128, 138], ["GMP", "CHEMICAL", 207, 210], ["rotavirus VP3", "ORGANISM", 58, 71], ["amino acid", "AMINO_ACID", 128, 138], ["GMP", "SIMPLE_CHEMICAL", 207, 210], ["guanylyltransferase", "SIMPLE_CHEMICAL", 374, 393], ["2 0 -OMTase", "SIMPLE_CHEMICAL", 417, 428], ["rotavirus VP3", "PROTEIN", 58, 71], ["BTV VP4", "PROTEIN", 159, 166], ["D265", "DNA", 334, 338], ["guanylyltransferase", "PROTEIN", 374, 393], ["BTV", "SPECIES", 159, 162], ["the single site specific mutations", "PROBLEM", 7, 41], ["rotavirus VP3", "TREATMENT", 58, 71], ["triple amino acid substitution", "TREATMENT", 121, 151], ["BTV VP4", "PROBLEM", 159, 166], ["GMP interaction", "PROBLEM", 207, 222], ["GMP interaction", "OBSERVATION", 207, 222]]], ["It was not surprising, as similar results have been reported for mutation of the aspartic residue for many class I AdoMet-dependent methyltransferases [1, 13, 26, 34] .", [["AdoMet", "CHEMICAL", 115, 121], ["AdoMet", "CHEMICAL", 115, 121], ["AdoMet", "SIMPLE_CHEMICAL", 115, 121], ["class I AdoMet-dependent methyltransferases", "PROTEIN", 107, 150], ["the aspartic residue", "PROBLEM", 77, 97]]], ["The D265 residue of VP4 is closely aligned to the residues bound to AdoMet and the guanosine of Cap0 [33] highlighting its importance for 2 0 -O MTase catalytic activity.", [["AdoMet", "CHEMICAL", 68, 74], ["guanosine", "CHEMICAL", 83, 92], ["AdoMet", "CHEMICAL", 68, 74], ["guanosine", "CHEMICAL", 83, 92], ["2 0 -O", "CHEMICAL", 138, 144], ["VP4", "GENE_OR_GENE_PRODUCT", 20, 23], ["AdoMet", "SIMPLE_CHEMICAL", 68, 74], ["guanosine", "SIMPLE_CHEMICAL", 83, 92], ["2 0 -O MTase", "SIMPLE_CHEMICAL", 138, 150], ["VP4", "PROTEIN", 20, 23], ["MTase", "PROTEIN", 145, 150], ["The D265 residue of VP4", "TREATMENT", 0, 23], ["AdoMet", "TREATMENT", 68, 74], ["the guanosine of Cap0", "TREATMENT", 79, 100]]], ["Previous biochemical analysis indicated that methylation of the cap structure by VP4 followed a conventional pathway with N7MTase preceding the 2 0 -O MTase activity [23] .", [["VP4", "GENE_OR_GENE_PRODUCT", 81, 84], ["N7MTase", "SIMPLE_CHEMICAL", 122, 129], ["cap structure", "PROTEIN", 64, 77], ["VP4", "PROTEIN", 81, 84], ["N7MTase", "PROTEIN", 122, 129], ["Previous biochemical analysis", "TEST", 0, 29], ["methylation of the cap structure", "PROBLEM", 45, 77]]], ["As the D265 mutation had abolished the 2 0 -O MTase activity of VP4, it was of interest to investigate whether the activity of the N7MT and 2 0 -O MT domains were independent, unlike what has been reported for flaviviruses [8] .", [["D265", "GENE_OR_GENE_PRODUCT", 7, 11], ["VP4", "GENE_OR_GENE_PRODUCT", 64, 67], ["N7MT", "GENE_OR_GENE_PRODUCT", 131, 135], ["D265", "DNA", 7, 11], ["VP4", "PROTEIN", 64, 67], ["N7MT and 2 0 -O MT domains", "DNA", 131, 157], ["VP4", "PROBLEM", 64, 67], ["flaviviruses", "PROBLEM", 210, 222]]], ["Our results demonstrated that the D265 mutant proteins were able to methylate the cap analogue GpppA (a cap structure that does not occur naturally for BTV), indicating that the N7MT activity had been retained albeit to lower levels than the WT.", [["D265", "GENE_OR_GENE_PRODUCT", 34, 38], ["GpppA", "GENE_OR_GENE_PRODUCT", 95, 100], ["N7MT", "GENE_OR_GENE_PRODUCT", 178, 182], ["D265 mutant proteins", "PROTEIN", 34, 54], ["GpppA", "PROTEIN", 95, 100], ["cap structure", "PROTEIN", 104, 117], ["N7MT", "PROTEIN", 178, 182], ["BTV", "SPECIES", 152, 155], ["the D265 mutant proteins", "PROBLEM", 30, 54], ["the N7MT activity", "PROBLEM", 174, 191]]], ["Although, further validation is required, these results would suggest that as hypothesized, N7MT activity was located in a discrete domain, separated from the 2 0 -O MTase domain.DiscussionThe importance of this residue in the catalytic tetrad of 2 0 -O MTase for virus replication was clear when the same mutations were introduced into the replicating virus.", [["N7MT", "GENE_OR_GENE_PRODUCT", 92, 96], ["2 0 -O MTase", "GENE_OR_GENE_PRODUCT", 247, 259], ["N7MT", "PROTEIN", 92, 96], ["2 0 -O MTase domain", "PROTEIN", 159, 178], ["O MTase", "PROTEIN", 252, 259], ["further validation", "TEST", 10, 28], ["this residue", "PROBLEM", 207, 219], ["virus replication", "TREATMENT", 264, 281], ["the same mutations", "PROBLEM", 297, 315]]], ["The fact that VP4 D265 mutations abolishes the 2 0 O-MTase activity and were lethal for virus replication, highlights the biological significance of this residue and the critical nature of 2 0 O-MT for BTV replication.", [["VP4", "GENE_OR_GENE_PRODUCT", 14, 17], ["O-MT", "GENE_OR_GENE_PRODUCT", 193, 197], ["BTV", "ORGANISM", 202, 205], ["VP4 D265", "PROTEIN", 14, 22], ["MTase", "PROTEIN", 53, 58], ["MT", "PROTEIN", 195, 197], ["BTV", "SPECIES", 202, 205], ["VP4 D265 mutations", "TREATMENT", 14, 32], ["virus replication", "TREATMENT", 88, 105], ["this residue", "PROBLEM", 149, 161], ["BTV replication", "TREATMENT", 202, 217]]], ["The formation of cap1 structure through the use of viral 2 0 -O MTase has been demonstrated to be an essential activity for virus replication for a number of RNA viruses (VSV, Coronavirus, Dengue, WNV, JEV; [1, 5, 7, 16] ).", [["Dengue", "DISEASE", 189, 195], ["cap1", "GENE_OR_GENE_PRODUCT", 17, 21], ["0 -O MTase", "GENE_OR_GENE_PRODUCT", 59, 69], ["VSV", "ORGANISM", 171, 174], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 176, 187], ["Dengue, WNV", "ORGANISM", 189, 200], ["JEV", "ORGANISM", 202, 205], ["cap1 structure", "PROTEIN", 17, 31], ["viral 2 0 -O MTase", "PROTEIN", 51, 69], ["VSV", "SPECIES", 171, 174], ["WNV", "SPECIES", 197, 200], ["JEV", "SPECIES", 202, 205], ["cap1 structure", "PROBLEM", 17, 31], ["viral", "TEST", 51, 56], ["virus replication", "TREATMENT", 124, 141], ["RNA viruses", "PROBLEM", 158, 169], ["VSV", "TEST", 171, 174], ["Coronavirus", "PROBLEM", 176, 187], ["Dengue", "PROBLEM", 189, 195], ["cap1 structure", "OBSERVATION", 17, 31]]], ["Such a drastic effect on virus replication due to a single mutation within the 2 0 -O MTase catalytic domain is not always observed for all viruses, most often only a reduction in the virus titres and growth kinetics has been observed [15, 20] .", [["2 0 -O MTase catalytic domain", "PROTEIN", 79, 108], ["a drastic effect", "PROBLEM", 5, 21], ["virus replication", "TREATMENT", 25, 42], ["a single mutation", "PROBLEM", 50, 67], ["all viruses", "PROBLEM", 136, 147], ["a reduction", "TREATMENT", 165, 176], ["the virus titres", "PROBLEM", 180, 196], ["growth kinetics", "PROBLEM", 201, 216], ["drastic", "OBSERVATION_MODIFIER", 7, 14], ["not always observed", "UNCERTAINTY", 112, 131], ["viruses", "OBSERVATION", 140, 147], ["reduction", "OBSERVATION_MODIFIER", 167, 176], ["virus titres", "OBSERVATION", 184, 196]]], ["There are a number of plausible explanations for the failure to recover BTV mutants in normal cells.", [["cells", "ANATOMY", 94, 99], ["BTV", "ORGANISM", 72, 75], ["cells", "CELL", 94, 99], ["normal cells", "CELL_TYPE", 87, 99], ["BTV", "SPECIES", 72, 75], ["the failure", "PROBLEM", 49, 60], ["BTV mutants in normal cells", "PROBLEM", 72, 99], ["failure", "OBSERVATION", 53, 60], ["normal cells", "OBSERVATION", 87, 99]]], ["It is currently not possible to test these hypotheses as the VP4 used to complement function is assembled into the virions.", [["virions", "ANATOMY", 115, 122], ["VP4", "GENE_OR_GENE_PRODUCT", 61, 64], ["VP4", "PROTEIN", 61, 64], ["the VP4", "PROBLEM", 57, 64], ["not possible", "UNCERTAINTY", 16, 28], ["virions", "ANATOMY", 115, 122]]], ["Unlike the capping enzyme for other viruses which are non-structural (Dengue, alphaviruses, coronaviruses) VP4 is a minor structural protein and therefore the WT VP4 present in the complementary cell line is assembled into the core particle and cannot be dissociated from the virus.DiscussionIt is clear that 2 0 -O MTase must recruit and position the newly synthesized cap0 within the catalytic site for the reaction to occur.", [["cell line", "ANATOMY", 195, 204], ["Dengue", "DISEASE", 70, 76], ["Dengue, alphaviruses", "ORGANISM", 70, 90], ["VP4", "GENE_OR_GENE_PRODUCT", 107, 110], ["WT VP4", "ORGANISM", 159, 165], ["cell line", "CELL", 195, 204], ["2 0 -O MTase", "SIMPLE_CHEMICAL", 309, 321], ["cap0", "GENE_OR_GENE_PRODUCT", 370, 374], ["capping enzyme", "PROTEIN", 11, 25], ["non-structural (Dengue, alphaviruses, coronaviruses) VP4", "PROTEIN", 54, 110], ["minor structural protein", "PROTEIN", 116, 140], ["WT VP4", "PROTEIN", 159, 165], ["complementary cell line", "CELL_LINE", 181, 204], ["O MTase", "PROTEIN", 314, 321], ["cap0", "PROTEIN", 370, 374], ["catalytic site", "PROTEIN", 386, 400], ["the capping enzyme", "TEST", 7, 25], ["other viruses", "PROBLEM", 30, 43], ["non-structural (Dengue", "PROBLEM", 54, 76], ["alphaviruses", "PROBLEM", 78, 90], ["coronaviruses", "PROBLEM", 92, 105], ["VP4", "PROBLEM", 107, 110], ["a minor structural protein", "PROBLEM", 114, 140], ["the WT VP4", "TREATMENT", 155, 165], ["the virus", "PROBLEM", 272, 281], ["the newly synthesized cap0 within the catalytic site", "PROBLEM", 348, 400], ["the reaction", "PROBLEM", 405, 417], ["complementary cell line", "OBSERVATION", 181, 204], ["cannot be", "UNCERTAINTY", 245, 254], ["virus", "OBSERVATION", 276, 281]]], ["We postulated that a disruption of the residues forming the substrate/cap binding pocket would have an effect on the overall function of the domain.", [["cap binding pocket", "PROTEIN", 70, 88], ["the residues", "PROBLEM", 35, 47], ["the substrate/cap binding pocket", "TREATMENT", 56, 88], ["cap", "OBSERVATION_MODIFIER", 70, 73], ["binding pocket", "OBSERVATION", 74, 88]]], ["The ligand interactions studies with VP4 [33] enabled us to identify three residues that may be involved in binding the cap0 and/or its recruitment.", [["cap0", "GENE_OR_GENE_PRODUCT", 120, 124], ["cap0", "PROTEIN", 120, 124], ["The ligand interactions studies", "TEST", 0, 31], ["VP4", "TEST", 37, 40]]], ["The substitution of the three residues (N311, Y334, and R367) in the cap binding pocket, whether singly or in combination, retained the upstream cap methylation activities (autoguanylation and guanylyltransferase).", [["guanylyltransferase", "SIMPLE_CHEMICAL", 193, 212], ["cap binding pocket", "PROTEIN", 69, 87], ["guanylyltransferase", "PROTEIN", 193, 212], ["the cap binding pocket", "PROBLEM", 65, 87], ["cap", "OBSERVATION", 69, 72], ["binding pocket", "OBSERVATION", 73, 87]]], ["Initially, the N311 and Y334 residues were hypothesized to interact with the guanosine residue while R367 is in proximity of the m7 of cap0.", [["guanosine", "CHEMICAL", 77, 86], ["R367", "CHEMICAL", 101, 105], ["N311", "CHEMICAL", 15, 19], ["Y334", "CHEMICAL", 24, 28], ["guanosine", "CHEMICAL", 77, 86], ["R367", "CHEMICAL", 101, 105], ["N311", "GENE_OR_GENE_PRODUCT", 15, 19], ["guanosine", "SIMPLE_CHEMICAL", 77, 86], ["R367", "SIMPLE_CHEMICAL", 101, 105], ["cap0", "GENE_OR_GENE_PRODUCT", 135, 139], ["N311 and Y334 residues", "PROTEIN", 15, 37], ["m7", "PROTEIN", 129, 131], ["cap0", "PROTEIN", 135, 139], ["the guanosine residue", "PROBLEM", 73, 94]]], ["Our autoguanylation and m7-GTP data suggest that residue R367 probably interacts with the guanosine residue while N311 interacts with the m7 as also corroborated with the ligand binding data from crystallisation studies [33] .DiscussionIn comparison to the D265 mutation, these mutant proteins exhibited the in vitro 2 0 -O MTase activity albeit at reduced level in comparison to WT VP4.", [["R367", "CHEMICAL", 57, 61], ["guanosine", "CHEMICAL", 90, 99], ["N311", "CHEMICAL", 114, 118], ["guanosine", "CHEMICAL", 90, 99], ["N311", "CHEMICAL", 114, 118], ["m7", "GENE_OR_GENE_PRODUCT", 24, 26], ["R367", "AMINO_ACID", 57, 61], ["guanosine", "SIMPLE_CHEMICAL", 90, 99], ["N311", "SIMPLE_CHEMICAL", 114, 118], ["D265", "GENE_OR_GENE_PRODUCT", 257, 261], ["0 -O MTase", "GENE_OR_GENE_PRODUCT", 319, 329], ["VP4", "GENE_OR_GENE_PRODUCT", 383, 386], ["m7", "PROTEIN", 24, 26], ["m7", "PROTEIN", 138, 140], ["D265", "DNA", 257, 261], ["mutant proteins", "PROTEIN", 278, 293], ["MTase", "PROTEIN", 324, 329], ["WT VP4", "PROTEIN", 380, 386], ["Our autoguanylation and m7-GTP data", "TEST", 0, 35], ["the guanosine residue", "PROBLEM", 86, 107], ["crystallisation studies", "TEST", 196, 219], ["these mutant proteins", "PROBLEM", 272, 293]]], ["Interestingly, mutagenesis of the surrounding three residues, the putative substrate binding pocket, had less drastic effect on virus replication.", [["putative substrate binding pocket", "PROTEIN", 66, 99], ["the putative substrate binding pocket", "PROBLEM", 62, 99], ["virus replication", "TREATMENT", 128, 145], ["binding pocket", "OBSERVATION", 85, 99], ["less", "OBSERVATION_MODIFIER", 105, 109], ["drastic", "OBSERVATION_MODIFIER", 110, 117], ["effect", "OBSERVATION_MODIFIER", 118, 124], ["virus replication", "OBSERVATION", 128, 145]]], ["Only the introduction of the triple mutation resulted in significant effect on in vivo virus replication.", [["the triple mutation", "TREATMENT", 25, 44], ["significant effect", "PROBLEM", 57, 75], ["vivo virus replication", "TREATMENT", 82, 104], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["effect", "OBSERVATION_MODIFIER", 69, 75]]], ["The diminished 2 0 -O MTase activity could have a 2-fold effect on the virus fitness; firstly decreased protein production would result in less virus progeny, and secondly the virus' inability to control the innate immune response.", [["0 -O MTase", "GENE_OR_GENE_PRODUCT", 17, 27], ["MTase", "PROTEIN", 22, 27], ["a 2-fold effect", "PROBLEM", 48, 63], ["the virus fitness", "PROBLEM", 67, 84], ["firstly decreased protein production", "PROBLEM", 86, 122], ["less virus progeny", "PROBLEM", 139, 157], ["the virus' inability", "PROBLEM", 172, 192], ["diminished", "OBSERVATION_MODIFIER", 4, 14], ["virus", "OBSERVATION", 71, 76]]], ["Previously, we and others have shown BTV proteins regulate the innate immune response during infection [25, 31] , lower viral protein production and growth may correspond with a more robust immune response early in infection.DiscussionWe have shown that structure-based rationally-designed mutations within the VP4 2 0 -O MTase domain did not affect the function of the other domains of the protein suggesting that each domain is likely to be functionally segregated.", [["infection", "DISEASE", 93, 102], ["infection", "DISEASE", 215, 224], ["BTV", "ORGANISM", 37, 40], ["BTV proteins", "PROTEIN", 37, 49], ["viral protein", "PROTEIN", 120, 133], ["VP4 2 0 -O MTase domain", "PROTEIN", 311, 334], ["BTV", "SPECIES", 37, 40], ["BTV proteins", "PROBLEM", 37, 49], ["infection", "PROBLEM", 93, 102], ["lower viral protein production", "PROBLEM", 114, 144], ["infection", "PROBLEM", 215, 224], ["designed mutations", "PROBLEM", 281, 299], ["the VP4", "TEST", 307, 314], ["functionally segregated", "PROBLEM", 443, 466], ["infection", "OBSERVATION", 215, 224], ["likely to be", "UNCERTAINTY", 430, 442]]], ["Our genetic and biochemical data demonstrates that mutations in VP4 have a deleterious effect on the kinetics of cap1 synthesis and virus replication.", [["VP4", "GENE_OR_GENE_PRODUCT", 64, 67], ["cap1", "GENE_OR_GENE_PRODUCT", 113, 117], ["VP4", "PROTEIN", 64, 67], ["cap1", "PROTEIN", 113, 117], ["Our genetic and biochemical data", "TEST", 0, 32], ["mutations in VP4", "PROBLEM", 51, 67], ["a deleterious effect", "PROBLEM", 73, 93], ["cap1 synthesis", "TREATMENT", 113, 127], ["virus replication", "TREATMENT", 132, 149], ["deleterious", "OBSERVATION", 75, 86]]], ["Thus, not only is the preservation of the catalytic tetrad important, the positioning the cap0 structure in the catalytic domain is critical for in vitro activity.", [["cap0", "GENE_OR_GENE_PRODUCT", 90, 94], ["cap0 structure", "PROTEIN", 90, 104], ["catalytic domain", "PROTEIN", 112, 128]]], ["The results presented here have contributed our understanding of the role of VP4 in BTV replication and increased our knowledge in mRNA cap methylation for the members of the Reoviridae.", [["VP4", "GENE_OR_GENE_PRODUCT", 77, 80], ["BTV", "ORGANISM", 84, 87], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 175, 185], ["VP4", "PROTEIN", 77, 80], ["BTV", "SPECIES", 84, 87], ["VP4 in BTV replication", "TREATMENT", 77, 99], ["mRNA cap methylation", "TREATMENT", 131, 151], ["the Reoviridae", "TREATMENT", 171, 185]]]], "1842bb195a368132b3f4b433e1b1a71590fdc31e": [["IntroductionOver the last years, the declining health of the honey bee (Apis mellifera) and other pollinators has caused concern all over the world.", [["honey bee", "ORGANISM", 61, 70], ["Apis mellifera", "ORGANISM", 72, 86], ["Apis mellifera", "SPECIES", 72, 86], ["honey bee", "SPECIES", 61, 70], ["Apis mellifera", "SPECIES", 72, 86]]], ["Particularly over the last six years, honey bee health has shown alarming rates of deterioration [1, 2, 3] , questioning the sustainability of our food production system.", [["honey bee", "SPECIES", 38, 47]]], ["There are many possible threats to honey bees health, including pesticides, malnutrition, management stress, and pathogens [3, 4, 5, 6, 7] .IntroductionNumerous studies suggest that novel or emerging pathogens play a role in honey bee health declines [1, 2, 3, 7, 8, 9] .", [["malnutrition", "DISEASE", 76, 88], ["honey bees", "SPECIES", 35, 45], ["honey bee", "SPECIES", 225, 234], ["malnutrition", "PROBLEM", 76, 88], ["management stress", "PROBLEM", 90, 107], ["pathogens", "PROBLEM", 113, 122], ["Numerous studies", "TEST", 152, 168], ["malnutrition", "OBSERVATION", 76, 88]]], ["However, insufficient knowledge on honey bee pathogens compromises our ability to assess their importance and to develop control measures.", [["honey bee", "SPECIES", 35, 44], ["honey bee pathogens", "PROBLEM", 35, 54], ["control measures", "TREATMENT", 121, 137]]], ["This is particularly true for honey bee viruses although their importance for honey bee losses has become evident in recent years [6, 7, 8, 10, 11, 12] .", [["honey bee losses", "DISEASE", 78, 94], ["honey", "ORGANISM", 30, 35], ["honey bee viruses", "SPECIES", 30, 47], ["honey bee", "SPECIES", 78, 87], ["honey bee viruses", "PROBLEM", 30, 47], ["honey bee losses", "PROBLEM", 78, 94]]], ["Specifically in combination with the ectoparasitic bee mite Varroa destructor [13, 14, 15 ] that serves as a vector, several viruses appear to become more virulent [16, 17, 18] .", [["Varroa destructor", "ORGANISM", 60, 77], ["Varroa destructor", "SPECIES", 60, 77], ["Varroa destructor", "SPECIES", 60, 77], ["several viruses", "PROBLEM", 117, 132]]], ["Viruses may cause covert infections [19] and were considered mostly harmless until Varroa mites were introduced to A. mellifera populations almost 30 years ago [20, 21, 22] .", [["infections", "DISEASE", 25, 35], ["A. mellifera", "ORGANISM", 115, 127], ["A. mellifera", "SPECIES", 115, 127], ["A. mellifera", "SPECIES", 115, 127], ["Viruses", "PROBLEM", 0, 7], ["covert infections", "PROBLEM", 18, 35], ["Varroa mites", "PROBLEM", 83, 95]]], ["The increased virulence of viruses has been confirmed experimentally by direct inoculation of bees with viruses [23, 24, 25, 26, 27] , opening an important research field to explore.IntroductionApproximately twenty honey bee viruses have been described so far [4, 16, 28, 29] , affecting the morphology, physiology, and behavior of bees.", [["honey bee viruses", "SPECIES", 215, 232], ["The increased virulence of viruses", "PROBLEM", 0, 34], ["viruses", "PROBLEM", 104, 111], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["virulence", "OBSERVATION_MODIFIER", 14, 23], ["viruses", "OBSERVATION", 27, 34]]], ["Most belong to the families Dicistroviridae [30] and Iflaviridae in the order Picornavirales.", [["the families Dicistroviridae", "TREATMENT", 15, 43], ["Iflaviridae", "TREATMENT", 53, 64]]], ["Viruses in these families have a positive sense RNA genome, covered by an icosahedral, pseudo T = 3 structure symmetry capsid (around 30 nm) that is responsible for RNA protection, host specificity, and tissue infection.", [["tissue", "ANATOMY", 203, 209], ["infection", "DISEASE", 210, 219], ["tissue", "TISSUE", 203, 209], ["positive sense RNA genome", "DNA", 33, 58], ["Viruses", "PROBLEM", 0, 7], ["a positive sense RNA genome", "PROBLEM", 31, 58], ["RNA protection", "TREATMENT", 165, 179], ["tissue infection", "PROBLEM", 203, 219], ["positive", "OBSERVATION_MODIFIER", 33, 41], ["sense RNA genome", "OBSERVATION", 42, 58], ["symmetry", "OBSERVATION_MODIFIER", 110, 118], ["capsid", "OBSERVATION_MODIFIER", 119, 125], ["responsible for", "UNCERTAINTY", 149, 164], ["RNA protection", "OBSERVATION", 165, 179], ["tissue", "ANATOMY", 203, 209], ["infection", "OBSERVATION", 210, 219]]], ["Picornaviruses are well known for their capacity to shut off the translational system of their host cells, by cleavage of translation factors leading to a decrease in cap-dependent host translation, a conserved replication strategy among all members studied to date [31, 32] .", [["cells", "ANATOMY", 100, 105], ["host cells", "CELL", 95, 105], ["cap-", "GENE_OR_GENE_PRODUCT", 167, 171], ["host cells", "CELL_TYPE", 95, 105], ["translation factors", "PROTEIN", 122, 141], ["Picornaviruses", "PROBLEM", 0, 14], ["their capacity", "PROBLEM", 34, 48], ["translation factors", "PROBLEM", 122, 141], ["a decrease in cap-dependent host translation", "PROBLEM", 153, 197], ["decrease", "OBSERVATION_MODIFIER", 155, 163]]], ["Picornavirus infection also triggers hostimmune responses (i.e., PKR) that result in decreased capdependent (host) translation.", [["infection", "DISEASE", 13, 22], ["PKR", "GENE_OR_GENE_PRODUCT", 65, 68], ["PKR", "PROTEIN", 65, 68], ["Picornavirus infection", "PROBLEM", 0, 22], ["infection", "OBSERVATION", 13, 22], ["decreased", "OBSERVATION_MODIFIER", 85, 94]]], ["Picornaviruses circumvent this immune response by encoding an internal ribosomal entry site (IRES) which is recognized and translated by the host machinery (non-canonical translation) [30, 32] .", [["ribosomal", "ANATOMY", 71, 80], ["ribosomal", "CELLULAR_COMPONENT", 71, 80], ["internal ribosomal entry site", "DNA", 62, 91], ["IRES", "DNA", 93, 97], ["Picornaviruses", "TREATMENT", 0, 14], ["internal", "OBSERVATION_MODIFIER", 62, 70], ["ribosomal entry", "OBSERVATION", 71, 86]]], ["Over time, the accumulation of produced virus particles and repression of the synthesis of essential cell components lead to cell death in most cases [32] .IntroductionLittle is known about the specific biology of the viruses in these families that infect honey bees, although they contain important bee pathogens, such as Deformed Wing Virus (DWV) and Israeli Acute Paralysis Virus (IAPV).", [["cell", "ANATOMY", 101, 105], ["cell", "ANATOMY", 125, 129], ["death", "DISEASE", 130, 135], ["Deformed Wing Virus (DWV)", "DISEASE", 323, 348], ["Acute Paralysis Virus", "DISEASE", 361, 382], ["cell", "CELL", 101, 105], ["cell", "CELL", 125, 129], ["honey bees", "ORGANISM", 256, 266], ["Deformed Wing Virus", "ORGANISM", 323, 342], ["DWV", "ORGANISM", 344, 347], ["Israeli Acute Paralysis Virus", "ORGANISM", 353, 382], ["honey bees", "SPECIES", 256, 266], ["Deformed Wing Virus", "SPECIES", 323, 342], ["DWV", "SPECIES", 344, 347], ["Israeli Acute Paralysis Virus", "SPECIES", 353, 382], ["IAPV", "SPECIES", 384, 388], ["produced virus particles", "PROBLEM", 31, 55], ["essential cell components", "PROBLEM", 91, 116], ["cell death", "PROBLEM", 125, 135], ["Deformed Wing Virus", "PROBLEM", 323, 342], ["Israeli Acute Paralysis Virus", "PROBLEM", 353, 382], ["virus particles", "OBSERVATION", 40, 55], ["essential cell", "OBSERVATION", 91, 105], ["viruses", "OBSERVATION", 218, 225], ["Acute", "OBSERVATION_MODIFIER", 361, 366], ["Paralysis", "OBSERVATION", 367, 376]]], ["IAPV has previously been associated with the unusual honey bee disappearance syndrome called Colony Collapse Disorder (CCD) [8] and is frequently seen in many honey bee pathogen surveys [6, 7] .", [["IAPV", "CHEMICAL", 0, 4], ["honey bee disappearance syndrome", "DISEASE", 53, 85], ["Colony Collapse Disorder", "DISEASE", 93, 117], ["IAPV", "GENE_OR_GENE_PRODUCT", 0, 4], ["IAPV", "PROTEIN", 0, 4], ["IAPV", "SPECIES", 0, 4], ["honey bee", "SPECIES", 159, 168], ["the unusual honey bee disappearance syndrome", "PROBLEM", 41, 85], ["Colony Collapse Disorder", "PROBLEM", 93, 117], ["honey bee", "OBSERVATION", 53, 62], ["disappearance syndrome", "OBSERVATION", 63, 85], ["Colony Collapse", "OBSERVATION", 93, 108]]], ["Despite the importance of IAPV and the feasibility to work with IAPV in the laboratory [25, 33] , little is known about IAPV's interactions with its host and resulting pathogenesis.IntroductionIn general, the lack of adequate tools for honey bee virus research has hampered our understanding of basic biology of the relevant viruses and little is known about the molecular bases of honey bee viruses replication and pathogenesis [18, 28] .", [["IAPV", "GENE_OR_GENE_PRODUCT", 26, 30], ["IAPV", "GENE_OR_GENE_PRODUCT", 120, 124], ["honey bee virus", "ORGANISM", 236, 251], ["honey bee", "ORGANISM", 382, 391], ["IAPV", "PROTEIN", 26, 30], ["honey bee virus", "SPECIES", 236, 251], ["honey bee viruses", "SPECIES", 382, 399], ["IAPV", "TREATMENT", 26, 30], ["resulting pathogenesis", "PROBLEM", 158, 180], ["honey bee virus", "TREATMENT", 236, 251], ["the relevant viruses", "PROBLEM", 312, 332], ["viruses", "OBSERVATION", 325, 332], ["bases", "ANATOMY_MODIFIER", 373, 378], ["honey bee viruses", "OBSERVATION", 382, 399]]], ["Therefore, many assumptions regarding their replication are made based on other picornaviruses (e.g., cricket paralysis virus [34, 35] and human poliovirus [32] ), highlighting the need of specific, mechanistic studies on honey bee viruses [36] .", [["paralysis", "DISEASE", 110, 119], ["cricket paralysis virus", "ORGANISM", 102, 125], ["human", "ORGANISM", 139, 144], ["poliovirus", "ORGANISM", 145, 155], ["honey bee", "ORGANISM", 222, 231], ["human", "SPECIES", 139, 144], ["cricket paralysis virus", "SPECIES", 102, 125], ["human", "SPECIES", 139, 144], ["honey bee viruses", "SPECIES", 222, 239], ["other picornaviruses", "PROBLEM", 74, 94], ["cricket paralysis virus", "PROBLEM", 102, 125], ["human poliovirus", "PROBLEM", 139, 155]]], ["Focusing on IAPV, we report here the development of an inoculation method of invitro reared honey bee worker pupae that provides the basis for mechanistic, in-depth studies of honey bee viruses.", [["honey", "ORGANISM", 176, 181], ["honey bee", "SPECIES", 92, 101], ["honey bee viruses", "SPECIES", 176, 193], ["honey bee viruses", "OBSERVATION", 176, 193]]], ["We report acute but variable disease symptoms, compare viral replication among pupae of two colonies and patrilines within these colonies, and report on measures of gene expression in response to viral infection that indicate major disruption of cellular homeostasis.Virus Preparation, Quantification and Electron MicroscopyInitially, approximately 20 adult bees from a heavily IAPVinfected colony were frozen in liquid nitrogen, ground to a fine powder, and homogenized in 10 ml extraction buffer (0.1 M potassium phosphate buffer, pH 7.5, 0.2% diethyldithiocarbamate, 1/5 volume of diethyl ether).", [["colonies", "ANATOMY", 92, 100], ["colonies", "ANATOMY", 129, 137], ["cellular", "ANATOMY", 246, 254], ["colony", "ANATOMY", 391, 397], ["viral infection", "DISEASE", 196, 211], ["potassium phosphate", "CHEMICAL", 505, 524], ["diethyldithiocarbamate", "CHEMICAL", 546, 568], ["diethyl ether", "CHEMICAL", 584, 597], ["nitrogen", "CHEMICAL", 420, 428], ["potassium phosphate", "CHEMICAL", 505, 524], ["diethyldithiocarbamate", "CHEMICAL", 546, 568], ["diethyl ether", "CHEMICAL", 584, 597], ["cellular", "CELL", 246, 254], ["potassium", "SIMPLE_CHEMICAL", 505, 514], ["diethyldithiocarbamate", "SIMPLE_CHEMICAL", 546, 568], ["diethyl ether", "SIMPLE_CHEMICAL", 584, 597], ["variable disease symptoms", "PROBLEM", 20, 45], ["viral replication", "PROBLEM", 55, 72], ["two colonies and patrilines within these colonies", "PROBLEM", 88, 137], ["gene expression", "PROBLEM", 165, 180], ["viral infection", "PROBLEM", 196, 211], ["cellular homeostasis", "PROBLEM", 246, 266], ["Virus Preparation", "TREATMENT", 267, 284], ["a heavily IAPVinfected colony", "PROBLEM", 368, 397], ["liquid nitrogen", "TREATMENT", 413, 428], ["a fine powder", "TREATMENT", 440, 453], ["potassium phosphate buffer", "TREATMENT", 505, 531], ["pH", "TEST", 533, 535], ["diethyl ether", "TREATMENT", 584, 597], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["variable", "OBSERVATION_MODIFIER", 20, 28], ["disease", "OBSERVATION", 29, 36], ["viral infection", "OBSERVATION", 196, 211], ["cellular homeostasis", "OBSERVATION", 246, 266]]], ["Emulsification ensued by adding 5 ml carbon tetrachloride and centrifuging at 10,000 rpm for at 4uC for 10 minutes (Rotor: Sorvall RC-5B) and collecting the supernatant.Virus Preparation, Quantification and Electron MicroscopyThe supernatant containing viruses was filtered through a 0.2micron filter (milex-GS, Millipore, #SLGS033SS) to remove small tissue debris, fungi, and bacteria.", [["supernatant", "ANATOMY", 157, 168], ["supernatant", "ANATOMY", 230, 241], ["tissue debris", "ANATOMY", 351, 364], ["carbon tetrachloride", "CHEMICAL", 37, 57], ["carbon tetrachloride", "CHEMICAL", 37, 57], ["carbon tetrachloride", "SIMPLE_CHEMICAL", 37, 57], ["tissue", "TISSUE", 351, 357], ["5 ml carbon tetrachloride", "TREATMENT", 32, 57], ["Virus Preparation", "TREATMENT", 169, 186], ["Electron Microscopy", "TEST", 207, 226], ["The supernatant containing viruses", "PROBLEM", 226, 260], ["a 0.2micron filter", "TREATMENT", 282, 300], ["small tissue debris", "PROBLEM", 345, 364], ["fungi", "PROBLEM", 366, 371], ["bacteria", "PROBLEM", 377, 385], ["viruses", "OBSERVATION", 253, 260], ["small tissue", "ANATOMY", 345, 357], ["debris", "OBSERVATION", 358, 364], ["bacteria", "OBSERVATION_MODIFIER", 377, 385]]], ["The filtrate was then centrifuged at 30,000 rpm (61,740 RCF) in a Beckman LB-70M ultracentrifuge with a 70.1/Ti rotor for six hours at 4uC to pellet picornavirus particles.", [["Ti", "CHEMICAL", 109, 111], ["4uC", "SIMPLE_CHEMICAL", 135, 138], ["The filtrate", "TREATMENT", 0, 12], ["a Beckman LB", "TEST", 64, 76], ["a 70.1/Ti rotor", "TREATMENT", 102, 117], ["filtrate", "OBSERVATION", 4, 12], ["picornavirus particles", "OBSERVATION", 149, 171]]], ["The pellet was resuspended in 0.2 ml of PBS and centrifuged against a CsCl gradient (0.44 g/ml) at 52,000 rpm (185,000 RFC) overnight (Beckman LB-70M ultracentrifuge, 70.1/Ti rotor).", [["pellet", "ANATOMY", 4, 10], ["CsCl", "CHEMICAL", 70, 74], ["CsCl", "CHEMICAL", 70, 74], ["The pellet", "TREATMENT", 0, 10], ["PBS", "TREATMENT", 40, 43], ["a CsCl gradient", "TREATMENT", 68, 83], ["RFC", "TEST", 119, 122]]], ["The fractions containing virus particles were dialyzed using ''Slide-A-Lyzer Dialysis Cassettes'' against cold (10uC) 0.2 ml of PBS overnight.", [["fractions", "ANATOMY", 4, 13], ["The fractions containing virus particles", "PROBLEM", 0, 40], ["Slide-A-Lyzer Dialysis Cassettes", "TREATMENT", 63, 95], ["cold (10uC)", "TREATMENT", 106, 117], ["PBS", "TREATMENT", 128, 131], ["virus particles", "OBSERVATION", 25, 40]]], ["RT-PCR was conducted to test for the presence of Acute Bee Paralysis Virus (ABPV), Israel Acute Paralysis Virus (IAPV), Kashmir Bee virus (KBV), Sacbrood virus (SBV), Chronic Bee Paralysis Virus (CBPV), Black Queen Cell Virus (BQCV), and Deformed Wing Virus (DWV).", [["Bee Paralysis", "DISEASE", 55, 68], ["Acute Paralysis", "DISEASE", 90, 105], ["Chronic Bee Paralysis", "DISEASE", 167, 188], ["Acute Bee Paralysis Virus", "ORGANISM", 49, 74], ["ABPV", "ORGANISM", 76, 80], ["Israel Acute Paralysis Virus", "ORGANISM", 83, 111], ["Kashmir Bee virus", "ORGANISM", 120, 137], ["KBV", "ORGANISM", 139, 142], ["Sacbrood virus", "ORGANISM", 145, 159], ["SBV", "ORGANISM", 161, 164], ["Bee Paralysis Virus", "ORGANISM", 175, 194], ["Queen Cell Virus", "ORGANISM", 209, 225], ["Deformed Wing Virus", "ORGANISM", 238, 257], ["Kashmir Bee virus", "SPECIES", 120, 137], ["Sacbrood virus", "SPECIES", 145, 159], ["Acute Bee Paralysis Virus", "SPECIES", 49, 74], ["ABPV", "SPECIES", 76, 80], ["Israel Acute Paralysis Virus", "SPECIES", 83, 111], ["IAPV", "SPECIES", 113, 117], ["Kashmir Bee virus", "SPECIES", 120, 137], ["KBV", "SPECIES", 139, 142], ["Sacbrood virus", "SPECIES", 145, 159], ["SBV", "SPECIES", 161, 164], ["Chronic Bee Paralysis Virus", "SPECIES", 167, 194], ["CBPV", "SPECIES", 196, 200], ["Black Queen Cell Virus", "SPECIES", 203, 225], ["BQCV", "SPECIES", 227, 231], ["Deformed Wing Virus (DWV", "SPECIES", 238, 262], ["RT-PCR", "TEST", 0, 6], ["Acute Bee Paralysis Virus", "PROBLEM", 49, 74], ["Israel Acute Paralysis Virus (IAPV)", "PROBLEM", 83, 118], ["Kashmir Bee virus", "PROBLEM", 120, 137], ["KBV", "TEST", 139, 142], ["Sacbrood virus (SBV)", "PROBLEM", 145, 165], ["Chronic Bee Paralysis Virus (CBPV)", "PROBLEM", 167, 201], ["Black Queen Cell Virus", "PROBLEM", 203, 225], ["Deformed Wing Virus", "PROBLEM", 238, 257], ["Acute", "OBSERVATION_MODIFIER", 49, 54], ["Paralysis", "OBSERVATION", 59, 68], ["Acute", "OBSERVATION_MODIFIER", 90, 95], ["Paralysis", "OBSERVATION", 96, 105], ["Chronic", "OBSERVATION_MODIFIER", 167, 174], ["Paralysis", "OBSERVATION", 179, 188], ["Cell Virus", "OBSERVATION", 215, 225], ["Deformed", "OBSERVATION", 238, 246]]], ["IAPV, and small amounts of ABPV, DWV, and BQCV were detected in the purified viral solution (positive amplification with PCR primers).", [["IAPV", "GENE_OR_GENE_PRODUCT", 0, 4], ["ABPV", "GENE_OR_GENE_PRODUCT", 27, 31], ["DWV", "ORGANISM", 33, 36], ["BQCV", "GENE_OR_GENE_PRODUCT", 42, 46], ["ABPV", "PROTEIN", 27, 31], ["PCR primers", "DNA", 121, 132], ["ABPV", "SPECIES", 27, 31], ["DWV", "SPECIES", 33, 36], ["BQCV", "SPECIES", 42, 46], ["IAPV", "TEST", 0, 4], ["small amounts of ABPV, DWV, and BQCV", "PROBLEM", 10, 46], ["PCR primers", "TREATMENT", 121, 132], ["small", "OBSERVATION_MODIFIER", 10, 15], ["amounts", "OBSERVATION_MODIFIER", 16, 23]]], ["Viral quantification was performed by absolute quantification using the Standard Curve Method as described previously [37] [38] .", [["Viral quantification", "TEST", 0, 20], ["the Standard Curve Method", "TREATMENT", 68, 93]]], ["5.0 ml of viral solution was examined for the presence of virus particles and their phenomenological characterization by electron microscopy.", [["viral solution", "TREATMENT", 10, 24], ["virus particles", "PROBLEM", 58, 73], ["their phenomenological characterization", "TEST", 78, 117], ["electron microscopy", "TEST", 121, 140]]], ["Virus particles were negatively stained with 2% Uranyl Acetate on a formvar-coated Ni grid and viewed in a Hitachi H-7000 electron microscope at 150,000X to 200,000X.Virus Preparation, Quantification and Electron MicroscopyIAPV replicates readily in pupae [25] .", [["Uranyl Acetate", "CHEMICAL", 48, 62], ["Uranyl Acetate", "CHEMICAL", 48, 62], ["Ni", "CHEMICAL", 83, 85], ["Virus", "ORGANISM", 0, 5], ["Uranyl", "SIMPLE_CHEMICAL", 48, 54], ["Acetate", "SIMPLE_CHEMICAL", 55, 62], ["formvar", "SIMPLE_CHEMICAL", 68, 75], ["Virus", "ORGANISM", 166, 171], ["Virus particles", "PROBLEM", 0, 15], ["2% Uranyl Acetate", "TREATMENT", 45, 62], ["a formvar-coated Ni grid", "TREATMENT", 66, 90], ["a Hitachi H", "TEST", 105, 116], ["electron microscope", "TEST", 122, 141], ["Virus Preparation", "TREATMENT", 166, 183]]], ["Therefore, white-eyed pupae were inoculated for virus propagation, using 1.0 ml of the viral suspension per pupa.", [["white-eyed pupae", "TREATMENT", 11, 27], ["virus propagation", "TREATMENT", 48, 65], ["the viral suspension", "TREATMENT", 83, 103]]], ["After 4 days of incubation, with disease symptoms apparent (Figure 1 ), viruses were purified using the approach outlined above. qRT-PCR showed ,10 5 more IAPV genomes than the second most detected virus, DWV after a single round of virus injection pupal amplification, and isolation.", [["DWV", "DISEASE", 205, 208], ["IAPV genomes", "DNA", 155, 167], ["DWV", "SPECIES", 205, 208], ["incubation", "TREATMENT", 16, 26], ["disease symptoms", "PROBLEM", 33, 49], ["viruses", "PROBLEM", 72, 79], ["qRT-PCR", "TEST", 129, 136], ["virus injection pupal amplification", "TREATMENT", 233, 268], ["isolation", "TREATMENT", 274, 283]]], ["This procedure was repeated twice using pupae from very strong hives to further reduce contaminating viruses and increase the amounts of IAPV.", [["IAPV", "GENE_OR_GENE_PRODUCT", 137, 141], ["IAPV", "PROTEIN", 137, 141], ["This procedure", "TREATMENT", 0, 14], ["pupae", "TREATMENT", 40, 45], ["very strong hives", "PROBLEM", 51, 68], ["contaminating viruses", "PROBLEM", 87, 108], ["IAPV", "TREATMENT", 137, 141], ["amounts", "OBSERVATION_MODIFIER", 126, 133]]], ["The high concentration of IAPV over other honey bee viruses in these purifications allowed us to strongly dilute the inoculum, decreasing the chances of cross inoculation with another virus.", [["IAPV", "CHEMICAL", 26, 30], ["IAPV", "GENE_OR_GENE_PRODUCT", 26, 30], ["honey bee", "ORGANISM", 42, 51], ["honey bee viruses", "SPECIES", 42, 59], ["The high concentration of IAPV", "PROBLEM", 0, 30], ["the inoculum", "PROBLEM", 113, 125], ["cross inoculation", "PROBLEM", 153, 170], ["another virus", "PROBLEM", 176, 189], ["high", "OBSERVATION_MODIFIER", 4, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22], ["viruses", "OBSERVATION", 52, 59], ["inoculum", "OBSERVATION", 117, 125]]], ["In the experiments described below, we injected 10 4 IAPV genome equivalents keeping the probability of cross contamination at negligible levels.RNA Extraction and qPCR ParametersPupae were individually homogenized and submitted to total RNA extraction, using TRIzolH (Invitrogen, Carlsbad CA) following the manufacturer's protocol.", [["cross contamination at negligible levels", "PROBLEM", 104, 144], ["RNA Extraction", "TREATMENT", 145, 159], ["total RNA extraction", "TREATMENT", 232, 252], ["TRIzolH (Invitrogen, Carlsbad CA", "TREATMENT", 260, 292], ["the manufacturer's protocol", "TREATMENT", 304, 331]]], ["The resultant RNA pellets were resuspended in diethyl pyrocarbonate-treated water in the presence of RNase inhibitor (Invitrogen, Carlsbad CA) and treated with DNase I (Invitrogen, Carlsbad CA) to remove any contaminating DNA.", [["diethyl pyrocarbonate", "CHEMICAL", 46, 67], ["diethyl pyrocarbonate", "CHEMICAL", 46, 67], ["diethyl", "SIMPLE_CHEMICAL", 46, 53], ["pyrocarbonate", "SIMPLE_CHEMICAL", 54, 67], ["RNase", "GENE_OR_GENE_PRODUCT", 101, 106], ["Carlsbad CA", "ORGANISM", 130, 141], ["DNase I", "GENE_OR_GENE_PRODUCT", 160, 167], ["Carlsbad CA", "ORGANISM", 181, 192], ["DNA", "CELLULAR_COMPONENT", 222, 225], ["RNase", "PROTEIN", 101, 106], ["DNase I", "PROTEIN", 160, 167], ["The resultant RNA pellets", "TREATMENT", 0, 25], ["diethyl pyrocarbonate", "TREATMENT", 46, 67], ["RNase inhibitor", "TREATMENT", 101, 116], ["Invitrogen", "TREATMENT", 118, 128], ["Carlsbad CA", "TREATMENT", 130, 141], ["DNase I (Invitrogen, Carlsbad CA", "TREATMENT", 160, 192], ["any contaminating DNA", "PROBLEM", 204, 225], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["RNA pellets", "OBSERVATION", 14, 25]]], ["The resulting RNA was quantified on a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE).", [["The resulting RNA", "PROBLEM", 0, 17], ["a Nanodrop spectrophotometer", "TREATMENT", 36, 64], ["RNA", "OBSERVATION", 14, 17]]], ["First-strand cDNA was then synthesized by incubating 2mg of total RNA per sample in a 96-well plate with master mix containing 50 U Superscript II (Invitrogen, Carlsbad, CA), 2 nmol dNTP mix, 2 nmol poly(dT)18, and 0.1 nmol poly (dT) (12) (13) (14) (15) (16) (17) (18) at 42uC for 50 minutes followed by 15 minutes at 70uC as described previously [39] .", [["dNTP", "CHEMICAL", 182, 186], ["poly(dT", "CHEMICAL", 199, 206], ["poly (dT", "CHEMICAL", 224, 232], ["dNTP", "CHEMICAL", 182, 186], ["poly(dT)18", "CHEMICAL", 199, 209], ["poly (dT) (12) (13) (14) (15) (16)", "CHEMICAL", 224, 258], ["Carlsbad, CA", "ORGANISM", 160, 172], ["poly (dT) (12) (13) (14) (15) (16) (17) (18)", "SIMPLE_CHEMICAL", 224, 268], ["-strand cDNA", "DNA", 5, 17], ["First-strand cDNA", "TREATMENT", 0, 17], ["total RNA", "TREATMENT", 60, 69], ["master mix", "TREATMENT", 105, 115], ["CA", "TEST", 170, 172], ["2 nmol dNTP mix", "TREATMENT", 175, 190], ["2 nmol poly(dT)", "TREATMENT", 192, 207], ["nmol poly (dT)", "TEST", 219, 233]]], ["The cDNA was diluted 1:5 with molecular-grade water.RNA Extraction and qPCR ParametersThe primers used in this study were validated for relative quantification of the target genes and are commonly used in honey bees [39, 40, 41] .", [["cDNA", "DNA", 4, 8], ["target genes", "DNA", 167, 179], ["honey bees", "SPECIES", 205, 215], ["The cDNA", "TREATMENT", 0, 8], ["RNA Extraction", "TREATMENT", 52, 66], ["qPCR Parameters", "TEST", 71, 86], ["The primers", "TREATMENT", 86, 97], ["this study", "TEST", 106, 116]]], ["Reactions to amplify the cDNA products were conducted in 96-well plates using the Applied Biosystems Step One Real Time PCR machine (Applied Biosystems, Carlsbad, California).", [["cDNA products", "DNA", 25, 38], ["the cDNA products", "TREATMENT", 21, 38], ["the Applied Biosystems Step", "TREATMENT", 78, 105]]], ["One microliter of diluted cDNA from each sample was used as a template for RT-qPCR reactions using SYBR Green TM (Applied Biosystems, Carlsbad, California) following the manufacturer's protocols.", [["sample", "ANATOMY", 41, 47], ["diluted cDNA", "DNA", 18, 30], ["diluted cDNA", "TREATMENT", 18, 30], ["a template", "TREATMENT", 60, 70], ["RT-qPCR reactions", "TREATMENT", 75, 92], ["the manufacturer's protocols", "TREATMENT", 166, 194]]], ["The reactions were conducted under a fixed thermal protocol consisting of 3 minutes at 95uC, followed by 40 cycles of a three-step protocol of 95uC for 20 sec, 60uC for 30 sec, 72uC for 1 minute.", [["95uC", "CHEMICAL", 143, 147], ["a fixed thermal protocol", "TREATMENT", 35, 59], ["a three-step protocol", "TREATMENT", 118, 139]]], ["Fluorescence measurements were taken at each cycle during the last 72uC step.", [["Fluorescence measurements", "TEST", 0, 25]]], ["This procedure was followed by a melt-curve dissociation analysis to confirm the specificity of the reactions.Experimental DesignBased on the results of the preliminary experiments 1 and 2 (Preliminary Experiments S1), a more extensive IAPV inoculation experiment was designed to study the time line of infection and associated gene expression patterns, and to assess bees for variability in IAPV susceptibility.Experimental DesignOne microliter of the inoculant (PBS as control or virus solution containing 10 4 genome equivalents of IAPV) was injected using a NanoJet TM syringe pump (Chemix, USA) with an infusion flow rate of 0.1ml/sec, following manufacturer's parameters.", [["infection", "DISEASE", 303, 312], ["IAPV", "CANCER", 392, 396], ["IAPV", "SPECIES", 392, 396], ["This procedure", "TREATMENT", 0, 14], ["a melt-curve dissociation analysis", "TEST", 31, 65], ["the reactions", "PROBLEM", 96, 109], ["a more extensive IAPV inoculation experiment", "PROBLEM", 219, 263], ["infection", "PROBLEM", 303, 312], ["associated gene expression patterns", "PROBLEM", 317, 352], ["variability in IAPV susceptibility", "PROBLEM", 377, 411], ["Experimental DesignOne microliter of the inoculant (PBS as control or virus solution", "TREATMENT", 412, 496], ["IAPV)", "TREATMENT", 535, 540], ["a NanoJet TM syringe pump", "TREATMENT", 560, 585], ["an infusion flow rate", "TREATMENT", 605, 626], ["manufacturer's parameters", "TEST", 651, 676], ["infection", "OBSERVATION", 303, 312], ["IAPV susceptibility", "OBSERVATION", 392, 411]]], ["The needle was inserted in the lateral abdomen between the fourth and fifth tergite of young, white-eye honey bee pupae ( Figure 2A ).Experimental DesignTwo strong, IAPV-free hives were selected from the UNCG research apiary, representing two distinct sources of bees for the experiment.", [["lateral abdomen", "ANATOMY", 31, 46], ["lateral abdomen", "ORGAN", 31, 46], ["The needle", "TREATMENT", 0, 10], ["free hives", "PROBLEM", 170, 180], ["needle", "OBSERVATION", 4, 10], ["lateral", "ANATOMY_MODIFIER", 31, 38], ["abdomen", "ANATOMY", 39, 46], ["fourth", "ANATOMY_MODIFIER", 59, 65], ["fifth tergite", "ANATOMY_MODIFIER", 70, 83], ["eye", "ANATOMY", 100, 103], ["honey bee pupae", "OBSERVATION", 104, 119], ["strong", "OBSERVATION_MODIFIER", 157, 163]]], ["From each hive, 200 white-eye pupae were collected for each of the following treatment groups: without inoculation (W/O), PBS inoculated (PBS), and IAPV inoculated (IAPV).", [["eye", "ANATOMY", 26, 29], ["IAPV", "CHEMICAL", 148, 152], ["IAPV", "SPECIES", 148, 152], ["IAPV", "SPECIES", 165, 169], ["inoculation", "PROBLEM", 103, 114], ["PBS", "TEST", 122, 125], ["PBS", "TEST", 138, 141], ["IAPV", "TEST", 148, 152], ["eye", "ANATOMY", 26, 29]]], ["From each treatment group and hive, 50 bees were frozen at 0 h, 5 h, 20 h and 48 h after inoculation and a subset of these samples was individually analyzed for viral titers and gene expression patterns.", [["samples", "ANATOMY", 123, 130], ["samples", "CANCER", 123, 130], ["inoculation", "PROBLEM", 89, 100], ["these samples", "TEST", 117, 130], ["viral titers", "PROBLEM", 161, 173], ["gene expression patterns", "PROBLEM", 178, 202]]], ["The first time point directly after inoculation was used as a control of the initial states of the bees in the experimental and control groups.", [["inoculation", "TREATMENT", 36, 47]]], ["The time point of five hours post-infection was chosen to measure the virus impact before completion of the replication cycle, based on the assumption that IAPV follows the picornavirus family average timing for a replication cycle, of 7-12 hours [32, 34, 35] .", [["picornavirus", "ORGANISM", 173, 185], ["IAPV", "PROTEIN", 156, 160], ["the replication cycle", "TREATMENT", 104, 125]]], ["Any gene expression changes at this time point represent the bees' response to inoculation without complications from virus-related tissue damage.", [["tissue", "ANATOMY", 132, 138], ["tissue damage", "DISEASE", 132, 145], ["tissue", "TISSUE", 132, 138], ["Any gene expression changes", "PROBLEM", 0, 27], ["inoculation", "PROBLEM", 79, 90], ["complications", "PROBLEM", 99, 112], ["virus", "PROBLEM", 118, 123], ["tissue damage", "PROBLEM", 132, 145], ["expression", "OBSERVATION", 9, 19], ["related tissue", "OBSERVATION_MODIFIER", 124, 138], ["damage", "OBSERVATION", 139, 145]]], ["The time point of 20 h postinfection was considered representative of events after one complete cycle of virus replication, and the 48 h time point represents the established diseased state, characterized by visual symptoms.Experimental DesignBased on the results of the preliminary experiments (Preliminary Experiments S1), we tested the effect of IAPV injection on gene expression of six commonly used reference genes that have been reported to be constantly expressed across different experimental conditions [4, 7, 41] .", [["IAPV", "CHEMICAL", 349, 353], ["IAPV", "CHEMICAL", 349, 353], ["IAPV", "SIMPLE_CHEMICAL", 349, 353], ["reference genes", "DNA", 404, 419], ["virus replication", "TREATMENT", 105, 122], ["the established diseased state", "PROBLEM", 159, 189], ["visual symptoms", "PROBLEM", 208, 223], ["IAPV injection", "TREATMENT", 349, 363], ["diseased", "OBSERVATION", 175, 183]]], ["We studied the transcription of Actin, ribosomal 28S RNA, ribosomal 18S RNA, ribosomal protein RPS5, MGST1, and Histone H2A, under IAPV infection.", [["infection", "DISEASE", 136, 145], ["Actin", "GENE_OR_GENE_PRODUCT", 32, 37], ["ribosomal", "CELLULAR_COMPONENT", 39, 48], ["28S", "CELLULAR_COMPONENT", 49, 52], ["ribosomal", "CELLULAR_COMPONENT", 58, 67], ["18S", "GENE_OR_GENE_PRODUCT", 68, 71], ["ribosomal", "CELLULAR_COMPONENT", 77, 86], ["RPS5", "GENE_OR_GENE_PRODUCT", 95, 99], ["MGST1", "GENE_OR_GENE_PRODUCT", 101, 106], ["Histone H2A", "GENE_OR_GENE_PRODUCT", 112, 123], ["IAPV", "GENE_OR_GENE_PRODUCT", 131, 135], ["Actin, ribosomal 28S RNA", "RNA", 32, 56], ["ribosomal 18S RNA", "RNA", 58, 75], ["ribosomal protein", "PROTEIN", 77, 94], ["RPS5", "PROTEIN", 95, 99], ["MGST1", "PROTEIN", 101, 106], ["Histone H2A", "PROTEIN", 112, 123], ["ribosomal 28S RNA", "TEST", 39, 56], ["ribosomal 18S RNA", "TEST", 58, 75], ["ribosomal protein RPS5", "TEST", 77, 99], ["MGST1", "TREATMENT", 101, 106], ["Histone H2A", "PROBLEM", 112, 123], ["IAPV infection", "PROBLEM", 131, 145], ["28S RNA", "OBSERVATION", 49, 56], ["18S RNA", "OBSERVATION", 68, 75], ["protein RPS5", "OBSERVATION", 87, 99], ["Histone H2A", "OBSERVATION", 112, 123], ["IAPV infection", "OBSERVATION", 131, 145]]], ["Histone H2A is not common used in honey bees, but it was added to our experiment because its expression is constitutive and cell-cycle independent, and it is commonly used on other models [42] .", [["cell", "ANATOMY", 124, 128], ["Histone H2A", "GENE_OR_GENE_PRODUCT", 0, 11], ["cell", "CELL", 124, 128], ["Histone H2A", "PROTEIN", 0, 11], ["honey bees", "SPECIES", 34, 44], ["Histone H2A", "PROBLEM", 0, 11], ["H2A", "OBSERVATION", 8, 11]]], ["The sequences of utilized H2A primers are: 59-AAAGGAAATTACG-CAGAACGA-39 (H2A Forward) and 59-CGGCTAAATATTC-CATAACGG-39 (H2A Reverse).", [["H2A", "GENE_OR_GENE_PRODUCT", 26, 29], ["H2A primers", "DNA", 26, 37], ["CATAACGG-39", "DNA", 107, 118], ["H2A", "PROTEIN", 120, 123], ["H2A primers", "TEST", 26, 37], ["AAAGGAAATTACG", "TEST", 46, 59], ["CAGAACGA-", "TEST", 60, 69], ["CGGCTAAATATTC", "TEST", 93, 106], ["CATAACGG", "TEST", 107, 115]]], ["In addition, the titers of IAPV and DWV were quantified in these samples.Patrilines GenotypingOne hind leg was removed from each pupa and stored at -20uC before DNA extraction to determine the subfamily (patriline) for each individual.", [["samples", "ANATOMY", 65, 72], ["hind leg", "ANATOMY", 98, 106], ["pupa", "ANATOMY", 129, 133], ["IAPV", "GENE_OR_GENE_PRODUCT", 27, 31], ["DWV", "ORGANISM", 36, 39], ["hind leg", "ORGAN", 98, 106], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["patriline", "SIMPLE_CHEMICAL", 204, 213], ["IAPV", "PROTEIN", 27, 31], ["IAPV", "SPECIES", 27, 31], ["DWV", "SPECIES", 36, 39], ["IAPV and DWV", "TREATMENT", 27, 39], ["these samples", "TEST", 59, 72], ["DNA extraction", "TREATMENT", 161, 175], ["hind leg", "ANATOMY", 98, 106]]], ["DNA was extracted from each leg using a standard Chelex 100H method [43] .", [["leg", "ANATOMY", 28, 31], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["leg", "ORGANISM_SUBDIVISION", 28, 31], ["DNA", "PROBLEM", 0, 3], ["a standard Chelex", "TREATMENT", 38, 55], ["leg", "ANATOMY", 28, 31]]], ["Briefly, each sample was incubated for 60 min at 55uC, 15 min at 99uC, 1 min at 37uC, and 15 min at 99uC in 150 ml of a 5% Chelex 100H solution with 5 ml 0.35 mg/ml proteinase K.Patrilines GenotypingSubfamily identification for each sample was determined using microsatellite alleles following previously described methods [44] .", [["sample", "ANATOMY", 14, 20], ["sample", "ANATOMY", 233, 239], ["Chelex 100H", "CHEMICAL", 123, 134], ["microsatellite alleles", "DNA", 261, 283], ["a 5% Chelex 100H solution", "TREATMENT", 118, 143], ["microsatellite alleles", "PROBLEM", 261, 283]]], ["This genomic paternity analysis was conducted using two multiplex PCR reactions (Plex 1 and Plex 2) with 10 ml reaction volumes containing approximately 100 ng sample DNA, 16PCR buffer (TakaraH without MgCl 2 ), 1 mg/ml BSA, 1.5 U Taq polymerase, 300 mM dNTPs, and either 1.5 mM (Plex 1) or 1.1 mM (Plex 2) MgCl 2 .", [["MgCl 2", "CHEMICAL", 202, 208], ["dNTPs", "CHEMICAL", 254, 259], ["MgCl 2", "CHEMICAL", 202, 208], ["dNTPs", "CHEMICAL", 254, 259], ["(Plex 2) MgCl 2", "CHEMICAL", 298, 313], ["DNA", "CELLULAR_COMPONENT", 167, 170], ["BSA", "SIMPLE_CHEMICAL", 220, 223], ["dNTPs", "SIMPLE_CHEMICAL", 254, 259], ["This genomic paternity analysis", "TEST", 0, 31], ["two multiplex PCR reactions", "PROBLEM", 52, 79], ["Plex", "TEST", 81, 85], ["reaction volumes", "TEST", 111, 127], ["16PCR buffer (TakaraH without MgCl", "TREATMENT", 172, 206], ["dNTPs", "TREATMENT", 254, 259]]], ["Following [45] , primer sets in Plex 1 included 2.0-2.5 pMol Am061, Am052, Am010, and Am553, and primer sets in Plex 2 included 2.5-3.5 pm Am043, Am098, Am125, and Am059.", [["Am061", "CHEMICAL", 61, 66], ["Am052", "CHEMICAL", 68, 73], ["Am043", "CHEMICAL", 139, 144], ["Am098", "CHEMICAL", 146, 151], ["Plex 1", "GENE_OR_GENE_PRODUCT", 32, 38], ["Plex 2", "GENE_OR_GENE_PRODUCT", 112, 118], ["Plex 1", "DNA", 32, 38], ["Am553", "DNA", 86, 91], ["Am059", "DNA", 164, 169], ["primer sets in Plex", "TEST", 17, 36], ["Am052", "TEST", 68, 73], ["Am010", "TEST", 75, 80], ["primer sets", "TEST", 97, 108], ["Plex", "TEST", 112, 116], ["Am098", "TEST", 146, 151]]], ["All reactions were performed using a ThermoH Px2 thermocycler with 7 min at 95uC followed by 30 cycles of 30 sec at 95uC, 30 sec at 55uC (Plex 1) or 54uC (Plex 2), and 30 sec at 72uC, then a final 10 min at 72uC.", [["a ThermoH Px2 thermocycler", "TREATMENT", 35, 61]]], ["The PCR products were run on an ABI 3730H DNA Analyzer at the Genomic Sciences Laboratory at NCSU.", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16], ["an ABI", "TEST", 29, 35]]], ["Data was acquired with Genemapper 4.0 (ABI) to score microsatellite fragment sizes.", [["Genemapper", "TEST", 23, 33], ["ABI", "TEST", 39, 42], ["score microsatellite fragment sizes", "PROBLEM", 47, 82], ["fragment", "OBSERVATION_MODIFIER", 68, 76], ["sizes", "OBSERVATION_MODIFIER", 77, 82]]], ["Loci with poor amplification were excluded from analyses and only samples for which more than half of the loci could be scored were used for analysis.", [["samples", "ANATOMY", 66, 73], ["samples", "CANCER", 66, 73], ["poor amplification", "PROBLEM", 10, 28], ["analysis", "TEST", 141, 149]]], ["The data were analyzed with the computer package Colony 1.2 to assign subfamily membership to each sample [46] .Gene Expression AnalysisAll experiments revealed that the absolute quantities (Ct values) of the standard reference genes were affected by the IAPV treatment (see Results) and that they did not fulfill the criterion of expression stability.", [["IAPV", "CHEMICAL", 255, 259], ["The data", "TEST", 0, 8], ["Gene Expression Analysis", "TEST", 112, 136], ["All experiments", "TEST", 136, 151], ["the absolute quantities", "TEST", 166, 189], ["Ct values", "TEST", 191, 200], ["the IAPV treatment", "TREATMENT", 251, 269]]], ["Therefore, a larger set of potential reference genes was evaluated in the main experiment (Raw Data S1).", [["reference genes", "DNA", 37, 52], ["larger", "OBSERVATION_MODIFIER", 13, 19]]], ["However in the absence of an internal control, the transcript level of these genes and IAPV could not be normalized by the customary DCt or DDCt methods [47, 48] .", [["IAPV", "GENE_OR_GENE_PRODUCT", 87, 91], ["IAPV", "DNA", 87, 91], ["an internal control", "TREATMENT", 26, 45]]], ["Instead, transcripts were evaluated by Ct values, based on the assumption that the amount of template after quantification and appropriate dilution did not differ systematically among treatment groups.", [["Ct values", "TEST", 39, 48], ["quantification", "TEST", 108, 122], ["appropriate dilution", "TREATMENT", 127, 147]]], ["To ensure consistency, a fixed fluorescence threshold for each gene and experiment was determined manually to avoid inter RT-qPCR runs inconsistencies.", [["a fixed fluorescence threshold", "TREATMENT", 23, 53]]], ["Tests of technical error indicated a high replicability for several genes, with variation between replicate Ct values of 1.3% on average (minimum: 0.002%, maximum: 2.6%).Gene Expression AnalysisAll statistical analyses of this study were done using The R Stats Package, version 2.15.0, http://www.r-project.org/ or with SPSS 20.0 (IBM).", [["replicate Ct values", "TEST", 98, 117], ["Gene Expression Analysis", "TEST", 170, 194], ["this study", "TEST", 222, 232]]], ["Heat maps were generated by Heatmap.Plus R Package version 1.3.", [["Heat maps", "TEST", 0, 9], ["Heatmap", "TEST", 28, 35], ["R Package version", "TEST", 41, 58]]], ["Patterns of gene expression were analyzed with parametric linear models, using time and treatment as fixed effects.", [["gene expression", "PROBLEM", 12, 27], ["parametric linear models", "TREATMENT", 47, 71], ["treatment", "TREATMENT", 88, 97], ["gene expression", "OBSERVATION", 12, 27]]], ["Bonferroni and Scheffe's post-hoc tests were performed and did not differ in their results.", [["Bonferroni", "TEST", 0, 10], ["Scheffe's post-hoc tests", "TEST", 15, 39]]], ["In the experiment, the virus titers of inoculated individuals were compared among colonies and patrilines within colonies.", [["colonies", "ANATOMY", 82, 90], ["colonies", "ANATOMY", 113, 121], ["the virus titers", "TEST", 19, 35], ["inoculated individuals", "PROBLEM", 39, 61]]], ["Patrilines that were represented by only one individual were omitted from the patrline but not the colony analysis.", [["colony", "ANATOMY", 99, 105], ["Patrilines", "GENE_OR_GENE_PRODUCT", 0, 10], ["Patrilines", "PROBLEM", 0, 10], ["the colony analysis", "TEST", 95, 114]]], ["Thus, separate ANOVAs were used instead of one nested ANOVA.IAPV PurificationAttempts to isolate pure IAPV directly from naturally infected adult bees were unsuccessful due to co-infection of the bees with other honey bee viruses.", [["IAPV", "CHEMICAL", 102, 106], ["IAPV", "GENE_OR_GENE_PRODUCT", 102, 106], ["honey bee viruses", "ORGANISM", 212, 229], ["IAPV", "SPECIES", 60, 64], ["IAPV", "SPECIES", 102, 106], ["honey bee viruses", "SPECIES", 212, 229], ["IAPV Purification", "TREATMENT", 60, 77], ["isolate pure IAPV", "TREATMENT", 89, 106], ["co-infection of the bees", "PROBLEM", 176, 200], ["co-infection", "OBSERVATION", 176, 188], ["honey bee viruses", "OBSERVATION", 212, 229]]], ["PCR tests resulted repeatedly in positive amplification of multiple viruses, such as BQCV, ABPV, and DWV.", [["BQCV", "SPECIES", 85, 89], ["ABPV", "SPECIES", 91, 95], ["DWV", "SPECIES", 101, 104], ["PCR tests", "TEST", 0, 9], ["multiple viruses", "PROBLEM", 59, 75], ["ABPV", "TREATMENT", 91, 95], ["DWV", "TREATMENT", 101, 104], ["multiple", "OBSERVATION_MODIFIER", 59, 67], ["viruses", "OBSERVATION", 68, 75]]], ["Co-infection seems to be the rule rather than the exception and it is generally rare to find bees infected with a single virus [49] .", [["Co-infection", "DISEASE", 0, 12], ["Co-infection", "PROBLEM", 0, 12]]], ["However, our artificial inoculation of pupae led to selective increases of IAPV, relative to the other viruses.", [["pupae", "ANATOMY", 39, 44], ["IAPV", "GENE_OR_GENE_PRODUCT", 75, 79], ["IAPV", "PROTEIN", 75, 79], ["our artificial inoculation of pupae", "PROBLEM", 9, 44], ["selective increases of IAPV", "PROBLEM", 52, 79], ["the other viruses", "PROBLEM", 93, 110], ["selective", "OBSERVATION_MODIFIER", 52, 61], ["increases", "OBSERVATION_MODIFIER", 62, 71], ["viruses", "OBSERVATION", 103, 110]]], ["After three rounds of pupae inoculation and subsequent virus purification, the amount of IAPV was at least 10 5 genome copies higher than all other common honey bee viruses found in our initial inoculum (BQCV, ABPV, DWV).", [["IAPV", "GENE_OR_GENE_PRODUCT", 89, 93], ["IAPV", "PROTEIN", 89, 93], ["IAPV", "SPECIES", 89, 93], ["honey bee viruses", "SPECIES", 155, 172], ["pupae inoculation", "TREATMENT", 22, 39], ["subsequent virus purification", "TREATMENT", 44, 73], ["IAPV", "TREATMENT", 89, 93], ["common honey", "ANATOMY", 148, 160], ["bee viruses", "OBSERVATION", 161, 172]]], ["After serial dilutions, IAPV was the only virus that could be detected by PCR.", [["IAPV", "GENE_OR_GENE_PRODUCT", 24, 28], ["IAPV", "SPECIES", 24, 28], ["serial dilutions", "TEST", 6, 22], ["IAPV", "TREATMENT", 24, 28], ["virus", "PROBLEM", 42, 47], ["PCR", "TEST", 74, 77]]], ["Electron Microscopy analysis of this sample showed uniform viral particles around 27 nm ( Figure 2B ), consistent with picornavirus particles.", [["sample", "ANATOMY", 37, 43], ["picornavirus", "ORGANISM", 119, 131], ["Electron Microscopy analysis", "TEST", 0, 28], ["this sample", "TEST", 32, 43], ["uniform viral particles", "PROBLEM", 51, 74], ["picornavirus particles", "PROBLEM", 119, 141], ["viral particles", "OBSERVATION", 59, 74], ["27 nm", "OBSERVATION_MODIFIER", 82, 87], ["consistent with", "UNCERTAINTY", 103, 118], ["picornavirus particles", "OBSERVATION", 119, 141]]], ["Sequence analysis verified these particles to be IAPV.In vitro IAPV Infection System StandardizationThe site for injection of the virus inoculum into the honey bee was chosen based on the ability of the pupae to complete development to become an adult after sham injections.", [["honey", "ORGANISM", 154, 159], ["IAPV", "SPECIES", 63, 67], ["honey bee", "SPECIES", 154, 163], ["Sequence analysis", "TEST", 0, 17], ["vitro IAPV Infection", "TREATMENT", 57, 77], ["the virus inoculum", "TREATMENT", 126, 144], ["the honey bee", "TREATMENT", 150, 163], ["the pupae", "TREATMENT", 199, 208], ["sham injections", "TREATMENT", 258, 273], ["Infection", "OBSERVATION", 68, 77], ["honey bee", "OBSERVATION", 154, 163]]], ["When the junction between the last abdominal sternites (Figure 2A ) was selected more than 95% of bees were able to complete development after PBS inoculation.", [["abdominal sternites", "ANATOMY", 35, 54], ["abdominal sternites", "MULTI-TISSUE_STRUCTURE", 35, 54], ["PBS inoculation", "PROBLEM", 143, 158], ["junction", "ANATOMY_MODIFIER", 9, 17], ["abdominal", "ANATOMY", 35, 44]]], ["This region is very soft, enabling smooth penetration of the needle with little physical damage to the pupae.", [["pupae", "ANATOMY", 103, 108], ["very", "OBSERVATION_MODIFIER", 15, 19], ["soft", "OBSERVATION", 20, 24], ["smooth", "OBSERVATION_MODIFIER", 35, 41], ["penetration", "OBSERVATION_MODIFIER", 42, 53], ["pupae", "ANATOMY", 103, 108]]], ["In addition, Varroa destructor nymphs were often observed in this same region when pupae were prepared for inoculations, suggesting that this area is an attractive feeding site.In vitro IAPV Infection System StandardizationIn the standardization process both controls, without inoculation (W/O) and PBS buffer injected bees (PBS), developed normally ( Figure 1A) , culminating in full development after 144 hours ( Figure 1C ).", [["pupae", "ANATOMY", 83, 88], ["Varroa destructor nymphs", "ORGANISM", 13, 37], ["Varroa destructor", "SPECIES", 13, 30], ["IAPV", "SPECIES", 186, 190], ["Varroa destructor nymphs", "PROBLEM", 13, 37], ["inoculations", "PROBLEM", 107, 119], ["an attractive feeding site", "PROBLEM", 150, 176], ["vitro IAPV Infection", "TREATMENT", 180, 200], ["the standardization process", "TREATMENT", 226, 253], ["inoculation", "PROBLEM", 277, 288], ["PBS buffer", "TREATMENT", 299, 309], ["Varroa", "OBSERVATION", 13, 19], ["destructor nymphs", "OBSERVATION", 20, 37], ["attractive", "OBSERVATION_MODIFIER", 153, 163], ["feeding site", "OBSERVATION", 164, 176], ["Infection", "OBSERVATION", 191, 200]]], ["IAPV-inoculated bees showed strong but variable symptomatology over time ( Figures 1A and 1B) , inhibited metamorphosis, and ultimately death.", [["IAPV", "CHEMICAL", 0, 4], ["death", "DISEASE", 136, 141], ["IAPV", "GENE_OR_GENE_PRODUCT", 0, 4], ["IAPV", "TEST", 0, 4], ["variable symptomatology", "PROBLEM", 39, 62], ["strong", "OBSERVATION_MODIFIER", 28, 34]]], ["Symptoms ranged from a complete cessation of development with no visual evidence of disease ( Figure 1B-1) , rapid darkening of body parts ( Figure 1B-3 and 1B-4) , simultaneous darkening and hindered development ( Figure 1B-5) , to apparently normal development ( Figure 1B-2) with eventual sudden death.", [["body parts", "ANATOMY", 128, 138], ["sudden death", "DISEASE", 292, 304], ["body", "ORGANISM_SUBDIVISION", 128, 132], ["Symptoms", "PROBLEM", 0, 8], ["disease", "PROBLEM", 84, 91], ["Figure 1B", "TEST", 94, 103], ["rapid darkening of body parts", "PROBLEM", 109, 138], ["Figure 1B", "TEST", 141, 150], ["1B", "TEST", 157, 159], ["simultaneous darkening", "PROBLEM", 165, 187], ["hindered development", "PROBLEM", 192, 212], ["Figure 1B", "TEST", 215, 224], ["eventual sudden death", "PROBLEM", 283, 304], ["disease", "OBSERVATION", 84, 91], ["body", "ANATOMY_MODIFIER", 128, 132], ["darkening", "OBSERVATION", 178, 187], ["normal", "OBSERVATION", 244, 250]]], ["IAPV titer increased in all inoculated bees but no correlation between symptomatology and virus titer determined by RT-qPCR at the end of the experiment was observed.Variation in IAPV SusceptibilityThe experiment investigated IAPV infections in pupae from two unrelated colonies to compare these two colonies and patrilines within the colonies.", [["colonies", "ANATOMY", 270, 278], ["colonies", "ANATOMY", 300, 308], ["colonies", "ANATOMY", 335, 343], ["infections", "DISEASE", 231, 241], ["IAPV", "GENE_OR_GENE_PRODUCT", 0, 4], ["IAPV", "GENE_OR_GENE_PRODUCT", 226, 230], ["IAPV", "PROTEIN", 179, 183], ["IAPV", "SPECIES", 0, 4], ["IAPV", "SPECIES", 226, 230], ["IAPV titer", "PROBLEM", 0, 10], ["symptomatology", "TEST", 71, 85], ["virus titer", "TEST", 90, 101], ["qPCR", "TEST", 119, 123], ["IAPV infections in pupae", "PROBLEM", 226, 250], ["two unrelated colonies", "PROBLEM", 256, 278], ["these two colonies and patrilines within the colonies", "PROBLEM", 290, 343], ["IAPV Susceptibility", "OBSERVATION", 179, 198], ["IAPV", "OBSERVATION_MODIFIER", 226, 230], ["infections", "OBSERVATION", 231, 241]]], ["RT-qPCR analyses showed no initial evidence of IAPV infection in either experimental colony and even the initial inoculum was below our detection limit (Figure 3) .", [["colony", "ANATOMY", 85, 91], ["infection", "DISEASE", 52, 61], ["IAPV", "GENE_OR_GENE_PRODUCT", 47, 51], ["IAPV", "SPECIES", 47, 51], ["RT-qPCR analyses", "TEST", 0, 16], ["IAPV infection", "PROBLEM", 47, 61], ["either experimental colony", "PROBLEM", 65, 91], ["the initial inoculum", "PROBLEM", 101, 121], ["no initial evidence of", "UNCERTAINTY", 24, 46], ["IAPV", "OBSERVATION_MODIFIER", 47, 51], ["infection", "OBSERVATION", 52, 61], ["experimental colony", "OBSERVATION", 72, 91]]], ["A twofactorial ANOVA indicated that the two colonies differed significantly in the build-up of virus titers (F Colony (1,104) = 5.3, P = 0.023; F Time (3,104) = 69.7, P,0.001; F Interaction (3,104) = 8.0, P,0.001).", [["colonies", "ANATOMY", 44, 52], ["A twofactorial ANOVA", "TEST", 0, 20], ["the two colonies", "PROBLEM", 36, 52], ["virus titers", "TEST", 95, 107], ["Colony", "TEST", 111, 117], ["P", "TEST", 133, 134], ["P,", "TEST", 167, 169], ["P,", "TEST", 205, 207]]], ["Specifically, a significant difference between the colonies was found at 20 hours (F Colony (1,42) = 39.2, P,0.001; Figure 3 ).", [["colonies", "ANATOMY", 51, 59], ["a significant difference between the colonies", "PROBLEM", 14, 59], ["Colony", "TEST", 85, 91], ["P,", "TEST", 107, 109], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["difference", "OBSERVATION_MODIFIER", 28, 38]]], ["Post-hoc tests also revealed a significant difference among all time points, except between 0 and 5 hours.", [["Post-hoc tests", "TEST", 0, 14], ["a significant difference", "PROBLEM", 29, 53], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["difference", "OBSERVATION", 43, 53]]], ["Within colonies, some patriline differences were suggestive ( Figure S1 ) but not significant after Bonferroni correction (Colony 1: Symptomatic differences were also observed between the two colonies (Table 1) .", [["colonies", "ANATOMY", 7, 15], ["some patriline differences", "PROBLEM", 17, 43], ["Symptomatic differences", "PROBLEM", 133, 156], ["not", "UNCERTAINTY", 78, 81], ["significant", "OBSERVATION_MODIFIER", 82, 93]]], ["Generally, pupae from Colony 1 showed some evidence of developmental completion, as evidenced by the presence of brown eye pigmentation and darkened abdomens.", [["eye", "ANATOMY", 119, 122], ["abdomens", "ANATOMY", 149, 157], ["eye", "ORGAN", 119, 122], ["abdomens", "ORGAN", 149, 157], ["pupae from Colony 1", "TEST", 11, 30], ["developmental completion", "PROBLEM", 55, 79], ["brown eye pigmentation", "PROBLEM", 113, 135], ["darkened abdomens", "PROBLEM", 140, 157], ["developmental", "OBSERVATION_MODIFIER", 55, 68], ["brown eye pigmentation", "OBSERVATION", 113, 135], ["darkened", "OBSERVATION_MODIFIER", 140, 148], ["abdomens", "ANATOMY", 149, 157]]], ["Pupae from Colony 2 showed higher development debilitation: few individuals developed eye pigmentation or darkened abdomens.", [["eye", "ANATOMY", 86, 89], ["abdomens", "ANATOMY", 115, 123], ["debilitation", "DISEASE", 46, 58], ["eye pigmentation", "DISEASE", 86, 102], ["Colony 2", "CELL", 11, 19], ["eye", "ORGAN", 86, 89], ["abdomens", "ORGAN", 115, 123], ["Pupae from Colony 2", "TEST", 0, 19], ["higher development debilitation", "PROBLEM", 27, 58], ["eye pigmentation", "PROBLEM", 86, 102], ["darkened abdomens", "PROBLEM", 106, 123], ["higher development", "OBSERVATION_MODIFIER", 27, 45], ["debilitation", "OBSERVATION", 46, 58], ["few", "OBSERVATION_MODIFIER", 60, 63], ["eye", "ANATOMY", 86, 89], ["pigmentation", "OBSERVATION", 90, 102], ["darkened", "OBSERVATION_MODIFIER", 106, 114], ["abdomens", "ANATOMY", 115, 123]]], ["No correlations between virus titer and symptomatology were found.Transcriptional Consequences of IAPV InfectionThree-factorial ANOVA revealed a significant treatment effect on the expression on all six genes ( Table 2 ).", [["virus titer", "TEST", 24, 35], ["symptomatology", "PROBLEM", 40, 54], ["IAPV Infection", "PROBLEM", 98, 112], ["a significant treatment effect", "PROBLEM", 143, 173], ["significant", "OBSERVATION_MODIFIER", 145, 156], ["treatment", "OBSERVATION", 157, 166]]], ["In general, gene expression also differed among time points but the differences for Actin were not significant.", [["Actin", "GENE_OR_GENE_PRODUCT", 84, 89], ["Actin", "PROTEIN", 84, 89]]], ["In contrast, the two colonies only differed in Actin expression (Table 2) .", [["colonies", "ANATOMY", 21, 29], ["Actin", "GENE_OR_GENE_PRODUCT", 47, 52], ["Actin", "PROTEIN", 47, 52], ["Actin expression", "OBSERVATION", 47, 63]]], ["Post-hoc tests of main treatment effects showed significantly higher gene expression in the IAPV-inoculated bees compared to the two control groups for Actin, 28S rRNA, and mGST1.", [["IAPV", "GENE_OR_GENE_PRODUCT", 92, 96], ["Actin", "GENE_OR_GENE_PRODUCT", 152, 157], ["28S", "GENE_OR_GENE_PRODUCT", 159, 162], ["rRNA", "CELLULAR_COMPONENT", 163, 167], ["mGST1", "GENE_OR_GENE_PRODUCT", 173, 178], ["Actin, 28S rRNA", "DNA", 152, 167], ["mGST1", "DNA", 173, 178], ["Post-hoc tests", "TEST", 0, 14], ["significantly higher gene expression in the IAPV", "PROBLEM", 48, 96], ["Actin, 28S rRNA", "TEST", 152, 167], ["mGST1", "TREATMENT", 173, 178], ["higher", "OBSERVATION_MODIFIER", 62, 68], ["gene expression", "OBSERVATION", 69, 84], ["28S rRNA", "OBSERVATION", 159, 167]]], ["Conversely, 18S rRNA was significantly less expressed in IAPV-inoculated bees than in both control groups.", [["18S", "GENE_OR_GENE_PRODUCT", 12, 15], ["rRNA", "CELLULAR_COMPONENT", 16, 20], ["18S rRNA", "RNA", 12, 20], ["18S rRNA", "TEST", 12, 20], ["18S rRNA", "OBSERVATION", 12, 20]]], ["For Histone H2A, significantly lower expression was found in the untreated group than in the PBS and virus injected group, and all treatment groups differed significantly in the RPS5 expression in the following order: ''control group'',''PBS-injected'',''IAPV-injected''.", [["Histone H2A", "GENE_OR_GENE_PRODUCT", 4, 15], ["RPS5", "GENE_OR_GENE_PRODUCT", 178, 182], ["IAPV", "SIMPLE_CHEMICAL", 255, 259], ["Histone H2A", "PROTEIN", 4, 15], ["RPS5", "PROTEIN", 178, 182], ["Histone H2A", "PROBLEM", 4, 15], ["significantly lower expression", "PROBLEM", 17, 47], ["''control group''", "TREATMENT", 218, 235]]], ["Post-hoc test results for time effects were more complex (Results S1).Transcriptional Consequences of IAPV InfectionThe ANOVA models also revealed many significant interaction terms (Results S1), indicating time-specific and colony-specific treatment effects (Figure 4) .", [["hoc test", "TEST", 5, 13], ["IAPV Infection", "PROBLEM", 102, 116], ["The ANOVA models", "TEST", 116, 132], ["Infection", "OBSERVATION", 107, 116], ["many", "OBSERVATION_MODIFIER", 147, 151], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["interaction", "OBSERVATION", 164, 175]]], ["The entire ANOVA model explained most of the gene expression variation for RPS5 (65.8%), followed by Actin (62.1%), mGST (40.7%), H2A (38.0%), 18S rRNA (35.0%), and 28S rRNA (18.9%).", [["RPS5", "GENE_OR_GENE_PRODUCT", 75, 79], ["Actin", "GENE_OR_GENE_PRODUCT", 101, 106], ["mGST", "GENE_OR_GENE_PRODUCT", 116, 120], ["H2A", "GENE_OR_GENE_PRODUCT", 130, 133], ["18S rRNA", "GENE_OR_GENE_PRODUCT", 143, 151], ["28S", "GENE_OR_GENE_PRODUCT", 165, 168], ["rRNA", "CELLULAR_COMPONENT", 169, 173], ["RPS5", "DNA", 75, 79], ["Actin", "PROTEIN", 101, 106], ["mGST", "PROTEIN", 116, 120], ["H2A", "PROTEIN", 130, 133], ["18S rRNA", "RNA", 143, 151], ["28S rRNA", "RNA", 165, 173], ["RPS5", "TEST", 75, 79], ["Actin", "TEST", 101, 106], ["mGST", "TEST", 116, 120], ["H2A", "TEST", 130, 133], ["18S rRNA", "TEST", 143, 151], ["28S rRNA", "TEST", 165, 173]]], ["The additionally performed ANCOVAs revealed that all associations between IAPV and transcripts were also significant, independently of treatment or timing ( Table 2) .", [["IAPV", "GENE_OR_GENE_PRODUCT", 74, 78], ["IAPV", "PROTEIN", 74, 78], ["treatment", "TREATMENT", 135, 144]]], ["No correlations between gene expression and symptomatology were found.DiscussionHoney bee viruses play an important role in the recent declines in honey bee health [8, 9, 16, 17, 50, 51] but very little is known about how virus infections damage honey bees.", [["infections", "DISEASE", 228, 238], ["honey bee", "SPECIES", 147, 156], ["honey bees", "SPECIES", 246, 256], ["symptomatology", "PROBLEM", 44, 58]]], ["The developed study model is a crucial step to much-needed mechanistic studies of honey bee viruses.", [["honey bee", "ORGANISM", 82, 91], ["honey bee viruses", "SPECIES", 82, 99], ["study model", "TEST", 14, 25], ["mechanistic studies", "TEST", 59, 78], ["honey bee viruses", "PROBLEM", 82, 99], ["honey bee viruses", "OBSERVATION", 82, 99]]], ["On the one hand, honey bee pupae do not require feeding and can be easily maintained under laboratory conditions until full development into adult.", [["honey bee", "SPECIES", 17, 26]]], ["On the other hand, IAPV has proven an excellent choice because its preferential replication in pupae [25] enables the production of inoculum that is virtually free of contaminating viruses.", [["IAPV", "CHEMICAL", 19, 23], ["inoculum", "PROBLEM", 132, 140], ["contaminating viruses", "PROBLEM", 167, 188], ["inoculum", "OBSERVATION", 132, 140]]], ["In addition, IAPV is relevant for bee health [8] but it is not ubiquitous in the bee population, which makes it possible to set up experiments with IAPV-free bees.DiscussionOur experiment showed significant differences in IAPV replication between the two studied colonies, and also suggested patrilineal variation, although small sample sizes per patriline precluded significance after correction for multiple testing.DiscussionEnvironmental factors are not to be disregarded and can include colony propolis [52] and pesticide [53] levels, or larval nutrition [54] .", [["colonies", "ANATOMY", 263, 271], ["colony propolis [52] and pesticide [53]", "CHEMICAL", 492, 531], ["patriline", "CHEMICAL", 347, 356], ["IAPV", "GENE_OR_GENE_PRODUCT", 13, 17], ["bee", "ORGANISM", 81, 84], ["IAPV", "CANCER", 222, 226], ["IAPV", "PROTEIN", 13, 17], ["significant differences in IAPV replication", "PROBLEM", 195, 238], ["patrilineal variation", "PROBLEM", 292, 313], ["small sample sizes", "PROBLEM", 324, 342], ["multiple testing", "TEST", 401, 417], ["significant", "OBSERVATION_MODIFIER", 195, 206], ["differences", "OBSERVATION_MODIFIER", 207, 218], ["patrilineal variation", "OBSERVATION", 292, 313], ["small", "OBSERVATION_MODIFIER", 324, 329], ["sizes", "OBSERVATION_MODIFIER", 337, 342]]], ["Colony 01 showed a more abrupt increase in virus titers, while IAPV increased more gradually in colony 02.", [["Colony 01", "CELL", 0, 9], ["IAPV", "PROTEIN", 63, 67], ["IAPV", "SPECIES", 63, 67], ["a more abrupt increase in virus titers", "PROBLEM", 17, 55], ["colony 02", "TREATMENT", 96, 105], ["more abrupt", "OBSERVATION_MODIFIER", 19, 30], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["virus titers", "OBSERVATION", 43, 55], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["more", "OBSERVATION_MODIFIER", 78, 82], ["gradually", "OBSERVATION_MODIFIER", 83, 92], ["colony 02", "OBSERVATION", 96, 105]]], ["However, the relative resistance of bees from colony 02 only delayed IAPV build-up and the IAPV titers were invariably high in pupae after 48 hours.", [["colony", "ANATOMY", 46, 52], ["IAPV", "GENE_OR_GENE_PRODUCT", 91, 95], ["IAPV", "SPECIES", 91, 95], ["colony 02", "TREATMENT", 46, 55], ["the IAPV titers", "TEST", 87, 102], ["resistance", "OBSERVATION_MODIFIER", 22, 32]]], ["The identification of genotypic variation in virus susceptibility would improve the prospect for selective breeding to improve honey bee health.", [["honey", "SPECIES", 127, 132], ["genotypic variation in virus susceptibility", "PROBLEM", 22, 65], ["selective breeding", "TREATMENT", 97, 115], ["genotypic variation", "OBSERVATION", 22, 41], ["virus susceptibility", "OBSERVATION", 45, 65]]], ["In any case, our study demonstrates significant heterogeneity in virus amplification and gene responses (see below), highlighting the importance of standardization in honey bee health studies.DiscussionDistinct symptomology patterns were observed between the two colonies (Table 01) .", [["colonies", "ANATOMY", 263, 271], ["honey bee", "SPECIES", 167, 176], ["our study", "TEST", 13, 22], ["significant heterogeneity in virus amplification", "PROBLEM", 36, 84], ["DiscussionDistinct symptomology patterns", "PROBLEM", 192, 232], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["heterogeneity", "OBSERVATION", 48, 61], ["virus amplification", "OBSERVATION", 65, 84]]], ["It is not clear whether virus-induced tissue damage and necrosis or melanization as part of the immune response is responsible for the observed darkening.", [["tissue", "ANATOMY", 38, 44], ["tissue damage", "DISEASE", 38, 51], ["necrosis", "DISEASE", 56, 64], ["tissue", "TISSUE", 38, 44], ["virus-induced tissue damage", "PROBLEM", 24, 51], ["necrosis", "PROBLEM", 56, 64], ["melanization", "PROBLEM", 68, 80], ["the observed darkening", "PROBLEM", 131, 153], ["not", "UNCERTAINTY", 6, 9], ["virus", "OBSERVATION", 24, 29], ["induced tissue", "OBSERVATION_MODIFIER", 30, 44], ["damage", "OBSERVATION", 45, 51], ["necrosis", "OBSERVATION", 56, 64], ["darkening", "OBSERVATION", 144, 153]]], ["Melanization is key component of insect immune response and is active in antiviral immunity [55, 56, 57] .", [["Melanization", "DISEASE", 0, 12], ["Melanization", "TREATMENT", 0, 12], ["insect immune response", "PROBLEM", 33, 55], ["insect immune response", "OBSERVATION", 33, 55], ["active", "OBSERVATION_MODIFIER", 63, 69]]], ["Melanization would be predicted to correlate with resistance to IAPV, contrary to our observations of the darkening of larvae.", [["Melanization", "TREATMENT", 0, 12], ["IAPV", "TREATMENT", 64, 68], ["the darkening of larvae", "PROBLEM", 102, 125]]], ["Therefore, necrosis or other forms of cell death are a more likely explanation for the tissue darkening [58] .", [["cell", "ANATOMY", 38, 42], ["tissue", "ANATOMY", 87, 93], ["necrosis", "DISEASE", 11, 19], ["death", "DISEASE", 43, 48], ["cell", "CELL", 38, 42], ["tissue", "TISSUE", 87, 93], ["necrosis", "PROBLEM", 11, 19], ["cell death", "PROBLEM", 38, 48], ["the tissue darkening", "PROBLEM", 83, 103], ["necrosis", "OBSERVATION", 11, 19], ["cell death", "OBSERVATION", 38, 48], ["more likely explanation for", "UNCERTAINTY", 55, 82]]], ["Quantifying gene expression responses to IAPV infection in the honey bee pupa according to standard protocols was complicated because IAPV infection significantly affected all investigated reference genes in all experiments (Preliminary Experiments S1 and Figure 4 ), precluding their meaningful incorporation into DCt or DDCt analyses [48] .", [["IAPV", "CHEMICAL", 41, 45], ["infection", "DISEASE", 46, 55], ["infection", "DISEASE", 139, 148], ["IAPV", "GENE_OR_GENE_PRODUCT", 41, 45], ["honey bee pupa", "ORGANISM", 63, 77], ["reference genes", "DNA", 189, 204], ["honey bee", "SPECIES", 63, 72], ["IAPV", "SPECIES", 134, 138], ["IAPV infection", "PROBLEM", 41, 55], ["IAPV infection", "PROBLEM", 134, 148], ["DDCt analyses", "TEST", 322, 335], ["infection", "OBSERVATION", 139, 148]]], ["Even though relative quantification has considerable advantages and is used almost universally, it depends on appropriate references [59] , which were not available for our study.", [["our study", "TEST", 169, 178], ["quantification", "OBSERVATION", 21, 35], ["considerable", "OBSERVATION_MODIFIER", 40, 52]]], ["Therefore, we relied on absolute quantification after standardizing the amount of RNA in each experiment.", [["absolute quantification", "TREATMENT", 24, 47], ["standardizing the amount of RNA", "TREATMENT", 54, 85]]], ["The Ct values were converted to another measure of absolute quantification (copy number) for IAPV by comparison to a standard curve.", [["IAPV", "PROTEIN", 93, 97], ["The Ct values", "TEST", 0, 13], ["a standard curve", "TEST", 115, 131]]], ["Variation in cDNA synthesis or other inequalities among samples might have contributed some experimental error.", [["Variation in cDNA synthesis", "PROBLEM", 0, 27], ["cDNA synthesis", "OBSERVATION", 13, 27], ["experimental error", "OBSERVATION", 92, 110]]], ["However, it is highly unlikely that technical errors are responsible for the observed significant differences among our experimental treatments, particularly given the consistency among our three separate experiments.", [["our experimental treatments", "TREATMENT", 116, 143], ["highly unlikely", "UNCERTAINTY", 15, 30]]], ["Thus, we conclude that Ct values are most appropriate for our study and absolute quantification is necessary in studies of the transcriptional response to virus infections in honey bees.", [["infections", "DISEASE", 161, 171], ["honey bees", "ORGANISM", 175, 185], ["honey bees", "SPECIES", 175, 185], ["Ct values", "TEST", 23, 32], ["our study", "TEST", 58, 67], ["absolute quantification", "TEST", 72, 95], ["virus infections", "PROBLEM", 155, 171]]], ["Caution needs to be exerted in general when interpreting relative gene expression patterns with respect to virus infections in honey bees and other organisms [60, 61] .DiscussionThe investigation of multiple reference genes confirmed the earlier conclusions that basic cellular pathways were significantly being affected by IAPV infection (Preliminary Experiments S1).", [["cellular", "ANATOMY", 269, 277], ["infections", "DISEASE", 113, 123], ["infection", "DISEASE", 329, 338], ["honey bees", "ORGANISM", 127, 137], ["cellular", "CELL", 269, 277], ["multiple reference genes", "DNA", 199, 223], ["honey bees", "SPECIES", 127, 137], ["virus infections", "PROBLEM", 107, 123], ["IAPV infection", "PROBLEM", 324, 338], ["infection", "OBSERVATION", 329, 338]]], ["Interestingly, the transcription of many genes in the PBS-injected bees was intermediate between the negative control and the IAPV group, demonstrating an effect of wounding itself.", [["PBS", "SIMPLE_CHEMICAL", 54, 57], ["IAPV", "CANCER", 126, 130], ["the PBS", "TREATMENT", 50, 57], ["wounding itself", "PROBLEM", 165, 180], ["wounding", "OBSERVATION", 165, 173]]], ["Overall, the expression of all genes was affected by time, although for Actin this effect was non-significant in the full factorial model.", [["Actin", "GENE_OR_GENE_PRODUCT", 72, 77], ["Actin", "PROTEIN", 72, 77]]], ["In contrast, Actin was the only gene that exhibited an overall expression difference between the two colonies.", [["colonies", "ANATOMY", 101, 109], ["Actin", "GENE_OR_GENE_PRODUCT", 13, 18], ["Actin", "PROTEIN", 13, 18], ["overall", "OBSERVATION_MODIFIER", 55, 62], ["expression", "OBSERVATION", 63, 73]]], ["Furthermore, all genes were significantly associated with IAPV titers, independently of the treatment effects.", [["IAPV", "GENE_OR_GENE_PRODUCT", 58, 62], ["IAPV titers", "TREATMENT", 58, 69], ["the treatment effects", "TREATMENT", 88, 109]]], ["In sum, all analyzed genes failed to fulfill the criteria for a reliable reference gene and instead indicated a profound disruption of fundamental cellular processes by IAPV.", [["cellular", "ANATOMY", 147, 155], ["cellular", "CELL", 147, 155], ["IAPV", "GENE_OR_GENE_PRODUCT", 169, 173], ["IAPV", "PROTEIN", 169, 173], ["a profound disruption of fundamental cellular processes", "PROBLEM", 110, 165], ["fundamental cellular processes", "OBSERVATION", 135, 165]]], ["In addition to treatment effects, the expression of the putative reference genes also changed over time or was dependent on genotype.", [["putative reference genes", "DNA", 56, 80], ["treatment effects", "TREATMENT", 15, 32]]], ["This transcriptional instability of putative reference genes might present a general disadvantage of the pupa as study system because the ongoing metamorphosis presumably affects numerous genes, independently of any treatment effects [62] .DiscussionThe biological interpretation of the main effects of host colony, time, and treatment is complicated by numerous significant interaction effects observed.", [["colony", "ANATOMY", 308, 314], ["putative reference genes", "DNA", 36, 60], ["study system", "TEST", 113, 125], ["the ongoing metamorphosis", "PROBLEM", 134, 159], ["treatment", "TREATMENT", 326, 335], ["numerous significant interaction effects", "PROBLEM", 354, 394], ["host colony", "OBSERVATION", 303, 314], ["numerous", "OBSERVATION_MODIFIER", 354, 362], ["significant", "OBSERVATION_MODIFIER", 363, 374], ["interaction", "OBSERVATION", 375, 386]]], ["For Actin all interactions among the three factors were significant and for the 28S rRNA no significant interactions were observed.", [["Actin", "GENE_OR_GENE_PRODUCT", 4, 9], ["28S", "CELLULAR_COMPONENT", 80, 83], ["rRNA", "CELLULAR_COMPONENT", 84, 88], ["Actin", "PROTEIN", 4, 9], ["28S rRNA", "DNA", 80, 88], ["significant interactions", "PROBLEM", 92, 116]]], ["Interactions between time and treatment are not surprising for any transcript because the treatment effects only appear at the later stages of the experiment.", [["treatment", "TREATMENT", 30, 39]]], ["However, interactions between colony and treatment confirm the finding that source colony significantly affects the interaction between IAPV and its host.", [["colony", "ANATOMY", 30, 36], ["colony", "ANATOMY", 83, 89], ["IAPV", "GENE_OR_GENE_PRODUCT", 136, 140], ["IAPV", "PROTEIN", 136, 140], ["treatment", "TREATMENT", 41, 50]]], ["Bees of the more resistant colony 02 showed a down-regulation of the 18S rRNA by IAPV injection.", [["colony", "ANATOMY", 27, 33], ["IAPV", "CHEMICAL", 81, 85], ["18S", "GENE_OR_GENE_PRODUCT", 69, 72], ["rRNA", "CELLULAR_COMPONENT", 73, 77], ["IAPV", "SIMPLE_CHEMICAL", 81, 85], ["resistant colony 02", "CELL_LINE", 17, 36], ["18S rRNA", "RNA", 69, 77], ["the more resistant colony 02", "PROBLEM", 8, 36], ["IAPV injection", "TREATMENT", 81, 95], ["resistant", "OBSERVATION_MODIFIER", 17, 26], ["colony", "OBSERVATION", 27, 33], ["18S rRNA", "OBSERVATION", 69, 77]]], ["In contrast, the transcript was increased by IAPV injection in bees from the more susceptible colony 01.", [["IAPV", "CHEMICAL", 45, 49], ["IAPV", "CHEMICAL", 45, 49], ["IAPV", "SIMPLE_CHEMICAL", 45, 49], ["IAPV injection", "TREATMENT", 45, 59], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["susceptible colony", "OBSERVATION", 82, 100]]], ["Similarly, for most other transcripts, the strongest up-regulation by IAPV occurred after 20 hours in colony 01 but after 48 hours in colony 02.", [["IAPV", "PROTEIN", 70, 74], ["colony 02", "TREATMENT", 134, 143]]], ["Further experiments are needed to determine the causal relationships among host genotype and environment, gene expression patterns, and IAPV replication.DiscussionThe observed gene expression patterns could be due to viral manipulation of the cells to increase virus replication or present cell compensatory responses to IAPV infection.", [["cells", "ANATOMY", 243, 248], ["cell", "ANATOMY", 290, 294], ["infection", "DISEASE", 326, 335], ["IAPV", "GENE_OR_GENE_PRODUCT", 136, 140], ["cells", "CELL", 243, 248], ["cell", "CELL", 290, 294], ["IAPV", "GENE_OR_GENE_PRODUCT", 321, 325], ["IAPV", "SPECIES", 321, 325], ["Further experiments", "TEST", 0, 19], ["IAPV replication", "TREATMENT", 136, 152], ["viral manipulation of the cells", "PROBLEM", 217, 248], ["increase virus replication", "TREATMENT", 252, 278], ["IAPV infection", "PROBLEM", 321, 335], ["cell compensatory", "OBSERVATION", 290, 307], ["infection", "OBSERVATION", 326, 335]]], ["Typically, picornaviruses express a protease that cleaves the scaffold eIF4G initiator factor.", [["picornaviruses", "ORGANISM", 11, 25], ["protease", "PROTEIN", 36, 44], ["scaffold eIF4G initiator factor", "PROTEIN", 62, 93], ["picornaviruses", "PROBLEM", 11, 25], ["a protease", "TREATMENT", 34, 44]]], ["This process inhibits the 59 cap mediated translation of cellular peptides and redirects the cell translational machinery to viral mRNAs that depend on Internal Ribosomal Entry Sites (IRES)-mediated translation [30, 31] .", [["cellular", "ANATOMY", 57, 65], ["cell", "ANATOMY", 93, 97], ["cellular", "CELL", 57, 65], ["cell", "CELL", 93, 97], ["viral mRNAs", "RNA", 125, 136], ["IRES", "DNA", 184, 188], ["cellular peptides", "TREATMENT", 57, 74], ["the cell translational machinery", "TREATMENT", 89, 121], ["viral mRNAs", "PROBLEM", 125, 136], ["cellular peptides", "OBSERVATION", 57, 74], ["viral mRNAs", "OBSERVATION", 125, 136]]], ["The proteasemediated shut-down of cellular translation is widespread [63, 64] and homologs of the protease gene have been identified in all members of the dicistroviruses so far [30] .", [["cellular", "ANATOMY", 34, 42], ["cellular", "CELL", 34, 42], ["protease gene", "DNA", 98, 111], ["the protease gene", "TREATMENT", 94, 111], ["widespread", "OBSERVATION_MODIFIER", 58, 68]]], ["However, direct evidence for a translational inhibition that increases transcriptional activities via feedback loops is so far missing for all honey bee viruses and insect picornaviruses in general.", [["honey bee viruses", "ORGANISM", 143, 160], ["insect picornaviruses", "ORGANISM", 165, 186], ["honey bee viruses", "SPECIES", 143, 160], ["a translational inhibition", "PROBLEM", 29, 55], ["transcriptional activities via feedback loops", "PROBLEM", 71, 116], ["all honey bee viruses", "PROBLEM", 139, 160], ["insect picornaviruses", "PROBLEM", 165, 186], ["picornaviruses", "OBSERVATION", 172, 186]]], ["RPS5 is a key component for IRES recognition in the dicistrovirus family [65, 66, 67] .", [["RPS5", "GENE_OR_GENE_PRODUCT", 0, 4], ["RPS5", "PROTEIN", 0, 4], ["IRES", "DNA", 28, 32]]], ["The up-regulation of this gene benefits virus replication directly, suggesting that RPS5's strong and consistent upregulation may be directly induced by IAPV.", [["RPS5", "GENE_OR_GENE_PRODUCT", 84, 88], ["IAPV", "GENE_OR_GENE_PRODUCT", 153, 157], ["RPS5", "PROTEIN", 84, 88], ["IAPV", "PROTEIN", 153, 157], ["this gene benefits virus replication", "TREATMENT", 21, 57], ["RPS5's", "TEST", 84, 90]]], ["However, the widespread transcriptional response to IAPV also suggests that the cell may respond to the lack of certain cell components by increasing their transcription.", [["cell", "ANATOMY", 80, 84], ["cell", "ANATOMY", 120, 124], ["IAPV", "GENE_OR_GENE_PRODUCT", 52, 56], ["cell", "CELL", 80, 84], ["cell", "CELL", 120, 124], ["IAPV", "PROTEIN", 52, 56], ["the cell", "PROBLEM", 76, 84], ["certain cell components", "PROBLEM", 112, 135], ["widespread", "OBSERVATION_MODIFIER", 13, 23], ["transcriptional response", "OBSERVATION", 24, 48]]], ["The up-regulation of Actin, MGST1, and the histone H2A in most experimental groups suggests a far-reaching, although variable, response in a range of basic cellular processes in addition to a disturbance of the ribosomal biogenesis pathway discussed below.", [["cellular", "ANATOMY", 156, 164], ["ribosomal", "ANATOMY", 211, 220], ["Actin", "GENE_OR_GENE_PRODUCT", 21, 26], ["MGST1", "GENE_OR_GENE_PRODUCT", 28, 33], ["histone H2A", "GENE_OR_GENE_PRODUCT", 43, 54], ["cellular", "CELL", 156, 164], ["ribosomal", "CELLULAR_COMPONENT", 211, 220], ["Actin", "PROTEIN", 21, 26], ["MGST1", "PROTEIN", 28, 33], ["histone H2A", "PROTEIN", 43, 54], ["Actin, MGST1", "TREATMENT", 21, 33], ["the histone H2A", "TREATMENT", 39, 54], ["a disturbance of the ribosomal biogenesis pathway", "PROBLEM", 190, 239], ["histone H2A", "OBSERVATION", 43, 54], ["far-reaching", "OBSERVATION", 94, 106], ["cellular processes", "OBSERVATION", 156, 174], ["ribosomal biogenesis", "OBSERVATION", 211, 231]]], ["More research is needed to understand these processes and it variability among environments and genotypes.DiscussionThe three components of the ribosomal biogenesis pathway studied exhibited different responses to IAPV injection.", [["ribosomal", "ANATOMY", 144, 153], ["IAPV", "CHEMICAL", 214, 218], ["IAPV", "CHEMICAL", 214, 218], ["ribosomal", "CELLULAR_COMPONENT", 144, 153], ["IAPV", "SIMPLE_CHEMICAL", 214, 218], ["the ribosomal biogenesis pathway", "TEST", 140, 172], ["IAPV injection", "TREATMENT", 214, 228]]], ["While 28S rRNA, and RPS5 transcripts were invariably increased after IAPV replication (20 and 48 hours post-injection), 18S rRNA transcripts were decreased in colony 02 at both time points and were only increased in the more susceptible colony 01 at the first time point.", [["colony", "ANATOMY", 237, 243], ["28S", "GENE_OR_GENE_PRODUCT", 6, 9], ["rRNA", "CELLULAR_COMPONENT", 10, 14], ["RPS5", "GENE_OR_GENE_PRODUCT", 20, 24], ["18S", "GENE_OR_GENE_PRODUCT", 120, 123], ["rRNA", "CELLULAR_COMPONENT", 124, 128], ["28S rRNA", "RNA", 6, 14], ["RPS5 transcripts", "RNA", 20, 36], ["18S rRNA transcripts", "RNA", 120, 140], ["colony 02", "CELL_LINE", 159, 168], ["IAPV", "SPECIES", 69, 73], ["28S rRNA", "TEST", 6, 14], ["RPS5 transcripts", "TREATMENT", 20, 36], ["IAPV replication", "TREATMENT", 69, 85], ["18S rRNA transcripts", "PROBLEM", 120, 140], ["colony 02", "TREATMENT", 159, 168], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["decreased", "OBSERVATION_MODIFIER", 146, 155], ["colony", "OBSERVATION_MODIFIER", 159, 165], ["increased", "OBSERVATION_MODIFIER", 203, 212]]], ["The reason for these disparities is unclear, particularly because the 18S rRNA and 28S rRNA transcripts are derived from a polycistronic precursor mRNA [68] .", [["18S", "GENE_OR_GENE_PRODUCT", 70, 73], ["rRNA", "CELLULAR_COMPONENT", 74, 78], ["28S rRNA", "GENE_OR_GENE_PRODUCT", 83, 91], ["18S rRNA", "RNA", 70, 78], ["28S rRNA transcripts", "RNA", 83, 103], ["polycistronic precursor mRNA", "RNA", 123, 151], ["these disparities", "PROBLEM", 15, 32], ["the 18S rRNA", "TEST", 66, 78], ["28S rRNA transcripts", "PROBLEM", 83, 103]]], ["However, the regulated balance between small and large ribosomal subunits [69] is controlled by independent maturation pathways [70] and IAPV presumably affects these pathways differently.", [["IAPV", "GENE_OR_GENE_PRODUCT", 137, 141], ["IAPV", "PROTEIN", 137, 141], ["small and large ribosomal subunits", "TREATMENT", 39, 73], ["balance", "OBSERVATION_MODIFIER", 23, 30], ["small", "OBSERVATION_MODIFIER", 39, 44], ["large", "OBSERVATION_MODIFIER", 49, 54], ["ribosomal subunits", "OBSERVATION", 55, 73]]], ["The differences between colonies may indicate that the more resistant individuals may have either resisted transcriptional manipulation by IAPV or dedicated more cellular resources to immediate immune functions instead of ribosomal biogenesis.", [["colonies", "ANATOMY", 24, 32], ["cellular", "ANATOMY", 162, 170], ["ribosomal", "ANATOMY", 222, 231], ["individuals", "ORGANISM", 70, 81], ["IAPV", "GENE_OR_GENE_PRODUCT", 139, 143], ["cellular", "CELL", 162, 170], ["ribosomal", "CELLULAR_COMPONENT", 222, 231], ["the more resistant individuals", "PROBLEM", 51, 81], ["ribosomal biogenesis", "PROBLEM", 222, 242], ["ribosomal biogenesis", "OBSERVATION", 222, 242]]], ["Consistent with this interpretation, gene expression patterns converged between the two colonies at the later time point.", [["colonies", "ANATOMY", 88, 96], ["this interpretation", "TEST", 16, 35], ["gene expression patterns", "PROBLEM", 37, 61]]], ["Ribosome biogenesis is a highly complex and energetically costly pathway that is essential for all eukaryotic cells [70] .", [["cells", "ANATOMY", 110, 115], ["Ribosome", "CELLULAR_COMPONENT", 0, 8], ["cells", "CELL", 110, 115], ["eukaryotic cells", "CELL_TYPE", 99, 115], ["Ribosome biogenesis", "PROBLEM", 0, 19], ["all eukaryotic cells", "PROBLEM", 95, 115], ["highly complex", "OBSERVATION_MODIFIER", 25, 39]]], ["It is highly regulated and integrated with other cell functions, such as p53 signaling, and deregulation of ribosomal biosynthesis has been associated with oncogenesis [71] and apoptosis [72] .", [["cell", "ANATOMY", 49, 53], ["ribosomal", "ANATOMY", 108, 117], ["cell", "CELL", 49, 53], ["p53", "GENE_OR_GENE_PRODUCT", 73, 76], ["ribosomal", "CELLULAR_COMPONENT", 108, 117], ["p53", "PROTEIN", 73, 76], ["other cell functions", "TEST", 43, 63], ["p53 signaling", "PROBLEM", 73, 86], ["deregulation of ribosomal biosynthesis", "PROBLEM", 92, 130], ["ribosomal biosynthesis", "OBSERVATION", 108, 130]]], ["Apoptosis is a widespread cellular response to virus infection [73] and could explain some of the observed differences in IAPV symptomology.", [["cellular", "ANATOMY", 26, 34], ["Apoptosis", "DISEASE", 0, 9], ["infection", "DISEASE", 53, 62], ["cellular", "CELL", 26, 34], ["IAPV", "GENE_OR_GENE_PRODUCT", 122, 126], ["IAPV", "SPECIES", 122, 126], ["Apoptosis", "PROBLEM", 0, 9], ["virus infection", "PROBLEM", 47, 62], ["IAPV symptomology", "PROBLEM", 122, 139], ["widespread", "OBSERVATION_MODIFIER", 15, 25], ["cellular response", "OBSERVATION", 26, 43]]], ["On the other hand, viruses can also directly interfere with the ribosomal biogenesis pathway by either up-or down-regulation [74, 75] .", [["ribosomal", "ANATOMY", 64, 73], ["ribosomal", "CELLULAR_COMPONENT", 64, 73], ["viruses", "PROBLEM", 19, 26], ["viruses", "OBSERVATION", 19, 26]]], ["In any case, our result of a disturbance of the ribosomal biogenesis corroborates an important microarray survey of transcripts in the honey bee intestine that has linked picornaviruses and 28S rRNA transcript abundance to Colony Collapse Disorder [9] .DiscussionThe injection of PBS served as an experimental control to account for the effect of wounding during IAPV inoculation.", [["ribosomal", "ANATOMY", 48, 57], ["intestine", "ANATOMY", 145, 154], ["IAPV", "CHEMICAL", 363, 367], ["ribosomal", "CELLULAR_COMPONENT", 48, 57], ["intestine", "ORGAN", 145, 154], ["honey bee", "SPECIES", 135, 144], ["IAPV", "SPECIES", 363, 367], ["the ribosomal biogenesis", "PROBLEM", 44, 68], ["picornaviruses", "PROBLEM", 171, 185], ["28S rRNA transcript abundance", "PROBLEM", 190, 219], ["Colony Collapse Disorder", "PROBLEM", 223, 247], ["The injection of PBS", "TREATMENT", 263, 283], ["an experimental control", "TREATMENT", 294, 317], ["wounding during IAPV inoculation", "TREATMENT", 347, 379], ["intestine", "ANATOMY", 145, 154], ["picornaviruses", "OBSERVATION", 171, 185], ["Colony Collapse", "OBSERVATION", 223, 238]]], ["For all genes, the observed transcription patterns of the PBS-injected bees were intermediate between the IAPV-injected and the negative control group.", [["IAPV", "CHEMICAL", 106, 110], ["PBS", "SIMPLE_CHEMICAL", 58, 61], ["the PBS", "TREATMENT", 54, 61], ["the IAPV", "TREATMENT", 102, 110]]], ["This observation may suggest that a similar disruption of basic cellular functions occurs in response to wounding and cellular trauma, resulting in profound changes at the transcriptome level [76] .", [["cellular", "ANATOMY", 64, 72], ["cellular", "ANATOMY", 118, 126], ["trauma", "DISEASE", 127, 133], ["cellular", "CELL", 64, 72], ["cellular", "CELL", 118, 126], ["a similar disruption of basic cellular functions", "PROBLEM", 34, 82], ["wounding and cellular trauma", "PROBLEM", 105, 133], ["profound changes", "PROBLEM", 148, 164], ["similar", "OBSERVATION_MODIFIER", 36, 43], ["disruption", "OBSERVATION", 44, 54], ["cellular functions", "OBSERVATION", 64, 82], ["cellular trauma", "OBSERVATION", 118, 133], ["profound", "OBSERVATION_MODIFIER", 148, 156]]], ["However, our data show also an increase of DWV titers in the PBS-injected pupae over time and relative to both other treatment groups.", [["pupae", "ANATOMY", 74, 79], ["PBS", "SIMPLE_CHEMICAL", 61, 64], ["DWV", "SPECIES", 43, 46], ["our data", "TEST", 9, 17], ["an increase of DWV titers", "PROBLEM", 28, 53], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["Increased DWV titers in response to wounding have been observed before [77] .", [["Increased DWV titers", "PROBLEM", 0, 20]]], ["The increase of another picorna-like virus may have triggered responses in the PBS-injected bees that were similar to the IAPV injection, supporting a similar gene expression pattern observed between PBS group and IAPV injected bees compared to the negative control groups.", [["IAPV", "CHEMICAL", 122, 126], ["picorna-like virus", "ORGANISM", 24, 42], ["PBS", "SIMPLE_CHEMICAL", 79, 82], ["IAPV", "SIMPLE_CHEMICAL", 122, 126], ["another picorna-like virus", "PROBLEM", 16, 42], ["the PBS", "TREATMENT", 75, 82], ["the IAPV injection", "TREATMENT", 118, 136], ["a similar gene expression pattern", "PROBLEM", 149, 182], ["PBS group and IAPV", "TREATMENT", 200, 218], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["expression pattern", "OBSERVATION", 164, 182]]], ["In contrast to the PBS-injected bees, the IAPV-injected bees did not show an increase in DWV titers, suggesting that IAPV or cellular responses to IAPV interfere with DWV replication [78] .DiscussionIn summary, this study introduces an important model system to advance mechanistic studies on virus-host interactions in insects.", [["cellular", "ANATOMY", 125, 133], ["IAPV", "CHEMICAL", 42, 46], ["IAPV", "CHEMICAL", 147, 151], ["PBS", "SIMPLE_CHEMICAL", 19, 22], ["IAPV", "SIMPLE_CHEMICAL", 42, 46], ["bees", "ORGANISM", 56, 60], ["IAPV", "GENE_OR_GENE_PRODUCT", 117, 121], ["cellular", "CELL", 125, 133], ["IAPV", "GENE_OR_GENE_PRODUCT", 147, 151], ["DWV", "SPECIES", 89, 92], ["DWV", "SPECIES", 167, 170], ["an increase in DWV titers", "PROBLEM", 74, 99], ["IAPV", "PROBLEM", 117, 121], ["DWV replication", "TREATMENT", 167, 182], ["this study", "TEST", 211, 221], ["mechanistic studies", "TEST", 270, 289], ["virus", "TREATMENT", 293, 298], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["DWV titers", "OBSERVATION", 89, 99]]], ["It is particularly valuable to study honey bee viruses and their role in compromising honey bee health.", [["honey bee viruses", "SPECIES", 37, 54], ["honey bee", "SPECIES", 86, 95]]], ["The results demonstrate significant variability and indicate sources for this variability.", [["significant variability", "PROBLEM", 24, 47], ["this variability", "PROBLEM", 73, 89], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["variability", "OBSERVATION", 36, 47]]], ["The transcriptional analyses show profound, correlated perturbations of basic cellular functions and call into question the use of typical reference genes in this system.", [["cellular", "ANATOMY", 78, 86], ["cellular", "CELL", 78, 86], ["The transcriptional analyses", "TEST", 0, 28], ["profound", "OBSERVATION_MODIFIER", 34, 42]]], ["The investigated responses to IAPV inoculation in honey bees seem typical for picornavirus infections and provide a first step towards understanding the basic biology of this important honey bee virus.", [["IAPV", "CHEMICAL", 30, 34], ["picornavirus infections", "DISEASE", 78, 101], ["honey", "ORGANISM", 50, 55], ["honey bee virus", "ORGANISM", 185, 200], ["honey bee virus", "SPECIES", 185, 200], ["honey bees", "SPECIES", 50, 60], ["honey bee virus", "SPECIES", 185, 200], ["IAPV inoculation", "TREATMENT", 30, 46], ["picornavirus infections", "PROBLEM", 78, 101]]], ["More detailed studies need to follow to manipulate virus and host and assess host responses to IAPV at the systemic level.", [["IAPV", "GENE_OR_GENE_PRODUCT", 95, 99]]], ["Figure S1 Patriline differences of IAPV titers within colonies suggest a genetic basis for virus resistance in honey bees.(JPG)Preliminary Experiments S1 Two experimental inoculations of a limited number of bees with IAPV suggested that viral infection causes broad-scale alterations of transcript patterns, including immune and reference genes.(PDF)Raw Data S1 Raw Ct values for all qPCRs run in the main experiment.", [["colonies", "ANATOMY", 54, 62], ["IAPV", "CHEMICAL", 217, 221], ["viral infection", "DISEASE", 237, 252], ["IAPV", "GENE_OR_GENE_PRODUCT", 35, 39], ["honey bees", "ORGANISM", 111, 121], ["IAPV", "PROTEIN", 35, 39], ["immune and reference genes", "DNA", 318, 344], ["honey bees", "SPECIES", 111, 121], ["Figure S1 Patriline", "PROBLEM", 0, 19], ["IAPV titers", "PROBLEM", 35, 46], ["virus resistance in honey bees", "PROBLEM", 91, 121], ["IAPV", "TREATMENT", 217, 221], ["viral infection", "PROBLEM", 237, 252], ["transcript patterns", "PROBLEM", 287, 306], ["Ct values", "TEST", 366, 375], ["all qPCRs", "TEST", 380, 389], ["honey bees", "OBSERVATION", 111, 121], ["viral", "OBSERVATION_MODIFIER", 237, 242], ["infection", "OBSERVATION", 243, 252], ["main experiment", "OBSERVATION", 401, 416]]], ["(PDF) Results S1 The expression of genes evaluated by full, 3factorial ANOVAs indicated that developmental time is a significant factor, that was as important as treatment but for most genes interacted with treatment.", [["treatment", "TREATMENT", 207, 216]]]]}